0000878526-18-000125.txt : 20180720 0000878526-18-000125.hdr.sgml : 20180720 20180720145835 ACCESSION NUMBER: 0000878526-18-000125 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 114 CONFORMED PERIOD OF REPORT: 20171231 FILED AS OF DATE: 20180720 DATE AS OF CHANGE: 20180720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATUS MEDICAL INC CENTRAL INDEX KEY: 0000878526 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 770154833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-33001 FILM NUMBER: 18962346 BUSINESS ADDRESS: STREET 1: 6701 KOLL CENTER PARKWAY, SUITE 120 CITY: PLEASANTON STATE: CA ZIP: 94566 BUSINESS PHONE: 9252236700 MAIL ADDRESS: STREET 1: 6701 KOLL CENTER PARKWAY, SUITE 120 CITY: PLEASANTON STATE: CA ZIP: 94566 10-K/A 1 baby12311710-ka3.htm 10-K/A Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
FORM 10-K/A
 
 
Amendment No. 3
 
 

ý
Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2017
 
OR
¨
Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from                      to                     .
Commission file number: 000–33001
 
 
 
 NATUS MEDICAL INCORPORATED
(Exact name of Registrant as specified in its charter)
Delaware
 
77–0154833
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification Number)
6701 Koll Center Parkway, Suite 120, Pleasanton, CA 94566
(Address of principal executive offices) (Zip Code)
(925) 223-6700
(Registrant’s telephone number, including area code)
Securities Registered Pursuant to Section 12(b) of the Act:
Title of each class
 
Name of each exchange on which registered
Common Stock, $0.001 par value per share
 
The NASDAQ Stock Market LLC
(Nasdaq Global Select Market)
Securities Registered Pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ý    No  ¨
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ¨    No  ý
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ý  No  ¨
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of the Form 10-K or any amendment to this Form 10-K.  ý
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:
 
Large accelerated filer ý
 
Accelerated filer ¨
 
 
 
 
 
Non-accelerated filer ¨
 
Smaller reporting company ¨
 
(Do not check if a smaller reporting company)
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ¨    No  ý
As of June 30, 2017, the last business day of Registrant’s most recently completed second fiscal quarter, there were 33,149,439 shares of Registrant’s common stock outstanding, and the aggregate market value of such shares held by non-affiliates of Registrant (based upon the closing sale price of such shares on the Nasdaq Global Select Market on June 30, 2017) was $1,236,474,075. Shares of Registrant’s common stock held by each executive officer and director and by each entity that owns 5% or more of Registrant’s outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
On July 16, 2018, the registrant had 33,590,351 shares of its common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
None.




EXPLANATORY NOTE
This Amendment No. 3 on Form 10-K/A amends our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, which we filed with the Securities and Exchange Commission ("SEC") on March 1, 2018 (the "Original Filing") and which was amended on March 12, 2018 to update the list of exhibits included therein ("Amendment No. 1") and on April 30, 2018 to include certain information required by Part III of Form 10-K ("Amendment No. 2"). We are filing this amendment to include certification required by Exhibits 31 and 32 that refer to our entire Annual Report on Form 10-K for fiscal year ended December 31, 2017.
This Amendment No. 3 does not amend the information in the Original Filing, Amendment No. 1 or Amendment No. 2 other than to provide the certifications referred to above, and we have not updated disclosures to reflect events that occurred subsequent to the March 2, 2018 with respect to information included in the Original Filing, March 1, 2018 with respect to the information included in Amendment No. 1, or April 30, 2018 with respect to the information provided in Amendment No. 2.




NATUS MEDICAL INCORPORATED
ANNUAL REPORT ON FORM 10-K
TABLE OF CONTENTS
 
 
 
ITEM 1.
ITEM 1A.
ITEM 1B.
ITEM 2.
ITEM 3.
ITEM 4.
 
 
ITEM 5.
ITEM 6.
ITEM 7.
ITEM 7A.
ITEM 8.
ITEM 9.
ITEM 9A.
 
 
ITEM 10.
ITEM 11.
ITEM 12.
ITEM 13.
ITEM 14.
 
 
ITEM 15.
ITEM 16.



PART I 
ITEM 1.    Business
This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about Natus Medical Incorporated (“Natus,” “we,” “us,” or “our Company”). These statements include, among other things, statements concerning our expectations, beliefs, plans, intentions, future operations, financial condition and prospects, and business strategies. The words “may,” “will,” “continue,” “estimate,” “project,” “intend,” “believe,” “expect,” “anticipate,” and other similar expressions generally identify forward-looking statements. Forward-looking statements in this Item 1 include, but are not limited to, statements regarding the effectiveness and advantages of our products, factors relating to demand for and economic advantages of our products, our plan to develop and acquire additional technologies, products or businesses, our marketing, technology enhancement, and product development strategies, and our ability to complete all of our backlog orders.
Forward-looking statements are not guarantees of future performance and are subject to substantial risks and uncertainties that could cause our actual results to differ materially from those that we predicted in the forward-looking statements. Investors should carefully review the information contained under the caption “Risk Factors” contained in Item 1A for a description of risks and uncertainties that could cause actual results to differ from those that we predicted. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements, except as required by Federal Securities laws.
“Natus” and other trademarks of ours appearing in this report are our property.
Overview
Natus is a leading provider of newborn care, neurology, and hearing and balance assessment healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Product Families
We are organized into three strategic business units, each with multiple product families:
Neuro—Includes products and services that provide diagnostic, therapeutic and surgical solutions in neurodiagnostics, neurocritical care and neurosurgery. Neurology's comprehensive neurodiagnostic solutions include electroencephalography (“EEG”) and long term monitoring (“LTM”), Intensive Care Unit (“ICU”) monitoring, electromyography (“EMG”), sleep analysis or polysomnography (“PSG”), intra-operative monitoring (“IOM”), and diagnostic and monitoring transcranial doppler (“TCD”) ultrasound technology. Additionally, Global Neuro-Diagnostic Services provides ambulatory EEG services with and without video in the patient's home. These solutions enhance the diagnosis of neurological conditions such as epilepsy, sleep disorders and neuromuscular diseases.
Our neurocritical care solutions include management of traumatic brain injury by continuous monitoring of intracranial pressure (“ICP”) and cerebrospinal fluid (“CSF”) drainage. Our neurosurgical solutions provide options that promote dural healing in the cranium as well as treatment solutions for procedures involving hydrocephalus. We acquired our neurocritical care and neurosurgical product lines from Integra LifeSciences in October 2017 (“Integra Asset Acquisition”).
Newborn Care—Includes products and services for newborn care including hearing screening, brain injury, ROP vision screening, thermoregulation, jaundice management, and various disposable newborn care supplies, as well as products for diagnostic hearing assessment for children through adult populations, and products to diagnose and assist in treating balance and mobility disorders.
Otometrics—Includes products for hearing and diagnostics and hearing aid fitting, including computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms for hearing and balance care professionals. Otometrics has a complete product and brand portfolio known for its sophisticated design technology in the hearing and balance assessment markets. Global brands include Aurical®, ICS® and Madsen®. We acquired the Otometrics business in January 2017.
Neuro
Our neurology business unit represents a comprehensive line of neurodiagnostic, neurocritical care, and neurosurgical products that are used by healthcare practitioners in the diagnosis and monitoring of neurological disorders of the central and peripheral nervous system. The environments in which these products are used include outpatient private practice facilities and inpatient hospital environments including diagnostic procedures and monitoring of patients during admissions, surgery, while under sedation, in post-operative care, and in intensive care units. Our neurology products and services include:
Neurodiagnostic


1


Electroencephalography—Equipment, supplies and services used to monitor and visually display the electrical activity generated by the brain and other key physiological signals for both diagnosis and monitoring of neurological disorders in the hospital, research laboratory, clinician office and patient’s home.
Electromyography—Equipment and supplies used to measure electrical activity in nerves, muscles, and critical pathways includes EMG, nerve conduction and evoked potential functionality.
Polysomnography—Equipment and supplies used to measure a variety of respiratory and physiologic functions to assist in the diagnosis and monitoring of sleep disorders, such as insomnia and obstructive sleep apnea, a condition that causes a person to stop breathing intermittently during sleep.
Intraoperative monitoring—Equipment and supplies used to monitor the functional integrity of certain neural structures (i.e. nerves, spinal cord and parts of the brain) during surgery. The goal of IOM is to provide real time guidance to the surgeon and anesthesiologist which will reduce the risk to the patient during surgery.
Transcranial Doppler—Equipment and supplies used to measure blood flow parameters such as velocity in key vascular structures in the brain. This vascular information is helpful in identifying strokes, infarcts and vasospasms.
Neurocritical Care
Intracranial pressure monitoring—Equipment and catheters used to monitor pressure in the cranium/brain and catheters to drain cerebrospinal fluid from the brain to aid in hydrocephalus and traumatic brain injury cases.
Neurosurgery
Shunts and Dural grafts—Shunts are used to manage the drainage of cerebrospinal fluid from the brain to maintain appropriate levels of CSF when treating hydrocephalus. Dural grafts are used in procedures to repair or substitute a patient's dura mater in the brain.
Diagnostic EEG and Long-term Monitoring
We design, manufacture, and market a full line of instruments and supplies used to help diagnose the presence of seizure disorders and epilepsy, look for causes of confusion, evaluate head injuries, tumors, infections, degenerative diseases, and metabolic disturbances that affect the brain, and assist in surgical planning. This type of testing is also done to diagnose brain death in comatose patients. These systems and instruments work by detecting, amplifying, and recording the brain’s electrical impulses, as well as other physiological signals needed to support clinical findings. Routine clinical EEG recording is done by placing electrodes on a patient’s scalp over various areas of the brain to record and detect patterns of activity and specific types of electrical events. EEG technologists perform the tests, and neurologists, neurophysiologists and epileptologists review and interpret the results.
Routine outpatient clinical EEG testing is performed in hospital neurology laboratories, private physician offices, and in ambulatory settings such as the patient’s home, providing physicians with a clinical assessment of a patient’s condition. Long-term inpatient monitoring of EEG and behavior (LTM) is used to determine complex treatment plans, and for patients with seizures that do not respond to conventional therapeutic approaches, surgical solutions may be appropriate. Patients suffering from severe head trauma and other acute conditions that may affect the brain are monitored in ICUs. In addition, research facilities use EEG equipment to conduct research on humans and laboratory animals.
Global Neuro-Diagnostic Services (“GND”) which we acquired in early 2015, provides in-home ambulatory EEG monitoring. GND works with physicians and hospitals to provide superior care and testing services to its patients. Upon receiving a physician referral, GND provides program services in the patient's home, professional oversight throughout the study and preliminary report generation for physician review. GND has received accreditation by The Joint Commission as a home EEG testing services company and also has achieved the American Board of Registered Electroencephalographic and Evoked Potential Technologists (ABRET) Laboratory Accreditation in routine EEG services. GND is a leader in EEG testing services because of our focus on meeting the most stringent quality standards and providing the highest quality patient care.
Diagnostic Electroencephalograph Monitoring Product Lines
Our EEG diagnostic monitoring product lines for neurology consist of signal amplifiers, workstations to capture and store synchronize video and EEG data, and proprietary software. These products are typically used in concert, as part of an EEG “system” by the neurology/neurophysiology department of a hospital or clinic to assist in the diagnosis and monitoring of neurological conditions.
NeuroWorks; Coherence; NicoletOne; Twin.    Our EEG Systems include a broad range of products, from software licenses and ambulatory monitoring systems to advanced laboratory systems with multiple capabilities for EEG, ICU monitoring, long-term monitoring of up to 256 channels, and physician review stations with quantitative EEG analysis capabilities.

2


Stellate/Gotman Spike and Seizure; GridView; NicoletOne Trends.    Our proprietary spike and seizure detection algorithm detects, summarizes, and reports EEG events that save health care professionals time by increasing the speed and accuracy of interpretation. GridView is a tool that allows the clinician to correlate EEG patterns with electrode contacts on a 3D view of the patient brain using magnetic resonance (“MR”) or computed tomography (“CT”) images, thus enabling the visualization and annotation of the brain surface and internal structures involved in the diagnosis of epilepsy. NicoletOne Trends provides a comprehensive set of EEG analysis algorithms that are used to generate compressed trends of large amounts of data to assist in the clinical evaluation and data review process.
Proprietary Signal Amplifiers.    Our proprietary signal amplifiers function as the interface between the patient and the computer. The headbox connects electrodes attached to the patient’s head to our EEG monitoring systems. Our proprietary amplifier products are sold for a wide variety of applications under the following brand names: Xltek, Trex, EEG32U, EMU40EX, Brain Monitor, Quantum, Schwarzer EEG, Nicolet v32 and v44 models, C series and Nicolet Wireless 32- and 64- channel amplifiers.
Nicolet Cortical Stimulator.    This product is our proprietary device that provides cortical stimulation to the brain during functional brain mapping either before or during surgery to help the surgeon protect the eloquent parts of the brain. The device can be used as a standalone unit or with the fully integrated NicoletOne software that supports control of the device from the software, automated mapping and comprehensive report generation.
Supplies.    We also manufacture and market a full line of proprietary EEG needles and other supplies used in the electroencephalography field.
Global Neuro-Diagnostic Services. GND provides ambulatory EEG services with and without video in the patient’s home. Other services such as Remote Monitoring, ICU monitoring, Virtual EMU monitoring and Detailed Video EEG Technical Descriptions with cloud-based test results are also provided. Our services are specifically designed to partner with hospitals and physicians to improve efficiency, results, and turn-around time, and to reduce costs.
Electrodiagnostic Monitoring
Our electrodiagnostic systems include EMG, nerve conduction (“NCS”), and often evoked potential (“EP”) functionality. EMG and NCS involve the measurement of electrical activity of muscles and nerves both at rest and during contraction. Measuring the electrical activity in muscles and nerves can help diagnose diseases of the peripheral, central nervous system or musculature system. An electromyogram is done to determine if there is any disease present that effects muscle tissue, nerves, or the junctions between nerve and muscle (neuromuscular junctions). An electromyogram can also be used to diagnose the cause of weakness, paralysis, and muscle twitching, and is also used as a primary diagnosis for carpal tunnel syndrome, which is the most frequently encountered peripheral compressive neuropathy. EMG is also used for clinical applications of botox to relieve muscle spasm and pain. We market both the clinical system and the needles used for these procedures.
In addition to EMG and NCS functionality, many of our Electrodiagnostic systems also include EP. Evoked potentials are elicited in response to a stimulus. These evoked potentials can come from the sensory pathways (such as hearing and visual) or from the motor pathways. An examination tests the integrity of these pathways including the associated area of the brain. Sophisticated amplifiers are required to recognize and average evoked potential EMG and NCS signals.
Electrodiagnostic Product Lines
Dantec Keypoint.    The Dantec Keypoint EMG and EP family of products features amplifiers, stimulators, and strong signal quality. The Keypoint is used for advanced neurodiagnostic applications such as single fiber EMG, visual and auditory evoked potentials, and in routine nerve conduction studies. The Keypoint system is also available in a portable laptop configuration.
Dantec Clavis.    The Dantec Clavis device is a hand-held EMG and current stimulation device that provides muscle and nerve localization information to assist with medication and botox injections. In conjunction with the Bo-ject hypodermic needle and electrodes, physicians can better localize the site of the injection.
Nicolet EDX family.    A hardware platform of amplifiers, base control units, stimulators and hand-held probes that are sold with Nicolet brand proprietary software. These mid to high end systems have full functionality, strong signal quality, and flexibility. They include EMG, NCS, EP’s, IOM and advanced data analysis features.
Nicolet VikingQuest.    An EMG system for the mid-range market. The device runs on our proprietary software.
Natus Neurology UltraPro.    This is a low to mid-level product that offers high quality data collection using the Dantec Keypoint amplifiers and the proprietary Natus EMG software.

3


Supplies.    We also manufacture and market a full line of proprietary EMG needles and other supplies used in the electrodiagnostic field.
Diagnostic Polysomnography Monitoring
PSG, which involves the analysis of respiratory patterns, brain electrical activity and other physiological data, has proven critical for the diagnosis and treatment of sleep-related diseases such as apnea, insomnia, and narcolepsy. A full polysomnographic sleep study entails a whole-night recording of brain electrical activity, muscle movement, airflow, respiratory effort, oxygen levels, electrical activity of the heart, and other parameters. In some studies patients are fitted with treatment devices using Positive Airway Pressure technology (“PAP”) during the sleep study and the proper settings for the treatment devices are determined. In many cases, the sleep study is performed in the patient’s home.
Diagnostic PSG Monitoring Product Lines
We market dedicated diagnostic PSG monitoring products that can be used individually or as part of a networked system for overnight sleep studies to assist in the diagnosis of sleep disorders. Additionally we offer products that are specifically designed to be used in the patient’s home. Some of our EEG systems described above can also be configured to perform diagnostic PSG monitoring. These products include software licenses, ambulatory monitoring systems, and laboratory systems that combine multiple capabilities, including EEG monitoring, physician review stations, and quantitative PSG analysis capabilities.
Embla REMlogic, and Sandman; Xltek SleepWorks; Schwartzer Coherence; and Grass Twin.    Our diagnostic PSG systems capture and store all data digitally. The systems enable users to specify rules and personal preferences to be used during analysis, summarizing the results graphically and incorporating them in detailed reports.
Proprietary Amplifiers.    Our data acquisition systems incorporate recent developments in superior amplifiers for sleep analysis and are sold under brand names such as Embla and MPR, Xltek Trex and SleepWorks, and Schwarzer. Our amplifiers are used in both hospitals and stand-alone clinics. In addition to exceptional signal quality, headboxes include various tools such as built-in oximeters and controls to allow the user to start and stop a study or perform electrode impedance testing either at the patient’s bedside or from the monitoring room.
Practice Management Software.    Our Embla Enterprise Practice Management Software provides a solution for institutions as well as private labs and physicians for patient scheduling, inventory control, staff scheduling, data management, business reports and billing interfaces. Enterprise may be used in conjunction with many Natus PSG products.
PMSD.    PastuerMatic Sterile Dryers are used in hospital and clinic sleep laboratories to provide non-chemical sterilization of products used in sleep therapy. An environmentally friendly approach to disinfection, the PMSD products offer cost effective sterilization for sleep labs of all sizes.
Supplies.    We also market a broad line of supplies, disposable products and accessories for the PSG laboratory.
Intraoperative Monitoring
Intraoperative monitoring (“IOM”) is the use of electrophysiological methods such as EEG, EMG, and evoked potentials to monitor the functional integrity of certain neural structures (i.e. nerves, spinal cord and parts of the brain) during surgery. The purpose of IOM is to reduce the risk to the patient’s nervous system, and/or to provide functional guidance to the surgeon and anesthesiologist during surgery.
Diagnostic IOM Product Lines
Xltek Protektor.    The Protektor system is an IOM system that provides medical professionals with all information necessary to make immediate and critical surgical decisions. The system combines flexibility with multi-modality allowing full coverage of IOM techniques. The Protektor comes in 16 or 32 channel options.
Nicolet Endeavor.    A dedicated multi-modality IOM system that offers complete flexibility in work flow and test protocols.
Nicolet EDX.    These combo systems are used in IOM applications where a smaller number of channels is sufficient. This approach is primarily followed in international markets that utilize the integrated system approach that allows for the use of the system in EMG clinical applications as well as in IOM applications.
Transcranial Doppler
Transcranial Doppler is the use of Doppler ultrasound technology to measure blood flow parameters such as velocity in key vascular structures in the brain. A Doppler probe is held against a specific location on the head and the device displays the information in both visual and auditory formats. This technology is used as preventative screening, diagnosis, and monitoring of various diseases and brain injuries such as stroke, embolism, reduced blood flow during surgery, and vasospasm.

4


Transcranial Doppler Products
Sonara and Sonara Tek.    The Sonara is an embedded system that is a self-contained unit that includes a CPU, data display screen and speakers. It uses proprietary software with a touch screen menu. Sonara Tek is a small portable device used with a laptop. Both models enable the uploading of images to the hospital information system.
Neurocritical Care Products
Intracranial pressure and temperature provide insight into the health of the brain, especially in patients experiencing a traumatic brain injury, other traumatic, ischemic or hemorrhagic incidents, or a major neurosurgical procedure. A small hole is drilled into the brain to allow insertion of a catheter that contains a pressure/temperature or pressure transducer that allows continuous monitoring of brain temperature and/or pressure.
Camino ICP Monitor. The Camino ICP Monitor is a compact, portable device that provides tools for continuously determining and monitoring intracranial pressure and intracranial temperature. It has a touch screen interface, physiological alarms, and can output data to either a patient bedside monitor or to remote media types via a USB drive. These systems are used in the intensive care unit (ICU) environment.
Camino Catheters. Camino catheters use either fiber optic or strain gauge technology to measure either pressure and temperature or just pressure. Camino catheters measure their respective values at the tip of the catheter which eliminates the need for a fluid-filled system that uses an external transducer to measure pressure. The Camino Flex Ventricular Intracranial Pressure Monitoring Kit has a catheter that allows both the measurement of ICP and CSF drainage.
Neurosurgical Products
During brain surgery, the dura of the brain may need to be repaired or replaced. A dural graft is used to serve as a dural substitute for the surgical repair of dural defects. Moreover, brain surgery is performed to place shunts in the brain to help drain excess CSF either externally or into the body for reabsorption to help treat hydrocephalus.
DURAFORM. DURAFORM Dural Graft Implant is an absorbable collagen matrix to provide a soft, conforming, and easy to use dural substitute. This product is used in the operating room to provide repair of the dura mater and promote dural healing.
Shunts. Shunts are used in the operating room to provide solutions for hydrocephalus.
Newborn Care
Our newborn care business unit represents a line of products and services that are used by healthcare practitioners in the diagnosis and treatment of common medical ailments in newborn care, as well as other products used in newborn through adult populations, including hearing diagnostics and balance & mobility systems. Our products are organized in nine modalities and include:
Newborn Hearing Screening—Products used to screen hearing in newborns.
Diagnostic Hearing Assessment—Products used to screen for or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems in patients of all ages.
Balance and Mobility—Systems to diagnose and assist in treating balance disorders in an evidence-based, multidisciplinary approach.
Thermoregulation—Products used to control the newborn environment including incubators and warmers.
Jaundice Management—Products used to treat jaundice, the single largest cause for hospital readmission of newborns in the U.S.
Newborn Brain Injury—Products used to diagnose the severity of brain injury, monitor the effectiveness of drug therapies, detect seizure activity and monitor general neurological status.
Vision—Imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging.
Essentials—Products used in the everyday operation of neonatal intensive care unit (“NICU”) and well-baby nursery department within the hospital environment.
NICVIEW—Live streaming video for families with babies in the NICU that enables family members and approved friends to see the new baby, 24/7, from anywhere in the world - from any device, within a secured environment.
Newborn Hearing Screening

5


Hearing impairment is the most common treatable chronic disorder in newborns, affecting as many as five babies out of every 1,000 newborns. It is estimated that 20,000 hearing-impaired babies are born in the United States (“U.S.”) every year, and as many as 60,000 more in the rest of the developed world. Until the introduction of universal newborn hearing screening programs, screening was generally performed only on those newborns that had identifiable risk factors for hearing impairment. However, screening only those newborns with risk factors for hearing impairment overlooks approximately half of newborns with some level of hearing impairment.
Early identification of hearing impairment and early intervention has been shown to improve language development significantly. Undetected hearing impairment often results in the failure to learn, process spoken language, and speak.
Newborn Hearing Screening Techniques
The two traditional technologies used to screen newborns and infants for hearing impairment are auditory brainstem response and otoacoustic emissions.
Auditory brainstem response (“ABR”).    ABR technology is the most accurate and comprehensive method for screening and diagnosing hearing impairment. ABR technology is based on detecting the brain’s electric impulses resulting from a specific auditory stimulus.
Otoacoustic emission (“OAE”).    OAEs are sounds created by the active biomechanical processes within the sensory cells of the cochlea. They occur both spontaneously and in response to acoustic stimuli. OAE screening uses a probe placed in the ear canal to deliver auditory stimuli and to measure the response of the sensory cells with a sensitive microphone.
Newborn Hearing Screening Product Lines
Our newborn hearing screening product lines consist of the ALGO, ABaer, AuDX, and Echo-Screen newborn hearing screeners. These hearing screening products utilize proprietary signal detection technologies to provide accurate and non-invasive hearing screening for newborns and are designed to detect hearing loss at 30 or 35 dB nHL or higher. Each of these devices is designed to generate a PASS or REFER result.
ALGO 5 and 3i Newborn Hearing Screeners.    These AABR devices deliver thousands of soft audible clicks to the newborn’s ears through sound cables and disposable earphones connected to the instrument. Each click elicits an identifiable brain wave, which is detected by disposable electrodes placed on the head of the child and analyzed by the screening device. These devices use our proprietary AABR signal detection algorithm.
ABaer Newborn Hearing Screener.    The ABaer, which is a PC-based newborn hearing screening device, offers a combination of AABR, OAE, and diagnostic ABR technologies in one system.
Echo-Screen.    Our hand-held Echo-Screen products provide a choice or combination of proprietary ABR and OAE technologies that can also be used for children through adults. The Echo-Screen III device is a compact, multi-modality handheld hearing screener that is tightly integrated with audible Lite Hearing Screening Data Management.
Hearing Screening Supply Products
For infection control, accuracy, and ease of use, the supply products used with our newborn hearing screening devices are designed as single-use, disposable products. Each screening supply product is designed for a specific hearing screening technology.
ABR Screening Supply Kits.    Each ABR screen is carried out with single-use earphones and electrodes, which are alcohol and latex-free. The adhesives used in these supply products are specially formulated for use on the sensitive skin of newborns. To meet the needs of our customers we offer a variety of packaging options. Echo-Screen and ABaer offer the choice of either an earphone or use of ear tips for perform ABR screening.
OAE Supply Products.    Each OAE screen is carried out with single-use ear tips that are supplied in a variety of sizes and packaging options.
Peloton Screening Services
Peloton Screening Services is a nationwide service offering that provides hearing screening services to hospital-based customers. The platform of the program meets the objectives of today’s healthcare environment by aligning with family centered care principals and Joint Committee on Infant Hearing (JCIH) recommendations. Peloton provides all aspects of the program: equipment, supplies, professional oversight by nurses or audiologists, screening personnel, case management, quality review & oversight, and state data management reporting.
Balance and Mobility
Balance is an ability to maintain the line of gravity of the body within the base of support with minimal postural sway. Maintaining balance requires coordination of input from multiple sensory systems including the vestibular (i.e. inner ear), somatosensory (i.e. touch, temperature, body position), and visual systems. Balance disorders impact a large percentage of the

6


population in all age ranges from children to adults. Common complaints include dizziness, vertigo, or an inability to walk or drive a vehicle, which can all lead to the curtailment of daily life activities. These symptoms are exacerbated in elderly patients and can result in falls, orthopedic injuries, and sometimes death.
Balance and Mobility Products
Our principal balance and mobility products are sold under the Neurocom brand:
EquiTest.    Proprietary protocols in the EquiTest family of devices objectively quantify and differentiate among sensory, motor, and central adaptive impairments to balance control. This approach is commonly referred to as computerized dynamic posturography (“CDP”). CDP is complementary to clinical tests designed to localize and categorize pathological mechanisms of balance disorders in that it can identify and differentiate the functional impairments associated with the identified disorders.
Balance Master.    A family of devices providing objective assessment and retraining of the sensory and voluntary motor control of balance.
VSR and VSR Sport.    The VSR provides objective assessment of sensory and voluntary motor control of balance with visual biofeedback. The VSR Sport is designed specifically for the athletic market as part of a concussion management program. It is portable, easy-to use and offers athletic trainers, sports medicine practitioners, and other sport professionals the data needed to make objective return-to-play decisions without relying on subjective evaluation.
inVision.    Our inVision device incorporates a set of proprietary diagnostic tests that quantify a patient’s ability to maintain visual acuity and stable gaze while actively moving the head. The objective information enables the clinician to assess the patient’s ability to live and move safely in a dynamic world and to participate in daily-life functions such as driving, walking through a grocery store, or actively engaging in family activities.
Thermoregulation
Incubators offer a controlled, consistent microenvironment for thermoregulation and humidification within a closed system to maintain skin integrity and body temperature.
Thermoregulation products
Incubators.    Our NatalCare incubators, including those used for transporting infants, provide high thermal performance with a double wall design, easy to use control panels and features such as improved weighing functionality with automatic centering and an electronic tilting mechanism. The easy to clean, smooth design, and choice of options make these customizable incubators appropriate for different use environments.
Jaundice Management
The American Academy of Pediatrics estimates that each year 60% of the approximately four million newborns in the U.S. become jaundiced. According to the Journal of the American Medical Association, neonatal jaundice is the single largest cause for hospital readmission of newborns in the U.S., and accounts for 50% of readmissions. Because of the serious consequences of hyperbilirubinemia, the American Academy of Pediatrics recommends that all newborns be closely monitored for jaundice and that phototherapy is the standard of care for the treatment of hyperbilirubinemia. The guidelines further recommend that all nurseries have the necessary equipment to provide intensive phototherapy, and specifically recommend the use of the “blue” light as incorporated into our neoBLUE products.
Jaundice Management Products
neoBLUE Product Family.    This product line consists of our neoBLUE, neoBLUE Mini, neoBLUE Cozy, neoBLUE Compact and neoBLUE blanket devices, which utilize light emitting diodes (“LEDs”) to generate a high-intensity, narrow spectrum of blue light that is clinically proven to be most effective in the treatment of newborn jaundice. Our neoBLUE phototherapy devices emit significantly less ultraviolet light and heat than conventional phototherapy devices, reducing the risk of skin damage and dehydration for infants undergoing treatment. Because of the high intensity of these lights, the treatment time associated with phototherapy is reduced.
Medix MediLED Product Family.    A full-size, free-standing LED phototherapy system and a MediLED mini light to be used on top of an incubator or attached to the Medix radiant warmer. The MediLED incorporates an array of blue and white LEDs, while the mini system utilizes blue “super LEDs” that provide high intensity phototherapy.
Newborn Brain Injury
For many years, newborn infants admitted to the NICU of a hospital have been routinely monitored for heart activity, temperature, respiration, oxygen saturation, and blood pressure. Recently it has also been considered important to monitor brain activity. A

7


cerebral function monitor, utilizing amplitude-integrated EEGs (“aEEGs”), is a device for monitoring background neurological activity. Our simplified aEEG devices introduced over ten years ago, allow neonatologists and nurses to set-up and interpret basic neurological traces without neurology oversight.
Newborn Brain Injury Products
Our newborn brain injury products record and display parameters that the neonatologist uses to assess and monitor neurological status in the newborn. These devices continuously monitor and record brain activity, aiding in the detection and treatment of HIE and seizures. The devices also monitor the effects of drugs and other therapies on brain activity and improve the accuracy of newborn neurological assessments. They are used with electrodes attached to the head of the newborn to acquire an EEG signal that is then filtered, compressed, and displayed graphically on the device or as a hardcopy printout. The monitors have touch screens for easy navigation and onscreen keyboards for data entry at the bedside.
Olympic Brainz Monitor.    The Olympic Brainz Monitor is our latest generation Cerebral Function Monitor. The device can be used in single-channel, two-channel or three-channel modes to continuously monitor and record brain activity.
Vision
Our RetCam devices incorporate a camera combined with proprietary imaging software that are used to diagnose and monitor a range of ophthalmic maladies in premature infants. RetCam is the market leader in NICU ophthalmic imaging used in the detection of retinopathy of prematurity in newborns.

Essentials
The Newborn Care Essentials products include such items as: Biliband® eye protectors, GumDrop® pacifiers, MiniMuffs® noise attenuators, NeatNick® heal lancets, Olympic® Circumstraint, Olympic® Papoose Boards, Olympic® Smart Scales, OraSwab, Save the Gonads® x-ray protection devices and SugarPlum® glucose lancets.

NICVIEW
The video streaming solution NICVIEW offers parents and families secured access to a live video stream of their baby. For hospitals, the system offers a step into family centered care.

Otometrics
Otometrics provides hearing diagnostic, hearing aid fitting and balance instrumentation and software solutions to hearing and balance care professionals worldwide. For more than 50 years, Otometrics has been helping hearing and balance care professionals succeed in improving the quality of life for their clients and patients by delivering expert knowledge, reliable solutions and services and trusted partnerships.
    
Otometrics develops, manufactures and markets computer-based audiological, otoneurologic and vestibular instrumentation in more than 80 countries. The Otometrics solutions portfolio covers key application areas within hearing assessment, hearing screening, hearing instrument fitting and balance assessment. Many of the Otometrics hearing and balance care solutions are industry-firsts and de-facto standards within the hearing care industry and used by thousands of clinicians around the world.

As an independent provider of hearing care diagnostic solutions, Otometrics works closely with leading hearing aid manufacturers to develop new solutions within hearing assessment and, hearing aid fitting.

Hearing Assessment
From otoacoustic emissions (OAE) and immittance screening to advanced audiological testing, Otometrics offers a wide range of flexible devices and PC-based solutions that are designed to screen, test and assess patients of all ages. Otometrics hearing assessment solutions offer functionality to support basic audiometric testing to advanced tinnitus and pediatric hearing assessment. Hearing care solutions by Otometrics help streamline the hearing screening and assessment process making it easier and convenient for the professional and the patient. Otometrics also manufacturers and markets a broad line of supplies and disposable products and accessories for hearing assessment.

Hearing Instrument Fitting and Verification
Otometrics' fitting solutions help professionals manage the entire hearing aid fitting process - from fitting and verifying the hearing aid to patient counseling and follow up. Used by thousands of hearing aid dispensers, audiologists and

8


clinicians around the world, Otometrics fitting solutions support otoscopy, audiometry, hearing aid testing and programming, fitting and verification with wireless design and binaural fitting capability. Otometrics fitting solutions are PC-based, Noah-compatible and supported by integrated audiometric software that helps to streamline the fitting process for greater efficiency and patient satisfaction. Otometrics also manufacturers and markets a broad line of supplies and disposable products and accessories for hearing instrument fitting and verification.
Audiometric Sound Rooms
Otometrics manufacturers and markets a wide range of sound room solutions specifically designed for audiometric testing. Otometrics Genie sound rooms are built to deliver a quality audiometry testing environment while providing efficiency for staff and comfort for patients. Certified staff help in the planning, choice and installation of each sound room so it becomes an integrated part of the clinic, equipment and workflow. Otometrics Genie sound rooms deliver unique features such as the Cam-Lock assembly system, high performance/low profile floor, window in the door, and excellent attenuation and acoustic capabilities to ensure acoustic performance, efficient workflow and maximum testing comfort.
Balance Assessment
Professionals who evaluate patients with balance disorders use Otometrics' vestibular diagnostic and ENG/VNG (elecrtonystagmography/videonystamography) systems and services. These solutions are used by audiologists, otolaryngologists, otologists and neurologists for identifying auditory and vestibular abnormalities. Otometrics balance care solutions are compact and include the world's first portable, gold standard video head impulse test (“vHIT”) and offer modular functionality to support vHIT, video frenzel, postional, oculomotor and SHIMP (suppression head impulse) testing. Otometrics also manufacturers and markets a broad line of supplies, disposable face cushions, and accessories for balance assessment.

Segment and Geographic Information
We operate in one reportable segment, which we have presented as the aggregation of our neurology, newborn care, and otometrics product families. Within this reportable segment we are organized on the basis of the healthcare products and services we provide which are used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, and sleep disorders.
Our end-user customer base includes hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Most of our international sales are to distributors, who in turn resell our products to end users or sub-distributors.
Information regarding our sales and long-lived assets in the U.S. and in countries outside the U.S. is contained in Note 19—Segment, Customer and Geographic Information of our Consolidated Financial Statements included in this report and is incorporated in this section by this reference.
Revenue by Product Family and Product Category
For the years ended December 31, 2017, 2016 and 2015, revenue from our product families as a percent of total revenue was approximately as follows: 
 
Year Ended December 31,
 
2017
 
2016
 
2015
Neurology
48
%
 
62
%
 
63
%
Newborn Care
29
%
 
38
%
 
37
%
Otometrics
23
%
 
%
 
%
Total
100
%
 
100
%
 
100
%
We also look at revenue as either being generated from sales of Devices and Systems, which are generally non-recurring, or related Supplies and Services, which are generally recurring. The products that are attributable to these categories are described above. Revenue from Devices and Systems, Supplies and Services as a percent of total revenue for the years ending December 31, 2017, 2016 and 2015 is as follows: 
 
Year Ended December 31,
 
2017
 
2016
 
2015
Devices and Systems
67
%
 
63
%
 
64
%
Supplies
26
%
 
28
%
 
29
%
Services
7
%
 
9
%
 
7
%
Total
100
%
 
100
%
 
100
%

9


In 2017, 2016 and 2015, no single end-user customer comprised more than 10% of our revenue.
Backlog
For the years ended December 31, 2017, 2016 and 2015, backlog was approximately as follows (in thousands): 
 
Year Ended December 31,
 
2017
 
2016
 
2015
Backlog
$
13,849

 
$
10,555

 
$
9,359

Marketing and Sales
Marketing
Our marketing strategy differentiates our products by their level of quality, performance, and customer benefit. We educate customers worldwide about our products through trade conferences and direct presentations to healthcare professionals.
Domestic Direct and Distributor Sales
We sell our products in North America primarily through a direct sales organization. We believe this direct sales organization allows us to maintain a higher level of customer service and satisfaction than would otherwise be possible by other distribution methods. We also sell certain products under private label and distribution arrangements.
For the years ended December 31, 2017, 2016 and 2015, domestic revenue as a percent of total revenue was approximately as follows: 
 
Year Ended December 31,
 
2017
 
2016
 
2015
Domestic revenue
54.1
%
 
65.6
%
 
64.4
%
International Direct and Distributor Sales
We sell some of our products outside the U.S. through direct sales channels in Australia, Canada, China, Denmark, France, Germany, Italy, the Netherlands, New Zealand, Nordics (Finland, Sweden, Norway) Spain, United Kingdom and parts of Latin America; we sell other products in those regions and into more than 100 other countries through a distributor sales channel.
For the years ended December 31, 2017, 2016 and 2015, international revenue as a percent of total revenue was approximately as follows: 
 
Year Ended December 31,
 
2017
 
2016
 
2015
International revenue
45.9
%
 
34.4
%
 
35.6
%
We sell products to our distributors under substantially the same terms as sales through our direct sales channels. Terms of sales to international distributors are generally “ex works,” where title and risk of loss are assumed by the distributor at the shipping point. Distributors are generally given exclusive rights in their territories to purchase products from Natus and to resell to end users or sub-distributors. Our distributors typically perform marketing, sales, and technical support functions in their respective markets. Each distributor may sell Natus products to their customer directly, via other distributors or resellers, or both. We actively train our distributors in product marketing, selling, and technical service techniques.
Seasonality in Revenue
We experience seasonality in our revenue. Demand for our products is historically higher in the second half of the year compared to the first. Our seasonality results from the purchasing habits of our hospital-based customers, whose purchases are often governed by calendar year budgets.
Group Purchasing Organizations
More than 90% of the hospitals in the U.S. are members of group purchasing organizations (“GPO”s), which negotiate volume purchase agreements for member hospitals, group practices, and other clinics.
For the years ended December 31, 2017, 2016 and 2015, direct purchases by GPO members as a percent of revenue were approximately as follows: 

10


 
Year Ended December 31,
 
2017
 
2016
 
2015
Direct purchases by GPO members
14.5
%
 
12.3
%
 
9.3
%
Third-Party Reimbursement
In the U.S., healthcare providers generally rely on third-party payors, including private health insurance plans, federal Medicare, state Medicaid, and managed care organizations, to reimburse all or part of the cost of the procedures they perform. Third-party payors can affect the pricing or the relative attractiveness of our products by regulating the maximum amount of reimbursement these payors provide for services utilizing our products. In addition, our Peloton hearing screening service and GND services are dependent on third-party payors to reimburse us for services provided.
Customer Service and Support
We generally provide a one-year warranty on our medical device products. We also sell extended service agreements on our medical device products. Service, repair, and calibration services for our domestic customers are provided by Company-owned service centers and our field service specialists. Service for international customers is provided by a combination of Company-owned facilities and vendors on a contract basis.
Manufacturing
Other companies manufacture a significant portion of the components used in our products; however, we perform final assembly, testing, and packaging of many of the devices ourselves to control quality and manufacturing efficiency. We also use contract vendors to manufacture some of our disposable supply and medical device products. We perform regular quality assessments of these vendors, which include on-site quality audits.
We purchase materials and components from qualified suppliers that are subject to our quality specifications and inspections. We conduct quality audits of our key suppliers, several of which are experienced in the supply of components to manufacturers of finished medical devices, or supplies for use with medical devices. Most of our purchased components are available from more than one supplier.
Our manufacturing, service, and repair facilities are subject to periodic inspection by local and foreign regulatory authorities. Our quality assurance system is subject to regulation by the U.S. Food and Drug Administration (“FDA”) and other government agencies. We are required to conduct our product design, testing, manufacturing, and control activities in conformance with the FDA’s quality system regulations and to maintain our documentation of these activities in a prescribed manner. In addition, our production facilities have received International Organization for Standardization (“ISO”) 13485 certification. ISO 13485 certification standards for quality operations have been developed to ensure that medical device companies meet the standards of quality on a worldwide basis. We have also received the EC Certificate pursuant to the European Union Medical Device Directive 93/42/EEC, which allows us to place a CE mark on our products.
Research and Development
We are committed to introducing new products and supporting current product offerings in our markets through a combination of internal as well as external efforts that are consistent with our corporate strategy.
Internal product development capabilities.    We believe that product development capabilities are essential to provide our customers with new product offerings. We plan to leverage our core technologies by introducing product line extensions as well as new product offerings.
Partnerships that complement our expertise.    We continue to seek strategic partners in order to develop products that may not otherwise be available to us. By taking advantage of our core competencies, we believe that we can bring products to market in an efficient manner and leverage our distribution channels.
New opportunities through technology acquisition.    We continue to evaluate new, emerging, and complementary technologies in order to identify new product opportunities. With our knowledge of our current markets we believe that we can effectively develop technologies into successful new products.
Our research and development expenses were $51.8 million or 10.3% of total revenue in 2017, $33.4 million or 8.8% of total revenue in 2016, and $30.4 million or 8.1% of total revenue in 2015.
Proprietary Rights
We protect our intellectual property through a combination of patent, copyright, trade secret, and trademark laws. We attempt to protect our intellectual property rights by filing patent applications for new features and products we develop. We enter into confidentiality or license agreements with our employees, consultants, and corporate partners, and seek to control access to our

11


intellectual property, distribution channels, documentation, and other proprietary information. However, we believe that these measures afford only limited protection.
The intellectual rights to some of the original patents for technology incorporated into our products are now in the public domain. However, we do not consider these patents, or any currently viable patent or related group of patents, to be of such importance that their expiration or termination would materially affect our business.
We capitalize the cost of purchased technology and intellectual property, as well as certain costs incurred in obtaining patent rights, and amortize these costs over the estimated economic lives of the related assets.
We have several registered trademarks and service marks. Our marks are pending or registered trademarks in the United States and several foreign countries. We intend to file for additional trademarks to strengthen our trademark rights, but we cannot be certain that our trademark applications will result in registration or that our trademarks will be enforceable.
Competition
We sell our products in competitive and rapidly evolving markets. We face competition from other companies in all of our product lines. Our competitors range from small privately-held companies to multinational corporations and their product offerings vary in scope and breadth. We do not believe that any single competitor is dominant in any of our product lines.
We derive a significant portion of our revenue from the sale of disposable supplies that are used with our medical devices. In the U.S., we sell our supply products in a mature market and we expect that our products could face increasing competition, including competitors offering lower prices, which could have an adverse effect on our revenue and profit margins.
Integra LifeSciences continues to offer products and services that compete with the neurosurgery product lines we acquired in the Integra Asset Acquisition, and we expect significant competition from Integra LifeSciences as we seek to maintain and expand this business.
We believe the principal factors that will draw clinicians and other buyers to our products, include:
Level of specificity, sensitivity, and reliability of the product;
Time required to obtain results with the product, such as to test for or treat a clinical condition;
Relative ease of use of the product;
Depth and breadth of the products features;
Quality of customer support for the product;
Frequency of product updates;
Extent of third-party reimbursement of the cost of the product or procedure;
Extent to which the products conform to standard of care guidelines; and
Price of the product.
We believe that our primary competitive strength relates to the functionality and reliability of our products. Different competitors may have competitive advantages in one or more of the categories listed above and they may be able to devote greater resources to the development, promotion, and sale of their products.
Government Regulation
FDA’s Premarket Clearance and Approval Requirements
Unless an exemption applies, the medical devices we sell in the United States, must first receive one of the following types of FDA premarket review authorizations under the Food, Drug, and Cosmetics Act, as amended:
Clearance via Section 510(k); or
Premarket approval via Section 515 if the FDA has determined that the medical device in question poses a greater risk of injury.
The FDA’s 510(k) clearance process usually takes from three to six months, but can take longer. The process of obtaining premarket approval via Section 515 is much more costly, lengthy, and uncertain. Premarket approval generally takes from one to three years, but can take longer. We cannot be sure that the FDA will ever grant either 510(k) clearance or premarket approval for any product we propose to market in the United States.
The FDA decides whether a device must undergo either the 510(k) clearance or premarket approval process based upon statutory criteria. These criteria include the level of risk that the FDA perceives to be associated with the device and a determination

12


of whether the product is a type of device that is substantially equivalent to devices that are already legally marketed. The FDA places devices deemed to pose relatively less risk in either Class I or Class II, which requires the manufacturer to submit a premarket notification requesting 510(k) clearance, unless an exemption applies. The premarket notification under Section 510(k) must demonstrate that the proposed device is substantially equivalent in intended use and in safety and effectiveness to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet called for the submission of premarket approval applications.
The FDA places devices deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed to be not substantially equivalent to a predicate device, in its Class III classification. The FDA requires these devices to undergo the premarket approval process via Section 515 in which the manufacturer must prove the safety and effectiveness of the device. A premarket approval application must provide extensive pre-clinical and clinical trial data.
The FDA may require results of clinical trials in support of a 510(k) submission and generally requires clinical trial results for a premarket approval application. In order to conduct a clinical trial on a significant-risk device, the FDA requires manufacturers to apply for and obtain, in advance, an investigational-device exemption. The investigational-device exemption application must be supported by appropriate data, such as animal and laboratory testing results. If the FDA and the Institutional Review Boards at the clinical trial sites approve the investigational-device exemption application for a significant-risk device, the manufacturer may begin the clinical trial. An investigational-device exemption approval provides for a specified clinical protocol, including the number of patients and study sites. If the manufacturer deems the product a non-significant risk device, the product will be eligible for more abbreviated investigational-device exemption requirements. If the Institutional Review Boards at the clinical trial sites concur with the non-significant risk determination, the manufacturer may begin the clinical trial.
Most of our products have been cleared by the FDA as Class II devices.
FDA Regulation
Numerous FDA regulatory requirements apply to our products. These requirements include:
FDA quality system regulations which require manufacturers to create, implement, and follow design, testing, control, documentation, and other quality assurance procedures;
Medical device reporting regulations, which require that manufacturers report to the FDA certain types of adverse and other events involving their products; and
FDA general prohibitions against promoting products for unapproved uses.
Class II and III devices may also be subject to special controls applied to them, such as performance standards, post-market surveillance, patient registries, and FDA guidelines that may not apply to Class I devices. We believe we are in compliance with applicable FDA guidelines, but we could be required to change our compliance activities or be subject to other special controls if the FDA changes existing regulations or adopts new requirements.
We are subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements. If the FDA finds that we have failed to adequately comply, the FDA can institute a wide variety of enforcement actions, including:
Issuance of a Form 483 citation;
Fines, injunctions, and civil penalties;
Recall or seizure of our products;
Issuance of public notices or warnings;
Imposition of operating restrictions, partial suspension, or total shutdown of production;
Refusal of our requests for 510(k) clearance or pre-market approval of new products;
Withdrawal of 510(k) clearance or pre-market approval already granted; or
Criminal prosecution.
The FDA also has the authority to require us to repair or replace any misbranded or adulterated medical device manufactured or distributed by us.
Other Regulations
We also must comply with numerous additional federal, state, and local laws relating to matters such as safe working conditions, manufacturing practices, environmental protection, biohazards, fire hazard control, and hazardous substance disposal. We believe we are currently in compliance with such regulations.

13


Countries outside of the U.S. regulate medical devices in a manner similar to that of the FDA. Our manufacturing facilities are subject to audit and have been certified to be ISO 13485:2003, Medical Device Directive 93/42/EEC, and CMDCAS compliant, which allows us to sell our products in Canada, Europe, and other territories around the world. All of our manufacturing facilities are subject to inspection by our notified bodies or other competent authorities, and in some cases without advance notice. We plan to seek approval to sell our products in additional countries, while maintaining our current approvals. The time and cost of obtaining new, and maintaining existing, market authorizations from countries outside of North America, and the requirements for licensing products in these countries may differ significantly from FDA requirements.
Employees
On December 31, 2017, we had approximately 1,726 full time employees worldwide. In Argentina, some of our production employees are represented by labor unions and our employees in Germany have established a works council. We have not experienced any work stoppages, and we consider our relations with our employees to be good.
Executives
The following table lists our executive officers and their ages as of March 1, 2018: 
Name
 
Age
 
Position(s)
James B. Hawkins
 
62

 
President and Chief Executive Officer
Jonathan Kennedy
 
47

 
Executive Vice President and Chief Financial Officer
D. Christopher Chung, M.D.

 
54

 
Vice President Medical Affairs, Quality & Regulatory

Carsten Buhl
 
44

 
President & CEO, Otometrics SBU
Leslie McDonnell
 
45

 
Vice President and General Manager, Newborn Care
Austin F. Noll, III

 
54

 
Vice President and General Manager, Neurology SBU

James B. Hawkins has served as Chief Executive Officer, and as a member of the Board of Directors, since joining Natus in April 2004, and as President from April 2004 through January 2011 and from June 2013 to present. In addition, he currently serves on the Board of Directors for Eldorado Resorts, Inc. and OSI Systems.  Prior to joining Natus, Mr. Hawkins was President, Chief Executive Officer and a Director of Invivo Corporation, a developer and manufacturer of multi-parameter vital sign monitoring equipment, and its predecessor, from August 1985 through January 2004. Mr. Hawkins also served as Secretary of Invivo from July 1986 until January 2004. He earned his undergraduate degree in Business Commerce from Santa Clara University and holds a Masters of Business Administration degree from San Francisco State University.
Jonathan A. Kennedy joined Natus as Senior Vice President and Chief Financial Officer in April 2013 and was appointed Executive Vice President and Chief Financial Officer in September 2016. In addition, he currently serves on the Board of Directors for IRadimed Corporation. Before joining Natus, Mr. Kennedy was Senior Vice President and Chief Financial Officer of Intersil Corporation, a global semiconductor manufacturer, since 2009. Prior to that, he was Intersil’s Corporate Controller since 2005 and Director of Finance since 2004. Before joining Intersil, Mr. Kennedy held management roles in Finance and Information Technology with Alcon Inc. and Harris Corporation. He holds a Bachelor of Science degree in Business Administration and a Master of Science degree in Accounting from the University of Central Florida. Mr. Kennedy is also a Certified Public Accountant.
D. Christopher Chung, M.D., has served as our Vice President Medical Affairs, Quality and Regulatory since June 2003, and has served as our Vice President Medical Affairs since February 2003. Dr. Chung also served as our Medical Director from October 2000 to February 2003. From 2000 to 2007, Dr. Chung also served as a Pediatric Hospitalist at the California Pacific Medical Center in San Francisco. From 1997 to 2000, Dr. Chung trained as a pediatric resident at Boston Children’s Hospital and Harvard Medical School. From 1986 to 1993, Dr. Chung worked as an Engineer at Nellcor, a medical device company. Dr. Chung holds a Bachelor of Arts degree in Computer Mathematics from the University of Pennsylvania and a Doctor of Medicine degree from the Medical College of Pennsylvania-Hahnemann University School of Medicine. He is board certified in Pediatrics and is a Fellow of the American Academy of Pediatrics.
Carsten Buhl joined Natus in February 2018 and is acting as President for Natus' strategic business unit Otometrics. Mr. Buhl has more than 15 years experience in the medical device industry and has a proven track record within commercial execution and global leadership positions. Prior to joining natus, Mr. Buhl acted as Executive Vice President and Chief Commercial Officer at Ambu, a successful medtech company within the fields of anesthesia, patient monitoring and emergency care. Previously, Mr. Buhl held various management positions at GN Hearing, which is one of the world's largest providers of hearing instruments, most recently as Senior Vice President of Europe and Strategic Accounts. Mr. Buhl holds a Master of Law from Copenhagen University and an E*MBA from SIMI/CBS Copenhagen supplemented by graduate diplomas in Finance and Accounting from CBS Copenhagen.

14


Leslie McDonnell joined Natus in February 2018 as the Vice President and General Manger, Newborn Care. Ms. McDonnell is a healthcare business executive with 17 years of global experience in medical devices and supplies. Prior to joining Natus, Ms. McDonnell served as Global Business Vice-President for the Critical & Chronic Care Solutions of 3M Healthcare. Prior to joining 3M Healthcare, Ms. McDonnell held leadership positions at Medtronic over a 12 year period in corporate M&A, business development, new therapy and product development, and marketing and business management in the Neuromodulation and Cardiac Rhythm Disease Management business. Ms. McDonnell holds a Bachelor of Science in Business and Masters of Busines Administration as an International Business Fellow from the Carlson School of Management at the University of Minnesota. In 2009, Ms. Donnell was selected as a 40 Under Forty honoree for business and community leadership by the Minneapolis/St. Paul Business Journal.
Austin F. Noll, III joined Natus in August 2012 as the Vice President and General Manager, Neurology. Prior to joining Natus, Mr. Noll served as the President and CEO of Simpirica Spine, a California-based start-up company that developed and commercialized a novel device for spinal stabilization. Prior to joining Simpirica Spine, Mr. Noll served as the President and CEO of NeoGuide Systems, a medical robotics company acquired by Intuitive Surgical. Prior to joining NeoGuide Systems, Mr. Noll held numerous management positions at Medtronic over a 13-year period, where he served as the Vice President and General Manager of the Powered Surgical Solutions and the Neurosurgery businesses. Before Medtronic, he held sales positions at C.R. Bard and Baxter Healthcare. He received a bachelor’s degree in business administration from Miami University and a master’s of business administration from the University of Michigan.
Other Information
Natus was incorporated in California in May 1987 and reincorporated in Delaware in August 2000.
We maintain corporate offices at 6701 Koll Center Parkway Suite 120, Pleasanton, California 94566. Our telephone number is (925) 223-6700. We maintain a corporate website at www.natus.com. References to our website address do not constitute incorporation by reference of the information contained on the website, and the information contained on the website is not part of this document.
We make available, free of charge on our corporate website, copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements, and all amendments to these reports, as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission pursuant to Section 13(a) or 15(d) of the Securities Exchange Act. We also show detail about stock trading by corporate insiders by providing access to SEC Forms 3, 4 and 5. This information may also be obtained from the SEC’s on-line database, which is located at www.sec.gov. Our common stock is traded on the Nasdaq Stock Market under the symbol “BABY”.

Item 1A.    Risk Factors
We have completed a number of acquisitions and expect to complete additional acquisitions in the future. There are numerous risks associated with acquisitions and we may not achieve the expected benefit of any of our acquisitions
Our acquisitions of products, technology assets, or businesses may have a negative impact on our business if we fail to achieve the anticipated financial, strategic, and other benefits of acquisitions or investments, and our operating results may suffer because of this.
We expect to continue to pursue opportunities to acquire other businesses in the future. The acquisitions that we have completed may not result in improved operating results for us, or in our achieving a financial condition superior to that which we would have achieved had we not completed them. Our results of operations may be adversely impacted by costs associated with our acquisitions, including one-time charges associated with restructurings. Further, our acquisitions could fail to produce the benefits that we anticipate, or could have other adverse effects that we currently do not foresee. In addition, some of the assumptions that we have relied upon, such as achievement of operating synergies, may not be realized. In this event, one or more of the acquisitions could result in reduced earnings as compared to the earnings that would have been achieved by us if the acquisition had not occurred.
Previously we have assumed, and may in the future enter into, contingent obligations associated with earnout provisions in some of our acquisitions. We believe these provisions help us to negotiate mutually agreeable purchase terms between us and the sellers. However, a disagreement between us and a seller about the terms of an earnout provision could result in our paying more for an acquisition than we intended.
If we are required to seek additional external financing to support our need for cash to fund future acquisitions, we may not have access to financing on terms that are acceptable to us, or at all. Alternatively, we may feel compelled to access additional financing on terms that are dilutive to existing holders of our common stock or that include covenants that restrict our business, or both.

15


In January 2017 we completed the acquisition of GN Otometrics, which is our largest acquisition to date in terms of purchase price and size of business acquired. Accordingly, the risks described above are potentially more material to us than would have otherwise been the case.
If we do not remediate a material weakness in our internal control over financial reporting, the accuracy and timeliness of our financial reporting may be adversely affected
Under Section 404 of the Sarbanes-Oxley Act of 2002 and rules promulgated by the SEC, companies are required to conduct an annual comprehensive evaluation of their internal control over financial reporting. As part of this internal control over financial reporting; and our independent registered public accounting firm is required to attest to and report on the effectiveness of our internal control over financial reporting. Management’s assessment of our internal control over financial reporting as of December 31, 2017, identified a control was not effective because we did not perform an effective risk assessment relating to significant acquisitions, and as a result, we did not adequately design control activities over the accounting for the acquisition of Otometrics. The first fiscal year exemption for internal controls over financial reporting does not apply to controls over purchase price accounting, which constituted a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. This material weakness is more fully described in Item 9A. Controls and Procedures-Management’s Report on Internal Control Over Financial Reporting. The existence of this material weakness and of any other ineffective controls over our financial reporting could result in one or all of the following:
Revision of previously filed financial statements;
Failure to meet our reporting obligations;
Loss of investor confidence; and
Negative impact on the trading price of our common stock.
Adverse economic conditions in markets in which we operate may harm our business
Unfavorable changes in U.S. and international economic environments may adversely affect our business and financial results. During challenging economic times, and in tight credit markets, our customers may delay or reduce capital expenditures. This could result in reductions in sales of our products, longer sales cycles, difficulties in collection of accounts receivable, slower adoption of new technologies, and increased price competition, all of which could impact our results of operations and financial condition. In addition, we expect these factors will cause us to be more cautious in evaluating potential acquisition opportunities, which could hinder our ability to grow through acquisition while these conditions persist. In 2016 voters in the United Kingdom approved "Brexit," calling for the United Kingdom to withdraw from the European Union and there is speculation that this exit could have adverse consequences for the economies of the United Kingdom and other European countries. We have a significant amount of sales in the European Union and this business could be adversely affected by these developments.
In October 2015, we announced a contract between our Argentinian subsidiary, Medix I.C.S.A, and the Ministry of Health of Venezuela under which our subsidiary would deliver products and services, including third party products, over a three year period pursuant to prepayments received from the Venezuelan Ministry of Health. Following the announcement of this contract, there have been elections in both Venezuela and Argentina leading to significant political changes in those countries. Further, Venezuela is experiencing a highly inflationary economy and recessionary economic conditions. These developments may impact the likelihood of the Venezuelan Ministry of Health’s following through with orders under the agreement. While Medix has received the first installment under this contract, the remainder of the contract will not be fulfilled until the outstanding consideration is received. If, for these or any other reasons, the Venezuelan Ministry of Health does not make the additional prepayments required to initiate deliveries under the Medix agreement, we will not receive any additional benefit from it.
Our operating results may suffer because of our exposure to foreign currency exchange rate fluctuations
Substantially all of our sales contracts with our U.S. based customers provide for payment in U.S. dollars. With the exception of our Canadian operations, substantially all of the revenue and expenses of our foreign subsidiaries are denominated in the applicable foreign currency. Our exposure to the currency fluctuations is enhanced as a result of the Otometrics acquisition. To date we have executed only limited foreign currency contracts to hedge these currency risks. Our future revenue and expenses may be subject to volatility due to exchange rate fluctuations that could result in foreign exchange gains and losses associated with foreign currency transactions and the translation of assets and liabilities denominated in foreign currencies.
Substantially all our sales from our U.S. operations to our international distributors provide for payment in U.S. dollars. A strengthening of the U.S. dollar relative to other foreign currencies could increase the effective cost of our products to our

16


international distributors as their functional currency is typically not the U.S. dollar. This could have a potential adverse effect on our ability to increase or maintain average selling prices of our products to our foreign-based customers.
Healthcare reforms, changes in healthcare policies, and changes to third-party reimbursements for our products may affect demand for our products
In March 2010 the U. S. government signed into law the Patient Protection and Affordable Care Act and the Health Care & Education Reconciliation Act (collectively, the “ACA”). The ACA contains many provisions designed to generate the revenues necessary to fund the coverage expansions and to reduce costs of Medicare and Medicaid, including imposing a 2.3% excise tax on domestic sales of many medical devices by manufacturers and importers. The Medical Device Excise Tax (“MDET”) went into effect on January 1, 2013 but was suspended for the period January 1, 2016 to December 31, 2017 with the signing of The Consolidated Appropriations Act, 2016 (Pub.L. 114-113).
No action by Congress was taken before the moratorium was set to expire on December 31, 2017. Therefore, MDET was reinstated on January 1, 2018. On January 22, 2018 the U.S. government signed funding bill HR 195 to extend an additional two-year moratorium on the MDET. The moratorium was retroactive to January 1, 2018. Unless there is legislative action prior to 2020, the MDET will automatically reinstate in 2020.
Uncertainty surrounding the ACA and the U.S. healthcare system may impact the way our customers spend on medical devices, supplies, and services in the future. If we fail to effectively react to the implementation of healthcare reform, our business may be adversely affect.
We have initiated changes to our information systems that could disrupt our business and our financial results
We plan to continuously improve our information systems to support the form, functionality, and scale of our business. These types of transitions frequently prove disruptive to the underlying business of an enterprise and may cause us to incur higher costs than we anticipate. Failure to manage a smooth transition to the new systems and the ongoing operations and support of the new systems could materially harm our business operations.
For example, beginning in 2012 we implemented the rollout of a world-wide, single-platform enterprise resource planning (“ERP”) application including customer relationship management, product lifecycle management, demand management, consolidation and financial statement generation, and business intelligence, and in 2015 we completed the final implementation of the ERP. In 2017 we completed a portion of the implementation of the ERP application for our Otometrics operations. We may fail to gain the efficiencies the implementation is designed to produce within the anticipated timeframe. We will continue to incur additional costs associated with stabilization and ongoing development of the new platform. The ongoing development and stabilization could also be disruptive to our operations, including the ability to timely ship and track product orders to customers, project inventory requirements, manage our supply chain and otherwise adequately service our customers. As we integrate the Otometrics operations and implement the ERP to cover its operations, we will incur costs and face challenges that could disrupt our operations.
Future changes in technology or market conditions could result in adjustments to our recorded asset balance for intangible assets, including goodwill, resulting in additional charges that could significantly impact our operating results
Our balance sheet includes significant intangible assets, including goodwill and other acquired intangible assets. The determination of related estimated useful lives and whether these assets are impaired involves significant judgment. Our ability to accurately predict future cash flows related to these intangible assets might be hindered by events over which we have no control. Due to the highly competitive nature of the medical device industry, new technologies could impair the value of our intangible assets if they create market conditions that adversely affect the competitiveness of our products. Further, declines in our market capitalization may be an indicator that our intangible assets or goodwill carrying values exceed their fair values which could lead to potential impairment charges that could impact our operating results. In the past we have recorded charges for goodwill impairment and impairments of our trade names.
We may not be able to preserve the value of our intellectual property because we may not be able to protect access to it or we may lose our intellectual property rights due to expiration of our licenses or patents
If we fail to protect our intellectual property rights or if our intellectual property rights do not adequately cover the technology we employ, other medical device companies could sell products with features similar to ours, and this could reduce demand for our products. We protect our intellectual property through a combination of patent, copyright, trade secret and trademark laws. Despite our efforts to protect our proprietary rights, others may attempt to copy or otherwise improperly obtain and use our products or technology. Policing unauthorized use of our technology is difficult and expensive, and we cannot be certain that the steps we have taken will prevent misappropriation. Our means of protecting our proprietary rights may be inadequate. Enforcing our intellectual property rights could be costly and time consuming and may divert our management’s attention and resources. Failing to enforce our intellectual property rights could also result in the loss of those rights.

17


If we are not able to maintain effective internal control over financial reporting in the future, the accuracy and timeliness of our financial reporting may be adversely affected.
The Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our internal control over financial reporting annually and disclosure controls and procedures quarterly. In particular, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on, and our independent registered public accounting firm to attest to, the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. If we are not able to maintain effective internal control over financial reporting and otherwise comply with the requirements of Section 404 in a timely manner, our reported financial results could be materially misstated or could be restated, we could receive an adverse opinion regarding our controls from our accounting firm and we could be subject to investigations or sanctions by regulatory authorities, which would require additional financial and management resources, and the market price of our stock could decline.
If health care providers are not adequately reimbursed for procedures conducted with our devices or supplies, or if reimbursement policies change adversely, we may not be successful marketing and selling our products or technologies
Clinicians, hospitals, and government agencies are unlikely to purchase our products if they are not adequately reimbursed for the procedures conducted with our devices or supplies. Unless a sufficient amount of conclusive, peer-reviewed clinical data about our products has been published, third-party payors, including insurance companies and government agencies, may refuse to provide reimbursement. Furthermore, even if reimbursement is provided, it may not be adequate to fully compensate the clinicians or hospitals. Some third-party payors may impose restrictions on the procedures for which they will provide reimbursement. If health care providers cannot obtain sufficient reimbursement from third-party payors for our products or the screenings conducted with our products, we may not achieve significant market acceptance of our products. Acceptance of our products in international markets will depend upon the availability of adequate reimbursement or funding within prevailing healthcare payment systems. Reimbursement, funding, and healthcare payment systems vary significantly by country. We may not obtain approvals for reimbursement in a timely manner or at all.
Adverse changes in reimbursement policies in general could harm our business. We are unable to predict changes in the reimbursement methods used by third-party health care payors, particularly those in countries and regions outside the U.S. For example, some payors are moving toward a managed care system in which providers contract to provide comprehensive health care for a fixed cost per person. In a managed care system, the cost of our products may not be incorporated into the overall payment for patient care or there may not be adequate reimbursement for our products separate from reimbursement for other procedures.
Our Peloton hearing screening service and our GND EEG service are dependent on third-party payors to reimburse us for services provided to patients. We have encountered challenges in obtaining reimbursement from third parties and are dedicating resources to the education of third-party payors to the benefits of these services. Our inability to obtain reimbursement for these services, and any adverse changes in reimbursement policies or amounts for either of these services, or other products or services that we provide, could harm our business.
Our business would be harmed if the FDA determines that we have failed to comply with applicable regulations governing the manufacture of our products and/or we do not pass an inspection
We and our suppliers are required to demonstrate and maintain compliance with the FDA’s Quality System Regulation. The Quality System Regulation sets forth the FDA’s requirements for good manufacturing practices of medical devices and includes requirements for, among other things, the design, testing, production processes, controls, quality assurance, labeling, packaging, storage and shipping of such products. In addition, we and our suppliers must engage in extensive recordkeeping and reporting and must make available our manufacturing facility and records for periodic unscheduled inspections by federal, state and foreign agencies, including the FDA. We cannot assure you that we and our suppliers are or will continue to be in full compliance with the Quality System Regulation, and that we will not encounter any manufacturing difficulties.
In 2014 and 2016 we received formal communications from the FDA regarding deficiencies in our manufacturing processes in our Seattle facility. As a result, we imposed ship-holds on certain of our products produced there and have discontinued certain other products produced in that facility. We are dedicating substantial resources to the resolution of the conditions identified by the FDA. These actions had an adverse effect on our results of operations in 2016 and 2017.
Our inability to address issues that have been raised by the FDA, or failure of us or our third party suppliers and manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including, among other things, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, seizures or recalls of products and manufacturing restrictions, any of which could harm our business.
If we fail in our efforts to educate clinicians, government agency personnel, and third-party payors about the effectiveness of our products, we may not achieve future sales growth

18


It is critical to the success of our sales efforts that we educate a sufficient number of clinicians, hospital administrators, and government agencies about our products and the costs and benefits of their use. The commercial success of our products depends upon clinician, government agency, and other third-party payer confidence in the economic and clinical benefits of our products as well as their comfort with the efficacy, reliability, sensitivity and specificity of our products. We believe that clinicians will not use our products unless they determine, based on published peer-reviewed journal articles and experience, that our products provide an accurate and cost-effective alternative to other means of testing or treatment. Our customers may choose to use competitive products, which may be less expensive or may provide faster results than our devices. Clinicians are traditionally slow to adopt new products, testing practices and clinical treatments, partly because of perceived liability risks and the uncertainty of third-party reimbursement. If clinicians, government agencies and hospital administrators do not adopt our products, we may not maintain profitability. Factors that may adversely affect the medical community’s acceptance of our products include:
Publication of clinical study results that demonstrate a lack of efficacy or cost-effectiveness of our products;
Changing governmental and physician group guidelines;
Actual or perceived performance, quality, price, and total cost of ownership deficiencies of our products relative to other competitive products;
Our ability to maintain and enhance our existing relationships and to form new relationships with leading physicians, physician organizations, hospitals, state laboratory personnel, and third-party payers;
Changes in federal, state and third-party payer reimbursement policies for our products; and
Repeal of laws requiring universal newborn hearing screening and metabolic screening.
Sales through group purchasing organizations and sales to high volume purchasers may reduce our average selling prices, which could reduce our operating margins
We have entered, and expect in the future to enter into agreements with customers who purchase a high volume of our products. Our agreements with these customers may contain discounts from our normal selling prices and other special pricing considerations, which could cause our operating margins to decline. In addition, we have entered into agreements to sell our products to members of GPOs, which negotiate volume purchase prices for medical devices and supplies for member hospitals, group practices and other clinics. While we make sales directly to GPO members, the GPO members receive volume discounts from our normal selling price and may receive other special pricing considerations from us. Sales to members of all GPOs accounted for approximately 14.5%, 12.3% and 9.3% of our total revenue during 2017, 2016 and 2015, respectively. Certain other existing customers may be members of GPOs with which we do not have agreements. Our sales efforts through GPOs may conflict with our direct sales efforts to our existing customers. If we enter into agreements with new GPOs and some of our existing customers begin purchasing our products through those GPOs, our operating margins could decline.
Consolidation in the healthcare industry could have an adverse effect on our revenues and results of operations
Many healthcare industry companies, include our customers and competitors, are consolidating to create new companies with greater market power. As the healthcare industry consolidates, competition to provide goods and services to our customers could become more intense. Our customers may try to use their market power to negotiate price concessions and our competitors may utilize their size and broad product lines to offer cheaper alternatives to our products. If we are forced to reduce our prices because of consolidation in the healthcare industry, our revenues would decrease and our consolidated earnings, financial condition, or cash flow would suffer.
Demand for some of our products depends on the capital spending policies of our customers, and changes in these policies could harm our business
A majority of customers for our products are hospitals, physician offices, and clinics. Many factors, including public policy spending provisions, available resources, and economic cycles have a significant effect on the capital spending policies of these entities and therefore the amount that they can spend on our equipment products. If budget resources limit the capital spending of our customers, they will be unlikely to either purchase any new equipment from us or upgrade to any of our newer equipment products. Lack of liquidity in credit markets and uncertainty about future economic conditions can have an adverse effect on the spending patterns of our customers. These factors can have a significant adverse effect on the demand for our products.
Our markets are very competitive and in the United States we sell certain of our products in a mature market
We face competition from other companies in all of our product lines. Our competitors range from small privately held companies to multinational corporations and their product offerings vary in scope and breadth. We do not believe that any single competitor is dominant in any of our product lines.
The markets for certain of our products in the U.S., including the newborn hearing screening and EEG monitoring markets, are mature and we are unlikely to see significant growth for such products in the U.S. The market for newborn care products is

19


affected by birthrates, and a declining U.S. birthrate has adversely affected our operating results in recent periods. In the U.S. we derive a significant portion of our revenue from the sale of disposable supplies that are used with our hearing screening devices. Our hearing disposable supply products could face increasing competition, including competitors offering lower prices, which could have an adverse effect on our revenue and margins.
Our competitors may have certain competitive advantages, which include the ability to devote greater resources to the development, promotion, and sale of their products. Consequently, we may need to increase our efforts, and related expenses for research and development, marketing, and selling to maintain or improve our position.
We expect recurring sales to our existing customers to generate a majority of our revenue in the future, and if our existing customers do not continue to purchase products from us, our revenue may decline.
In October 2017 we completed the acquisition of our neurosurgery business from Integra LifeSciences. We are relying on Integra LifeSciences for certain transition services to support the acquired business and at the same time we are competing with them in the sale of neurosurgery products. Integra LifeSciences may face conflicting interests in performing required services for us and this may results in adverse effects on the acquire business.
Our operating results may decline if we do not succeed in developing, acquiring, and marketing additional products or improving our existing products
We intend to develop additional products and technologies, including enhancements of existing products, for the screening, detection, treatment, monitoring and tracking of common medical ailments. Developing new products and improving our existing products to meet the needs of current and future customers requires significant investments in research and development. If we fail to successfully sell new products, update our existing products, or timely react to changes in technology, our operating results may decline as our existing products reach the end of their commercial life cycles.
Our growth in recent years has depended substantially on the completion of acquisitions and we may not be able to complete acquisitions of this nature or of a relative size in the future to support a similar level of growth
The acquisitions that we have completed have contributed to our growth in recent years. We expend considerable effort in seeking to identify attractive acquisition candidates and ultimately, to negotiate mutually agreeable acquisition terms. If we are not successful in these efforts in the future, our growth rate will not increase at a rate corresponding to that which we have achieved in recent years. Further, as we grow larger it will be necessary to complete the acquisition of larger companies and product lines to support a growth similar to that which we have achieved in the past. The market for attractive acquisitions is competitive and others with greater financial resources than we have may be better positioned than we are to acquire desirable targets. Further, we may not be able to negotiate acquisition terms with target companies that will allow us to achieve positive financial returns from the transaction.
We have substantial international operations which are subject to numerous risks; if our international operations are not successful, our business will be adversely affected
In 2017, approximately 45.9% of our sales were made outside the U.S. We plan to expand our international sales and marketing efforts to increase sales of our products in foreign countries. We may not realize corresponding growth in revenue from growth in international unit sales, due to the lower average selling prices we receive on sales outside of the U.S. Even if we are able to successfully expand our international selling efforts, we cannot be certain that we will be able to create or increase demand for our products outside of the U.S. Our international operations are subject to other risks, which include:
Impact of possible recessions in economies outside the U.S.;
Political and economic instability, including instability related to war and terrorist attacks and to political and diplomatic matters such as the BREXIT of the United Kingdom from the European Union;
Contractual provisions governed by foreign law, such as local law rights to sales commissions by terminated distributors;
Decreased healthcare spending by foreign governments that would reduce international demand for our products;
Strengthening of the U.S. dollar relative to foreign currencies that could make our products less competitive because approximately half of our international sales are denominated in U.S. dollars;
Greater difficulty in accounts receivable collection and longer collection periods;
Difficulties of staffing and managing foreign operations;
Reduced protection for intellectual property rights in some countries and potentially conflicting intellectual property rights of third parties under the laws of various foreign jurisdictions;
Difficulty in obtaining and maintaining foreign regulatory approval;

20


Attitudes by clinicians, and cost reimbursement policies, towards use of disposable supplies that are potentially unfavorable to our business;
Complying with U.S. regulations that apply to international operations, including trade laws, the U.S. Foreign Corrupt Practices Act, and anti-boycott laws, as well as international laws such as the U.K. Bribery Act;
Loss of business through government tenders that are held annually in many cases; and
Potentially negative consequences from changes in tax laws, including legislative changes concerning taxation of income earned outside of the U.S.
In particular, our international sales could be adversely affected by a strengthening of the U.S. dollar relative to other foreign currencies, which makes our products more costly to international customers for sales denominated in U.S. dollars.
U.S Tax Reform
The Tax Cuts and Jobs Act was signed into law in December 2017. The new law made numerous changes to federal corporate tax law that we expect will impact our effective tax rate in future periods. The changes included in the Tax Act are broad and complex. The final transition impacts of the Tax Act may differ from our current estimates, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the Company has utilized to calculate the transition impacts.
If guidelines mandating universal newborn hearing screening do not continue to develop in foreign countries and governments do not mandate testing of all newborns as we anticipate, or if those guidelines have a long phase-in period, our sales of newborn hearing screening products may not achieve the revenue growth we have achieved in the past
We estimate that approximately 95% of the children born in the U.S. are currently being tested for hearing impairment prior to discharge from the hospital. To date, there has been only limited adoption of newborn hearing screening prior to hospital discharge by foreign governments, and when newborn hearing screening programs are enacted by foreign governments there can be a phase-in period spanning several years. The widespread adoption of guidelines depends, in part, on our ability to educate foreign government agencies, neonatologists, pediatricians, third-party payors, and hospital administrators about the benefits of universal newborn hearing screening as well as the use of our products to perform the screening and monitoring. Our revenue from our newborn hearing screening product lines may not grow if foreign governments do not require universal newborn hearing screening prior to hospital discharge, if physicians or hospitals are slow to comply with those guidelines, or if governments provide for a lengthy phase-in period for compliance.
Because we rely on distributors or sub-distributors to sell our products in most of our markets outside of the U.S., our revenue could decline if our existing distributors reduce the volume of purchases from us, or if our relationship with any of these distributors is terminated
We currently rely on our distributors or sub-distributors for a majority of our sales outside the U.S. Some distributors also assist us with regulatory approvals and education of clinicians and government agencies. Our contracts with our distributors or sub-distributors do not assure us significant minimum purchase volume. If a contract with a distributor or sub-distributor is terminated for cause or by us for convenience, the distributor or sub-distributor will have no obligation to purchase products from us. We intend to continue our efforts to increase our sales in Europe, Japan, and other developed countries. If we fail to sell our products through our international distributors, we would experience a decline in revenue unless we begin to sell our products directly in those markets. We cannot be certain that we will be able to attract new international distributors to market our products effectively or provide timely and cost-effective customer support and service. Even if we are successful in selling our products through new distributors, the rate of growth of our revenue could be harmed if our existing distributors do not continue to sell a large dollar volume of our products. None of our existing distributors are obligated to continue selling our products.
We may be subject to foreign laws governing our relationships with our international distributors. These laws may require us to make payments to our distributors if we terminate our relationship for any reason, including for cause. Some countries require termination payments under local law or legislation that may supersede our contractual relationship with the distributor. Any required payments would adversely affect our operating results.
If we lose our relationship with any supplier of key product components or our relationship with a supplier deteriorates or key components are not available in sufficient quantities, our manufacturing could be delayed and our business could suffer
We contract with third parties for the supply of some of the components used in our products and the production of our disposable products. Some of our suppliers are not obligated to continue to supply us. We have relatively few sources of supply for some of the components used in our products and in some cases we rely entirely on sole-source suppliers. In addition, the lead-time involved in the manufacturing of some of these components can be lengthy and unpredictable. If our suppliers become

21


unwilling or unable to supply us with components meeting our requirements, it might be difficult to establish additional or replacement suppliers in a timely manner, or at all. This would cause our product sales to be disrupted and our revenue and operating results to suffer.
Replacement or alternative sources might not be readily obtainable due to regulatory requirements and other factors applicable to our manufacturing operations. Incorporation of components from a new supplier into our products may require a new or supplemental filing with applicable regulatory authorities and clearance or approval of the filing before we could resume product sales. This process may take a substantial period of time, and we may not be able to obtain the necessary regulatory clearance or approval. This could create supply disruptions that would harm our product sales and operating results.
We depend upon key employees in a competitive market for skilled personnel, and, without additional employees, we cannot grow or maintain profitability
Our products and technologies are complex, and we depend substantially on the continued service of our senior management team. The loss of any of our key employees could adversely affect our business and slow our product development process. Our future success also will depend, in part, on the continued service of our key management personnel, software engineers, and other research and development employees, and our ability to identify, hire, and retain additional personnel, including customer service, marketing, and sales staff. Demand for these skilled employees in our industry is very competitive due to the limited number of people available with the necessary technical skills and understanding of our product technologies. We may be unable to attract and retain personnel necessary for the development of our business.
Our ability to market and sell products depends upon receipt of domestic and foreign regulatory approval of our products and manufacturing operations. Our failure to obtain or maintain regulatory approvals and compliance could negatively affect our business
Our products and manufacturing operations are subject to extensive regulation in the United States by the FDA and by similar regulatory agencies in other countries. Our products are classified as medical devices. Medical devices are subject to extensive regulation by the FDA pursuant to regulations that are wide ranging and govern, among other things: design and development; manufacturing and testing; labeling; storage and record keeping; advertising, promotion, marketing, sales distribution and export; and surveillance and reporting of deaths or serious injuries.
Unless an exemption applies, each medical device that we propose to market in the U.S. must first receive one of the following types of FDA premarket review authorizations:
Clearance via Section 510(k) of the Food, Drug, and Cosmetics Act of 1938, as amended; or
Premarket approval via Section 515 of the Food, Drug, and Cosmetics Act if the FDA has determined that the medical device in question poses a greater risk of injury.
The FDA will clear marketing of a medical device through the 510(k) process if it is demonstrated that the new product is substantially equivalent to other 510(k)-cleared products. The premarket approval application process is much more costly, lengthy and uncertain than the 510(k) process, and must be supported by extensive data from preclinical studies and human clinical trials. The FDA may not grant either 510(k) clearance or premarket approval for any product we propose to market. Further, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a premarket approval application. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer’s decision. If the FDA requires us to seek 510(k) clearance or premarket approval for modification of a previously cleared product for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. Further, our products could be subject to recall if the FDA determines, for any reason, that our products are not safe or effective.
Delays in receipt of, or failure to receive, clearances or approvals, the loss of previously received clearances or approvals, or the failure to comply with existing or future regulatory requirements could adversely impact our operating results. If the FDA finds that we have failed to comply with these requirements, the FDA can institute a wide variety of enforcement actions, ranging from a public warning letter to more severe sanctions such as:
Fines, injunctions and civil penalties;
Recall or seizure of our products;
Issuance of public notices or warnings;
Imposition of operating restrictions, partial suspension, or total shutdown of production;
Refusal of our requests for Section 510(k) clearance or premarket approval of new products;

22


Withdrawal of Section 510(k) clearance or premarket approvals already granted;
Criminal prosecution; or
Domestic regulation of our products and manufacturing operations, other than that which is administered by the FDA, includes the Environmental Protection Act, the Occupational Safety and Health Act, and state and local counterparts to these Acts.
Our business may suffer if we are required to revise our labeling or promotional materials, or if the FDA takes an enforcement action against us for off-label uses
We are prohibited by the FDA from promoting or advertising our medical device products for uses not within the scope of our clearances or approvals, or from making unsupported promotional claims about the benefits of our products. If the FDA determines that our claims are outside the scope of our clearances, or are unsupported, it could require us to revise our promotional claims or take enforcement action against us. If we were subject to such an action by the FDA, our sales could be delayed, our revenue could decline, and our reputation among clinicians could be harmed. Likewise, if we acquire new products, either through the purchase of products, technology assets, or businesses, that are subsequently deemed to have inadequate supporting data, we may be required to (i) obtain adequate data, which could be costly and impede our ability to market these products, or (ii) modify the labeling on these products, which could impair their marketability, as described above.
If we deliver products with defects, we may incur costs to repair and, possibly, recall that product and market acceptance of our products may decrease.
The manufacturing and marketing of our products involve an inherent risk of our delivering a defective product or products that do not otherwise perform as we expect. We may incur substantial expense to repair any such products and may determine to recall such a product, even if not required to do so under applicable regulations. Any such recall would be time consuming and expensive. Product defects or recalls may adversely affect our customers’ acceptance of the recalled and other of our products.
If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.
We could be subject to healthcare fraud regulation and enforcement by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include: (i) the federal healthcare programs Anti-Kickback Law, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as Medicare or Medicaid, (ii) federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent, and which may apply to entities like us which provide coding and billing advice to customers, and/or (iii) state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, many of which differ from their federal counterparts in significant ways, thus complicating compliance efforts.
If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. The risk of our being found in violation of these laws is increased by the fact that their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.
Our operating results would suffer if we were subject to a protracted infringement claim
The medical technology industry is characterized by a substantial amount of litigation and related administrative proceedings regarding patents and intellectual property rights. We expect that medical screening and diagnostic products may become increasingly subject to third-party infringement claims as the number of competitors in our industry grows and the functionality of products overlap. Third parties such as individuals, educational institutions, or other medical device companies may claim that we infringe their intellectual property rights. Any claims, with or without merit, could have any of the following negative consequences:
Result in costly litigation and damage awards;
Divert our management’s attention and resources;
Cause product shipment delays or suspensions; or

23


Require us to seek to enter into royalty or licensing agreements.
We are currently subject to cases based on third-party patent infringement claims. A successful claim of infringement against us from any current or future claim could result in a substantial damage award and materially harm our financial condition. Our failure or inability to license the infringed or similar technology, or design and build non-infringing products, could prevent us from selling our products and adversely affect our business and financial results.
We may also find it necessary to bring infringement actions against third parties to seek to protect our intellectual property rights. Litigation of this nature, even if successful, is often expensive and disruptive of our management’s attention, and in any event may not lead to a successful result relative to the resources dedicated to any such litigation.
We license intellectual property rights from third parties and would be adversely affected if our licensors do not appropriately defend their proprietary rights or if we breach any of the agreements under which we license commercialization rights to products or technology from others
We license rights from third parties for products and technology that are important to our business. If our licensors are unsuccessful in asserting and defending their proprietary rights, including patent rights and trade secrets, we may lose the competitive advantages we have through selling products that we license from third parties. Additionally, if it is found that our licensors infringe on the proprietary rights of others, we may be prohibited from marketing our existing products that incorporate those proprietary rights. Under our licenses, we are subject to commercialization and development, sublicensing, royalty, insurance and other obligations. If we fail to comply with any of these requirements, or otherwise breach a license agreement, the licensor may have the right to terminate the license in whole or to terminate the exclusive nature of the license.
Product liability suits against us could result in expensive and time consuming litigation, payment of substantial damages, and an increase in our insurance rates
The sale and use of our products could lead to the filing of a product liability claim by someone claiming to have been injured using one of our products or claiming that one of our products failed to perform properly. We are currently subject to one such lawsuit. A product liability claim could result in substantial damages and be costly and time consuming to defend, either of which could materially harm our business reputation or financial condition. Our product liability insurance may not protect our assets from the financial impact of defending a product liability claim. Any product liability claim brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing any coverage in the future.
We have experienced seasonality in the sale of our products
We experience seasonality in our revenue. For example, our sales typically decline from the second half of our fiscal year to the first half of the fiscal year, due to patterns in the capital budgeting and purchasing cycles of our customers, many of which are government agencies, and the compensation arrangements of our direct sales employees, as those arrangements are tied to calendar-year sales plans. We anticipate that we will continue to experience seasonal fluctuations, which may lead to fluctuations in our quarterly operating results. We believe that you should not rely on our results of operations for interim periods as an indication of our expected results in any future period.
An interruption in or breach of security of our information or manufacturing systems, including the occurrence of a cyber-incident or a deficiency in our cybersecurity, or disclosure of private patient health information, may result in a loss of business or damage to our reputation.
We rely on communications, information and manufacturing systems to conduct our business. Any failure, interruption or cyber incident of these systems could result in failures or disruptions in our customer relationship management or product manufacturing. A cyber incident is an intentional attack or an unintentional event that can include gaining unauthorized access to information systems to disrupt operations, corrupt data, or steal confidential information. The occurrence of any failures, interruptions or cyber incidents could result in a loss of customer business or reputation and have a material effect on our business, financial condition, results of operations and cash flows.
In the course of performing our business we obtain, from time to time, confidential patient health information. For example, we may learn patient names and be exposed to confidential patient health information when we provide training on our products to our customers’ staff. Complying with federal and state privacy and security requirements imposes compliance related costs, subjects us to potential regulatory audits, and may restrict our business operations. These various laws may be subject to varying interpretations by courts and government agencies creating potentially complex compliance issues for our business. If we were to violate any of our legal obligations to safeguard any confidential patient health information or protected health information against improper use and disclosure, we could lose customers and be exposed to liability, and our reputation and business could be harmed. Concerns or allegations about our practices with regard to the privacy or security of personal health information or other privacy-related matters, even if unfounded, could damage our reputation and harm our business.
We are also subject to laws and regulations in foreign countries covering data privacy and other protection of health and employee information that may be more onerous than corresponding U.S. laws. These regulations may require that we obtain

24


individual consent before we collect or process any personal data, restrict our use or transfer of personal data, impose technical and organizational measures to ensure the security of personal data, and require that we notify regulatory agencies, individuals or the public about any data security breaches. As we expand our international operations, we may be required to expend significant time and resources to put in place additional mechanisms to ensure compliance with multiple data privacy laws. Failure to comply with these laws may result in significant fines and other administrative penalties and harm our business.
Our stock price may be volatile, which may cause the value of our stock to decline or subject us to a securities class action litigation.
The trading price of our common stock price may be volatile and could be subject to wide fluctuations in price in response to various factors, many of which are beyond our control, including:
general economic, industry and market conditions;
actions by institutional or other large stockholders;
the depth and liquidity of the market for our common stock;
volume and timing of orders for our products;
developments generally affecting medical device companies;
the announcement of new products or product enhancements by us or our competitors;
changes in earnings estimates or recommendations by securities analysts;
investor perceptions of us and our business, including changes in market valuations of medical device companies; and
our results of operations and financial performance.
In addition, the stock market in general, and the NASDAQ Stock Market and the market for medical devices in particular, have experienced substantial price and volume volatility that is often seemingly unrelated to the operating performance of particular companies. These broad market fluctuations may cause the trading price of our common stock to decline. In the past, securities class action litigation has often been brought against a company after a period of volatility in the market price of its common stock. We may become involved in this type of litigation in the future. Any securities litigation claims brought against us could result in substantial expense and the diversion of management’s attention from our business.
ITEM 1B.    Unresolved Staff Comments.
None.
ITEM 2.    Properties
Our corporate headquarters are located in Pleasanton, California, in a facility covering 8,200 square feet pursuant to a lease that expires in October 2019.
We also utilize the following properties:
Company-owned Facilities:
116,000 square feet in Buenos Aires, Argentina, utilized substantially for manufacturing;
44,900 square feet in Oakville, Ontario, Canada, utilized substantially for research and development;
42,600 square feet in Gort, Ireland, utilized substantially for manufacturing;
26,000 square feet in Mundelein, Illinois, previously utilized substantially for manufacturing. Currently held for sale; and
6,400 square feet in Old Woking, England, utilized substantially for research and development.
Leased Facilities:
Following is a listing of our most significant leased properties; we have a number of smaller facilities under lease in various countries where we operate.
124,000 square feet in Middleton, Wisconsin, pursuant to a lease that expires in April 2024, that is primarily utilized for manufacturing;
65,000 square feet in Seattle, Washington, pursuant to a lease that expires in December 2020, that is utilized substantially for manufacturing;
52,000 square feet in Taastrup, Denmark, pursuant to a lease that expires in January 2032, that is utilized for manufacturing, research and development, marketing and sales, and general and administrative;

25


43,000 square feet in Planegg, Germany, pursuant to a lease that expires in December 2021 that is utilized substantially for sales and marketing and a large portion is subleased to third parties;
37,282 square feet in San Diego, California, pursuant to a lease that expires in June 2019, that is utilized substantially for manufacturing;
25,128 square feet in Schaumberg, Illinois, pursuant to a lease that expires in July 2021, that is utilized substantially for marketing and sales;
23,860 square feet in Quebec, Canada, pursuant to a lease that expires in December 2023, that is utilized substantially for manufacturing; and
14,300 square feet in Skovlunde, Denmark, pursuant to a lease that expires with six-month notice that is utilized for research and development.
ITEM 3.    Legal Proceedings
We may from time to time become a party to various legal proceedings or claims that arise in the ordinary course of business. We are not currently involved in any legal or administrative proceedings that we believe are likely to have a material effect on our business, financial condition, or results of operations, although we cannot be assured of the outcome of such matters.
In January 2017, a putative class action lawsuit (Badger v. Natus Medical Incorporation, et al., No. 17-cv-00458-JSW) alleging violations of federal securities laws was filed in the United States District Court for the Northern District of California, naming as defendants the Company and certain officers and a director. In July 2017, plaintiffs filed an amended complaint with a new lead plaintiff (Costabile v. Natus Medical Incorporation, et al., No. 17-cv-00458-JSW) alleging violations of federal securities laws based on allegedly false and misleading statements. The defendants moved to dismiss the Amended Complaint, and in February 2018 the motion to dismiss was granted with leave to amend. The Company believes that the plaintiffs’ allegations are without merit, and intends to vigorously defend against the claims.  In July 2017, a putative shareholder derivative action was filed in California Superior Court (Mortman v. Gunst, et. al., No. RG17867679) against certain of the Company’s officers and directors and naming the Company as a nominal defendant. The action is based on allegations similar to those in the securities class action litigation described above.

ITEM 4.    Mine Safety Disclosures
The disclosure required by this item is not applicable.

PART II
ITEM 5.    Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock trades on the Nasdaq Global Select Market under the symbol “BABY”. The following table sets forth, for the periods indicated, the high and low sale price per share of our common stock, as reported on the Nasdaq Global Select Market. 
 
High
 
Low
Fiscal Year Ended December 31, 2017:
 
 
 
Fourth Quarter
$
43.60

 
$
37.10

Third Quarter
39.50

 
31.65

Second Quarter
41.25

 
33.28

First Quarter
39.75

 
33.55

Fiscal Year Ended December 31, 2016:
 
 
 
Fourth Quarter
$
43.85

 
$
33.15

Third Quarter
44.39

 
36.80

Second Quarter
39.81

 
29.54

First Quarter
47.24

 
32.00


26


As of February 21, 2018, there were 33,160,428 shares of our common stock issued and outstanding and held by approximately 23 stockholders of record. We estimate that there are approximately 22,712 beneficial owners of our common stock.
Dividends
We have never declared or paid cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future.
Stock Performance Graph
The following information of Part II Item 5 is being furnished and shall not be deemed to be “soliciting material” or to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor will it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate such information by reference thereto.
The following graph shows a comparison, from January 1, 2012 through December 31, 2017, of cumulative total return for our common stock, the Nasdaq Composite Index and the Standard & Poor’s 500 Health Care Equipment Index. Such returns are based on historical results and are not intended to suggest future performance. Data for the Nasdaq Composite Index and the Standard & Poor’s 500 Health Care Equipment Index assumes reinvestment of dividends.
chart-73c62e9208d152b1b2b.jpg
 
 
 
 
 
2012
 
2013
 
2014
 
2015
 
2016
 
2017
Natus Medical Inc.
 
Return %
 
 
 
101.61

 
60.18

 
33.32

 
(27.58
)
 
9.77

 
 
Cum $
 
100.00

 
201.61

 
322.94

 
430.56

 
311.83

 
342.29

NASDAQ Composite-Total Returns
 
Return %
 
 
 
40.12

 
14.75

 
6.96

 
8.87

 
29.64

 
 
Cum $
 
100.00

 
140.12

 
160.78

 
171.97

 
187.22

 
242.71

S&P 500 Health Care Equipment Index
 
Return %
 
 
 
27.69

 
26.28

 
5.97

 
6.48

 
30.90

 
 
Cum $
 
100.00

 
127.69

 
161.24

 
170.88

 
181.96

 
238.17


Purchases of Equity Securities by the Issuer

27


In June 2014, the Board of Directors authorized the repurchase of up to $10 million of common stock pursuant to a stock repurchase program. In June 2015, the program was expanded to include up to an additional $20 million of our common stock. In June 2016, the program was again expanded to include an additional $20 million of our common stock, for an aggregate purchase amount of $50 million. The expiration date for the program was June 1, 2017. On February 22, 2018, the Board of Directors authorized the repurchase of up to $30 million in common stock with an expiration date of February 26, 2018.

ITEM 6.    Selected Financial Data
The following tables set forth certain selected consolidated financial data for each of the years in the five-year period ended December 31, 2017, and is derived from the Consolidated Financial Statements of Natus Medical Incorporated and its subsidiaries. The Consolidated Financial Statements for each of the years in the three-year period ended December 31, 2017 are included elsewhere in this report. The selected consolidated balance sheet data as of December 31, 2015, 2014 and 2013 and the consolidated statements of operations data for the years ended December 31, 2014 and 2013 are derived from our Consolidated Financial Statements, which are not included in this report. The selected consolidated financial data set forth below is qualified in its entirety by, and should be read in conjunction with, the Consolidated Financial Statements and Notes thereto and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included elsewhere in this report. 
 
Year ended December 31,
 
2017
 
2016
 
2015
 
2014
 
2013
 
(in thousands, except per share amounts)
Consolidated Statement of Operations Data (a) (b):
 
 
 
 
 
 
 
 
Revenue
$
500,970

 
$
381,892

 
$
375,865

 
$
355,834

 
$
344,112

Cost of revenue
213,376

 
144,632

 
145,492

 
138,480

 
138,788

Intangibles amortization
6,380

 
2,327

 
2,836

 
2,967

 
2,912

Gross profit
281,214

 
234,933

 
227,537

 
214,387

 
202,412

Operating expenses:
 
 
 
 
 
 
 
 
 
Marketing and selling
126,166

 
84,834

 
87,675

 
85,729

 
83,138

Research and development
51,822

 
33,443

 
30,434

 
30,100

 
30,786

General and administrative
74,424

 
50,877

 
46,363

 
45,444

 
43,380

Intangibles amortization
19,171

 
8,983

 
7,447

 
3,025

 
5,681

Restructuring
914

 
1,536

 
2,145

 
4,238

 
4,767

Total operating expense
272,497

 
179,673

 
174,064

 
168,536

 
167,752

Income from operations
8,717

 
55,260

 
53,473

 
45,851

 
34,660

Other income (expense), net
(3,567
)
 
(357
)
 
(1,064
)
 
158

 
(2,716
)
Income before provision for income tax
5,150

 
54,903

 
52,409

 
46,009

 
31,944

Provision for income tax
25,443

 
12,309

 
14,485

 
13,531

 
8,797

Net income (loss)
$
(20,293
)
 
$
42,594

 
$
37,924

 
$
32,478

 
$
23,147

Earnings per share:
 
 
 
 
 
 
 
 
 
Basic
$
(0.62
)
 
$
1.31

 
$
1.17

 
$
1.03

 
$
0.77

Diluted
$
(0.62
)
 
$
1.29

 
$
1.14

 
$
1.00

 
$
0.75

Weighted average shares used in the calculation of earnings per share:
 
 
 
 
 
 
 
 
 
Basic
32,564

 
32,460

 
32,348

 
31,499

 
29,993

Diluted
32,564

 
33,056

 
33,241

 
32,568

 
30,821


28


 
December 31,
 
2017
 
2016
 
2015
 
2014
 
2013
 
(in thousands)
Consolidated Balance Sheet Data:
 
 
 
 
 
 
 
 
 
Cash, cash equivalents, and short-term investments
$
88,950

 
$
247,750

 
$
82,469

 
$
66,558

 
$
56,106

Working capital
213,491

 
325,858

 
164,248

 
148,665

 
118,585

Total assets
709,919

 
649,012

 
479,496

 
434,821

 
429,457

Long-term debt (including current portion) and short-term borrowings
154,283

 
140,000

 

 

 
38,017

Total stockholders’ equity
422,097

 
417,374

 
390,710

 
352,715

 
308,214

(a)
Results of operations and financial position of the businesses we have acquired are included from their acquisition dates as follows: Grass in February 2013, Peloton in January 2014, GND and NicView in January 2015, Monarch in November 2015, NeuroQuest in March 2016, RetCam in July 2016, Otometrics in January 2017, and Integra Asset Acquisition in October 2017.
(b)
Data for 2014 and 2013 reflects reclassifications from Cost of revenue to Intangibles amortization, from Marketing and selling, Research and development, and General and administrative to Intangible amortization, and from General and administrative to Restructuring.
ITEM 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the Consolidated Financial Statements and the accompanying footnotes. MD&A includes the following sections:
Business
Natus is a leading provider of newborn care, neurology, and hearing and balance assessment healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
We have completed a number of acquisitions since 2003, consisting of either the purchase of a company, substantially all of the assets of a company, or individual products or product lines. In 2017 we completed two acquisitions, Otometrics in January and the Integra Asset Acquisition in October. We expect to continue to pursue opportunities to acquire other businesses in the future.
Year 2017 Overview
In 2017, we completed the acquisitions mentioned above for total cash consideration of $191.0 million. These acquisitions allowed us to expand our hearing diagnostic and balance assessment target market as well as enter into the neurosurgery business.
Our consolidated revenue increased by $119.1 million for the year ended December 31, 2017 compared to the year ended December 31, 2016. This increase was driven by acquisitions, organic growth in our Newborn care business, partially offset by weakness in our Neurology markets.
Net loss was $20.3 million, or ($0.62) per share in the year ended December 31, 2017, compared with net income of $42.6 million, or $1.29 per diluted share in 2016. This decrease in income was primarily the result of a one-time tax cost of $20.5 million relating to the transition tax on the deemed repatriation of all foreign subsidiary earnings (excluding state and FIN 48 tax impacts) and a non-cash charge to establish a valuation allowance against a significant portion of the U.S. deferred tax assets related to carryforward of foreign tax credits, each due to the enactment in December 2017 of Tax Cuts and Jobs Act of 2017 (the “Act”). We incurred $0.9 million of restructuring charges in 2017, as compared to $1.5 million in 2016, as we continue to eliminate redundant costs.
Application of Critical Accounting Policies
We prepare our financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In so doing, we must often make estimates and use assumptions that can be subjective and, consequently,

29


our actual results could differ from those estimates. For any given individual estimate or assumption we make, there may also be other estimates or assumptions that are reasonable.
We believe that the following critical accounting policies require the use of significant estimates, assumptions, and judgments. The use of different estimates, assumptions, and judgments could have a material effect on the reported amounts of assets, liabilities, revenue, expenses, and related disclosures as of the date of the financial statements and during the reporting period.
Revenue recognition
Revenue, net of discounts, is recognized from sales of medical devices and supplies, including sales to distributors, when the following conditions have been met: a purchase order has been received, title has transferred, the selling price is fixed or determinable, and collection of the resulting receivable is reasonably assured. Terms of sale for most domestic sales are FOB origin, reflecting that title and risk of loss are assumed by the purchaser at the shipping point; however, terms of sale for some neurology, sleep-diagnostic, and head cooling systems are FOB destination, reflecting that title and risk of loss are assumed by the purchaser upon delivery. Terms of sales to international distributors are generally EXW, reflecting that goods are shipped “ex works,” in which title and risk of loss are assumed by the distributor at the shipping point. For products shipped under FOB origin or EXW terms, delivery is generally considered to have occurred when the product is shipped. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue. We generally do not provide rights of return on products.
For products containing embedded software, we have determined that the hardware and software components function together to deliver the products’ essential functionality, and therefore, the revenue from the sale of these products does not fall within the scope of the software revenue recognition rules. Our revenue recognition policies for sales of these products are substantially the same as for our other tangible products.
Revenue from sales of certain of our products that remain within the scope of the software revenue recognition rules under ASC Subtopic 985-605 is not significant.
Revenue from extended service and maintenance agreements, for both medical devices and data management systems, is recognized ratably over the service period. Revenue from installation or training services is deferred until such time service is provided. Hearing screening and ambulatory EEG monitoring revenue is recorded when the procedure is performed at the estimated net realizable value based on contractual agreements with payers and historical collections.
Certain revenue transactions include multiple element arrangements. We allocate revenue in these arrangements to each unit of accounting using the relative selling price method. The selling prices used during the allocation process are based on vendor specific objective evidence (“VSOE”) if available, third-party evidence (“TPE”) if VSOE is not available, or estimated selling price (“ESP”) if neither VSOE or TPE is available.
GPOs negotiate volume purchase prices for member hospitals, group practices, and other clinics. Our agreements with GPOs typically contain preferential terms for the GPO and its members, including provisions for some, if not all, of the following:
Payment of marketing fees by Natus to the GPO, usually based on purchasing experience of group members; and
Non-recourse cancellation provisions.
We do not sell products to GPOs. Hospitals, group practices, and other clinics that are members of a GPO purchase products directly from us under the terms negotiated by the GPO. Negotiated pricing and discounts are recognized as a reduction of the selling price of products at the time of the sale. Revenue from sales to members of GPOs is otherwise consistent with general revenue recognition policies as previously described.
Allowance for Doubtful Accounts
We maintain an allowance for doubtful accounts for estimated losses resulting from potential uncollectible accounts receivable. We estimate the allowance for all receivable risks by reviewing the status of each matter and recording reserves based on our experience and knowledge of the particular client and historical collection patterns. However, our actual experience may vary from our estimates. If the financial condition of our clients were to deteriorate or resulting in their inability or unwillingness to pay our fees, we may need to record additional allowances or write-offs in future periods. This risk related to a client’s inability to pay may be partially mitigated to the extent that we may receive retainers from some of our clients prior to performing services.
Inventory

30


Inventories are carried at the lower of cost or market, with cost being determined using the first-in, first-out method. The carrying value of our inventories is reduced for any difference between cost and estimated market value of inventories that is determined to be obsolete or unmarketable, based upon assumptions about future demand and market conditions. Adjustments to the value of our inventory establish a new cost basis and are considered permanent even if circumstances later suggest that increased carrying amounts are recoverable. Decreases in demand may result in further impairment of inventory, while increases in demand may result in the sale of inventory that had previously been written down.
Acquisition Accounting
We have made a number of acquisitions in the past and may continue to make acquisitions in the future. We account for acquired business combinations using the acquisition method of accounting. The assets acquired and liabilities assumed are recorded based on their respective fair values at the date of acquisition, with limited exceptions. Valuations are generally completed for business acquisitions using a discounted cash flow analysis. The most significant estimates and assumptions inherent in a discounted cash flow analysis include the amount and timing of projected future cash flows, the discounted rate used to measure the risks inherent in the future cash flows, the assessment of the asset's life cycle, and the competitive and other trends impacting the asset, including consideration of technical, legal, regulatory, economic and other factors. Each of these factors and assumptions can significantly affect the value of the intangible asset. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill.

Determining the useful life of an intangible asset also requires judgment, as different types of intangibles assets will have different useful lives and certain assets may even be considered to have indefinite useful lives. Useful life is the period over which the intangible asset is expected to contribute directly and indirectly to our future cash flows. We determine the useful lives of intangible assets based on a number of factors, such as legal, regulatory, or contractual provisions that may limit the useful life, and the effects of obsolescence, anticipated demand, existence or absence of competition, and other economic factors on useful life.
Carrying value of intangible assets and goodwill
We amortize intangible assets with finite lives over their useful lives; any future changes that would limit their useful lives or any determination that these assets are carried at amounts greater than their estimated fair value could result in additional charges.
During the second quarter of 2015, we initiated a strategy to increase the brand strength of Natus by replacing acquired product trade names with Natus branded products over time. The implementation of this strategy places definite expected future lives on our acquired trade names which previously had indefinite lives. We assigned these trade names lives of seven years based on the timeline of our branding strategy. We will continue to assess the lives of these assets based on the timing and execution of this strategy. Amortization expense for trade names is recorded as a component of operating expense.
Goodwill is not amortized but is subject to an annual impairment analysis, which is performed as of October 1st; this assessment is also performed whenever there is a change in circumstances that indicates the carrying value of these assets may be impaired.
In 2017, 2016 and 2015, we performed a qualitative assessment to test goodwill for impairment. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on our qualitative assessment, we determined that the fair value was more likely than not to be greater than its carrying amount, and no further analysis was needed.
If the fair value was less than its carrying amount, the Company would perform a two-step impairment test on goodwill. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit. If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.
Goodwill impairment analysis and measurement is a process that requires significant judgment. Future changes in the judgments and estimates underlying our analysis of goodwill for possible impairment, including expected future cash flows and

31


discount rate, could result in a significantly different estimate of the fair value of the reporting units and could result in additional impairment of goodwill.
Long lived assets
We continually monitor events and changes in circumstances that could indicate that carrying amounts of its long-lived assets, including property and equipment and intangible assets that may not be recoverable. When such events or changes in circumstances occur, we assess the recoverability by determining whether the carrying value of such assets or asset groups will be recovered through their undiscounted expected future cash flows. If the future undiscounted cash flows are less than the carrying amount of these assets, we will recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets.
Liability for product warranties
We provide a warranty with our products that is generally one year in length and in some cases, regulations may require us to provide repair or remediation beyond our typical warranty period. If any of our products contain defects, we may be required to incur additional repair and remediation costs. Service for domestic customers is provided by Company-owned service centers that perform all service, repair, and calibration services. Service for international customers is provided by a combination of Company-owned facilities and vendors on a contract basis.
A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management’s best estimate of probable liability. We consider a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of the reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.
Income Taxes
We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and for tax losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
As part of the process of preparing our consolidated financial statements, we must estimate our income tax expense for each of the jurisdictions in which we operate. This process requires significant management judgments and involves estimating our current tax exposures in each jurisdiction including the impact, if any, of additional taxes resulting from tax examinations as well as judging the recoverability of deferred tax assets. To the extent recovery of deferred tax assets is not likely based on our estimation of future taxable income in each jurisdiction, a valuation allowance is established. Tax exposures can involve complex issues and may require an extended period to resolve. Frequent changes in tax laws in each jurisdiction complicate future estimates. To determine the tax rate, we are required to estimate full-year taxable income or loss and the related income tax expense or benefit in each jurisdiction. We update the estimated effective tax rate for the effect of significant unusual items as they are identified. Changes in the geographic mix or estimated level of annual pre-tax income can affect the overall effective tax rate, and such changes could be material.
Regarding accounting for uncertainty in income taxes, we recognize the benefit from a tax position only if it is more likely than not that the position would be sustained upon audit based solely on the technical merits of the tax position. We measure the income tax benefits from the tax positions that are recognized, assess the timing of the derecognition of previously recognized tax benefits and classify and disclose the liabilities within the consolidated financial statements for any unrecognized tax benefits based on the guidance in the interpretation of related accounting guidance for income taxes. The interpretation also provides guidance on how the interest and penalties related to tax positions may be recorded and classified within our Consolidated Statement of Income and presented in the Consolidated Balance Sheet. We classify interest and penalties related to uncertain tax positions as additional income tax expense.
Share-based compensation
We recognize share-based compensation expense associated with employee stock options under the single-option straight line method over the requisite service period, which is generally a four-year vesting period and ten-year contractual term pursuant to ASC Topic 718, Compensation-Stock Compensation. See Note 14 of our Consolidated Financial Statements.

32


For employee stock options, the value of each option is estimated on the date of grant using the Black-Scholes option pricing model, which was developed for use in estimating the value of freely traded options. Similar to other option pricing models, the Black-Scholes method requires the input of highly subjective assumptions, including stock price volatility. Changes in the subjective input assumptions can materially affect the estimated fair value of our employee stock options.
We recognize share-based compensation associated with Restricted Stock Awards (“RSA”) and Restricted Stock Units (“RSU”). RSAs and RSUs vest ratably over a three-year period for employees. RSAs and RSUs for executives vest over a four-year period; 50% on the second anniversary of the vesting start date and 25% on each of the third and fourth anniversaries of the vesting date. RSAs and RSUs for non employees (Board of Directors) vest over a one-year period; 100% on the first anniversary. The value is estimated based on the market value of our stock on the date of issuance pursuant to ASC Topic 718, Compensation-Stock Compensation.
We issue new shares of common stock upon the exercise of stock options and the vesting of RSAs and RSUs.
Forfeitures of employee stock options and awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share-based compensation expense is recorded net of estimated forfeitures, such that expense is recorded only for those share-based awards that are expected to vest.

Results of Operations
The following table sets forth for the periods indicated selected consolidated statement of income data as a percentage of total revenue. Our historical operating results are not necessarily indicative of the results for any future period.
 
 
Percent of Revenue
Years Ended December 31,
 
2017
 
2016
 
2015
Revenue
100.0
 %
 
100.0
 %
 
100.0
 %
Cost of revenue
42.6
 %
 
37.9
 %
 
38.7
 %
Intangibles amortization
1.3
 %
 
0.6
 %
 
0.8
 %
Gross profit
56.1
 %
 
61.5
 %
 
60.5
 %
Operating expenses:
 
 
 
 
 
Marketing and selling
25.2
 %
 
22.2
 %
 
23.3
 %
Research and development
10.3
 %
 
8.8
 %
 
8.1
 %
General and administrative
14.9
 %
 
13.3
 %
 
12.3
 %
Intangibles amortization
3.8
 %
 
2.4
 %
 
2.0
 %
Restructuring
0.2
 %
 
0.4
 %
 
0.6
 %
Total operating expenses
54.4
 %
 
47.0
 %
 
46.3
 %
Income from operations
1.7
 %
 
14.5
 %
 
14.2
 %
Other income (expense), net
(0.7
)%
 
(0.1
)%
 
(0.3
)%
Income before provision for income tax
1.0
 %
 
14.4
 %
 
13.9
 %
Provision for income tax expense
5.1
 %
 
3.2
 %
 
3.9
 %
Net income
(4.1
)%
 
11.2
 %
 
10.1
 %

33


Comparison of 2017 and 2016
Revenue 
 
Year ended December 31,
 
2017
 
2016
 
Change
Neuro
 
 
 
 
 
Devices and Systems
$
171,315

 
$
168,200

 
2
 %
Supplies
59,955

 
58,681

 
2
 %
Services
11,886

 
11,641

 
2
 %
Total Neurology Revenue
243,156

 
238,522

 
2
 %
Newborn Care
 
 
 
 
 
Devices and Systems
77,573

 
72,562

 
7
 %
Supplies
43,732

 
47,674

 
(8
)%
Services
22,325

 
23,134

 
(3
)%
Total Newborn Care Revenue
143,630

 
143,370

 
 %
Otometrics
 
 
 
 
 
Devices and Systems
$
86,920

 
$

 
 %
Supplies
27,264

 

 
 %
Services

 

 
 %
Total Otometrics Revenue
114,184

 

 
 %
Total Revenue
$
500,970

 
$
381,892

 
31
 %
For the year ended December 31, 2017, Neurology revenue increased by 2% compared to the prior year with the growth in our international markets partly offset by a decline in our domestic market. Devices and Systems revenue increased by 2% for the year ended December 31, 2017 compared to the prior year due mainly to the addition of acquired Neurosurgery products partly offset by declines in core Neurology products. Supplies revenue for 2017 increased 2%. Services revenue increased by 2% compared to the prior year due mainly to growth in existing markets for GND.
For the year ended December 31, 2017, Newborn Care revenue remained flat compared to the prior year. Devices and Systems revenue increased by 7% due primarily from revenue generated from our RetCam acquisition in July 2016 and sales to the Venezuela Ministry of Health in the first quarter of 2017. Supplies revenue decreased 8% compared to the prior year on lower demand due to lower birth rates and supplies customers converting to our Peloton screening service. Services revenue decreased by 3% compared to the prior year due primarily to the completion of services performed for the Venezuela Ministry of Health in 2016 and the completion of certain contracted services in our Neometrics Data Management business.
For the year ended December 31, 2017, all Otometrics revenue was incremental as we acquired this business on January 3, 2017.
No single customer accounted for more than 10% of our revenue in either 2017 or 2016. Revenue from domestic sales increased 8% to $270.9 million in 2017, from $250.7 million in 2016 due to the acquisition of Otometrics and growth in our Newborn care business. Revenue from international sales increased 75% in 2017 to $230.1 million from $131.2 million in 2016 primarily due to the 2017 acquisition of Otometrics. Revenue from domestic sales was 54% of total revenue in 2017 compared to 66% of total revenue in 2016, and revenue from international sales was 46% of total revenue in 2017 compared to 34% of total revenue in 2016.
Cost of Revenue and Gross Profit 
 
Year ended December 31,
 
2017
 
2016
Revenue
$
500,970

 
$
381,892

Cost of revenue
213,376

 
144,632

Intangibles amortization
6,380

 
2,327

Gross profit
281,214

 
234,933

Gross profit percentage
56.1
%
 
61.5
%

34


For the year ended December 31, 2017, our gross profit as a percentage of sales decreased by 5.4% compared to the prior year. This decrease in gross profit was driven by the acquisition of Otometrics whose products have lower margins than our neurol and newborn care products, higher warranty reserve for our NeoBLUE® phototherapy system recall, and unfavorable geographic mix as we sold more product through our international distributor channels which yield low gross margin than our direct sales.
Operating Costs 
 
Year ended December 31,
 
2017
 
2016
Marketing and selling
$
126,166

 
$
84,834

Percentage of revenue
25.2
%
 
22.2
%
Research and development
$
51,822

 
$
33,443

Percentage of revenue
10.3
%
 
8.8
%
General and administrative
$
74,424

 
$
50,877

Percentage of revenue
14.9
%
 
13.3
%
Intangibles amortization
$
19,171

 
$
8,983

Percentage of revenue
3.8
%
 
2.4
%
Restructuring
$
914

 
$
1,536

Percentage of revenue
0.2
%
 
0.4
%
Marketing and Selling
Marketing and selling expenses increased in 2017 compared to 2016. This is primarily driven by our acquisition of Otometrics.
Research and Development
Research and development expenses increased during the year ended December 31, 2017 compared to the prior year. This is primarily driven by activities related primarily to the remediation of certain deficiencies identified by the FDA in our Newborn Care business as well as the Otometrics acquisition.
General and Administrative
General and administrative expenses increased during the year ended December 31, 2017 compared to the prior year. The increase is related primarily to the Otometrics acquisition.
Intangibles Amortization
Intangibles amortization increased in 2017 compared to 2016. The increase is mainly driven by additional intangible amortization from the acquisition of Otometrics and, to a lesser extent, the Integra Asset Acquisition as well as the 2016 NeuroQuest and RetCam acquisitions.
Restructuring
Restructuring costs decreased during the year ended December 31, 2017 compared to the prior year. In the prior year we experienced higher expenses related to facilities consolidation and severance expense to reduce redundant costs as well as restructuring charges related mostly to the abandonment of two facilities.
Other Income (Expense), net
Other income (expense), net consists of interest income, interest expense, net currency exchange gains and losses, and other miscellaneous income and expense. We reported other expense, net of $3.6 million in 2017, compared to $0.4 million in 2016. We reported $1.0 million of foreign currency exchange gains in 2017 versus $0.3 million of foreign currency losses in 2016. This increase was driven primarily by the changing value of foreign currencies in which we transact. Interest expense was $5.1 million in 2017 compared to $0.4 million in 2016 due to interest expense payments on our $155.0 million debt outstanding while interest income of $0.4 million in 2017 was $0.3 million more than the amount reported for 2016.
Provision for Income Tax

35


The effective tax rate (“ETR”) for 2017 was 494.0% as compared to 22.4% for 2016. The significantly higher effective tax rate in 2017 compared with 2016 is primarily due to the impacts of the 2017 Tax Act, including the repatriation tax on accumulated foreign earnings and re-measurement of net deferred tax assets. Other increases include withholding taxes from distribution of income and additional tax expense related to the settlement of tax audits in foreign jurisdictions, offset by change in geographic mix of income and utilization of certain tax credits in domestic and foreign jurisdictions.
Comparison of 2016 and 2015
Revenue 
 
Year ended December 31,
 
2016
 
2015
 
Change
Neuro
 
 
 
 
 
Devices and Systems
$
168,200

 
$
168,776

 
 %
Supplies
58,681

 
60,205

 
(3
)%
Services
11,641

 
8,320

 
40
 %
Total Neurology Revenue
238,522

 
237,301

 
1
 %
Newborn Care
 
 
 
 
 
Devices and Systems
72,562

 
72,669

 
 %
Supplies
47,674

 
49,982

 
(5
)%
Services
23,134

 
15,913

 
45
 %
Total Newborn Care Revenue
143,370

 
138,564

 
3
 %
Total Revenue
$
381,892

 
$
375,865

 
2
 %
For the year ended December 31, 2016, Neurology revenue increased by 1% compared to the prior year with the growth in our domestic market partly offset by a decline in our international markets. Devices and Systems revenue remained constant for the year ended December 31, 2016 compared to the prior year. Supplies revenue for 2016 decreased 3% compared to the prior year due mainly to softness in our domestic market.  Services revenue increased by 40% compared to the prior year due mainly to the acquisition of NeuroQuest in March 2016 to complement our GND and Monarch acquisitions.
For the year ended December 31, 2016, Newborn Care revenue increased by 3% compared to the prior year with growth in both international and domestic markets. Devices and Systems revenue remained flat year over year, as revenue generated from the RetCam acquisition and the Venezuela contract was offset by lower revenue from hearing devices, due to Peloton cannibalization, voluntary ship holds, and lower revenue on Incubators and Warmers, due to exiting the U.S. market, and lower revenue from Brain Injury devices, due to higher revenue from China in 2015 that did not repeat in 2016. Supplies revenue for the twelve-month period decreased 5% compared to the prior year mainly due to our ability to convert customers over to our Peloton screening service business. Services revenue increased by 45% compared to the prior year due mainly to the growth in Peloton and our Neometrics Data Management services.
No single customer accounted for more than 10% of our revenue in either 2016 or 2015. Revenue from domestic sales increased 4% to $250.7 million in 2016, from $242.1 million in 2015 primarily due to an increase in our services business and continued strong demand for our devices and systems in the U.S. Revenue from international sales decreased 2% in 2016 to $131.2 million from $133.8 million in 2015 due to on-going weakness in our international markets due, in part, to the strong dollar against the Euro and Canadian dollar. Revenue from domestic sales was 66% of total revenue in 2016 compared to 64% of total revenue in 2015, and revenue from international sales was 34% of total revenue in 2016 compared to 36% of total revenue in 2015.
Cost of Revenue and Gross Profit 
 
Year ended December 31,
 
2016
 
2015
Revenue
$
381,892

 
$
375,865

Cost of revenue
144,632

 
145,492

Intangibles amortization
2,327

 
2,836

Gross profit
234,933

 
227,537

Gross profit percentage
61.5
%
 
60.5
%

36


For the year ended December 31, 2016, our gross profit as a percentage of sales increased by 1% compared to the prior year. This increase in gross profit was driven by a $6.6 million charge in 2015 recorded to accrue for the estimated costs of bringing certain NeoBLUE® phototherapy products into U.S. regulatory compliance. These increases in gross profit were also driven by higher domestic revenues which generally have higher gross margins than international sales, as well as cost reduction initiatives which resulted in higher margins primarily in Neurology devices.
Operating Costs 
 
Year ended December 31,
 
2016
 
2015
Marketing and selling
$
84,834

 
$
87,675

Percentage of revenue
22.2
%
 
23.3
%
Research and development
$
33,443

 
$
30,434

Percentage of revenue
8.8
%
 
8.1
%
General and administrative
$
50,877

 
$
46,363

Percentage of revenue
13.3
%
 
12.3
%
Intangibles Amortization
$
8,983

 
$
7,447

Percentage of revenue
2.4
%
 
2.0
%
Restructuring
$
1,536

 
$
2,145

Percentage of revenue
0.4
%
 
0.6
%
Marketing and Selling
Marketing and selling expenses decreased in 2016 compared to 2015. This is primarily related to a favorable change in estimate in the GND earnout liability in 2016 based on projected GND annual revenue.
Research and Development
Research and development expenses increased during the year ended December 31, 2016 compared to the prior year. This is primarily driven by activities related to the remediation of certain deficiencies identified in our Seattle quality system as well as the RetCam acquisition.
General and Administrative
General and administrative expenses increased during the year ended December 31, 2016 compared to the prior year. The increase is related to an increase of $0.6 million in billing costs due to Peloton growth and the addition of $1.6 million expenses following the NeuroQuest and RetCam acquisitions.
Intangibles Amortization
Intangibles amortization increased in 2016 compared to 2015. The increase is partly due to additional intangible amortization from the 2016 acquisitions of NeuroQuest and RetCam. Additionally, we assigned our previously indefinite lived trade names definite lives of seven years in the second quarter of 2015. As such, there is a full year of amortization for trade names in 2016 compared to a half year in 2015.
Restructuring
Restructuring costs decreased during the year ended December 31, 2016 compared to the prior year. In 2015 we experienced higher expenses related to facilities consolidation and severance expense compared to 2016 in which restructuring charges related mostly to the abandonment of two facilities.
Other Income (Expense), net
Other income (expense), net consists of interest income, interest expense, net currency exchange gains and losses, and other miscellaneous income and expense. We reported other expense, net of $0.3 million in 2016, compared to $1.0 million in 2015. We reported $0.3 million of foreign currency exchange losses in 2016 versus $1.4 million in 2015. This increase was driven primarily by the declining value of foreign currencies in which we transact. Interest expense was $0.4 million in 2016 compared to $0.3 million in 2015. This was offset by interest income of $0.3 million in 2016 which was $0.3 million more than the amount reported for 2015.

37


Provision for Income Tax
The effective tax rate (“ETR”) for 2016 was 22.4% as compared to 27.6% for 2015. The lower effective tax rate in 2016 compared with 2015 is primarily due to the effect from adoption of ASU 2016-09 which resulted in excess tax benefits being recorded in income tax expense as discrete items, lower state tax expense, reduction of certain uncertain tax positions, and the change in geographic mix of income, offset by additional tax expense related to the settlement of a tax audit in a foreign jurisdiction.

Liquidity and Capital Resources
Liquidity is our ability to generate sufficient cash flows from operating activities to meet our obligations and commitments. In addition, liquidity includes the ability to obtain appropriate financing and to raise capital. Therefore, liquidity cannot be considered separately from capital resources that consist of our current funds and the potential to increase those funds in the future. We plan to use these resources in meeting our commitments and in achieving our business objectives.
We believe that our current cash and cash equivalents and any cash generated from operations will be sufficient to meet our ongoing operating requirements for the foreseeable future.
As of December 31, 2017, we had cash and cash equivalents outside the U.S. in certain of our foreign operations of $74.0 million. We intend to permanently reinvest this cash held by our foreign subsidiaries except for Excel-Tech and Natus Ireland subsidiaries, which we intend to repatriate. If, however, a portion of these permanently reinvested funds were needed and distributed to our operations in the United States, we may be subject to additional U.S. income taxes and foreign withholding taxes depending on facts and circumstances at the time of distribution. The amount of taxes due would depend on the amount and manner of repatriation, as well as the location from where the funds were repatriated.
On September 23, 2016, we entered into a Credit Agreement with JP Morgan Chase Bank (“JP Morgan”) and Citibank, NA (“Citibank”). The Credit Agreement provides for an aggregate $150.0 million of secured revolving credit facility (the “Credit Facility”). On September 15, 2017, we exercised our right to increase the amount available under the facility by $75.0 million, bringing the aggregate revolving credit facility to $225.0 million. The Credit Agreement contains covenants, including covenants relating to maintenance of books and records, financial reporting and notification, compliance with laws, maintenance of properties and insurance, and limitations on guaranties, investments, issuance of debt, lease obligations and capital expenditures. The Credit Agreement provides for events of default, including failure to pay any principal or interest when due, failure to perform or observe covenants, bankruptcy or insolvency events and the occurrence of a material adverse effect. The Company has no other significant credit facilities. As of December 31, 2017 we had $155.0 million outstanding under the Credit Facility.
 
December 31, 2017
 
December 31, 2016
 
December 31, 2015
Cash, cash equivalents, and investments
$
88,950

 
$
247,570

 
$
82,469

Debt
154,283

 
140,000

 

Working capital
213,491

 
325,858

 
164,248

 
Year Ended
 
December 31, 2017
 
December 31, 2016
 
December 31, 2015
Net cash provided by operating activities
$
19,726

 
$
72,687

 
$
36,852

Net cash used in investing activities
(160,935
)
 
(53,264
)
 
(19,478
)
Net cash provided by financing activities
5,826

 
118,417

 
832

Comparison of 2017, 2016, and 2015
During 2017 cash generated from operating activities of $19.7 million was the result of $20.3 million of net loss, non-cash adjustments to net loss of $53.5 million, and net cash outflows of $13.3 million from changes in operating assets and liabilities. The non-cash adjustments were $30.1 million of depreciation and amortization expense, $10.0 million of accounts receivable reserves, $9.4 million from share-based compensation, $5.4 million of warranty reserves and $1.7 million from intangible impairments. The change in operating assets and liabilities was driven primarily by an increase in accounts receivable and lower collections during the year compared to the prior year, and a decrease in deferred revenue related to the Venezuelan contract, partially offset by an increase in accrued liabilities for the transition tax under the Act for the deemed repatriation of foreign earnings and decreases in inventories and other assets. Cash used in investing activities during the period was $161.1 million and consisted primarily of the acquisition of Otometrics for $143.6 million, net of cash, and the Integra Asset Acquisition for $46.4

38


million, offset by sales of short-term investments of $34.0 million. Cash used to acquire other property and equipment was $4.1 million. Cash provided by financing activities during the year ended December 31, 2017 was $5.8 million and consisted of proceeds from borrowings under the Credit Facility of $60.0 million along with proceeds from stock option exercises and Employee Stock Purchase Program (“ESPP”) purchases of $3.5 million, offset by $45.0 million repayment of debt under the Credit Facility, $7.0 million for taxes paid related to net share settlement of equity awards, $3.0 million for contingent acquisition consideration, $2.3 million for repurchases of common stock under our share repurchase program, and $0.3 million of deferred debt issuance costs.
During 2016 cash generated from operating activities of $72.7 million was the result of $42.6 million of net income, non-cash adjustments to net income of $29.9 million, and net cash outflows of $0.1 million from changes in operating assets and liabilities. The change in operating assets and liabilities was driven primarily by a decrease in accounts receivable following increased collections efforts, an increase in deferred revenue following receipt of payment from the Ministry of Health of Venezuela, and an increase in prepaid expenses related to prepayments we made to our distribution partner for the Venezuelan contract. Cash used in investing activities during the period was $53.3 million and consisted primarily of purchases of short-term investments of $34.0 million, as well as cash used in the acquisitions of RetCam of $10.6 million and NeuroQuest of $4.6 million, in each case net of cash acquired. Cash used to acquire other property and equipment and intangible assets was $3.4 million. Cash provided by financing activities during the year ended December 31, 2016 was $118.4 million and consisted primarily of outstanding debt under the current Credit Facility of $140.0 million along with proceeds from stock option exercises and Employee Stock Purchase Program (“ESPP”) purchases and their related tax benefits of $3.6 million, offset by $19.3 million for repurchases of common stock under our share repurchase program, $4.1 million for taxes paid related to net share settlement of equity awards, $1.3 million for contingent acquisition consideration, and $0.5 million of deferred debt issuance costs. Under the prior credit facility that was terminated in connection with our entry into the new facility, the Company borrowed and repaid a total of $16.0 million as of December 31, 2016.
During 2015 cash generated from operating activities of $36.9 million was the result of $37.9 million of net income, non-cash adjustment to net income of $28.0 million, and net cash outflows of $29.1 million from changes in operating assets and liabilities. Cash used in investing activities during the period was $19.5 million and consisted primarily of cash used related to the acquisition of GND, Monarch and NicView. Cash used to acquire other property and equipment and intangible assets was $5.4 million. Cash provided by financing activities during the year ended December 31, 2015 was $0.8 million and consisted of proceeds from stock option exercises and ESPP purchases and their related tax benefits of $17.4 million, offset by $11.5 million for repurchases of common stock under our share repurchase program, $4.3 million for taxes paid related to net share settlement of equity awards, and $0.7 million for contingent acquisition consideration, which we acquired in 2014.
Future Liquidity
Our future liquidity and capital requirements will depend on numerous factors, including the:
Amount and timing of revenue;
Extent to which our existing and new products gain market acceptance;
Extent to which we make acquisitions;
Cost and timing of product development efforts and the success of these development efforts;
Cost and timing of marketing and selling activities; and
Availability of borrowings under line of credit arrangements and the availability of other means of financing.
Contractual Obligations
In the normal course of business, we enter into obligations and commitments that require future contractual payments. The commitments result primarily from purchase orders placed with contract vendors that manufacture some of the components used in our medical devices and related disposable supply products, purchase orders placed for employee benefits and outside services, as well as commitments for leased office space, leased equipment, and bank debt. The following table summarizes our contractual obligations and commercial commitments as of December 31, 2017 (in thousands): 

39


 
 
 
Payments Due by Period
 
Total
 
Less than
1 Year
 
1-3 Years
 
4-5 Years
 
More than
5 Years
Unconditional purchase obligations
$
50,035

 
$
47,842

 
$
2,193

 
$

 
$

Operating lease obligations
30,078

 
7,038

 
10,340

 
5,849

 
6,851

Bank debt
155,000

 

 

 
155,000

 

Interest payments
14,813

 
5,950

 
7,726

 
1,137

 

Repatriation tax
12,135

 
$
971

 
$
1,942

 
$
1,942

 
$
7,280

Total
$
262,061

 
$
61,801

 
$
22,201

 
$
163,928

 
$
14,131

Purchase obligations are defined as agreements to purchase goods or services that are enforceable and legally binding. Included in the purchase obligations category above are obligations related to purchase orders for inventory purchases under our standard terms and conditions and under negotiated agreements with vendors. We expect to receive consideration (products or services) for these purchase obligations. The purchase obligation amounts do not represent all anticipated purchases in the future, but represent only those items for which we are contractually obligated. The table above does not include obligations under employment agreements for services rendered in the ordinary course of business.
We are not able to reasonably estimate the timing of any potential payments for uncertain tax positions under ASC 740, Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement 109. As a result, the preceding table excludes any potential future payments related to our ASC 740 liability for uncertain tax positions. See Note 17 of our Consolidated Financial Statements for further discussion on income taxes.
Quantitative and Qualitative Disclosures about Market Risk
We develop products in the U.S, Canada, Europe, and Argentina, and sell those products into more than 100 countries throughout the world. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets. Most of our sales in Europe and Asia are denominated in the U.S. Dollar and Euro and with a portion of our sales denominated in Canadian dollar, Argentine peso and British pound. As our sales in currencies other than the U.S. dollar increase, our exposure to foreign currency fluctuations may increase.
In addition, changes in exchange rates also may affect the end-user prices of our products compared to those of our foreign competitors, who may be selling their products based on local currency pricing. These factors may make our products less competitive in some countries.
If the U.S. Dollar uniformly increased or decreased in strength by 10% relative to the currencies in which our sales were denominated, our net income would have correspondingly increased or decreased by an immaterial amount for the year ended December 31, 2017.
Our interest expense is sensitive to changes in interest rates and may vary with the federal funds rate and London Interbank Offered Rate (LIBOR). However, we may decrease interest rate risk by keeping our debt leverage low, as a hypothetical decrease of 10% in market interest rates would not result in a material decrease in interest expense paid on debt held at December 31, 2017.
All of the potential changes noted above are based on sensitivity analyses performed on our financial position as of December 31, 2017. Actual results may differ as our analysis of the effects of changes in interest rates does not account for, among other things, sales of securities prior to maturity and repurchase of replacement securities, the change in mix or quality of the investments in the portfolio, and changes in the relationship between short-term and long-term interest rates.
Off-Balance Sheet Arrangements
Under our bylaws, we have agreed to indemnify our officers and directors for certain events or occurrences arising as a result of the officer or director’s serving in such capacity. We have a directors and officers' liability insurance policy that limits our exposure and enables us to recover a portion of any future amounts paid resulting from the indemnification of our officers and directors. In addition, we enter into indemnification agreements with other parties in the ordinary course of business. In some cases we have obtained liability insurance providing coverage that limits our exposure for these other indemnified matters. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. We believe the estimated fair value of these indemnification agreements is minimal and have not recorded a liability for these agreements as of December 31, 2017. We had no other off-balance sheet arrangements during any of fiscal 2017, 2016 or 2015 that had, or are reasonably likely to have, a material effect on our consolidated financial condition, results of operations, or liquidity.
Recent Accounting Pronouncements

40


See Note 1—Organization and Significant Accounting Policies to the Consolidated Financial Statements contained herein for a full description of recent accounting pronouncements including the respective expected dates of adoption and effects on results of our operations and financial condition.
Cautionary Information Regarding Forward Looking Statements
This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about Natus Medical Incorporated. These statements include, among other things, statements concerning our expectations, beliefs, plans, intentions, future operations, financial condition and prospects, and business strategies. The words “may,” “will,” “continue,” “estimate,” “project,” “intend,” “believe,” “expect,” “anticipate,” and other similar expressions generally identify forward-looking statements. Forward-looking statements in this Item 7 include, but are not limited to, statements regarding the following: our ability to capitalize on improving market conditions, the sufficiency of our current cash, cash equivalents and short-term investment balances, and any cash generated from operations to meet our ongoing operating and capital requirements for the foreseeable future, and our intent to acquire additional technologies, products or businesses.
Forward-looking statements are not guarantees of future performance and are subject to substantial risks and uncertainties that could cause the actual results predicted in the forward-looking statements as well as our future financial condition and results of operations to differ materially from our historical results or currently anticipated results. Investors should carefully review the information contained under the caption “Risk Factors” contained in Item 1A of this report for a description of risks and uncertainties. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements.
ITEM 7A.     Quantitative and Qualitative Disclosures About Market Risk
The information required by this Item is set forth in the section entitled Management’s Discussion and Analysis of Financial Condition and Results of Operations—Quantitative and Qualitative Disclosures About Market Risk, and is incorporated by reference in this section.
ITEM 8.     Financial Statements and Supplementary Data
The Consolidated Financial Statements and Supplementary Data required by this Item are set forth where indicated in Item 15 of this report.
Selected Quarterly Financial Data (Unaudited)
The following table presents our operating results for each of the eight quarters in the period ending December 31, 2017. The information for each of these quarters is unaudited and has been prepared on the same basis as our audited financial statements appearing elsewhere in this report.
In the opinion of our management all necessary adjustments, including normal recurring adjustments, have been included to present fairly the unaudited quarterly results when read in conjunction with our audited Consolidated Financial Statements and the related notes appearing elsewhere in this report. These operating results are not necessarily indicative of the results of any future period. 

41


 
Quarters Ended
 
December 31, 2017
 
September 30, 2017
 
June 30, 2017
 
March 31, 2017
 
December 31, 2016
 
September 30, 2016
 
June 30, 2016
 
March 31, 2016
 
(in thousands, except per amounts)
Revenue
$
131,440

 
$
122,643

 
$
122,227

 
$
124,660

 
$
107,699

 
$
90,906

 
$
95,958

 
$
87,329

Cost of revenue
54,762

 
47,112

 
54,589

 
56,913

 
42,090

 
32,194

 
37,879

 
32,469

Intangibles amortization
2,590

 
1,290

 
1,500

 
1,000

 
510

 
612

 
604

 
601

Gross profit
74,088

 
74,241

 
66,138

 
66,747

 
65,099

 
58,100

 
57,475

 
54,259

Operating expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketing and selling
31,060

 
32,537

 
30,354

 
32,215

 
23,255

 
19,746

 
21,237

 
20,596

Research and development
13,724

 
11,632

 
13,713

 
12,753

 
10,847

 
7,689

 
7,105

 
7,802

General and administrative
16,923

 
17,329

 
24,156

 
16,016

 
13,652

 
12,821

 
11,923

 
12,481

Intangibles amortization
7,330

 
3,882

 
3,885

 
4,074

 
2,243

 
2,409

 
2,197

 
2,134

Restructuring

 
321

 
307

 
286

 
221

 
197

 
1,083

 
35

Total operating expenses
69,037

 
65,701

 
72,415

 
65,344

 
50,218

 
42,862

 
43,545

 
43,048

Income from operations
5,051

 
8,540

 
(6,277
)
 
1,403

 
14,881

 
15,238

 
13,930

 
11,211

Other income (expense), net
(2,300
)
 
150

 
(378
)
 
(1,039
)
 
55

 
(893
)
 
25

 
456

Income before provision for income tax
2,751

 
8,690

 
(6,655
)
 
364

 
14,936

 
14,345

 
13,955

 
11,667

Provision for income tax
9,845

 
17,203

 
(1,621
)
 
16

 
4,705

 
1,032

 
3,443

 
3,129

Net income (loss)
$
(7,094
)
 
$
(8,513
)
 
$
(5,034
)
 
$
348

 
$
10,231

 
$
13,313

 
$
10,512

 
$
8,538

Earnings per share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
$
(0.22
)
 
$
(0.26
)
 
$
(0.15
)
 
$
0.01

 
$
0.32

 
$
0.41

 
$
0.32

 
$
0.26

Diluted
$
(0.22
)
 
$
(0.26
)
 
$
(0.15
)
 
$
0.01

 
$
0.31

 
$
0.40

 
$
0.32

 
$
0.26

Weighted average shares used in the calculation of net earnings per share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
32,648

 
32,593

 
32,529

 
32,485

 
32,405

 
32,388

 
32,438

 
32,606

Diluted
32,648

 
32,593

 
32,529

 
33,040

 
33,009

 
32,981

 
32,983

 
33,222


ITEM 9.    Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
None.
ITEM 9A.     Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the rules of the Securities and Exchange Commission, “disclosure controls and procedures” are controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.
We do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud due to inherent limitations of internal controls. Because of such limitations, there is a risk that material

42


misstatements will not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.
We have evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, we have concluded that our disclosure controls and procedures were not effective as of December 31, 2017. This conclusion was based solely on the material weakness in our internal control over financial reporting further described below.
However, giving full consideration to the deficiency, we have concluded that the Consolidated Financial Statements included in this annual report present fairly, in all material respects, the Company's financial position, results of operations and cash flows for the periods disclosed in conformity with U.S. generally accepted accounting principles.
Management’s Report on Internal Control Over Financial Reporting
Our management, including our chief executive officer and chief financial officer, is responsible for establishing, maintaining and reviewing adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). The Company's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that:
1.
pertains to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company
2.
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorization of management and directors of the Company; and
3.
provide reasonable assurance regarding prevention of timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements
Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.
We conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2017 based on criteria set forth in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In accordance with guidance issued by the Securities and Exchange Commission, companies are permitted to exclude acquisition from their final assessment of internal control over financial reporting for the first fiscal year in which the acquisition occurred. The first fiscal year exemption for internal controls over financial reporting does not apply to controls over purchase price allocation. Our evaluation of internal control over financial reporting excluded the internal control activities of Otometrics, which we acquired on January 3, 2017 and the internal control activities of our Neurosurgery acquisition which we acquired on October 6, 2017. Otometrics and Neurosurgery constituted 23% and 2% of consolidated revenue, respectively, and 8% and 2% of our total assets (excluding acquired intangible assets and goodwill) for the year ended December 31, 2017.
A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis.
Based on our assessment, we did not perform an effective risk assessment relating to significant acquisitions, and as a result we did not adequately design control activities over the accounting for the acquisition of Otometrics.
The control deficiencies described above did not result in material misstatements in the consolidated financial statements as of and for the fiscal year ended December 31, 2017. However, the control deficiencies create a reasonable possibility that a future material misstatement will not be prevented or detected on a timely basis. Accordingly, we have concluded that the control deficiencies represent a material weakness in our internal control over financial reporting as of December 31, 2017.
KPMG LLP, an independent registered public company accounting firm, has audited the Consolidated Financial Statements included in this Annual Report on Form 10-K and, as part of its audit, has issued an adverse opinion on the effectiveness of our internal control over financial reporting. This report appears in Part II, Item 9A of this Annual Report on Form 10-K.
Changes in Internal Control over Financial Reporting
In addition to the control deficiency described above, during the fourth quarter of 2017, we completed a substantial amount of the effort required to transition the critical information technology systems of Otometrics to Natus' legacy

43


information technology systems. The remaining information technology systems integration for Otometrics is expected to be completed during 2018.
Remediation Efforts to Address Material Weakness
We expect to remediate the material weakness during 2018 as we operate our redesigned purchase price allocation controls to account for the acquisition of our Neurosurgery business which we acquired during the fourth quarter of 2017. Our remediation actions will include:
improving the design of internal controls related to our review of key assumptions and data used to allocate acquisition purchase price by evaluating the specific financial reporting risks associated with each acquisition as they occur;
improving the design of internal controls related to the evidence and documentation of internal control procedures with respect to the process of determining purchase price allocation; and
sufficiently distinguishing our internal controls from the process we undertake to allocate purchase price.


44


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors
Natus Medical Incorporated:
Opinion on Internal Control Over Financial Reporting
We have audited Natus Medical Incorporated and subsidiaries (the “Company”) internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, because of the effect of the material weakness, described below, on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheets of the Company as of December 31, 2017 and 2016, the related consolidated statements of operations and comprehensive income, stockholders' equity, and cash flows for each of the years in the three-year period ended December 31, 2017, and the related notes (collectively, the “consolidated financial statements”), and our report dated March 1, 2018 expressed an unqualified opinion on those consolidated financial statements.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. Management concluded that there was a material weakness because the Company did not perform an effective risk assessment relating to significant acquisitions, and as a result, the Company did not adequately design control activities over the accounting for the acquisition of Otometrics. The material weakness was considered in determining the nature, timing, and extent of audit tests applied in our audit of the 2017 consolidated financial statements, and this report does not affect our report on those consolidated financial statements.
The Company acquired the Otometrics business on January 3, 2017 and the Neurosurgery business on October 6, 2017. Management excluded from its assessment of the effectiveness of the Company's internal control over financial reporting as of December 31, 2017, the internal control activities of Otometrics and Neurosurgery which represented 23% and 2%, respectively, of total revenue and 8% and 2%, respectively, of total assets (excluding acquired intangible assets and goodwill) of the related consolidated financial statement amounts of the Company as of and for the year ended December 31, 2017. Our audit of internal control over financial reporting of the Company also excluded an evaluation of the internal control over financial reporting of Otometrics and Neurosurgery.
Basis for Opinion
The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

45


Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
    
(signed) KPMG LLP
San Francisco, California
March 1, 2018


46


PART III

ITEM 10.    Directors, Executive Officers, and Corporate Governance
Board of Directors
Our Board currently consists of six directors and is divided into three classes. Each class is elected for a term of three years, so that the term of one class of directors expires at each meeting. There are no family relationships among our executive officers and directors. Information regarding the business experience and age as of April 30, 2018 of each nominee and other members of the Board is provided below.

Doris E. Engibous
Director since 2004
Age 62
Ms. Engibous has served as a consultant and advisor to medical technology companies and executives since 2010. From 2004 to 2010, she served as President and CEO of Hemosphere Inc., an early commercialization stage, venture capital funded, medical technology company, prior to its acquisition by CryoLife Inc. (NYSE: CRY). Prior to 2004, Ms. Engibous served from 2000 through 2003 as President of Nellcor, a business of Tyco Healthcare Group/Tyco International Ltd. (now Covidien/Medtronic, NYSE: MDT). From 1986 through 2000, Ms. Engibous served in several executive capacities at Nellcor and its successors Nellcor Puritan Bennett Inc. and Mallinckrodt Inc., including as vice president, general manager and global business leader and senior director of marketing, and was responsible for the integration of Nellcor into Mallinckrodt and later Tyco Healthcare. Ms. Engibous has served on the board of directors of GI Supply, Inc., a family-owned medical technology company since 2014 and as its Chair since 2016. Ms. Engibous served on the board of directors of the National Kidney Foundation serving Minnesota, the Dakotas and Iowa from 2006 to 2010. She holds a Bachelor of Science degree in Chemical Engineering from the University of Michigan.

Ms. Engibous is distinguished by her technical background in Chemical Engineering, coupled with strong operational experience in manufacturing, regulatory affairs, quality assurance and marketing. She brings to the Natus Board over 30 years of experience in the medical device industry, including knowledge of organizational and operational management, financial expertise, marketing, R&D, human resources and integration experience relevant to a public company in the healthcare industry.

William M. Moore
Director Since 1989
Age: 69
Mr. Moore currently is the Chief Executive Officer and President and Chairman of the board of directors of IRIDEX Corporation, a medical device company, and has served in that capacity, or as interim Chief Executive Officer and President, since August 2012. Mr. Moore has served as the Managing Partner of Alpine Partners LLC since May 2008 as well as from 2003 to 2004. From 2004 until May 2008 Mr. Moore was a special limited partner for medical technology at Blue Line Partners, a private equity firm. He also has served on the boards of directors of Criticare Systems, Inc. from 2006 until it was acquired by Opto Circuits (India) Limited in April 2008 and Urologix Inc. from 2008 until June 2010. Mr. Moore holds a Bachelor of Science degree in Business from the University of Utah. Mr. Moore brings to the Board more than 25 years of executive experience in the worldwide medical technology field, particularly in the areas of sales, marketing, and product development. Mr. Moore is one of our co-founders and resigned as CEO of the Company in 1992.

James B. Hawkins
Chief Executive Officer
Director Since 2004
Age: 62
James B. Hawkins has served as Chief Executive Officer, and as a member of the Board, since joining Natus in April 2004 and as President since June 2013. He previously served as President from April 2004 through January 2011. Since December 2015, he has served as a member of the board of directors of OSI Systems, Inc., and he has served as a member of the board of directors of El Dorado Resorts since September 2014. Mr. Hawkins previously served as a director at Iradimed Corporation from 2005 until June 2016, IRIDEX Corporation from October 2007 until December 2014 and Digirad Corporation from April 2012 to October 2014. Prior to joining Natus, Mr. Hawkins was President, Chief Executive Officer and a director of Invivo Corporation, a developer and manufacturer of multi-parameter vital sign monitoring equipment, and its predecessor, from August 1985 through January 2004. He earned his undergraduate degree in Business Commerce from Santa Clara University and holds a Masters of Business Administration degree from San Francisco State University. Mr. Hawkins’ brings to the Board highly relevant leadership experience in the medical technology industry as well as a unique perspective on our operations due to his position as our Chief Executive Officer.

47



Robert A. Gunst
Chairman of the Board
Director Since 2004
Age: 70
Robert A. Gunst is Chairman of the Board of Directors of Natus Medical. Currently a private investor, Mr. Gunst served from 1990 to 1999 as President and Chief Executive Officer of The Good Guys, Inc., one of the largest specialty retailers of higher-end entertainment electronics in the nation. During that time he grew the business from a few stores in the San Francisco area to a chain of stores in four western states with approximately $1 billion in revenue. Earlier in his career, he held executive positions at several large corporations, including Shaklee Corporation, La Petite Boulangerie, Inc. and PepsiCo Foods International (both subsidiaries of PepsiCo, Inc.), Victoria Station Incorporated and The First National Bank of Chicago.

Mr. Gunst has served on a variety of public and private boards, including serving as a Director of The Good Guys, Inc. from 1986 to 1999, Director of Phoenix Footwear Group, Inc. from 2006 to 2007, Director of PortalPlayer, Inc. from 2005 to 2007, Director of AmNet Mortgage, Inc. (formerly American Residential Investment Trust Inc.) from 2004 to 2005, Director of Garden Fresh Restaurant Corp. from 1996 to 2004 and Chairman of Garden Fresh Restaurant Corp. from 2003 to 2004. He served as a member of the Deans Advisory Council of the Graduate School of Management at the University of California, Davis from 1997 to 2008. Mr. Gunst holds an MBA in Finance from the University of Chicago’s Graduate School of Business and a Bachelor of Arts degree in Economics from Dartmouth College.

Mr. Gunst brings to the Natus Board nearly five decades of leadership, strategy, financial and operational experience, as well as experience in overseeing the operations of companies in various stages of development and is therefore uniquely qualified to serve as chairman of our Board.

Kenneth E. Ludlum
Director since 2002
Age 64
Mr. Ludlum currently serves as a board member, and has acted as a board member and as an advisor to and investor in a number of public and private medical and biotechnology companies. He served as Chief Financial Officer of CareDx, Inc., a medical diagnostic company, from March 2014 to April 2016. From April 2011 to October 2013, Mr. Ludlum served as Vice President and Chief Financial Officer, and Head of Operations for Endogastric Solutions, Inc., a medical device company. Prior to that, Mr. Ludlum also served as CFO for two other publicly-held companies, Perclose, Inc. from 1995 to 2000, and Alteon, Inc. from 1992 to 1994. He has also served on the board of directors and as Chair of the Audit Committee of several public and private medical or biotechnology companies. Mr. Ludlum holds a B.S. in Business Administration from Lehigh University and a M.B.A. from Columbia University Graduate School of Business. Mr. Ludlum brings to the Board over 30 years of business and financial experience working with healthcare and biotechnology companies. His service as chief financial officer at several public companies has provided him with extensive financial and accounting experience, and knowledge of accounting principles, financial reporting rules, and regulations. With his background in investment banking, he also brings a broad perspective to the Board.

Barbara R. Paul, M.D.
Director since 2016
Age 64
Dr. Paul serves as an advisor and board member to healthcare companies. In addition to her role on the board of Natus Medical, she serves on the board of Quorum Health Corporation, an owner and operator of general acute care hospitals and outpatient service providers. She served as Senior Vice President & Chief Medical Officer at Community Health Systems (CHS) from July 2007 to January 2015. Prior to CHS, Dr. Paul was Senior Vice President & Chief Medical Officer for Beverly Enterprises, Inc. (now Golden Living, Inc.). Dr. Paul is a board-certified internist and she practiced as a full-time primary care physician for twelve years. She also worked at the federal Medicare program (Centers for Medicare & Medicaid Services, CMS), where she was Director of the Department of Quality Measurement & Health Assessment. Dr. Paul has a bachelor of science from the University of Wisconsin - Madison and earned her medical degree from Stanford University School of Medicine. Dr. Paul brings the perspective of a physician to the Board and also brings insight into quality measures and reporting, as well as federal government regulation of hospital-practitioner relationships.

Our Executive Officers
The names of our current executive officers, their ages as of April 30, 2018 and their positions are shown below: 

48


Name
 
Age
 
Position(s)
James B. Hawkins
 
62

 
President and Chief Executive Officer
Jonathan A. Kennedy
 
47

 
Executive Vice President and Chief Financial Officer
D. Christopher Chung, M.D.

 
54

 
Vice President Medical Affairs, Quality & Regulatory

Carsten Buhl
 
44

 
President & CEO, Otometrics SBU
Leslie McDonnell
 
45

 
Vice President and General Manager, Newborn Care
Austin F. Noll, III

 
51

 
Vice President and General Manager, Neurology SBU

There is no family relationship between any of the directors or executive officers and any other director or executive officer of Natus.
James B. Hawkins has served as Chief Executive Officer, and as a member of the Board of Directors, since joining Natus in April 2004, and as President from April 2004 through January 2011 and from June 2013 to present. In addition, he currently serves on the Board of Directors for Eldorado Resorts, Inc. and OSI Systems.  Prior to joining Natus, Mr. Hawkins was President, Chief Executive Officer and a Director of Invivo Corporation, a developer and manufacturer of multi-parameter vital sign monitoring equipment, and its predecessor, from August 1985 through January 2004. Mr. Hawkins also served as Secretary of Invivo from July 1986 until January 2004. He earned his undergraduate degree in Business Commerce from Santa Clara University and holds a Masters of Business Administration degree from San Francisco State University.
Jonathan A. Kennedy joined Natus as Senior Vice President and Chief Financial Officer in April 2013 and was appointed Executive Vice President and Chief Financial Officer in September 2016. In addition, he currently serves on the Board of Directors for IRadimed Corporation. Before joining Natus, Mr. Kennedy was Senior Vice President and Chief Financial Officer of Intersil Corporation, a global semiconductor manufacturer, since 2009. Prior to that, he was Intersil’s Corporate Controller since 2005 and Director of Finance since 2004. Before joining Intersil, Mr. Kennedy held management roles in Finance and Information Technology with Alcon Inc. and Harris Corporation. He holds a Bachelor of Science degree in Business Administration and a Master of Science degree in Accounting from the University of Central Florida. Mr. Kennedy is also a Certified Public Accountant.
D. Christopher Chung, M.D., has served as our Vice President Medical Affairs, Quality and Regulatory since June 2003, and has served as our Vice President Medical Affairs since February 2003. Dr. Chung also served as our Medical Director from October 2000 to February 2003. From 2000 to 2007, Dr. Chung also served as a Pediatric Hospitalist at the California Pacific Medical Center in San Francisco. From 1997 to 2000, Dr. Chung trained as a pediatric resident at Boston Children’s Hospital and Harvard Medical School. From 1986 to 1993, Dr. Chung worked as an Engineer at Nellcor, a medical device company. Dr. Chung holds a Bachelor of Arts degree in Computer Mathematics from the University of Pennsylvania and a Doctor of Medicine degree from the Medical College of Pennsylvania-Hahnemann University School of Medicine. He is board certified in Pediatrics and is a Fellow of the American Academy of Pediatrics.
Carsten Buhl joined Natus in February 2018 and is acting as President for Natus' strategic business unit Otometrics. Mr. Buhl has more than 15 years experience in the medical device industry and has a proven track record within commercial execution and global leadership positions. Prior to joining natus, Mr. Buhl acted as Executive Vice President and Chief Commercial Officer at Ambu, a successful medtech company within the fields of anesthesia, patient monitoring and emergency care. Previously, Mr. Buhl held various management positions at GN Hearing, which is one of the world's largest providers of hearing instruments, most recently as Senior Vice President of Europe and Strategic Accounts. Mr. Buhl holds a Master of Law from Copenhagen University and an E*MBA from SIMI/CBS Copenhagen supplemented by graduate diplomas in Finance and Accounting from CBS Copenhagen.
Leslie McDonnell joined Natus in February 2018 as the Vice President and General Manger, Newborn Care. Ms. McDonnell is a healthcare business executive with 17 years of global experience in medical devices and supplies. Prior to joining Natus, Ms. McDonnell served as Global Business Vice-President for the Critical & Chronic Care Solutions of 3M Healthcare. Prior to joining 3M Healthcare, Ms. McDonnell held leadership positions at Medtronic over a 12 year period in corporate M&A, business development, new therapy and product development, and marketing and business management in the Neuromodulation and Cardiac Rhythm Disease Management business. Ms. McDonnell holds a Bachelor of Science in Business and Masters of Busines Administration as an International Business Fellow from the Carlson School of Management at the University of Minnesota. In 2009, Ms. Donnell was selected as a 40 Under Forty honoree for business and community leadership by the Minneapolis/St. Paul Business Journal.
Austin F. Noll, III joined Natus in August 2012 as the Vice President and General Manager, Neurology. Prior to joining Natus, Mr. Noll served as the President and CEO of Simpirica Spine, a California-based start-up company that developed and commercialized a novel device for spinal stabilization. Prior to joining Simpirica Spine, Mr. Noll served as the President and CEO

49


of NeoGuide Systems, a medical robotics company acquired by Intuitive Surgical. Prior to joining NeoGuide Systems, Mr. Noll held numerous management positions at Medtronic over a 13-year period, where he served as the Vice President and General Manager of the Powered Surgical Solutions and the Neurosurgery businesses. Before Medtronic, he held sales positions at C.R. Bard and Baxter Healthcare. He received a bachelor’s degree in business administration from Miami University and a master’s of business administration from the University of Michigan.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our directors, executive officers and holders of more than 10% of our common stock to file with the Securities and Exchange Commission reports regarding their ownership and changes in ownership of our securities. We believe that, during fiscal 2017, our directors, executive officers and 10% stockholders complied with all Section 16(a) filing requirements. In making this statement, we have relied upon examination of the copies of Forms 3, 4 and 5, and amendments thereto, provided to us, and the written representations of our directors, named executive officers and 10% stockholders.
Code of Conduct and Code of Ethics
We have a code of conduct and ethics that applies to all of our employees, including our principal executive officer, principal financial officer, and principal accounting officer or controller. This code of conduct and ethics is posted on our internet website. The internet address for our website is www.natus.com, and the code of conduct and ethics may be found in the “Governance” section of our “Investor” webpage.
We intend to satisfy the disclosure requirement under Item 10 of Form 8-K regarding certain amendments to, or waivers from, provisions of this code of conduct and ethics by posting such information on our website, at the address and location specified above, or as otherwise required by The NASDAQ Stock Market.
Audit Committee and Financial Expert
Our Audit Committee oversees and monitors our financial reporting and disclosure processes, our financial statement audits, the integrity of our financial statements, the qualifications, independence and performance of our independent registered public accounting firm, and our internal accounting and financial controls. The Committee also pre-approves audit and non-audit services, reviews, approves and monitors our Code of Business Conduct and Ethics with respect to our Chief Executive Officer, Chief Financial Officer, and other senior financial officers, and establishes procedures for receiving and handling complaints regarding accounting, internal accounting controls, or auditing matters.

The members of the Audit Committee of our Board of Directors are Kenneth E. Ludlum, Robert A. Gunst, and William M. Moore. Our Board of Directors has determined that Kenneth E. Ludlum is an audit committee financial expert as defined in Item 407(d) of Regulation S-K. All of the members of our audit committee are considered “independent” as the term is used in Item 7(d)(3)(iv) of Schedule 14A under the Exchange Act.

ITEM 11.    Executive Compensation
Executive Compensation and Related Information
Compensation Discussion & Analysis (CD&A)
 
General
Our executive compensation program is designed to:
attract and retain individuals with the skills and performance needed to achieve our business objectives
reward and incentivize individuals fairly over time
align the short and long-term compensation of those individuals with the Company’s performance

Executive Summary
In 2017 we completed two significant acquisitions that we believe lay the groundwork for our future revenue growth and growth in profitability, the Otometrics acquisition completed in January 2017, and the acquisition of neurocritical care and neurosurgical product lines from Integra LifeSciences in October 2017. In addition, we continued our efforts to strengthen our

50


neurology and newborn care franchises. With our acquisitions, we achieved record revenue in 2017, exceeding the goal of $500 million in annual revenue that we have shared with investors in recent years.
Notwithstanding our revenue growth of 31.2% in 2017, our net income was below our target levels and below the net income achieved in 2016. This was primarily due to lower profitability in our newborn care business unit driven by lower gross profit margins due to unfavorable revenue mix and increased investments in product engineering and required to meet regulatory standards.
Similar to the cash bonus plans we adopted in prior years, our executive officers were eligible to receive cash bonuses for 2017 based on the attainment of specific performance objectives, as further described below. The 2017 plan included a threshold requirement for all executive officers that consolidated earnings must exceed 85% of the plan target as a condition to the payment of any cash bonuses. While many of the other performance metrics were attained at a level that would result in the payment of cash bonuses, no cash bonuses were paid for 2017 because our earnings per share did not meet the threshold. We believe that the cash bonus plan operated effectively in 2017 to establish meaningful performance criteria, resulting in no bonus payments as our earnings target was not satisfied. This being the case, we recognize that the responsibilities of our executive officers were increased substantially with the addition of the Otometrics and neurocritical care/neurosurgical product lines in 2017, and that our executves expended significant additional efforts to integrate these new businesses.
At our annual meeting in 2017, approximately 91% of the stockholders who voted on our 2017 Say on Pay proposal voted in favor of the proposal. Considering this outcome, the Compensation Committee determined that it would continue to apply the same philosophy and guiding principles to the 2018 compensation for the Company’s named executive officers, and, as a result, did not change the structure of our executive compensation for 2018.
Our Business and Our Compensation Philosophy
We believe that opportunities exist for us to increase stockholder value by increasing our per-share earnings, and believe that the optimal manner of doing so is to increase the revenue base of the Company. We seek revenue growth through organic growth involving, primarily, the introduction of existing products into new markets and the internal development of new products, as well as via acquisitions of complementary products and businesses. Our business plans challenge our executives to seek growth through both of these means, and we expect over time to achieve a higher level of overall growth than could be achieved through either method alone. Further, we expect our business, including the businesses that we acquire, to be operated efficiently so that earnings can grow as we increase revenue. We also seek to achieve earnings growth by managing our business efficiently and implementing cost reduction efforts from time to time when we determine that we can do so without impairing our ability to operate effectively.
Pursuit of this business model is demanding on our executives. They must implement efforts to enhance sales opportunities of existing products, oversee effective and efficient new product development and enhancements, successfully identify and complete the acquisition of complementary products and businesses and integrate these operations with our existing businesses, as well as conduct our business in an efficient manner.
In consideration of these factors, the primary objectives of our executive compensation are:
Retain Qualified Executive Talent. During the period from 2003 to 2017 we have substantially increased the size of our company. In this time period, we have completed 28 acquisitions of companies with principal offices in six different countries. We believe that maintaining continuity within our executive team has contributed significantly to our ability to achieve this growth. Our business is competitive and our corporate headquarters is in an area where there is significant competition for executive talent. In light of these factors, a key objective of our compensation is to allow us to retain qualified executives.
Attract Qualified Executives. We understand that we may find it in our interests to, or may be required to, add new individuals to our executive team from to time. For example, in February 2018 we added two new executive officers to head our newborn care and Otometrics operations. For us to be appropriately positioned to attract new talent as needed, we must be prepared to, and be perceived as an employer that is willing to, offer competitive compensation.
Link Compensation to Achievement of Our Business Objectives. We believe that a significant portion of the current period cash compensation that our executives are eligible to receive should be tied to attainment of goals that our Compensation Committee has determined are most capable of increasing stockholder value for the Company. Accordingly, our annual bonus plan has been tied to earnings and revenue goals and, for certain of our executives, the attainment key business objectives.
Provide Direct Incentives for the Enhancement of Stockholder Value Over the Long Term. The effectiveness of our management in operating our business has a strong influence on the value of our common stock over time. We believe that our executives should be positioned to share, with our stockholders, in the gains and losses from changes in the value of our common

51


stock over time and that this form of compensation will further motivate our executives to seek to increase long-term stockholder value.
Elements of Compensation
Our executive officers’ compensation currently has two primary elements of compensation: (i) cash compensation in the form of salary and annual incentive awards, and (ii) equity awards in the form of restricted stock awards. In addition, we provide our executive officers with benefits that are available generally to all salaried employees.
We believe that we would impair our ability to retain our executives or, as required, attract new executives if we did not offer a competitive salary. As such, our goal is to provide salaries that are sufficient to make us reasonably confident of our ability to retain our executive team without overpaying. We further believe that a substantial portion of the cash compensation that our executives are eligible to receive should be directly tied to corporate performance. We believe that our annual business plans represent reasonably challenging targets, as evidenced by our paying no cash bonuses for 2017 and paying cash bonuses in the range of 17% to 64% of target for 2016. Our long-term equity-based incentive awards are designed to provide a competitive compensation package and to motivate our executives to increase stockholder value.
In establishing compensation, we take into account the compensation that is payable by companies that we believe to be our competitors and by other companies with which we believe we generally compete for executives. To this end, our Compensation Committee works with an outside compensation consultant, Willis Towers Watson, to define the criteria used to identify appropriate market comparisons for establishing compensation levels and the mix of salary, incentive compensation, and equity compensation. When determining our peer companies, we focus on identifying companies with whom we compete directly for customers and employees, as well as other medical device companies in the United States. In addition, we select companies that are similar to our size, limiting the peer group to companies whose trailing twelve-month revenue is generally within a range of approximately 0.5x to 2.0x of our projected annual revenue.
Our Compensation Committee requested and received a formal report from, Willis Towers Watson, to assist it in its deliberations for 2017 cash and equity compensation. The peer companies used in that report were: ABIOMED, Inc.; Accuray; Analogic; AngioDynamics; CONMED Corporation; Globus Medical, Inc.; Haemonetics Corporation; ICU Medical; Insulet Corporation; Integra LifeSciences; Masimo Corporation; Merit Medical Systems, Inc.; NuVasive, Inc.; Nxstage Medical, Inc.; Omnicell; and The Spectranetics Corporation. For the purpose of establishing competitive compensation ranges for elements of compensation, Willis Towers Watson considered the most recently reported compensation information for the peer group companies as well as the applicable compensation survey information based on our size and industry. The peer group was revised from the previous year group with the assistance of Willis Towers Watson in establishing compensation with two companies removed, as one company was acquired (Cyberonics), and another was deemed too small (Abaxis). Three companies were added (Integra LifeSciences, Insulet and Haemonetics) to the peer group based on the criteria described above. In addition to the reports from Willis Towers Watson, in determining the compensation of each of our executive officers other than that the Chief Executive Officer, our Compensation Committee considers the recommendations of the Chief Executive Officer.
Willis Towers Watson has worked directly with the Compensation Committee (and not on behalf of management) to assist the Compensation Committee in satisfying its responsibilities and will undertake no projects for management except at the request of our Compensation Committee chair and in the capacity of our Compensation Committee’s agent. To date, Willis Towers Watson has not undertaken any projects for management or for the Company other than advising the Compensation Committee with respect to compensation matters and assisting the Company in the preparation of the pay ratio disclosure required for the first time in this Annual Report on Form 10-K for the year ended December 31, 2017. The Compensation Committee has concluded that none of Willis Towers Watson’s work to date has raised any conflicts of interest that will prevent Willis Towers Watson from being independent consultants to the Compensation Committee.
We view the cash and equity elements of compensation as distinct. We think that each of these main components must be perceived by our executives as largely competitive with the corresponding compensation element paid by our peer companies. While we view cash and equity elements of compensation as distinct, we do link these two components of compensation insofar as it is our goal to establish aggregate cash and equity compensation that is between the median and the 75th percentile of our peer group, assuming achievement of target level of performance, with the understanding that we may from time to time elect to provide compensation above this level in connection with the hiring of a new executive if we determine that it is necessary to provide compensation at this level to attract an executive with skills and experience we desire.
Because we seek to provide cash compensation that our executives regard as competitive with relevant market conditions, when setting salaries and aggregate cash compensation we are mindful of the corresponding amounts of cash consideration of our peer group. However, we may set an individual officer’s salary and target bonus above or below median levels of our peer group, as determined to be appropriate by the Compensation Committee. We believe that this approach is sufficient to achieve our retention goals. For the achievement of performance goals above plan, our executives can earn aggregate cash consideration that is

52


substantially above the median level of the peer group. We believe that this is appropriate because we adopt business plans that are a challenge for us to attain, and we believe that if our executives exceed the demanding targets in these plans they should be eligible to receive higher levels of compensation.
We view our compensation decisions as an exercise in paying competitive compensation, with desired performance goals, on an annual basis. Our cash compensation is not tied to performance beyond one year. Our equity awards vest over a period of time, and as such are impacted by the value of our common stock over the vesting period of the restricted stock. We do not take account of prior wealth accumulation by our executives from the receipt of cash on exercise or vesting of equity awards as we do not believe these prior period returns provide a significant motivation or retention benefit in the current period. Further, we do not set the compensation of our executives at any multiple or ratio to the compensation of other executives or employees. Our Compensation Committee has not adopted any formal or informal policies or guidelines for allocating compensation between long-term and immediate compensation, between cash and non-cash compensation, or among different forms of non-cash compensation, other than as described in this Compensation Discussion and Analysis for the manner in which we make restricted stock awards to executives.
Our Compensation Committee’s current intent is to perform on a regular basis a strategic review of our executive officers’ overall compensation packages to determine whether they provide adequate incentives and motivation and whether they adequately compensate our executive officers relative to comparable officers in our peer group companies.
Base Salaries
Our Compensation Committee reviews the base salaries of our executives annually and may adjust an officer’s salary if it determines that such a change is merited on the basis of the officer’s personal performance and market conditions. As set forth in the “Summary Compensation” table below, the Compensation Committee approved 2017 salary increases for executive officers based on market conditions, individual performance of the executives, the Company’s growth and the Company’s increased complexity of operation.
Cash Incentive Plan
As noted above, one element of our cash compensation has been a performance-based incentive plan. In 2015, upon the recommendation of the Board and Compensation Committee, our stockholders approved a Cash Incentive Plan, or CIP, for the Company to preserve our ability to deduct “performance-based compensation” awards pursuant to Section 162(m) of the Internal Revenue Code of 1986. The 2017 CIP further described below, which is the performance-based cash incentive plan for 2017, was adopted pursuant to the CIP.

Maximum Bonus and Performance Goals

The 2017 CIP applied the same performance metrics, with the same weighting, as the 2016 CIP for our CEO and CFO. In both plans, the bonus opportunity for our CEO and CFO was based primarily on consolidated adjusted pre-tax earnings per share with a lesser weighting for consolidated revenue. For our CEO and CFO the target bonus for 2017 was weighted (i) at 80% for attainment of the consolidated pre-tax earnings per share contained in the Company’s 2017 business plan approved by the Board (“2017 Plan”) and (ii) at 20% for attainment of the consolidated revenue contained in the 2017 Plan.
For Mr. Noll, the Vice President and General Manager of our Neurology strategic business units (“SBUs”) and Mr. Traverso, who served through the first quarter of 2017 as the general manager of our Newborn care SBU, the target bonus under the 2017 CIP was based on the achievement of five metrics: (i) the consolidated pre-tax earnings per share contained in the 2017 Plan weighted at 15%, (ii) the consolidated revenue contained in the 2017 Plan weighted at 15% (iii) the pre-tax earnings per share of their respective strategic business units contained in the 2017 Plan weighted at 25%, (iv) the revenue of their SBUs contained in the 2017 Plan weighted at 25%, and (v) successful completion of discrete operational goals for their respective SBUs in 2017 weighted at 20%. These performance metrics were the same performance categories implemented in the 2016 CIP. Dr. Chung’s bonus was based on the achievement of the following three metrics: (i) the consolidated pre-tax earnings per share contained in the 2017 Plan weighted at 60%, (ii) the consolidated revenue contained in the 2017 Plan weighted at 20% and (iii) the successful completion of discrete operational goals weighted at 20%. These performance metrics were the same performance categories implemented in the 2016 CIP for Dr. Chung.
    
The target consolidated revenue for 2017 was $519,400,000.00. The target amount of consolidated non-GAAP EPS was $ 1.89. The 2017 CIP required as a threshold to the payment of cash bonuses to any executive officers that we achieve the non-GAAP EPS target at a minimum of the 85% level. Because it was clear that no bonus payments would be made for 2017 in light of our actual operating results, the actual adjustments to EPS were not calculated. Had it been necessary to determine adjusted EPS for 2017, the likely adjustments would have been to eliminate restructuring costs, costs of acquisitions, and remediation costs at the Company’s Seattle facility.

53



Target amounts for our named executive officers under the 2017 CIP were established as a percentage of the base salaries of the respective officers and were as follows:

Name:
($)
Minimum Bonus
($)
Target Bonus
($)
Maximum Bonus
James B. Hawkins, Chief Executive Officer  
400,000
  800,000
1,600,00
Jonathan A. Kennedy, Senior Vice President Finance and Chief Financial Officer
156,000
  312,000
624,000
Austin A. Noll, III, Vice President, General Manager, Neurology
90,000
  180,000
360,000
Kenneth M. Traverso, Vice President, General Manager, Newborn Care (1)
82,500
165,000
330,000
D. Christopher Chung, M.D., Vice President Medical Affairs, Quality and Regulatory Affairs
60,000
   120,000
240,000

(1) Mr. Traverso served as the general manager of our Newborn Care SBU, and as an executive officer, through the first quarter of 2017, following which time he continued as an employee.
Equity-Based Compensation Element
Equity-based compensation provides employees with a common interest with our stockholders to increase the value of our common stock. Equity awards are granted to employees, including our executive officers, in the form of restricted stock and restricted stock units. Equity grants help retain key employees because they typically cannot be fully exercised or are subject to a right of repurchase for four years. In addition, the four-year vesting schedule also helps focus our employees on long-term performance.
From 2006 until December 2014, we sought to achieve the equity portion of aggregate compensation through stock option grants and restricted stock awards, with each comprising approximately half of the value of the annual equity award. From December 2014 forward, the annual equity award is comprised solely of restricted stock awards.
Equity-based compensation is granted to an executive officer when the executive first joins us. Additional equity-based compensation may be granted in connection with a significant change in responsibilities. Further, we typically make annual equity awards to our executive officers. In making these awards our Compensation Committee applied the compensation philosophy discussed above. In particular, the Compensation Committee used equity awards to help to provide total annual compensation that was consistent with its goals for total compensation, to incent our executives to increase the per share value of the Company over the course of the vesting period of these awards and to provide a mechanism for the retention of the executives over the course of the vesting of the awards. The Compensation Committee’s procedure for timing of equity awards provides assurances that grant timing is not being manipulated to result in a price that is favorable to employees. In 2015, the Compensation Committee revised its practice with regard to the granting of equity awards to employees and did so at the beginning of the year in connection with its establishment of cash compensation. Previously, equity awards were made promptly following the annual meeting of stockholders, typically in June of each year. The exercise price for all option grants is the closing price on the last completed day of trading prior to the meeting of the Compensation Committee at which the options are granted.
In 2018 we revised the form of award agreement for our equity-based awards to provide that unvested awards would vest upon retirement if the employee had attained the age of 65 and had been continuously employed for at least 10 years. Our Compensation Committee elected to make this change because it sought to have the ability to continue to motivate employees to remain in our employ following the attainment of age 65, even if the employee might not otherwise be committed to working through the full customary vesting term. This provision applies to all recipients of equity awards made after the adoption of this change, including Executive Officers.
Employment Agreements and Change in Control Arrangements
We entered into employment agreements with Kenneth M. Traverso in November 2002 and D. Christopher Chung, M.D. in February 2003, both of which were amended in December 2008, and with James B. Hawkins in April 2004, which was amended in April 2008, December 2008, and April 2014. We entered into an employment agreement with Austin A. Noll, III on August 1, 2012 and Jonathan A. Kennedy on April, 11, 2013. In addition, with the exception of Mr. Hawkins and Mr. Kennedy, the other executives entered into Amended Employment Agreements with the Company in August, 2014. Other than Mr. Hawkins, the terms of these agreements are substantially the same. Upon termination of employment for cause, death, or disability, the executive

54


will only be eligible for severance benefits, if any, in accordance with the Company’s established policies for all employees as then in effect, which consist primarily of short-term disability and group life insurance benefits.
Should an officer’s, other than Mr. Hawkins’ employment with us terminate for other than cause, death or disability, the officer shall be entitled to:
Receive continuing payments of severance pay, less applicable withholding taxes, at a rate equal to the officer’s then current base salary rate for a period of twelve months commencing with the latest payroll date that is also within 70 days from the date of “separation from service” (with earlier commencement possible only if in compliance with Section 409A of the Internal Revenue Code and with payments that would have been made on earlier payroll dates, but for this provision, cumulated and paid on such payroll date);
The immediate vesting and exercisability of any unvested stock options and of restricted stock, or other equity awards, which in the case of stock options would be exercisable for a period of 30 days after such termination; and
Continued payment by the Company of COBRA benefits through the lesser of (i) six to eighteen months from the effective date of such termination, (ii) the date upon which the officer and the officer’s eligible dependents become covered under similar plans, or (iii) the date the officer no longer constitutes a “Qualified Beneficiary”, as such term is defined in Section 4980B(g) of the Internal Revenue Code of 1986, as amended.
These agreements provide for the same severance benefits as above if the officer terminates his employment for “good reason” within 12 months following a change-in-control transaction, in which case the executive also is eligible to receive a cash payment equal to the amount of the officer’s target bonus in effect at the time of the change-in-control event occurs or the actual bonus at the time of the officer’s termination. Employment termination is for “good reason” if it follows a material reduction in the officer’s duties or responsibilities, a reduction in base salary, a material reduction in employee benefits, relocation of more than 35 miles from the officer’s present location, or the failure of a successor entity to assume the employment agreement. A change in control for such employment agreements is a transaction by which someone acquires more than 50% of the Company’s outstanding voting power, a change in the Board within a two-year period such that fewer than a majority are incumbent directors, a merger or consolidation following which the stockholders of the Company own 40% or less of the combined voting power of the Company or the surviving entity, or the sale of all or substantially all of the assets of the Company.
Should Mr. Hawkins’ employment with us terminate for other than cause, death or disability, Mr. Hawkins shall be entitled to:
Receive a lump sum payment due and payable within thirty (30) days after the date of separation, less applicable withholding taxes, equal to two times his then current base salary;
The immediate vesting of any unvested stock options, restricted stock, or other equity awards, which in the case of stock options would be exercisable for a period of 30 days after such termination; and
Continued payment by the Company of COBRA benefits through the lesser of (i) 18 months from the effective date of such termination, or (ii) the date upon which he or his eligible dependents become covered under similar plans
The agreement provides that if within twelve months of a change in control transaction Mr. Hawkins terminates his employment for “good reason” or is terminated without cause, then Mr. Hawkins will receive (i) a lump sum payment due and payable within thirty (30) days after the date of separation, less applicable withholding taxes, equal to two times the sum of (A) the greater of his then current base salary rate and his base salary rate in effect immediately prior to the change in control transaction and (B) the greater of 100% of his target bonus then in effect and 100% of his target bonus as in effect immediately prior to the change in control transaction; (ii) continued provision of COBRA or similar benefits through the lesser of twenty-four months or the date upon which Mr. Hawkins becomes covered under similar plans; and (iii) the immediate vesting of unvested stock options, restricted stock and other equity awards. Employment termination is for “good reason” if it follows a material reduction in the officer’s duties or responsibilities, a material reduction in base salary, a material reduction in employee benefits, relocation of more than 35 miles from the officer’s present location, or the failure of a successor entity to assume the employment agreement. A change in control for purposes of this employment agreement is a transaction by which someone acquires more than 50% of the Company’s outstanding voting power, a merger or consolidation following which the stockholders of the Company own 40% or less of the combined voting power of the Company or the surviving entity, stockholder approval of a plan to liquidate the Company, or the sale of all or substantially all of the assets of the Company.
To be eligible for termination benefits, all executives must comply with certain non-compete and non-solicitation provisions and retention is conditioned on execution of a release of claims.

55


The base salaries for our named executive officers for 2017 were as follows: James B. Hawkins, $820,000; Jonathan A. Kennedy, $490,000; Austin A. Noll, III, $370,000; Kenneth M. Traverso, $340,000; and D. Christopher Chung, M.D., $310,000.
We believe that these agreements appropriately balance our needs to offer a competitive level of severance protection to our executives and to induce our executives to remain in our employ through the potentially disruptive conditions that may exist around the time of a change in control, while not unduly rewarding executives for a termination of their employment. We note that our change in control terms include so-called “double trigger” provisions, so that the executive is not entitled to the severance payment by the mere occurrence of the change in control. This feature, we believe, will be an incentive to the executive to remain in the employ of the Company if such continuation is required by our partner in a change in control transaction.
Our 2011 Stock Awards Plan provides for the grant of options to purchase our common stock to employees, directors and consultants. Under the predecessor plan, prior to June 14, 2006, options granted to employees had a contractual term of ten years; options granted since June 14, 2006 have a contractual term of six years. The 2011 plan and the predecessor plan provide that after certain “change in control” events, including, for example, our merger with or into another corporation or the sale of all or substantially all of our assets, outstanding options may be assumed or equivalent options may be substituted, by the successor corporation. The plans provide that the plan administrator may provide that if an optionee’s options are assumed or substituted and the optionee’s status as our employee or employee of the successor corporation is terminated within 12 months other than by a voluntary resignation or termination for cause, the option may become fully exercisable. Further, if the successor corporation does not assume an outstanding option or substitute for it an equivalent option, the option becomes fully vested and exercisable.
For further detailed financial information concerning the severance and change in control arrangements with our executive officers, please see the tabular information contained in the section entitled “Potential Payments Upon Termination or Change in Control.”
Other Benefits
Executive officers are eligible to participate in all of our employee benefit plans, such as medical, dental, vision, group life, disability, and accidental death and dismemberment insurance, and our 401(k) plan, in each case on the same basis as other employees, subject to applicable law. We also provide vacation and other paid holidays to all employees, including our executive officers, which we intend to be comparable to those provided at peer companies.
Accounting Treatment
We account for equity compensation paid to our employees under ASC Topic 718 which requires us to estimate and record an expense over the service period of the award. Our cash compensation is recorded as an expense at the time the obligation is accrued. We structure the cash compensation element of our incentive compensation so that it is taxable to our executives at the time it becomes available to them. We currently intend that all cash compensation paid will be tax deductible by us. However, with respect to equity compensation awards, while any gain recognized by employees from nonqualified options granted at fair market value should be deductible, to the extent that an option constitutes an incentive stock option, gain recognized by the optionee will not be deductible if there is no disqualifying disposition by the optionee. In addition, if we grant restricted stock or restricted stock unit awards that are not subject to performance vesting, they may not be fully deductible by us at the time the award is otherwise taxable to employees.
Tax Deductibility of Executive Compensation
Section 162(m) of the Tax Code generally disallows public companies a tax deduction for federal income tax purposes of remuneration in excess of $1 million paid to certain executive officers.  While our Compensation Committee may consider the deductibility of awards as one factor in determining executive compensation, our Compensation Committee also looks at other factors in making its decisions and retains the flexibility to award compensation that it determines to be consistent with the goals of our executive compensation program even if the awards are not deductible by us for tax purposes.

Recent changes to Section 162(m) in connection with the passage of the Tax Cuts and Jobs Act repealed exceptions to the deductibility limit that were previously available for “qualified performance-based compensation” (including stock option grants, performance-based cash bonuses and performance-based equity awards, such as performance-based restricted stock units) effective for taxable years after December 31, 2017.  As a result, any compensation paid to certain of our executive officers in excess of $1 million following December 31, 2017 will be non-deductible. However, compensation payable pursuant to certain binding arrangements in effect on November 2, 2017 may qualify for transition relief afforded by the Tax Cuts and Jobs Act and remain deductible. Because of uncertainties in the interpretation and implementation of the changes to Section 162(m) in the Tax Cuts and Jobs Act, including the scope of the transition relief, we can offer no assurance of such deductibility.
Compensation Risk

56


The Compensation Committee regularly reviews the Company’s compensation policies and practices, including the risks created by the Company’s compensation plans. The Compensation Committee concluded that the compensation plans reflected the appropriate compensation goals and philosophy and that any risks arising from the Company’s compensation policies and practices are not reasonably likely to have a material adverse effect on the Company.


SUMMARY COMPENSATION TABLE

The following table sets forth information concerning compensation of our Chief Executive Officer, Chief Financial Officer, and the other three most highly compensated executive officers (the “named executive officers”), all of whom were serving as executive officers of the Company as of December 31, 2017, except for Mr. Traverso, who served as an executive officer through the first quarter of 2017, following which time he continued as an employee1.
Name and Principal Position
Year
Salary
Stock Awards 3
Option Awards 2
Non-Equity Incentive Plan Compensation ($) 3
All Other Compensation 4 
Total

James B. Hawkins
Chief Executive Officer

2017
2016
2015

$820,000
750,000
700,000

$4,106,400
3,999,905
2,811,120

$--
--
--
$ 0
   985,502
1,080,301

$6,144
6,064
7,522

$4,932,544
5,741,471
4,598,943
Jonathan A. Kennedy
Senior Vice President Finance and Chief Financial Officer

2017
2016
2015

490,000
440,000
410,000
1,113,600
1,000,090
792,159
--
--
--
           0
375,195
410,514
5,578
5,560
4,250
1,609,178
1,820,845
1,616,923
Austin A. Noll, III
Vice President, General Manager, Neurology
2017
2016
2015
370,000
340,000
320,000
556,800
530,075
419,866

--
--
--
           0
139,859
197,060
6,020
1,242
   828
   932,820
1,011,176
   937,754
Kenneth M. Traverso
Vice President, General
Manager, Newborn Care
2017
2016
2015
340,000
330,000
310,000
501,120
500,045
225,000

--
--
--
          0
225,229
156,055
7,124
7,072
4,319
  848,244
1,062,346
   945,008
D. Christopher Chung, M.D.
Vice President Medical Affairs, Quality and Regulatory
2017
2016
2015

310,000
286,000
277,000
320,160
299,845
237,504
--
--
--
          0
146,637
152,083
6,020
5,992
6,114

 
636,180
742,474
673,906


(1) Each of the named executive officers has an Employment Agreement with us that provided for an initial base salary that is subject to subsequent review and to adjustments. These agreements provide that the executive’s employment with us is on an “at will” basis. These agreements also provide for certain payments and other benefits upon termination of employment in certain circumstances, as further described under “Employment Agreements and Change in Control Arrangements” in the “Compensation Discussion and Analysis” above, and in the “Potential Payments Upon Termination or Change in Control” section below.
(2) The amounts included in the “Stock Awards” and “Option Awards” columns represent the grant-date fair value of the awards on the date of grant, computed in accordance with ASC Topic 718, except that in the case of option awards, a forfeiture rate of zero percent has been used. The assumptions we use in calculating these amounts, other than the exclusion of the impact of estimated forfeitures, are discussed in Note 14-Share Based Compensation of the Notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017. See the “Grants of Plan Based Awards Table” for more information regarding the equity awards granted by the Company in 2017. Refer to the “Compensation Discussion and Analysis” above for a discussion of these awards.
(3) The amounts in this column reflect bonuses under our CIP for 2015 and 2016 that were paid in March 2016 and 2017. See the “Grants of Plan Based Awards Table” for more information regarding non-equity incentive plan compensation. Refer to the “Compensation Discussion and Analysis” above for a discussion of non-equity incentive plan compensation.
(4) The amounts included in the “All Other Compensation” column consist of matching contributions paid by the Company into our 401(k) plan on behalf of the named executive officers, the value of group life insurance benefits.

57


GRANTS OF PLAN BASED AWARDS - FISCAL 2017
This table discloses the actual numbers of stock options and restricted stock awards granted to our named executive officers in 2017 and the grant date fair value of these awards. It also captures the payouts under the Company’s 2017 Management EMIP.


Name
Grant Date
Estimated Future Payouts Under
Non-Equity Incentive Plan Awards 1

Threshold Target Maximum
($)($)($)
All Other Stock Awards:
Number of Shares of Stock or Units 2
All Other Option Awards: Number of Securities Underlying Options
Exercise or Base Price of Option Awards ($/Share)
Grant Date Fair Value of Stock and Option Awards ($)3 
Mr. Hawkins
01/02/2017
400,000
800,000
1,600,000
118,000






$
4,106,400

Mr. Kennedy
01/02/2017
156,000
312,000
624,000
32,000
 
 
1,113,600

Mr. Noll
01/02/2017
90,000
180,000
360,000
16,000
 
 
556,800

Dr. Chung
01/02/2017
60,000
120,000
240,000
9,200
 
 
320,160

Mr. Traverso
01/02/2017
82,500
65,000
330,000
14,400
 
 
501,120


(1) Each of the named executive officers had a range of payouts targeted for 2017 non‑equity incentive compensation under our 2017 CIP based on the Company’s performance as described in “Compensation Discussion and Analysis” above.
(2) Each of the named executive officers received a grant of restricted shares in 2017 that vest as follows: 50% in January 2019, 25% in January 2020, and 25% in January 2021.
(3) Represents the grant date fair market value of restricted stock awards granted to the named executive officers in 2016 computed in accordance with ASC Topic 718. The assumptions we use in calculating these amounts are discussed in Note 14-Share Based Compensation of the Notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017.
OUTSTANDING EQUITY AWARDS AT 2017 FISCAL YEAR-END
 
Option Awards 1
Stock Awards
Name
Number of Securities Underlying Unexercised Options (#)
Exercisable
Number of Securities Underlying Unexercised Options (#)
Unexercisable
Option Exercise Price ($)
Option Expiration Date
Number of Shares or Units of Stock That Have Not Vested (#)
Market Value of Shares or Units of Stock That Have Not Vested ($) 3
Mr. Hawkins
160,000
150,000
107,708
--
--
2,292
10.69
14.34
22.50
06/07/20182
06/03/20192 
01/01/20202
            181,455
6,931,581
Mr. Kennedy

31,345
16,767

--
833

13.24
22.50

04/08/20192
01/01/20202
48,990
649,018
Mr. Noll
  
  9,375
14,250
19,583
 
--
--
417

11.92
14.34
22.50

06/07/20182
02/14/20192
01/01/20202
24,950
953,090
Dr. Chung

15,358
16,000
13,708


--
 --
292


10.69
14.34
22.50


06/07/20182
06/07/20192
01/01/20202

14,495
553,709
Mr. Traverso
         
36,000
30,000
19,583

--
--
417

10.69
14.34
22.50
   
06/07/20182
06/07/20192
01/01/20202
22,770
869,814

58



(1) Initial grants of options to the named executive officers upon employment vest 1/8th after the completion of six months of service with the remainder vesting ratably over the next 42 months. Subsequent grants of options vest ratably over a 48 month period.
(2) Options expire 6 years from the date of grant.
(3) Represents the value of these awards based on the closing price of our stock on December 30, 2017 of $38.20.

OPTION EXERCISES AND STOCK VESTED - FISCAL 2017
The following table sets forth certain information regarding options and stock awards exercised and vested, respectively, during 2017 for the named executive officers.
 
Option Awards
Stock Awards
Name
Number of Shares Acquired on Exercise (#)
Value Realized on Exercise ($)
Number of Shares Acquired on Vesting (#) 1
Value Realized on Vesting ($) 1
Mr. Hawkins
--
--
           148,705

        5,425,244

Mr. Kennedy
--
--
             53,990

        2,009,868

Mr. Noll
--
--
             24,700

           895,565

Mr. Chung
12,642
407,333
14,795

537,519

Mr. Traverso
32,000
633,738
22,870

830,397


(1)
Represents the value of restricted stock awards that were granted on June 7, 2013, and January 1, 2014, and January 1, 2015, and January 4, 2016 that vested in 2017.

POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL
Under the employment agreements between the Company and the named executive officers, upon termination of employment for cause, death or disability, the executive will only be eligible for severance benefits, if any, in accordance with the Company's established policies for all employees as then in effect. The table that follows reflects the amount of compensation due to our named executive officers if their employment is terminated for other than cause, death or disability, or their employment is terminated or the executive terminates his employment for good cause, following a change in control, as more fully described under “Employment Agreements and Change in Control Arrangements” in the “Compensation Discussion and Analysis” above. The amounts shown below assume that such termination or change in control event was effective as of December 31, 2017.  For a discussion of the amount of compensation due to our named executive officers if their employment is terminated without cause other than in connection with a change of control, see “Employment Agreements and Change in Control Arrangements” in the “Compensation Discussion and Analysis” above.

Name
Cash Severance Payment
Continuation of Medical and Welfare Benefits
Acceleration of Equity Awards 1
Total Termination Benefits
   Mr. Hawkins
$2,440,000
$42,030
$6,967,565
$9,449,595
   Mr. Kennedy
810,000
38,543
1,884,496
2,773,039
   Mr. Noll
550,000
38,543
959,637
1,548,180
   Dr. Chung
430,000
38,543
558,293
1,026,836
   Mr. Traverso
505,000
38,543
876,361
1,419,904

(1)
The amounts shown in the table represent the payments to which the officer is entitled for a termination following a change in control. For termination without cause other than in connection with a change of his control, his cash severance

59


payment and other benefits are detailed in the “Employment Agreements and Change in Control Arrangements” Section, above.

Pay Ratio Disclosure
Our ratio of the annual total compensation of our Chief Executive Officer to the median of the annual total compensation of all our employees (excluding our Chief Executive Officer) for 2017 is 90 to 1. We believe this ratio, which was calculated in a manner consistent with Item 402(u) of Regulation S-K, to be a reasonable estimate, based upon the assumptions and adjustments described below. As disclosed in the 2017 Summary Compensation Table, the annual total compensation for 2017 for our Chief Executive Officer was $4,932,544. The annual total compensation for 2017 for our median employee was $55,061. In identifying the median employee under Item 402(u), reporting companies are permitted to use reasonable estimates, assumptions and methodologies based on their own facts and circumstances. As a result, the disclosure regarding the compensation of our median employee may not be directly comparable to similar disclosure by other reporting companies.
Calculation Methodology
We identified the employee with compensation at the median of the compensation of all of our employees (the “median employee”) by considering our employee population as of December 20, 2017 (the “employee population determination date”). We considered all individuals, excluding our Chief Executive Officer, who were employed by us on a world-wide basis (including our consolidated subsidiaries) on the employee population determination date, whether employed on a full-time, part-time, seasonal or temporary basis, including employees on a partial year leave of absence (our “employee population”), subject to the application of the “de minimis” exemption as described below.
The de minimis exemption allows us to exclude up to 5% of our total employees who are non-U.S. employees. Our total number of employees, including U.S. and non-U.S. employees as of the employee population determination date was 2,176, and we used this number to calculate the maximum number of employees excludable under the de minimis exemption. Accordingly, in identifying the median employee, we used the de minimis exemption to exclude the following numbers of employees who are employed in the following countries: Australia (12), Brazil (1), China (36), Spain (9), Finland (2), Hong Kong (3), India (2), Jordan (2), Lebanon (1), Mexico (2), Malaysia (1), Netherlands (3), Norway (2), New Zealand (1), Portugal (1), Sweden (4), Singapore (4) and South Africa (1).
Multiple consistently applied calculation measures (“CACM”) were reviewed before selecting base salary as the CACM for purposes of identifying the median employee. The employee compensation data under review reflects 2017 figures.
For employees paid other than in U.S. dollars, we converted their compensation to U.S. dollars using foreign exchange rates in effect on the employee population determination date. We did not make any cost-of-living adjustments for employees outside of the United States. For employees hired between January 1, 2017 and the employee population determination date, we calculated their cash compensation described above as if they had been employed for the entire measurement period.
We believe our methodology represents a CACM that strikes a balance in terms of administrative burden while consistently treating all the primary compensation components for our worldwide employee population.
Using this methodology, we identified the median employee who was in the sales department and based in the United States.
We calculated the annual total compensation for the median employee using the same methodology we use to calculate the amount reported for our named executive officers in the “Total” column of the Summary Compensation Table.

DIRECTOR COMPENSATION
Directors who are employees receive no additional compensation for serving on the Board or its committees. The table below discloses the annual compensation provided during the year ended December 31, 2017 to directors who are not employees:


60


Name
Fees Earned or Paid in Cash
($) 1
Stock Awards
($) 2
Option Awards
($) 2, 3
Total
($)
Mr. Gunst
166,000
149,468
--
312,985
Ms. Engibous4
88,775
               149,468
--
235,760
Mr. Ludlum5
101,000
               149,468
--
247,985
Mr. Moore6
95,549
             149,468
--
242,534
Ms. Paul7
77,218
149,468
--
224,203

(1) For 2017, fees earned and paid in cash were based on the following retainer and payment schedule:
Board Retainer                    $60,000
Audit Committee Member Retainer            $15,000
Compensation Committee Member Retainer        $10,000
Nominating Committee Member Retainer        $5,000
Chairman of the Board                $75,000
Audit Chair Retainer                $20,000
Compensation Chair Retainer            $10,000
Nominating Chair Retainer            $7,500
Compliance Chair Retainer            $10,000
Compliance Committee Member Retainer        $10,000

(2) Represents the grant‑date fair market value of restricted stock awards granted to the directors in 2017 computed in accordance with ASC Topic 718. Assumptions we use in calculating these amounts, other than the exclusion of the impact of estimated forfeitures, are discussed in Note 12-Share Based Compensation of the Notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017.
(3) At December 31, 2017, Ms. Engibous had 18,000 options and 4,400 unvested restricted shares outstanding, Mr. Gunst had 18,000 options and 4,400 unvested restricted shares outstanding, Mr. Ludlum had 13,000 options and 4,400 unvested restricted shares outstanding, Mr. Moore had 13,000 options and 4,400 unvested restricted shares outstanding, and Ms. Paul had 4,400 unvested restricted shares outstanding.
 
(4) Nominating and Governance Committee Chair.

(5) Audit Committee Chair.

(6) Compensation Committee Chair.

(7) Compliance Committee Chair.
Compensation Committee Interlocks and Insider Participation
Our Compensation Committee consists of Ms. Engibous, Mr. Ludlum and Mr. Gunst. Mr. Moore, who served on the Compensation Committee for a portion of 2017, served as our Chief Executive Officer 26 years ago, from April 1989 to May 1992.
Compensation Committee Report
The Compensation Committee of the Board of Natus has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with management and, based on such review and discussions, the Compensation Committee recommended to the Board that the Compensation Discussion and Analysis be included in this Annual Report on Form 10-k for the fiscal year ended December 31, 2017.
                        
Respectfully submitted by:
THE COMPENSATION COMMITTEE
                        
DORIS E. ENGIBOUS, Chair

61


ROBERT A. GUNST
KENNETH E. LUDLUM

ITEM 12.     Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Equity Compensation Plan Information
The following table sets forth information about the number of shares of common stock that can be issued under our 2011 Stock Awards Plan, as amended, and our 2011 Employee Stock Purchase Plan as of December 31, 2017. 
Plan Category
 
Number of Securities
to be Issued upon
Exercise of
Outstanding
Options, Warrants,
Awards and Rights
 
Weighted-Average
Exercise Price of
Outstanding
Options, Warrants,
Awards and Rights
 
Number of Securities
Remaining Available for
Future Issuance under
Equity Compensation Plans
(excluding securities
reflected in the first column)
Equity compensation plans approved by security holders
 
819,073

 
$
15.18

 
779,298

Equity compensation plans not approved by security holders
 

 

 

Total
 
819,073

 
15.18

 
779,298


Security Ownership of Certain Beneficial Owners and Management
The following table sets forth information, as of March 31, 2017, concerning:
Beneficial owners of more than 5% of Natus common stock;
Beneficial ownership by current Natus directors and nominees, and the named executive officers set forth in the “Summary Compensation Table”; and
Beneficial ownership by all current Natus directors and executive officers as a group.
The information provided in the table is based on Natus’ records, information filed with the Securities and Exchange Commission and information provided to Natus, except where otherwise noted.
The number of shares beneficially owned by each entity, person, director or executive officer is determined under rules of the Securities and Exchange Commission, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares as to which the individual has the sole or shared voting power or investment power and also any shares that the individual has the right to acquire within 60 days of the measurement date through the exercise of any stock option or other right. The address for those individuals for which an address is not otherwise provided is c/o Natus Medical Incorporated, 6701 Koll Center Parkway Suite 120, Pleasanton, CA, 94566. Unless otherwise indicated, each person has sole voting and investment power (or shares such powers with his or her spouse) with respect to the shares set forth in the following table. For each individual and group included in the table below, percentage ownership is calculated by dividing the number of shares beneficially owned by such person or group by the sum of the 33,273,137 shares of common stock outstanding on March 31, 2018, plus the number of shares of common stock that such person or group had the right to acquire on or within 60 days after March 31, 2018.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT



62


Name and Address of Beneficial Owner
Shares
Beneficially Owned
Right to acquire beneficial ownership under options exercisable within 60 days
Total
Beneficially Owned
Percent of Class
Principal Stockholders
 
 
 
 

BlackRock, Inc.
55 East 52nd Street
New York, NY 10055 (1)
4,032,681
--
4,032,681
 12.2%
Dimensional Fund Advisors LP
Building One
6300 Bee Cave Road
Austin, TX 78746 (2)
1,619,337
--
1,619,337
4.9%
Janus Henderson Group plc (3)
2,164,927
--
2,164,927
6.5%
Silvercrest Asset Management Group LLC
1330 Avenue of the Americas, 38th Floor
New York, NY 10019 (4)
1,587,355
--
1,587,355
4.8%
Vanguard Group, Inc.
100 Vanguard Blvd.
Malvern, PA 19355 (5)
2,245,064
--
2,245,064
6.8%
Wellington Management Group LLP
280 Congress Street
Boston, MA 02210 (6)
1,924,157
--
1,924,157
5.8%
Directors, Nominees and Named Executive Officers
 
 
 
 
Mr. Noll (7)
  81,901
               43,625
     125,526
*
Dr. Chung (8)
136,373
               45,358
     181,731
*
Ms. Engibous (9)
  21,750
               13,000
       34,750
*
Mr. Gunst (10)
  50,850
               13,000
       63,850
*
Mr. Hawkins (11)
639,257
             420,000
  1,059,257
3.1%
Mr. Ludlum (12)
  88,825
                 8,000
       97,825
*
Mr. Moore (13)
123,962
                 8,000
     131,962
*
Mr. Kennedy (14)
107,588
               48,945
     156,533
*
Mr. Traverso (15)
107,889
               86,000
     193,889
*
Dr. Paul (16)
    7,460
--
         7,460
*
Officers and Directors as a group (17)
1,366,865
642,303
1,927,267
6.0%

* Represents holdings of less than one percent.

(1) Based on information reported on Schedule 13-G/A filed with the Securities and Exchange Commission on January 19, 2018 by BlackRock, Inc. (“BlackRock”). BlackRock is a parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G) of the Securities Exchange Act of 1934. BlackRock has sole voting power with respect to 3,962,335 of the shares and sole dispositive power with respect to 4,032,681 of the shares. The Schedule 13-G/A states that the following subsidiaries of Blackrock acquired the securities reported on the schedule: BlackRock (Netherlands) B.V.; BlackRock Advisors, LLC; BlackRock Asset Management Canada Limited; BlackRock Asset Management Ireland Limited; BlackRock Asset Management Schweiz AG; BlackRock Financial Management, Inc.; BlackRock Fund Advisors; BlackRock Institutional Trust Company, National Association.; BlackRock Investment Management (Australia) Limited; BlackRock Investment Management (UK) Ltd; and

63


BlackRock Investment Management, LLC. The Schedule 13-G/A indicates that BlackRock Fund Advisors beneficially owns 5% or greater of the outstanding shares of our common stock.

(2) Based on information reported on Schedule 13-G filed with the Securities and Exchange Commission on February 9, 2018 by Dimensional Fund Advisors LP (“Dimensional”). Dimensional is an investment advisor in accordance with Rule 13d-1(b)(1)(ii)(E) of the Securities Exchange Act of 1934. Dimensional reported that is has sole power to vote or to direct the vote of 1,528,550 and sole power to dispose or to direct the disposition of 1,619,337 shares. The shares as to which the Schedule 13-G are filed represent shared held by certain investment companies, trusts and accounts to which Dimensional furnishes investment advice and are not held by Dimensional itself.
(3) Based on information reported on Schedule 13-G filed with the Securities and Exchange Commission on February 12, 2018 by Janus Henderson Group plc. (“Janus”). Janus is a parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G) of the Securities Exchange Act of 1934. Janus reported that is has shared voting power as to 2,164,927 shares and has shared dispositive power as to 2,164,927. The Schedule 13-G states that the following subsidiaries of Janus acquired the securities reported on the schedules: Janus Capital Management LLC, Intech Investment Management LLC, Perkins Investment Management LLC, Geneva Capital Management LLC, Henderson Global Investors Limited, Janus Henderson Investors Australia Institutional Funds Management Limited, and Henderson Global Investors North America Inc. The shares as to which the Schedule 13-G are filed represent shares held by individual and/or institutional clients of Janus and its named subsidiaries.
(4) Based on information reported on Schedule 13-G filed with the Securities and Exchange Commission on February 14, 2018 by Silvercrest Asset Management Group LLC (“Silvercrest”). Silvercrest is an investment advisor in accordance with Rule 13d-1(b)(1)(ii)(E) of the Securities Exchange Act of 1934 and a parent holding company or control person in accordance with Rule 240.13d-(b)(1)(ii)(G). Silvercrest reported that it has shared voting power with respect to 1,587,355 shares and shared dispositive power with respect to 1,587,355 shares. The shares as to which the Schedule 13-G are filed represent shares held by investment advisory clients of Silvercrest Asset Management Group LLC.
(5) Based on information reported on Schedule 13-G/A filed with the Securities and Exchange Commission on February 9, 2018 by The Vanguard Group. Inc. (“Vanguard”). Vanguard is an investment advisor in accordance with Rule 13d-1(b)(1)(ii)(E) of the Securities Exchange Act of 1934. Vanguard reported that it has sole power to vote or direct the vote of 60,127 shares that it beneficially owns, has shared power to vote or direct the vote of 4,500 shares, has sole power to dispose or to direct the disposition of 2,183,137 shares and has shared power to dispose or to direct the disposition of 61,927 shares. Vanguard further reported that (a) Vanguard Fiduciary Trust Company, a wholly-owned subsidiary of Vanguard, is the beneficial owner of 57,427 shares, or 0.17%, of our common stock as a result of its serving as investment manager of collective trust accounts and (b) Vanguard Investments Australia, Ltd., a wholly-owned subsidiary of The Vanguard Group, Inc., is the beneficial owner of 7,200 shares, or 0.02%, of our common stock as a result of its serving as investment manager of Australian investment offerings.
(6) Based on information reported on Schedule 13-G filed with the Securities and Exchange Commission on February 8, 2018 by Wellington Group Holdings LLP (“Wellington”). Wellington is an investment advisor in accordance with Rule 13d-1(b)(1)(ii)(E) of the Securities Exchange Act of 1934 and a parent holding company or control person in accordance with Rule 240.13d-(b)(1)(ii)(G). Wellington reported that is has shared voting power with respect to 1,632,404 shares and shared dispositive power with respect to 1,924,157 of the shares. The Schedule 13-G states that the following holding companies of Wellington acquired the securities reported on the schedule: Wellington Group Holdings LLP, Wellington Investment Advisors LLP, Wellington Management Global Holdings, Ltd (“Wellington Holding Companies”). The shares as to which the Schedule 13-G are filed are held by the Wellington Holding Companies and owned of record by clients of Wellington Management Company LLP, Wellington Management Canada LLC, Wellington Management Singapore Pte Ltd., Wellington Management Hong Kong Ltd., Wellington International Ltd., Wellington Management Japane Pte Ltd., and Wellington Management Australia Pty Ltd.
(7) Includes 24,950 shares subject to a right of repurchase that expire as to 14,037 shares in 2019, 6,913 shares in 2020, and 4,000 shares in 2021 and 43,625 shares that Mr. Noll has the right to acquire within 60 days after March 31, 2018.
(8) Includes 14,495 shares subject to a right of repurchase that expire as to 8,247 shares in 2019, 3,948 shares in 2020, and 2,300 shares in 2021 and 45,358 shares that Dr. Chung has the right to acquire within 60 days after March 31, 2018.
(9) Includes 4,100 shares subject to a right of repurchase by the Company that expires in 2018 and 13,000 shares that Ms. Engibous has the right to acquire within 60 days after March 31, 2018.
(10) Includes 4,100 shares subject to a right of repurchase by the Company that expires in 2018 and 13,000 shares that Mr. Gunst has the right to acquire within 60 days after March 31, 2018.
(11) Includes 181,455 shares subject to a right of repurchase by the Company that expires with respectas to 100,477 shares in 2019, 51,478 shares in 2020, and 29,500 shares in 2021 and 420,000 shares that Mr. Mr. Hawkins has the right to acquire within 60 days after March 31, 2018.

64


(12) Includes 4,100 shares subject to a right of repurchase by the Company that expires in 2018 and 13,000 shares that Mr. Ludlum has the right to acquire within 60 days after March 31, 2018.
(13) Includes 4,100 shares subject to a right of repurchase by the Company that expires in 2018 and 8,000 shares that Mr. Moore has the right to acquire within 60 days after March 31, 2018.
(14) Includes 48,990 shares subject to a right of repurchase by the Company that expires as to 27,495 shares in 2019, 13,495 shares in 2020, and 8,000 shares in 2021 and 48,945 shares that Mr. Kennedy has the right to acquire within 60 days after March 31, 2018.

(15) Includes 22,770 shares subject to a right of repurchase by the Company that expires as to 12,822 shares in 2019, 6,348 shares in 2020, and 3,600 shares in 2021 and 86,000 shares that Mr. Traverso has the right to acquire within 60 days after March 31, 2018.

(16) Includes 4,100 shares subject to a right of repurchase by the Company that expires in 2018.

(17) Includes all shares referenced in notes 1 through 16 above.

ITEM 13.     Certain Relationships and Related Transactions, and Director Independence
Certain Relationships and Policies on Related Party Transactions
The Company has adopted and maintains a Code of Business Conduct and Ethics (the “Code”) that applies to all members of the Company’s Board, all executive officers of the Company, and to all other persons who are employees of the Company. This Code covers matters that the Company believes are supportive of high standards of legal and ethical business conduct, including those relating to fair dealing with those with whom the Company does business, the avoidance of conflicts of interest, confidentiality, the protection of corporate assets, special obligations applicable to those involved in our financial reporting, the Company’s obligation to make full, fair, accurate and timely disclosure in its filings with the Securities and Exchange Commission and in other public communications, compliance with laws, insider trading, and the reporting of violations of the Code. The Code can be found at the Company’s website, www.natus.com, under “Investors/Governance/Governance Documents.” We intend to disclose any future amendments to certain provisions of the Code, or waivers of these provisions, on our website and/or in public filings.
The Code does not distinguish between potential conflict of interest transactions with executive officers or directors and those with other employees. It notes that all covered persons must avoid situations where their interests conflict, or would appear to conflict, with those of the Company. The Code notes that it is not possible to list all types of conflict situations, but provides examples of several types of scenarios that would involve a conflict of interest, including:
Use of Company property
Dealings with customers and suppliers
Interests in or relationships with other companies
Dealings with relatives
Reporting obligations
Loans
The Code requires that covered persons report to the Company’s Chief Executive Officer ownership interest or other relationship that might affect their ability to exercise impartial, ethical judgments. The Code does not expressly set forth the standards that would be applied in reviewing or approving transactions in which directors or executive officers of the Company have a material interest. In general, any such transactions that are so identified would be submitted for approval to the Audit Committee of the Board, which is authorized by the Charter of the Audit Committee to review related party transactions. The Company expects that in reviewing, and potentially approving, any such transactions, that the Audit Committee would be provided with all material facts relative to the proposed transaction, the nature and extent of the director’s or executive officer’s interest in the transaction, and the terms upon which the products, services or other subject matter of the transaction could be provided by alternative sources. The Company further expects that any such transaction would be approved only if the Audit Committee determined that it was in the interest of the Company to proceed with it. The Company expects that pre-approval would be sought for any such transaction whenever practicable, and if pre-approval is not obtained, any such transaction would be submitted for ratification as soon as practicable.
Board Independence
The Board has determined that, except for James B. Hawkins, our Chief Executive Officer, each of our current directors has no material relationship with Natus (either directly or as a partner, shareholder or officer of another organization that has a

65


material relationship with Natus) and is independent within the meaning of the Nasdaq Stock Market (“Nasdaq”) director independence standards. Furthermore, the Board has determined that each of the members of each of the committees of the Board has no material relationship with Natus (either directly or as a partner, stockholder or officer of an organization that has a material relationship with Natus) and is “independent” within the meaning of the Nasdaq director independence standards, including in the case of the members of the Audit Committee, the heightened “independence” standard required for such committee members set forth in the applicable SEC rules.

ITEM 14.     Principal Accounting Fees and Services
The Audit Committee of the Board has appointed KPMG LLP, an independent registered public accounting firm, to audit Natus’ consolidated financial statements for the year ending December 31, 2018. We intend to seek stockholder ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2018 at the 2018 annual meeting of stockholders.
Fees Paid to KPMG LLP for 2016 and 2017, respectively
 
2016
2017
Audit Fees (1)
$  1,891,679

$  3,058,102
Audit-Related Fees (2)

       70,345
Tax Fees (3)
        35,473

        35,024
All Other Fees (4)
          1,780

          1,780
     Total
$  1,928,933

$  3,165,251

(1) Audit fees associated with the annual audit of our consolidated financial statements and statutory audits. 
(2) Audit-related fees are fees associated with assurance and related services that are reasonably related to the performance of the audit or review of the Company’s financial statements. This category includes primarily fees for assistance in financial due diligence, and attestation services related to mergers and acquisitions.  
(3) Tax fees are fees associated primarily with tax advice and planning services.
(4) Includes fees for online research tools. 

Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors
Our Audit Committee pre-approves all audit and permissible non-audit services provided by our independent auditors. These services may include audit services, audit-related services, tax services and other services. Pre-approval is generally detailed as to the particular service or category of services and is generally subject to a specific budget. Our independent auditors and management are required to periodically report to the Audit Committee regarding the extent of services provided by our independent auditors in accordance with this pre-approval, and the fees for the services performed to date. Our Audit Committee may also pre-approve particular services on a case-by-case basis.

PART IV 
ITEM 15.    Exhibits, Financial Statement Schedules
(a)(2) Financial Statement Schedule
SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS
For the years ended December 31, 2017, 2016 and 2015
(In thousands) 

66


 
Balance at
Beginning
of Period
 
Additions
Charged to
Expense
 
Deductions
 
Balance
at End
of Period
Year ended December 31, 2017
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
4,182

 
$
10,017

 
$
(5,221
)
 
$
8,978

Valuation allowance
3,706

 
2,156

 

 
5,862

Year ended December 31, 2016
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
4,686

 
$
1,123

 
$
(1,627
)
 
$
4,182

Valuation allowance
3,972

 

 
(266
)
 
3,706

Year ended December 31, 2015
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
4,324

 
$
1,496

 
$
(1,134
)
 
$
4,686

Valuation allowance
3,151

 
821

 

 
3,972

(a)(3) Exhibits 
The Exhibits listed in the Index to Exhibits, which appears immediately following the signature page and is incorporated herein by reference, are filed as part of this 10-K.

67


 
 
 
 
Incorporated By Reference
Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
3.1
 
Natus Medical Incorporated Amended and Restated Certificate of Incorporation
 
S-1
 
3.1.1

 
333-44138
 
8/18/2000
3.2
 
Certificate of Amendment of the Amended and Restated Certificate of Incorporation
 
8-K
 
3.1

 
000-33001
 
9/13/2012
3.3
 
Natus Medical Incorporated Certificate of Designation of Rights, Preferences and Privileges of Series A Participating Preferred Stock
 
8-A
 
3.1.2

 
000-33001
 
9/6/2002
3.4
 
Bylaws of Natus Medical Incorporated
 
8-K
 
3.1

 
000-33001
 
6/18/2008
3.5
 
Amended and Restated Bylaws of Natus Medical Incorporated
 
10-Q
 
3.1

 
000-33001
 
5/9/2012
10.1
 
Form of Indemnification Agreement between Natus Medical Incorporated and each of its directors and officers
 
S-1
 
10.1

 
333-44138
 
8/18/2000
10.2*
 
Natus Medical Incorporated Amended and Restated 2000 Stock Awards Plan
 
8-K
 
10.1

 
000-33001
 
1/4/2006
10.2.1*
 
Form of Option Agreement under the Amended and Restated 2000 Stock Awards Plan
 
S-1
 
10.3.1

 
333-44138
 
8/18/2000
10.2.2*
 
Form of Restricted Stock Purchase Agreement under the Amended and Restated 2000 Stock Awards Plan
 
10-Q
 
10.2

 
000-33001
 
8/9/2006
10.2.3*
 
Form of Restricted Stock Unit Agreement under the Amended and Restated 2000 Stock Awards Plan
 
10-K
 
10.2.3

 
000-33001
 
3/14/2008
10.3*
 
Natus Medical Incorporated 2000 Director Option Plan
 
10-Q
 
10.02

 
000-33001
 
5/9/2008
10.3.1*
 
Form of Option Agreement under the 2000 Director Option Plan
 
S-1
 
10.4.1

 
333-44138
 
8/18/2000
10.4*
 
Natus Medical Incorporated 2000 Supplemental Stock Option Plan
 
S-1
 
10.15

 
333-44138
 
2/9/2001
10.4.1*
 
Form of Option Agreement for 2000 Supplemental Stock Option Plan
 
S-1
 
10.15.1

 
333-44138
 
2/9/2001
10.5*
 
Natus Medical Incorporated 2000 Employee Stock Purchase Plan and form of subscription agreement thereunder
 
8-K
 
10.2

 
000-33001
 
1/4/2006
10.6*
 
[Amended] 2011 Stock Awards Plan
 
14-A
 

 
000-33001
 
4/20/2011
10.6.1*
 
Form of Stock Option Award Agreement under the [Amended] 2011 Stock Plan
 
10-Q
 
10.1

 
000-33001
 
11/7/2011
10.6.2*
 
Form of Restricted Stock Award Purchase Agreement
 
10-Q
 
10.2

 
000-33001
 
11/7/2011
10.6.3*
 
Form of Restricted Stock Unit Agreement
 
10-Q
 
10.3

 
000-33001
 
11/7/2011
10.7*
 
2011 Employee Stock Purchase Plan
 
14-A
 

 
000-33001
 
4/20/2011
10.7.1*
 
2011 Employee Stock Purchase Plan Subscription Agreement
 
14-A
 

 
000-33001
 
4/20/2011
10.8*
 
Form of Employment Agreement between Natus Medical Incorporated and each of its executive officers other than its Chief Executive Officer and Chief Financial Officer
 
10-K
 
10.10

 
000-33001
 
3/10/2009



68


 
 
 
 
Incorporated By Reference
Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
10.8.1*
 
Form of Amendment to Employment Agreement between Natus Medical Incorporated and each of its executive officers other than its Chief Executive Officer and Chief Financial Officer
 
10-K
 
 
 
000-33001
 
3/16/2015
10.9*
 
Amended employment agreement between Natus Medical Incorporated and its Chief Executive Officer, James B. Hawkins dated April 19, 2013
 
8-K
 
99.1

 
000-33001
 
4/22/2013
10.10*
 
Form of Employment Agreement between Natus Medical Incorporated and Jonathan A. Kennedy dated April 8, 2013
 
10-Q
 
10.1

 
000-33001
 
8/8/2013
10.11
 
Credit Agreement between Natus Medical Incorporated and CitiBank, NA dated October 9, 2015
 
8-K
 
10.1

 
000-33001
 
10/9/2015
10.12
 
Agreement For the Acquisition of Medical Devices between Medix ICSA and the Ministry of Health of the Republic of Venezuela dated October 15, 2015
 
10-Q
 
 
 
000-33001
 
2/29/2016
10.13
 
Amendment to Agreement For the Acquisition of Medical Devices between Medix ICSA and the Ministry of Health of the Republic of Venezuela dated October 15, 2015
 
10-Q
 
10.2

 
000-33001
 
11/3/2016
10.14
 
Credit Agreement, dated September 23, 2016, between the Company, JP Morgan Chase Bank, N.A. and Citibank, N.A.
 
10-Q
 
10.1

 
000-33001
 
11/3/2016
10.15
 
Master Purchase Agreement, dated September 25, 2016, between GN Hearing A/S, GN Nord A/S and the Company
 
10-Q
 
10.3

 
000-33001
 
11/3/2016
16.1
 
Letter Regarding Change in Certifying Accountant
 
8-K
 
16.1

 
000-33001
 
3/28/2014
21.1
 
Significant Subsidiaries of the Registrant
 
 
 
 
 
 
 
 
23.1
 
Consent of Independent Registered Public Accounting Firm
 
 
 
 
 
 
 
 
24.1
 
Power of Attorney
 
 
 
 
 
 
 
 
31.5
 
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
 
 
 
 
 
31.6
 
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
 
 
 
 
 
32.3
 
Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
 
 
 
 
 
 
101.INS
 
XBRL Instance Document
 
 
 
 
 
 
 
 
101.SCH
 
XBRL Taxonomy Extension Schema Document
 
 
 
 
 
 
 
 
101.CAL
 
XBRL Taxonomy Extension Label Calculation Linkbase Document
 
 
 
 
 
 
 
 



69


 
 
 
 
Incorporated By Reference
Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
101.DEF
 
XBRL Taxonomy Extension Definition Document
 
 
 
 
 
 
 
 
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
 
 
 
 
 
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 
 
 
 
 
 
 *    Indicates a management contract or compensatory plan or arrangement

70


SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned thereunto duly authorized. 
 
 
 
NATUS MEDICAL INCORPORATED
 
 
By
 
/s/    JONATHAN A. KENNEDY        
 
 
Jonathan A. Kennedy
President and Chief Executive Officer
Dated: July 20, 2018


71


NATUS MEDICAL INCORPORATED
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
 

F-1


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors
Natus Medical Incorporated:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Natus Medical Incorporated and subsidiaries (the Company) as of December 31, 2017 and 2016, the related consolidated statements of operations and comprehensive income, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2017, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2017, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated March 1, 2018 expressed an adverse opinion on the effectiveness of the Company's internal control over financial reporting.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
(signed) KPMG LLP
We have served as the Company's auditor since 2014.

San Francisco, California
March 1, 2018


F-2


NATUS MEDICAL INCORPORATED
CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts) 
 
December 31,
 
2017
 
2016
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
88,950

 
$
213,551

Short-term investments

 
34,019

Accounts receivable, net of allowance for doubtful accounts of $8,978 and $4,182
126,809

 
86,638

Inventories
71,529

 
49,587

Prepaid expenses and other current assets
18,340

 
22,004

Total current assets
305,628

 
405,799

Property and equipment, net
22,071

 
17,333

Intangible assets, net
172,582

 
77,165

Goodwill
172,998

 
113,112

Deferred income tax
10,709

 
14,915

Other assets
25,931

 
20,688

Total assets
$
709,919

 
$
649,012

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
25,242

 
$
18,700

Accrued liabilities
51,738

 
37,895

Deferred revenue
15,157

 
23,346

Total current liabilities
92,137

 
79,941

Long-term liabilities:
 
 
 
Other liabilities
21,995

 
8,013

Long-term debt
154,283

 
140,000

Deferred income tax
19,407

 
3,684

Total liabilities
287,822

 
231,638

Commitments and contingencies (Note 20)

 

Stockholders’ equity:
 
 
 
Common stock, $0.001 par value; 120,000,000 shares authorized; shares issued and outstanding 33,134,101 in 2017 and 32,920,246 in 2016
316,577

 
312,986

Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding in 2017 and in 2016

 

Retained earnings
129,115

 
149,408

Accumulated other comprehensive loss
(23,595
)
 
(45,020
)
Total stockholders’ equity
422,097

 
417,374

Total liabilities and stockholders’ equity
$
709,919

 
$
649,012

The accompanying notes are an integral part of these Consolidated Financial Statements.

F-3


NATUS MEDICAL INCORPORATED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(In thousands, except per share amounts) 
 
Years Ended December 31,
 
2017
 
2016
 
2015
Revenue
$
500,970

 
$
381,892

 
$
375,865

Cost of revenue
213,376

 
144,632

 
145,492

Intangibles amortization
6,380

 
2,327

 
2,836

Gross profit
281,214

 
234,933

 
227,537

Operating expenses:
 
 
 
 
 
Marketing and selling
126,166

 
84,834

 
87,675

Research and development
51,822

 
33,443

 
30,434

General and administrative
74,424

 
50,877

 
46,363

Intangibles amortization
19,171

 
8,983

 
7,447

Restructuring
914

 
1,536

 
2,145

Total operating expenses
272,497

 
179,673

 
174,064

Income from operations
8,717

 
55,260

 
53,473

Other income (expense), net
(3,567
)
 
(357
)
 
(1,064
)
Income before provision for income tax
5,150

 
54,903

 
52,409

Provision for income tax
25,443

 
12,309

 
14,485

Net income (loss)
$
(20,293
)
 
$
42,594

 
$
37,924

Net income (loss) per share:
 
 
 
 
 
Basic
$
(0.62
)
 
$
1.31

 
$
1.17

Diluted
$
(0.62
)
 
$
1.29

 
$
1.14

Weighted average shares used in the calculation of net income (loss) per share:
 
 
 
 
 
Basic
32,564

 
32,460

 
32,348

Diluted
32,564

 
33,056

 
33,241

Other Comprehensive income:
 
 
 
 
 
Unrealized losses on available-for-sale investments
$
(45
)
 
$
(168
)
 
$

Foreign currency translation adjustment
21,470

 
(5,003
)
 
(8,378
)
Total other comprehensive income
21,425

 
(5,171
)
 
(8,378
)
Comprehensive income
$
1,132

 
$
37,423

 
$
29,546

The accompanying notes are an integral part of these Consolidated Financial Statements.

F-4


NATUS MEDICAL INCORPORATED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except share amounts) 
 
Common Stock
 
Retained
Earnings
 
Accumulated
Other
Comprehensive
Loss
 
Stockholders’
Equity
 
Shares
 
Amount
 
Balances, December 31, 2014
32,649,158

 
$
315,296

 
$
68,890

 
$
(31,471
)
 
$
352,715

Tax benefit of options exercises

 
7,104

 

 

 
7,104

Vesting of restricted stock units
21,619

 

 

 

 

Net issuance of restricted stock awards
199,620

 

 

 

 

Employee stock purchase plan
35,467

 
1,251

 

 

 
1,251

Stock-based compensation expense

 
6,953

 

 

 
6,953

Repurchase of company stock
(281,915
)
 
(11,526
)
 

 

 
(11,526
)
Taxes paid related to net share settlement of equity awards
(102,112
)
 
(4,341
)
 

 

 
(4,341
)
Exercise of stock options
631,663

 
9,008

 

 

 
9,008

Other comprehensive income

 

 

 
(8,378
)
 
(8,378
)
Net income

 

 
37,924

 

 
37,924

Balances, December 31, 2015
33,153,500

 
$
323,745

 
$
106,814

 
$
(39,849
)
 
$
390,710

Vesting of restricted stock units
20,937

 

 

 

 

Net issuance of restricted stock awards
191,492

 

 

 

 

Employee stock purchase plan
45,515

 
1,360

 

 

 
1,360

Stock-based compensation expense

 
9,008

 

 

 
9,008

Repurchase of company stock
(545,109
)
 
(19,289
)
 

 

 
(19,289
)
Taxes paid related to net share settlement of equity awards
(97,231
)
 
(4,107
)
 

 

 
(4,107
)
Exercise of stock options
151,142

 
2,269

 

 

 
2,269

Other comprehensive income

 

 

 
(5,171
)
 
(5,171
)
Net income

 

 
42,594

 

 
42,594

Balances, December 31, 2016
32,920,246

 
$
312,986

 
$
149,408

 
$
(45,020
)
 
$
417,374

Vesting of restricted stock units
35,929

 

 

 

 

Net issuance of restricted stock awards
249,366

 

 

 

 

Employee stock purchase plan
48,470

 
1,581

 

 

 
1,581

Stock-based compensation expense

 
9,445

 

 

 
9,445

Repurchase of company stock
(60,800
)
 
(2,268
)
 

 

 
(2,268
)
Taxes paid related to net share settlement of equity awards
(193,212
)
 
(7,052
)
 

 

 
(7,052
)
Exercise of stock options
134,102

 
1,885

 

 

 
1,885

Other comprehensive income

 

 

 
21,425

 
21,425

Net loss

 

 
(20,293
)
 

 
(20,293
)
Balances, December 31, 2017
33,134,101

 
$
316,577

 
$
129,115

 
$
(23,595
)
 
$
422,097

The accompanying notes are an integral part of these Consolidated Financial Statements.

F-5


NATUS MEDICAL INCORPORATED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands) 
 
Year Ended December 31,
 
2017
 
2016
 
2015
Operating activities:
 
 
 
 
 
Net income (loss)
$
(20,293
)
 
$
42,594

 
$
37,924

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
 
 
Provision for losses on accounts receivable
10,017

 
1,123

 
1,496

Excess tax benefit on the exercise of stock options

 

 
(7,104
)
Depreciation and amortization
30,098

 
16,879

 
15,987

Gain on disposal of property and equipment
(21
)
 
(29
)
 
(5
)
Impairment of intangible assets
1,674

 

 

Warranty reserve
5,370

 
2,934

 
10,729

Stock-based compensation
9,445

 
9,008

 
6,953

Changes in operating assets and liabilities, net of assets and liabilities acquired in acquisitions:
 
 
 
 
 
Accounts receivable
(30,473
)
 
19,723

 
(15,272
)
Inventories
7,581

 
(7,668
)
 
(12,232
)
Other assets
5,492

 
(11,387
)
 
858

Accounts payable
(1,385
)
 
(4,965
)
 
3,270

Accrued liabilities
5,421

 
(6,967
)
 
(6,177
)
Deferred revenue
(7,232
)
 
13,879

 
(1,118
)
Deferred taxes
4,032

 
(2,437
)
 
1,543

Net cash provided by operating activities
19,726

 
72,687

 
36,852

Investing activities:
 
 
 
 
 
Acquisition of businesses, net of cash acquired
(190,888
)
 
(15,849
)
 
(14,284
)
Acquisition of property and equipment
(4,066
)
 
(3,186
)
 
(4,068
)
Acquisition of intangible assets

 
(210
)
 
(1,126
)
Purchases of short-term investments

 
(34,019
)
 

Sales of short-term investments
34,019

 

 

Net cash used in investing activities
(160,935
)
 
(53,264
)
 
(19,478
)
Financing activities:
 
 
 
 
 
Proceeds from stock option exercises and ESPP
3,466

 
3,630

 
10,258

Excess tax benefit on the exercise of stock options

 

 
7,104

Repurchase of company stock
(2,268
)
 
(19,289
)
 
(11,525
)
Taxes paid related to net share settlement of equity awards
(7,052
)
 
(4,107
)
 
(4,341
)
Proceeds from short-term borrowings

 
16,000

 

Proceeds from long-term borrowings
60,000

 
140,000

 

Deferred debt issuance costs
(354
)
 
(533
)
 

Contingent consideration earn-out
(2,966
)
 
(1,284
)
 
(664
)
Payments on borrowings
(45,000
)
 
(16,000
)
 

Net cash provided by financing activities
5,826

 
118,417

 
832

Exchange rate effect on cash and cash equivalents
10,782

 
(6,758
)
 
(2,295
)
Net increase (decrease) in cash and cash equivalents
(124,601
)
 
131,082

 
15,911

Cash and cash equivalents, beginning of year
213,551

 
82,469

 
66,558

Cash and cash equivalents, end of year
$
88,950

 
$
213,551

 
$
82,469

Supplemental disclosure of cash flow information:
 
 
 
 
 
Cash paid for interest
$
4,464

 
$
41

 
$

Cash paid for income taxes
$
5,740

 
$
16,344

 
$
10,164

Non-cash investing activities:
 
 
 
 
 
Property and equipment included in accounts payable
$
148

 
$
134

 
$
289

Inventory transferred to property and equipment
$
1,006

 
$
1,303

 
$
1,056

 The accompanying notes are an integral part of these Consolidated Financial Statements.

F-6


NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Years Ended December 31, 2017, 2016 and 2015
1—ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES
Organization
Natus Medical Incorporated (“Natus”, the “Company”) was incorporated in California in May 1987 and reincorporated in Delaware in August 2000. Natus is a leading provider of newborn care, neurology, and hearing and balance assessment healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, software systems for managing and tracking disorders and diseases for public health laboratories, computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms for hearing and balance care professionals.
Basis of Presentation and Principles of Consolidation
The accompanying Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain reclassifications to the prior periods have been made to conform to the current period presentation.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Consolidated Financial Statements and the reported amount of revenue and expenses during the reporting period. Such estimates include allowances for potentially uncollectible accounts receivable, valuation of inventory, intangible assets, goodwill, share-based compensation, deferred income taxes, reserves for warranty obligations, and the provision for income taxes. Actual results could differ from those estimates.
Revenue recognition
Revenue, net of discounts, is recognized from sales of medical devices and supplies, including sales to distributors, when the following conditions have been met: a purchase order has been received, title has transferred, the selling price is fixed or determinable, and collection of the resulting receivable is reasonably assured. Terms of sale for most domestic sales are FOB origin, reflecting that title and risk of loss are assumed by the purchaser at the shipping point; however, terms of sale for some neurology, sleep-diagnostic, and head cooling systems are FOB destination, reflecting that title and risk of loss are assumed by the purchaser upon delivery. Terms of sales to international distributors are generally EXW, reflecting that goods are shipped “ex works,” in which title and risk of loss are assumed by the distributor at the shipping point. For products shipped under FOB origin or EXW terms, delivery is generally considered to have occurred when the product is shipped. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue. The Company generally does not provide rights of return on products.
For products containing embedded software, the Company has determined that the hardware and software components function together to deliver the products’ essential functionality, and therefore, the revenue from the sale of these products does not fall within the scope of the software revenue recognition rules. The Company's revenue recognition policies for sales of these products are substantially the same as for other tangible products. 
Revenue from sales of certain products that remain within the scope of the software revenue recognition rules under ASC Subtopic 985-605 is not significant.
Revenue from extended service and maintenance agreements, for both medical devices and data management systems, is recognized ratably over the service period. Revenue from installation or training services is deferred until such time service is provided. Hearing screening and ambulatory EEG monitoring revenue is recorded when the procedure is performed at the estimated net realizable value based on contractual agreements with payers and historical collections.
Certain revenue transactions include multiple element arrangements. The Company allocates revenue in these arrangements to each unit of accounting using the relative selling price method. The selling prices used during the allocation process are based on vendor specific objective evidence (“VSOE”) if available, third party evidence (“TPE”) if VSOE is not available, or estimated selling price (“ESP”) if neither VSOE or TPE is available.

F-7

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

Group purchasing organization (“GPOs”) negotiate volume purchase prices for member hospitals, group practices, and other clinics. The Company's agreements with GPOs typically contain preferential terms for the GPO and its members, including provisions for some, if not all, of the following:
Payment of marketing fees by Natus to the GPO, usually based on purchasing experience of group members; and
Non-recourse cancellation provisions.
Natus does not sell products to GPOs. Hospitals, group practices, and other clinics that are members of a GPO purchase products directly from the Company under the terms negotiated by the GPO. Negotiated pricing and discounts are recognized as a reduction of the selling price of products at the time of the sale. Revenue from sales to members of GPOs is otherwise consistent with general revenue recognition policies as previously described.
Inventory
Inventories are carried at the lower of cost or market, with cost being determined using the first-in, first-out method. The carrying value of the Company's inventories is reduced for any difference between cost and estimated market value of inventories that is determined to be obsolete or unmarketable, based upon assumptions about future demand and market conditions. Adjustments to the value of inventory establish a new cost basis and are considered permanent even if circumstances later suggest that increased carrying amounts are recoverable. If demand is higher than expected, Natus may sell inventory that had previously been impaired.
Carrying value of intangible assets and goodwill
The Company amortizes intangible assets with finite lives over the useful lives; any future changes that would limit the useful lives or any determination that these assets are carried at amounts greater than the estimated fair value could result in additional charges.
Goodwill is not amortized but is subject to an annual impairment analysis, which is performed as of October 1st; this assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired.
In 2017, 2016 and 2015, the Company performed a qualitative assessment to test goodwill for impairment. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on the qualitative assessment, the Company determined that the fair value was more likely than not to be greater than its carrying amount, and no further analysis was needed.
If the fair value was less than its carrying amount, the Company would perform a two-step impairment test on goodwill. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. The Company uses a projected discounted cash flow model to determine the fair value of a reporting unit. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit. If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.
Prior to the assignment of definite lives to trade names in the second quarter of 2015 (See Note 6 - Intangible Assets), the Company tested indefinite lived intangibles for impairment by comparing the carrying value of those assets to be fair value as of the assessment date. The Company used the relief from royalty method to determine the fair value of the assets. This analysis is dependent upon a number of quantitative and qualitative factors including estimates of forecasted revenue, royalty rate, and taxes. The discount rate applied also has an impact on the estimates of fair value, as use of a higher rate will result in a lower estimate of fair value.
Long lived assets
The Company continually monitors events and changes in circumstances that could indicate that carrying amounts of its long-lived assets, including property and equipment and intangible assets, may not be recoverable. When such events or changes in circumstances occur, the Company assess the recoverability by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the future undiscounted cash flows are less than the carrying amount of these assets, the Company will recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets.

F-8

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

Liability for product warranties
The Company provides a warranty for products that is generally one year in length. In some cases, regulations may require the Company to provide repair or remediation beyond the typical warranty period. If any products contain defects, the Company may be required to incur additional repair and remediation costs. Service for domestic customers is provided by Company-owned service centers that perform all service, repair, and calibration services. Service for international customers is provided by a combination of Company-owned facilities and vendors on a contract basis.
A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management’s best estimate of probable liability. The Company considers a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of the reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.
Share-based compensation
The Company recognizes share-based compensation expense associated with employee stock options under the single-option straight line method over the requisite service period, which is generally a four-year vesting period and ten-year contractual term pursuant to ASC Topic 718, Compensation-Stock Compensation. See Note 14 of the Consolidated Financial Statements.
For employee stock options, the value of each option is estimated on the date of grant using the Black-Scholes option pricing model, which was developed for use in estimating the value of freely traded options. Similar to other option pricing models, the Black-Scholes method requires the input of highly subjective assumptions, including stock price volatility. Changes in the subjective input assumptions can materially affect the estimated fair value of the employee stock options.
The Company recognizes share-based compensation associated with Restricted Stock Awards (“RSA”) and Restricted Stock Units (“RSU”). RSAs and RSUs vest ratably over a three-year period for employees. RSAs and RSUs for executives vest over a four-year period; 50% on the second anniversary of the awarded date and 25% on each of the third and fourth anniversaries. RSAs and RSUs for non employees (Board of Directors) vest over a one-year period; 100% on the first anniversary. The value is estimated based on the market value of Natus common stock on the date of issuance pursuant to ASC Topic 718, Compensation-Stock Compensation.
The Company issues new shares of common stock upon the exercise of stock options and the vesting of RSAs and RSUs.
Forfeitures of employee stock options and awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share-based compensation expense is recorded net of estimated forfeitures, such that expense is recorded only for those share-based awards that are expected to vest.
Cash Equivalents and Short-term Investments
All highly liquid investments purchased with an original maturity of three months or less are classified as cash equivalents. Investments with maturities greater than one year are classified as current because management considers all investments to be available for current operations. Cash equivalents and investments are stated at amounts that approximate fair value based on quoted market prices.
The Company's investments have been classified and accounted for as available-for-sale. Such investments are recorded at fair value and unrealized holding gains and losses are reported as a separate component of comprehensive income until realized. Realized gains and losses on sales of investments, if any, are determined on the specific identification method and are reclassified from accumulated other comprehensive loss to results of operations as other income (expense).
Allowance for Doubtful Accounts
The Company estimates the allowance for potentially uncollectible accounts receivable based on historical collection experience within the markets in which the Company operates and other customer-specific information, such as bankruptcy filings or customer liquidity problems. When all internal efforts have been exhausted to collect the receivable, it is written off and relieved from the reserve.
Fair Value of Financial Instruments
Financial instruments include cash and cash equivalents, investments, accounts receivable, and accounts payable. Cash is reported at its fair value on the balance sheet dates. The recorded carrying amounts of investments, accounts receivable and accounts payable approximate the fair values due to the short-term maturities.

F-9

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over estimated useful lives of the respective assets, which are three to ten years for office furniture and equipment, three to five years or the length of the license for computer software and hardware, three to five years for demonstration and loaned equipment, and 30 to 40 years for buildings. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life. Land is not depreciated. Costs associated with acquiring and installing software to be used for internal purposes are capitalized and amortized on a straight-line basis over three years.
Research & Development Costs
Costs incurred in research and development are charged to operations as incurred.
Income Taxes
The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
The Company records net deferred tax assets to the extent it is more likely than not that the assets will be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. To the extent that previously reserved deferred tax assets are estimated to be realizable, the Company adjusts the valuation allowance which reduces the provision for income taxes.
The Company recognizes the tax benefit of uncertain tax positions in the financial statements as defined in ASC Topic 740, Income Tax. When the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50 percent likely of being ultimately realized upon settlement, as defined in ASC 740-10-05. 
On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, Income Taxes. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements.
Foreign Currency
The functional currency of the Company's subsidiaries outside of North America is generally the local currency of the country where the subsidiary is located. Accordingly, foreign currency translation adjustments relating to the translation of foreign subsidiary financial statements are included as a component of accumulated other comprehensive loss. The Company recorded $21.5 million, $(5.0) million, and $(8.4) million of foreign currency translation gains (losses) for the years ended December 31, 2017, 2016 and 2015, respectively.
Gains and losses from transactions denominated in currencies other than the functional currencies are included in other income and expense. In 2017, 2016, and 2015, net foreign currency transaction gains (losses) were $1.0 million, $(0.4) million, and $(1.4) million, respectively. Foreign currency gains and losses result primarily from fluctuations in the exchange rate between the U.S. Dollar, Canadian Dollar, Euro, Argentine Peso, British Pound, and Danish Kroner.
Comprehensive Income
The Company reports by major components and as a single total the change in net assets during the period from non-owner sources as defined in ASC Topic 220, Comprehensive Income. The consolidated statement of comprehensive income has been included with the consolidated statements of operations. Accumulated other comprehensive income consists of translation gains and losses on foreign subsidiary financial statements as well as unrealized gains and losses on investments.
Basic and Diluted Net Income per Share
Natus computes net income per share as defined in ASC Topic 260, Earnings per Share. Basic net income per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalents outstanding during the period.

F-10

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

Common stock equivalents are options granted and shares of restricted stock issued under the stock awards plans and are calculated under the treasury stock method. Common equivalent shares from unexercised stock options and restricted stock are excluded from the computation when there is a loss as the effect is anti-dilutive, or if the exercise price of such options is greater than the average market price of the stock for the period.
Recent Adopted Accounting Pronouncements
In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330). This standard requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is estimated selling prices in the ordinary course of business, less reasonable predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted ASU 2015-11in January 2017 and no impact was recorded by the Company.
In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805). This update is to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisition (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. ASU 2017-01 is effective for annual periods beginning after December 15, 2017, including interim periods within those periods, and must be applied prospectively. The Company will apply this guidance to business combinations that occur on or after the effective date.
Recent Issued Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance. The standard's core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard creates a five-step model to achieve its core principle: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction's price to the separate performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. In addition, entities must disclose sufficient information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Qualitative and quantitative disclosures are required about: (i) the entity's contracts with customers; (ii) the significant judgments, and changes in judgments, made in applying the guidance to those contracts; and (iii) any assets recognized from the costs to obtain or fulfill a contract with a customer. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 616) - Deferral of the Effective Date, which deferred the effective date of ASU 2014-09 to interim and annual periods beginning January 1, 2018. The standard allows entities to apply the standard retrospectively to each prior period presented (“full retrospective adoption”) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application (“modified retrospective adoption”). The Company adopted the modified retrospective approach of this guidance on January 1, 2018 and has determined that its adoption will not have a material effect on its financial position or results of operations.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This standard requires a lessee to recognize the lease assets and lease liabilities arising from operating leases in the statement of financial position. Qualitative along with specific quantitative disclosures are required by lessees to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 including interim periods within those fiscal years. The Company is currently evaluating the impact that will result from adopting ASU 2016-02.
    
In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). This update modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Because these amendments eliminate a step from the goodwill impairment test, they should reduce the cost and complexity of evaluating goodwill for impairment. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company will adopt ASU 2017-04 to goodwill impairment testing on the effective date.
In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. This update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This guidance is effective for annual periods beginning after December

F-11

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

15, 2017, including interim periods within that year, and must be applied prospectively to an award modified on or after the adoption date. The Company will adopt this guidance and will apply to all future share-based modifications.
2—BUSINESS COMBINATIONS
The assets acquired and liabilities assumed at the date of acquisition are recorded in the Consolidated Financial Statements at the respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets is recorded as goodwill. 
The determination of estimated fair value of acquired assets and liabilities requires management to make significant estimates and assumptions. The Company determines the fair value by applying established valuation techniques, based on information that management believes to be relevant to this determination. The Company also utilizes independent third parties to assist in the valuation of goodwill and intangible assets.
The results of operations from acquisitions are included in the Consolidated Financial Statements from the date of the acquisition.
Integra
On October 6, 2017, the Company acquired certain neurosurgery business assets from Integra LifeSciences (“Integra” or “Neurosurgery”) for $46.4 million in cash. As part of the acquisition, the Company acquired a global product line, including the manufacturing facility it leases from a third party and the U.S. rights related to four other product lines. The total purchase price has been preliminarily allocated to $12.5 million of tangible assets, $19.5 million of intangible assets with an associated weighted average life of 9 years being amortized on the straight line method, and $15.5 million of goodwill, offset by $1.1 million of net liabilities. Purchase price allocation is considered preliminary at this time although no material adjustments are anticipated. Pro form financial information for the Integra acquisition is not presented as the data necessary to present pro forma net income and pro forma earnings per share is not available. However, pro forma revenue assuming the acquisition occurred on January 1, 2016 would be $539.1 million and $432.4 million for the years ended December 31, 2017 and 2016, respectively.
Otometrics
On January 3, 2017, the Company acquired the Otometrics business from GN Store Nord A/S for a cash purchase price of $149.2 million, which includes a $4.2 million net working capital adjustment. Otometrics is a manufacturer of hearing diagnostics and balance assessment equipment, disposables and software. Otometrics provides computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms to hearing and balance care professionals worldwide. Otometrics has a complete product and brand portfolio known for its sophisticated design technology in the hearing and balance assessment markets.
The following table summarizes the purchase price allocation of the fair value of the assets acquired and liabilities assumed at the date of acquisition, (in thousands):
Cash and cash equivalents
$
5,604

Accounts receivable
26,851

Inventories
22,182

Property and equipment
2,256

Intangible assets
90,913

Goodwill
39,355

Other assets
1,748

Accounts payable
(7,655
)
Accrued liabilities
(16,069
)
Deferred revenue
(745
)
Deferred income tax
(15,193
)
Total purchase price
$
149,247

The goodwill recorded represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. The goodwill recorded as part of the acquisition of Otometrics is not amortized and includes the following:
The expected synergies and other benefits that the Company believes will result from combining the operations of Otometrics with the operations of Natus;

F-12

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

Any intangible assets that did not qualify for separate recognition, as well as future, yet unidentified projects and products; and
The value of the going-concern element of Otometrics's existing businesses (the higher rate of return on the assembled collection of net assets versus if Natus has acquired all of the net assets separately).
Management worked with an independent valuation firm to determine fair values of the identifiable intangible assets. The Company used a combination of income approaches including relief from royalty and multi-period excess earnings methods. The valuation models were based on estimates of future operating projections of the acquired business and rights to sell products as well as judgments on the discount rates used and other variables. The Company determined the forecasts based on a number of factors, included their best estimate of near-term net sales expectations and long-term projections, which included review of internal and independent market analyses.
Otometrics's revenue of $114.2 million and loss from operations of $1.0 million are included in the condensed consolidated statement of operations for the period from January 3, 2017 (acquisition date) to December 31, 2017.
The unaudited pro forma financial results presented below for the twelve months ended December 31, 2017 and December 31, 2016, include the effects of pro forma adjustments as if the acquisition occurred on January 1, 2016. The pro forma results were prepared using the acquisition method of accounting and combine the historical results of Natus and Otometrics for the twelve months ended December 31, 2017 and December 31, 2016, including the effects of the business combination, primarily amortization expense related to the fair value of identifiable intangible assets acquired, interest expense associated with the financing obtained by Natus in connection with the acquisition, and the elimination of acquisition-related costs incurred.
The pro forma financial information is presented for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of the earliest period presented, nor is it intended to be a projection of future results.
Unaudited Pro forma Financial Information
(in thousands)
 
Year Ended  December 31,
 
2017
 
2016
Revenue
$
500,970

 
$
491,994

Net income (loss)
$
(15,965
)
 
$
17,385

 
 
 
 
Earnings (loss) per share:
 
 
 
Basic
$
(0.49
)
 
$
0.54

Diluted
$
(0.49
)
 
$
0.53

Weighted average shares used in the calculation of earnings per share:
 
 
 
Basic
32,564

 
32,460

Diluted
32,564

 
33,056

The pro forma results for the year ended December 31, 2017 were adjusted to exclude $4.3 million of nonrecurring expense related to the fair value adjustment of acquisition-date inventory.
The pro forma results for the year ended December 31, 2016 were adjusted to include $3.0 million of amortization of intangible assets, and $4.6 million of interest expense.
RetCam
On July 6, 2016, the Company acquired the portfolio of RetCam Imaging Systems (“RetCam”) from Clarity Medical Systems, Inc. for $10.6 million in cash. RetCam is an imaging system used to diagnose and monitor a range of ophthalmic maladies in premature infants. The purchase agreement also included a holdback of $2.0 million which was paid on February 16, 2017. Subsequent to the acquisition, an additional $1.1 million was paid by the Company to Clarity Medical Systems as a

F-13

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

result of a working capital adjustment. Results of operations for RetCam are included in the consolidated financial statements from the date of acquisition. The total purchase price was allocated $7.2 million to tangible assets, $4.9 million to intangible assets with an assigned weighted average life of 5 years being amortized on the straight line method, and $1.7 million to goodwill, offset by $2.0 million to net liabilities. Pro forma financial information for the RetCam acquisition is not presented as it is not considered material.
NeuroQuest
On March 2, 2016, the Company acquired NeuroQuest, LLC (“NeuroQuest”) through an asset purchase. NeuroQuest complements the Global Neuro-Diagnostics (“GND”) and Monarch Medical Diagnostics, LLC (“Monarch”) acquisitions which offer patients a convenient way to complete routine-electroencephalography and extended video electronencephalography (“VEEG”) testing. The cash consideration for NeuroQuest was $4.6 million. The purchase agreement included a consideration holdback of $0.5 million which was paid on April 30, 2017. The total purchase price was allocated to $0.5 million of tangible assets, $1.3 million of intangible assets with an assigned weighted average life of 5 years being amortized on the straight line method, and $3.5 million of goodwill, offset by $0.1 million of net liabilities. Pro forma financial information for the NeuroQuest acquisition is not presented as it is not considered material.
Monarch
The Company acquired Monarch Medical Diagnostics, LLC (“Monarch”) through an asset purchase on November 13, 2015. Monarch's service compliments the Global Neuro-Diagnostics acquisition which offers patients a more convenient way to complete routine diagnostic electroencephalography and video electromyography testing which can be performed at the home, hospital or physician's office. The service also provides comprehensive reporting and support to the physician. The cash consideration for Monarch was $2.7 million. The purchase agreement also included contingent consideration which was paid on January 11, 2016 of $1.0 million. The total purchase price was allocated to $112,000 of tangible assets, $1.2 million of intangible assets with an assigned weighted average life of 5 years being amortized on the straight line method, and $2.4 million of goodwill. Pro forma financial information for the Monarch acquisition is not presented as it is not considered material.
Global Neuro-Diagnostics
The Company acquired GND through an equity purchase on January 23, 2015. GND's service offers patients a more convenient way to complete routine EEG and EMG testing which can be performed at the home, hospital or physician's office. The service also provides comprehensive reporting and support to the physician. The cash consideration for GND was $11.4 million, which consists primarily of $1.5 million of tangible assets, $4.8 million of intangible assets with an assigned weighted average life of 5 years being amortized on the straight line method, and $8.9 million of goodwill, offset by $0.5 million of net liabilities. The purchase agreement also included an earn-out condition which was originally estimated to be $3.2 million. The earn-out condition was subsequently not achieved. Pro forma financial information for the GND acquisition is not presented as it is not considered material.
NicView
On January 2, 2015, the Company purchased the assets of NicView. NicView provides streaming video for families with babies in the neonatal intensive care unit. The cash consideration for NicView was $1.1 million, of which $0.3 million was allocated to tangible assets and $2.7 million to goodwill, offset by $0.6 million allocated to net liabilities. The asset purchase agreement included an earn-out condition contingent upon orders received in and installed by February 28, 2016. The Company settled this earnout for $1.3 million in March 2016. Pro forma financial information for the NicView acquisition is not presented as it is not considered material.
3—CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS
The Company has invested its excess cash in highly liquid marketable securities such as corporate debt instruments, U.S. government agency securities and asset-backed securities. Investments with maturities greater than one year are classified as current because management considers all investments to be available for current operations.

The Company's investments are designed to provide liquidity, preserve capital and maximize total return on invested assets with a focus on high credit-quality securities.

The Company's investments have been classified and accounted for as available-for-sale. Such investments are recorded at fair value, and unrealized holding gains and losses are reported as a separate component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses on sales of investments, if any, are

F-14

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

determined on the specific identification method and are reclassified from accumulated other comprehensive income (loss) to results of operations as other income (expense).

The Company, to date, has not determined that any of the unrealized losses on its investments are considered to be other-than-temporary. The Company reviews its investment portfolio to determine if any security is other-than-temporarily impaired, which would require the Company to record an impairment charge in the period any such determination is made. In making this judgment, the Company evaluates, among other things: the duration and extent to which the fair value of a security is less than its cost; the financial condition of the issuer and any changes thereto; and the Company's intent and ability to hold its investment for a period of time sufficient to allow for any anticipated recovery in market value, or whether the Company will more likely than not be required to sell the security before recovery of its aggregated cost basis.    

Cash, cash equivalents and short-term investments consisted of the following (in thousands):

    
 
December 31, 2017
 
December 31, 2016
Cash and cash equivalents:
 
 
 
Cash
88,950

 
213,551

Short-term investments:
 
 
 
U.S. investment grade bonds

 
24,477

Developed investment grade bonds

 
9,542

Total short-term investments

 
34,019

Total cash, cash equivalents and short-term investments
88,950

 
247,570


Short-term investments by investment type are as follows (in thousands):
  
 
December 31, 2017
 
December 31, 2016
 
Aggregated Cost Basis
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Aggregated Fair Value
 
Aggregated Cost Basis
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Aggregated Fair Value
U.S. investment grade bonds

 

 

 

 
24,531

 

 
(54
)
 
24,477

Developed investment grade bonds

 

 

 

 
9,567

 

 
(25
)
 
9,542

Total short-term investments
$

 
$

 
$

 
$

 
$
34,098

 
$

 
$
(79
)
 
$
34,019


Short-term investments by contractual maturity are as follows (in thousands):

 
December 31, 2017
 
December 31, 2016
 
Investments
 
Investments
Due in one year or less
$

 
$
21,655

Due after one year through five years

 
12,364

Total short-term investment
$

 
$
34,019


See Note 21 to these Consolidated Financial Statements for additional discussion regarding the fair value of the Company's short-term investments.


4—INVENTORIES
Inventories consist of (in thousands): 

F-15

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

 
December 31,
 
2017
 
2016
Raw materials and subassemblies
$
44,699

 
$
28,245

Work in process
3,788

 
1,507

Finished goods
43,488

 
34,908

Total Inventories
91,975

 
64,660

Less: Non-current Inventories
(20,446
)
 
(15,073
)
Inventories
$
71,529

 
$
49,587

At December 31, 2017 and 2016, the Company has classified $20.4 million and $15.1 million, respectively, of inventories as non-current. This inventory consists of service components used to repair products held by customers pursuant to warranty obligations and extended service contracts, including service components for products that the Company no longer sells, inventory purchased for lifetime buys, and inventory that is turning at a slow rate. The Company believes that these inventories will be utilized for the intended purpose.

5—PROPERTY AND EQUIPMENT
Property and equipment consist of (in thousands): 
 
December 31,
 
2017
 
2016
Land
$
2,815

 
$
2,856

Buildings
5,096

 
5,219

Leasehold improvements
3,295

 
2,386

Office furniture and equipment
25,612

 
18,398

Computer software and hardware
9,760

 
9,100

Demonstration and loaned equipment
11,932

 
11,393

 
58,510

 
49,352

Accumulated depreciation
(36,439
)
 
(32,019
)
Total
$
22,071

 
$
17,333

Depreciation expense of property and equipment was $4.1 million, $3.7 million, and $4.2 million in the years ending December 31, 2017, 2016 and 2015, respectively.

6—INTANGIBLE ASSETS
The following table summarizes the components of gross and net intangible asset balances (in thousands): 
 
December 31, 2017
 
December 31, 2016
 
Gross
Carrying
Amount
 
Accumulated
Impairment
 
Accumulated
Amortization
 
Net Book
Value
 
Gross
Carrying
Amount
 
Accumulated
Impairment
 
Accumulated
Amortization
 
Net Book
Value
Technology
$
101,045

 
(1,058
)
 
$
(42,048
)
 
$
57,939

 
$
62,563

 

 
$
(34,683
)
 
$
27,880

Customer related
108,074

 
(50
)
 
(28,972
)
 
79,052

 
38,087

 

 
(17,610
)
 
20,477

Trade names
49,313

 
(3,916
)
 
(13,273
)
 
32,124

 
32,106

 
(3,290
)
 
(7,135
)
 
21,681

Internally developed software
15,610

 

 
(12,293
)
 
3,317

 
16,978

 

 
(10,220
)
 
6,758

Patents
2,778

 
(133
)
 
(2,495
)
 
150

 
2,620

 

 
(2,251
)
 
369

Total Definite-lived intangible assets
276,820

 
(5,157
)
 
(99,081
)
 
172,582

 
152,354

 
(3,290
)
 
(71,899
)
 
77,165

Finite lived intangible assets are amortized over their weighted average lives, which are 13 years for patents, 14 years for technology, 10 years for customer-related intangibles, 10 years for trade names, and 6 years for internally developed software.

F-16

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

Internally developed software consists of $14.8 million relating to costs incurred for development of internal use computer software and $2.2 million for development of software to be sold.
Amortization expense related to intangible assets with finite lives was as follows (in thousands): 
 
Years Ended December 31,
 
2017
 
2016
 
2015
Technology
$
7,705

 
$
3,407

 
$
3,916

Customer related
10,945

 
3,452

 
2,938

Trade names
6,479

 
4,115

 
3,159

Internally developed software
2,117

 
2,069

 
1,620

Patents
244

 
112

 
112

Total amortization
$
27,490

 
$
13,155

 
$
11,745

Expected annual amortization expense related to amortizable intangible assets is as follows (in thousands): 
2018
$
27,014

2019
25,836

2020
23,634

2021
22,210

2022
18,564

Thereafter
55,324

Total expected amortization expense
$
172,582

        
7—GOODWILL
The carrying amount of goodwill and the changes in those balances are as follows (in thousands): 
As of December 31, 2015
$
107,466

Acquisitions/Purchase Accounting Adjustments
6,705

Foreign currency translation
(1,059
)
As of December 31, 2016
$
113,112

Acquisitions/Purchase Accounting Adjustments
54,746

Foreign currency translation
5,140

As of December 31, 2017
$
172,998


8—ACCRUED LIABILITIES
Accrued liabilities consist of (in thousands): 

F-17

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

 
December 31,
 
2017
 
2016
Compensation and related benefits
$
22,816

 
$
16,064

Accrued federal, state, and local taxes
8,155

 
4,160

Warranty reserve
10,995

 
10,670

Accrued amounts due to customers
2,424

 
1,625

Accrued professional fees
2,280

 
1,191

Accrued selling expenses
1,704

 
292

Contingent consideration
147

 
3,043

Accrued travel
338

 

Deferred rent
161

 
132

Other
2,718

 
718

Total
$
51,738

 
$
37,895


9—LONG-TERM OTHER LIABILITIES
Long-term other liabilities consist of (in thousands): 
 
December 31,
 
2017
 
2016
Contingent tax obligations
$
17,934

 
$
6,125

Non-current deferred revenue
4,039

 
1,885

Other
22

 
3

Total
$
21,995

 
$
8,013


10—DEBT AND CREDIT ARRANGEMENTS
The Company has a Credit Agreement with JP Morgan Chase Bank ("JP Morgan") and Citibank, NA (“Citibank”). The Credit Agreement provides for an aggregate $150 million of secured revolving credit facility. In the third quarter of 2017, the Company exercised the right to increase the amount available under the facility by $75.0 million, bringing the aggregate revolving credit facility to $225.0 million. The Credit Agreement contains covenants relating to maintenance of books and records, financial reporting and notification, compliance with laws, maintenance of properties and insurance, and limitations on guaranties, investments, issuance of debt, lease obligations and capital expenditures, and is secured by virtually all of the Company's assets. The Credit Agreement provides for events of default, including failure to pay any principal or interest when due, failure to perform or observe covenants, bankruptcy or insolvency events and the occurrence of a material adverse effect. The Company has no other significant credit facilities.
In addition to the customary restrictive covenants listed above, the Credit Agreement also contains financial covenants that require the Company to maintain a certain leverage ratio and fixed charge coverage ratio, each as defined in the Credit Agreement:
Leverage Ratio, as defined, to be no higher than 2.75 to 1.00.
Interest Coverage Ratio, as defined, to be at least 1.75 to 1.00 at all times.
As of December 31, 2017, the Company was in compliance with the Leverage Ratio at 2.44 to 1.00 and the Interest Coverage Ratio at 10.16 to 1.00.
As of December 31, 2017, the Company had $155 million outstanding under the Credit Agreement.
Pursuant to the terms of the Credit Agreement, the outstanding principal balance will bear interest at either (a) a fluctuating rate per annum equal to the Applicable Rate, as defined in the Credit Agreement, depending on the leverage ratio plus the higher of (i) the federal funds rate plus one-half of one percent per annum; (ii) the prime rate in effect on such a day; and (iii) the LIBOR rate plus one percent, or (b) a fluctuating rate per annum of LIBOR Rate plus the Applicable Rate, which ranges between 1.75% to 2.75%. The effective interest rate during the twelve months ended December 31, 2017 was 3.34%.

F-18

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

The Credit Agreement matures on September 23, 2021, at which time all principal amounts outstanding under the Credit Agreement will be due and payable.

Long-term debt consists of (in thousands):
 
December 31,
 
2017
 
2016
Revolving credit facility
$
155,000

 
$
140,000

Debt issuance costs
(717
)
 

Less: current portion of long-term debt

 

Total long-term debt
$
154,283

 
$
140,000

Maturities of long-term debt as of December 31, 2017 are as follows (in thousands):
 
December 31,
 
2017
 
2016
2018
$

 
$

2019

 

2020

 

Thereafter
154,283

 
140,000

Total
$
154,283

 
$
140,000

As of December 31, 2017, the carrying value of the total debt approximated fair market value.
11—RESERVE FOR PRODUCT WARRANTIES
The Company provides a warranty for products that is generally one year in length and in some cases, regulations may require them to provide repair or remediation beyond the typical warranty period. If any of the products contain defects, the Company may be required to incur additional repair and remediation costs. Service for domestic customers is provided by Company-owned service centers that perform all service, repair and calibration services. Service for international customers is provided by a combination of Company-owned facilities and vendors on a contract basis.
A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management's best estimate of probable liability. The Company considers a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.
As of December 31, 2017, the Company has accrued $5.4 million to bring certain NeoBLUE® phototherapy products into U.S. regulatory compliance. The Company's estimate of the costs associated with bringing the NeoBLUE® phototherapy products into compliance is primarily based upon the number of units outstanding that may require the repair, costs associated with shipping and repairing the product, and the assumption that the FDA will approve the Company's plan for compliance.
The details of activity in the warranty reserve are as follows (in thousands): 
 
Balance at
Beginning
of Period
 
Assumed
Through
Acquisitions
 
Additions
Charged to
Expense
 
Reductions
 
Balance
at End
of Period
December 31, 2017
$
10,670

 
$
1,159

 
$
5,370

 
$
(6,204
)
 
$
10,995

December 31, 2016
$
10,386

 
$
222

 
$
2,711

 
$
(2,649
)
 
$
10,670

December 31, 2015
$
2,753

 
$

 
$
10,729

 
$
(3,096
)
 
$
10,386

The estimates the Company uses in projecting future product warranty costs may prove to be incorrect. Any future determination that product warranty reserves are understated could result in increases to cost of sales and reductions in operating profits and results of operations.


F-19

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

12—STOCKHOLDERS’ EQUITY
Common Stock—The Company has 120,000,000 shares of common stock authorized at a par value or $0.001 per share. 
Preferred Stock—The Company has 10,000,000 shares of preferred stock authorized at a par value of $0.001 per share. In accordance with the terms of the amended and restated certificate of incorporation, the Board of Directors is authorized to provide for the issuance of one or more series of preferred stock, including increases or decreases to the series. The Board of Directors has the authority to set the rights, preferences, and terms of such shares. As of December 31, 2017, no shares of preferred stock were issued and outstanding.

13—EARNINGS PER SHARE
The components of basic and diluted EPS are as follows (in thousands, except per share amounts): 
 
December 31,
 
2017
 
2016
 
2015
Net income (loss)
$
(20,293
)
 
$
42,594

 
$
37,924

Weighted average common shares
32,564

 
32,460

 
32,348

Dilutive effect of stock based awards

 
596

 
893

Diluted Shares
32,564

 
33,056

 
33,241

Basic earnings per share
$
(0.62
)
 
$
1.31

 
$
1.17

Diluted earnings per share
$
(0.62
)
 
$
1.29

 
$
1.14

Shares excluded from calculation of diluted EPS
565

 
2

 


14—SHARE-BASED COMPENSATION
Share-Based Compensation Expense—The Company accounts for share-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation. Share-based compensation was recognized as follows in the consolidated statement of income (in thousands):
 
December 31,
 
2017
 
2016
 
2015
Cost of revenue
$
232

 
$
219

 
$
156

Marketing and selling
540

 
821

 
808

Research and development
1,332

 
1,515

 
1,264

General and administrative
7,341

 
6,453

 
4,725

Total expense
9,445

 
9,008

 
6,953

Stock Awards Plans—Natus' 2011 Stock Awards Plan (the “Plan”) provides for the granting of the following:
Incentive stock options to employees;
Non-statutory stock options to employees, directors and consultants;
Restricted stock awards and restricted stock units;
Stock bonuses; and
Stock appreciation rights.
As of December 31, 2017, there were 779,298 shares available for future awards under the plan.
Under the Plan, stock options may be issued at not less than the fair market value of the common stock on the date of grant, as determined by the Board of Directors. Options issued under the Plan become exercisable as determined by the Board of Directors and expire no more than six years after the date of grant. Most options vest ratably over four years.

F-20

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

Stock Option Activity—Stock option activity under the stock awards plans for the year ended December 31, 2017 is summarized as follows:  
 
Number of
Shares
 
Weighted
Average
Exercise Price
Outstanding, December 31, 2016 (816,691 shares exercisable at a weighted average exercise price of $14.54 per share)
933,096

 
$
15.02

Granted

 
$

Exercised
(134,102
)
 
$
14.06

Forfeited
(1,317
)
 
$
13.83

Expired
(2,592
)
 
$
16.31

Outstanding, December 31, 2017 (790,573 shares exercisable at a weighted average exercise price of $15.14 per share)
795,085

 
$
15.18

As of December 31, 2017, unrecognized compensation related to the unvested portion of stock options was approximately $1.0 thousand, which is expected to be recognized at the beginning of 2018. The intrinsic value of options exercised, representing the difference between the closing stock price of common stock on the date of the exercise and the exercise price, in the years ended December 31, 2017, 2016 and 2015 was $3.1 million, $3.4 million, and $17.7 million, respectively.
As of December 31, 2017, there were: (i) 795,085 options vested and expected to vest with a weighted average exercise price of $15.18, an intrinsic value of $18.3 million, and a weighted average remaining contractual term of 1.2 years; and (ii) 790,573 options exercisable with a weighted average exercise price of $15.14, an intrinsic value of $18.2 million, and a weighted average remaining contractual term of 1.2 years.
The expected life of options is based primarily on historical share option exercise experience of the employees for options granted by the Company. All options are treated as a single group in the determination of expected life, as the Company does not currently expect substantially different exercise or post-vesting termination behavior among the employee population. The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the awards in effect at the time of grant. Expected volatility is based primarily on historical volatility data of the Company's common stock. The Company has no history or expectation of paying dividends on common stock.
Share-based compensation expense associated with options is based on awards ultimately expected to vest. At the time of an option grant, the Company estimates the expected future rate of forfeitures based on historical experience. These estimates are revised, if necessary, in subsequent periods if actual forfeiture rates differ from those estimates. If the actual forfeiture rate is lower than estimated the Company will record additional expense and if the actual forfeiture is higher than estimated the Company will record a recovery of prior expense.
Restricted Stock Awards Activity—The following table summarizes the activity for restricted stock awards during the year ended December 31, 2017:  
 
Shares
 
Weighted
Average
Grant
Date Fair
Value
Unvested at December 31, 2016
506,389

 
$
34.82

Granted
265,449

 
$
34.94

Vested
(391,947
)
 
$
32.41

Forfeited
(16,083
)
 
$
35.87

Unvested at December 31, 2017
363,808

 
$
37.46

As of December 31, 2017, unrecognized compensation related to the unvested portion of stock awards was $10.8 million, which is expected to be recognized over a weighted average period of 2.3 years. The fair market value of outstanding restricted stock awards at December 31, 2017 was $13.9 million. For the restricted stock awards units that vested during the years ended December 31, 2017, 2016, and 2015, the total intrinsic value was $14.3 million, $9.0 million, and $10.3 million, respectively.

F-21

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

Restricted Stock Units Activity—The following table summarizes restricted stock units activity for the year ended December 31, 2017:  
 
Shares
 
Weighted
Average
Grant
Date Fair
Value
Outstanding at December 31, 2016
29,903

 
$
34.39

Awarded
55,176

 
$
35.16

Released
(35,929
)
 
$
33.65

Forfeited
(25,006
)
 
$
34.47

Outstanding at December 31, 2017
24,144

 
$
37.17

As of December 31, 2017, unrecognized compensation related to the unvested portion of stock units was $0.9 million, which is expected to be recognized over a weighted average period of 1.8 years. The aggregate intrinsic value of outstanding restricted stock units at December 31, 2017 was $0.9 million. For the restricted stock units that vested during the years ended December 31, 2017, 2016, and 2015, the total intrinsic value was $1.3 million, $0.9 million, and $0.9 million, respectively.
Employee Stock Purchase Plan—Under Natus' 2011 Employee Stock Purchase Plan (the “ESPP”), U.S. employees can elect to have salary withholdings of up to 15% of eligible compensation to a maximum of $10,625 per offering period, to purchase shares of common stock on April 30 and October 31 of each year. The purchase price for shares acquired under the ESPP is 85% of the fair market value on the last day of the offering period. As of December 31, 2017, there were 117,270 shares reserved for future issuance under the ESPP.
Because the ESPP does not have a “look back” feature, the compensation expense associated with the Plan is not measured by the use of the Black-Scholes pricing model, but rather by measuring the difference between the fair market value of common stock on the last day of the offering period and the purchase price for the offering period, which is 85% of the fair market value. Compensation expense associated with the ESPP for the years ended December 31, 2017, 2016 and 2015, respectively, was $0.3 million, $0.2 million, and $0.2 million. 

15—RESTRUCTURING RESERVE
The Company has historically incurred an ongoing level of restructuring-type activities to maintain a competitive cost structure, including manufacturing and workforce optimization resulting from acquisitions.
The balance of the restructuring reserve is included in accrued liabilities on the accompanying consolidated balance sheets. Employee termination benefits are included as a part of restructuring expenses.
Activity in the restructuring reserves for these plans for the years ended December 31, 20172016 and 2015 is as follows (in thousands): 

F-22

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

 
Personnel
Related
 
Facility
Related
 
Total
Balance as of December 31, 2014
$
368

 

 
$
368

Additions
1,905

 
156

 
2,061

Reversals
(124
)
 

 
(124
)
Payments
(473
)
 
(156
)
 
(629
)
Balance as of December 31, 2015
1,676

 

 
1,676

Additions
1,093

 
725

 
1,818

Reversals
(436
)
 

 
(436
)
Payments
(1,990
)
 
(573
)
 
(2,563
)
Balance as of December 31, 2016
343

 
152

 
495

Additions
431

 

 
431

Reversals
(182
)
 

 
(182
)
Payments
(631
)
 
(93
)
 
(724
)
Balance as of December 31, 2017
$
(39
)
 
59

 
$
20

16—OTHER INCOME (EXPENSE), NET
Other income (expense), net consists of (in thousands): 
 
Years Ended December 31,
 
2017
 
2016
 
2015
Interest income
$
425

 
$
315

 
$
27

Interest expense
(5,081
)
 
(430
)
 
(352
)
Foreign currency gain (loss)
1,013

 
(359
)
 
(1,415
)
Other
76

 
117

 
676

Total other income (expense), net
$
(3,567
)
 
$
(357
)
 
$
(1,064
)

17—INCOME TAXES
Income before provision for income tax is as follows (in thousands): 
 
Years Ended December 31,
 
2017
 
2016
 
2015
U.S.
$
(18,059
)
 
$
68

 
$
20,507

Foreign
23,209

 
54,835

 
31,902

Income before provision for income tax
$
5,150

 
$
54,903

 
$
52,409


The components of income tax expense for the years ended December 31, 2017, 2016 and 2015 (in thousands): 

F-23

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

 
Years Ended December 31,
 
2017
 
2016
 
2015
Current
 
 
 
 
 
U.S. Federal
$
10,110

 
$
(1,388
)
 
$
13,497

U.S. State and local
1,079

 
692

 
1,984

Non-U.S.
12,764

 
15,069

 
2,239

Total current tax expense
23,953

 
14,373

 
17,720

Deferred
 
 
 
 
 
U.S. Federal
6,345

 
(1,534
)
 
(3,410
)
U.S. State and local
(1,333
)
 
(378
)
 
(385
)
Non-U.S.
(3,522
)
 
(152
)
 
560

Total deferred tax benefit
1,490

 
(2,064
)
 
(3,235
)
Total income tax expense
$
25,443

 
$
12,309

 
$
14,485

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities as of December 31, 2017 and 2016 are as follows (in thousands): 
 
December 31,
 
2017
 
2016
Deferred tax assets:
 
 
 
Net operating loss carryforwards
$
3,958

 
$
6,557

Credit carryforwards
4,466

 
2,512

Accruals deductible in different periods
11,969

 
16,157

Employee benefits
1,085

 
2,389

Total deferred tax assets
21,478

 
27,615

Valuation allowance
(5,862
)
 
(3,706
)
Total net deferred tax assets
$
15,616

 
$
23,909

Deferred tax liabilities:
 
Basis difference in fixed and intangible assets
(23,934
)
 
(12,678
)
Foreign earnings to be repatriated
(380
)
 

Total deferred tax liabilities
(24,314
)
 
(12,678
)
Total net deferred tax assets
$
(8,698
)
 
$
11,231

The income tax expense in the accompanying statements of income differs from the provision calculated by applying the U.S. federal statutory income tax rate of 35% in 2017, 2016, and 2015 to income before taxes due to the following: 

F-24

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

 
Years Ended December 31,
 
2017
 
2016
 
2015
Federal statutory tax expense
$
1,802

 
$
19,216

 
$
18,343

State tax expense
(318
)
 
188

 
1,249

Foreign taxes at rates less than U.S. rates
(3,101
)
 
(6,838
)
 
(1,760
)
Deferred charges on sales of U.S. intellectual property
980

 
980

 
(5,878
)
Equity compensation
606

 
(530
)
 
204

Tax credits
(1,498
)
 
(911
)
 
(935
)
Uncertain tax position
2,048

 
485

 
3,897

Lapse of statute
(1,521
)
 
(495
)
 
(784
)
Change of valuation allowance on foreign tax credit
314

 

 

Earnout adjustment
(190
)
 
(1,184
)
 

Repatriation tax net of foreign tax credits
16,564

 

 

Net deferred tax asset re-measurement

3,883

 

 

Tax audits
726

 
543

 

Withholding taxes
2,880

 

 

Return to provision
711

 

 

AMT on acquisition
621

 

 

Other
936

 
855

 
149

Total expense
$
25,443

 
$
12,309

 
$
14,485

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017, the transition of U.S. international taxation from a worldwide tax system to a modified territorial system, and a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017. On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. The Company has calculated its best estimate of the impact of the Act in its year end income tax provision in accordance with its understanding of the Act and guidance available as of the date of this filing. As a result, the Company has recorded $20.5 million as an additional income tax expense in the fourth quarter of 2017, the period in which the legislation was enacted. The provisional amount related to the re-measurement of certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future was $3.9 million. The provisional amount related to the one-time transition tax on the mandatory deemed repatriation of foreign earnings, net of foreign tax credits was $16.6 million based on cumulative foreign earnings of $181.0 million.
In accordance with SAB 118, the Company has determined that the $16.6 million of current tax expense recorded in connection with the transition tax on the mandatory deemed repatriation of foreign earnings was a provisional amount and a reasonable estimate at December 31, 2017. Additional work is necessary to do a more detailed analysis of historical foreign earnings as well as potential correlative adjustments. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete.
As of December 31, 2017, the Company has not assessed the impact of the changes arising from the Act that are effective in tax year 2018 and onward and will be included in the 2018 as interpreted guidance is further released. The Company has also not yet made a policy election with respect to its treatment of potential global intangible low-taxed income (“GILTI”). Companies can either account for taxes on GILTI as incurred or recognize deferred taxes when basis differences exist that are expected to affect the amount of the GILTI inclusion upon reversal. The Company is still in the process of analyzing the provisions of the Act associated with GILTI and the expected impact of GILTI on the Company in the future.
At December 31, 2017, the Company had deferred tax assets attributable to U.S. state net operating loss carryforwards of $1.2 million, which will begin to expire in 2018. At December 31, 2017, the Company had U.S. state R&D credit carryforwards of $0.4 million, which will begin to expire in 2021. At December 31, 2017, the Company had $4.2 million of U.S. foreign tax credit carryforwards that can be used to offset future U.S. tax liabilities related to foreign source taxable income. The foreign tax credits will start to expire in 2022.

F-25

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

At December 31, 2017, certain foreign subsidiaries had deferred tax assets attributable to net operating loss carryforwards as follows: $0.03 million in Germany, $1.4 million in France, $0.5 million in Canada, and $0.5 million in Denmark. These foreign net operating loss carryforwards, if not utilized to offset taxable income in future periods, will expire in various amounts beginning in 2028.
A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, valuation allowances of $5.9 million and $3.7 million were recorded at December 31, 2017 and 2016, respectively. The increase of $2.2 million in valuation allowance was primarily due to a valuation allowance recorded against the Company's current year generation of the Foreign Tax Credit in U.S.
The realizability of the deferred tax assets is primarily dependent on the Company's ability to generate sufficient taxable income in future periods. The Company's management weighed the aggregate effect of all positive evidence and negative evidence in determining the likelihood of realization of the deferred tax assets. The factors used by management to collect evidence included historical earnings of the applicable taxing jurisdiction, the cash refund opportunity to utilize the tax losses, and the future forecast of profitability in the jurisdiction. Weighing all the positive and negative evidence, the Company has recorded a valuation allowance related primarily to net operating losses in certain foreign jurisdictions and U.S. foreign tax credits where it is more likely than not that the tax benefit of the net operating losses and tax credits will not be realized.
There are no changes to the position on the Company's permanent reinvestment of its earnings from foreign operations, with the exception of Excel-Tech and Natus Ireland. As of December 31, 2017, the Company intends to distribute all of the earnings from Excel-Tech and Natus Ireland in excess of their operational needs. The Company has recorded a deferred tax liability of $0.4 million accordingly for 5% Canadian withholding tax on the expected Excel-Tech distribution to Natus Ireland. Natus Ireland has 0% withholding tax under domestic exemption and therefore, no liability has been recorded. The Company intends on permanently reinvesting the earnings of its remaining foreign subsidiaries. The other remaining foreign subsidiaries have both the intent and ability to indefinitely reinvest its undistributed earnings.
Uncertain Tax Positions
A reconciliation of the beginning and ending amount of unrecognized tax benefits (excluding interest and penalties) is as follows (in thousands): 
Balance at January 1, 2015
$
3,395

Increases for tax positions related to prior years
281

Increases for tax positions related to the current year
3,302

Lapse of statutes of limitations
(664
)
Balance at January 1, 2016
$
6,314

Increases for tax positions related to prior years
174

Increases for tax positions related to the current year
70

Lapse of statutes of limitations
(475
)
Foreign exchange difference
(185
)
Balance at January 1, 2017
$
5,898

Increases for tax positions related to prior years
747

Increases for tax positions related to the current year
1,712

Lapse of statutes of limitations
(1,393
)
Foreign exchange difference
53

Balance at December 31, 2017
$
7,017

For the year ended December 31, 2017, unrecognized tax benefits increased by $1.1 million and $0.6 million of tax expense in the income tax provision were recorded. The increase was primarily attributable to the increase in uncertain tax positions related to the current year in certain jurisdictions.
The unrecognized tax benefits for the tax years ended December 31, 2017, 2016 and 2015 were $7.0 million, $5.9 million and $6.3 million, respectively which include $4.0 million, $2.5 million and $2.4 million, respectively that would impact the effective tax rate if recognized.
The Company expects a range from zero to $0.9 million of unrecognized tax benefit that will impact the effective tax rate in the next 12 months due to the lapse of statute of limitations provided that no taxing authority conducts a new examination.

F-26

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

At December 31, 2017, 2016 and 2015, the Company had cumulatively accrued $0.6 million, $0.6 million, and $0.4 million for estimated interest and penalties related to uncertain tax positions. The Company records interest and penalties related to recognized tax positions as a component of income tax expense (benefit), which totaled approximately $(0.01) million, $0.2 million, and $0.1 million for the years ended December 31, 2017, 2016, and 2015, respectively.
The Company is currently unaware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation in this estimate over the next 12 months.
The Company's tax returns remain open to examination as follows: U.S. federal, 2014 through 2017; U.S. states, generally 2013 through 2017; and significant foreign jurisdictions, generally 2013 through 2017.

18—EMPLOYEE BENEFIT PLAN
The Company offers pre-tax and after-tax 401(k) savings plan options under which eligible U.S. employees may elect to have a portion of their salary deferred and contributed to the plan. Employer matching contributions are determined by management and are discretionary. Employer matching contributions were $2.5 million, $1.5 million, and $1.3 million respectively, in the years ended December 31, 2017, 2016, and 2015. For new hires, employer contributions vest ratably over the first two years of employment.

19—SEGMENT, CUSTOMER, AND GEOGRAPHIC INFORMATION
The Company operates in one reportable segment, which is presented as the aggregation of the Neurology, Newborn Care, and Otometrics operating segments. Through the one reportable segment the Company is organized on the basis of the healthcare products and services provided which are used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, and sleep disorders.
End-users customer base includes hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Most of the Company's international sales are to distributors who resell products to end users or sub-distributors. The Company's foreign countries’ revenue is determined based on the customer’s billing address.
Revenue and long-lived asset information by geographic region is as follows (in thousands): 

F-27

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

 
Years Ended December 31,
 
2017
 
2016
 
2015
Consolidated Revenue:
 
United States
$
270,860

 
$
250,694

 
$
242,050

Foreign countries
230,110

 
131,198

 
133,815

 
$
500,970

 
$
381,892

 
$
375,865

Revenue by End Market:
 
Neuro
 
Devices and Systems
$
171,315

 
$
168,200

 
$
168,776

Supplies
59,955

 
58,681

 
60,205

Services
11,886

 
11,641

 
8,320

Total Neurology Revenue
$
243,156

 
$
238,522

 
$
237,301

Newborn Care
 
Devices and Systems
$
77,573

 
$
72,562

 
$
72,669

Supplies
43,732

 
47,674

 
49,982

Services
22,325

 
23,134

 
15,913

Total Newborn Care Revenue
$
143,630

 
$
143,370

 
$
138,564

Otometrics
 
Devices and Systems
$
86,920

 
$

 
$

Supplies
27,264

 

 

Services

 

 

Total Otometrics Revenue
$
114,184

 
$

 
$

Total Revenue
$
500,970

 
$
381,892

 
$
375,865

 
 
 
 
 
 
Property and equipment, net:
 
United States
$
10,128

 
$
7,024

 
 
Canada
5,068

 
4,941

 
 
Argentina
1,591

 
2,121

 
 
Ireland
3,178

 
2,530

 
 
Denmark
1,158

 
17

 
 
Other foreign countries
948

 
700

 
 
 
$
22,071

 
$
17,333

 
 
During the years ended December 31, 2017, 2016 and 2015, no single customer or foreign country contributed to more than 10% of revenue.

20—COMMITMENTS AND CONTINGENCIES
Leases—The Company has entered into noncancelable operating leases for some of the facilities including related office equipment located in the U.S. and Europe through 2024. Minimum lease payments under noncancelable operating leases as of December 31, 2017 are as follows (in thousands):  

F-28


 
Operating
Leases
Year Ending December 31,
 
2018
$
7,038

2019
5,732

2020
4,609

2021
3,392

2022
2,457

Thereafter
6,850

Total minimum lease payments
$
30,078

 
Rent expense, which is recorded on the straight-line method from commencement over the period of the lease, totaled $6.7 million, $5.3 million and $4.4 million in 2017, 2016, and 2015, respectively.
Purchase commitments—The Company has various purchase obligations for goods or services totaling $47.8 million at December 31, 2017, which are expected to be paid within the next year.
Indemnifications—Under the bylaws, the Company has agreed to indemnify the officers and directors for certain events or occurrences arising as a result of the officer or director serving in such capacity. The Company has a director and officer liability insurance policy that limits the exposure under these indemnifications and enables them to recover a portion of any future loss arising out of them. In addition, the Company entered into indemnification agreements with other parties in the ordinary course of business. The Company has determined that these agreements fall within the scope of ASC 460, Guarantees. In some cases liability insurance is obtained to provide coverage that limits its exposure for these other indemnified matters. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. The Company believes the estimated fair value of these indemnification agreements is minimal and have not recorded a liability for these agreements as of December 31, 2017.
Legal matters—The Company may from time to time become a party to various legal proceedings or claims that arise in the ordinary course of business. The Company does not believe that any current legal or administrative proceedings are likely to have a material effect on business, financial condition, or results of operations.
In January 2017, a putative class action lawsuit (Badger v. Natus Medical Incorporation, et al., No. 17-cv-00458-JSW) alleging violations of federal securities laws was filed in the United States District Court for the Northern District of California, naming as defendants the Company and certain officers and a director. In July 2017, plaintiffs filed an amended complaint with a new lead plaintiff (Costabile v. Natus Medical Incorporation, et al., No. 17-cv-00458-JSW) alleging violations of federal securities laws based on allegedly false and misleading statements. The defendants moved to dismiss the Amended Complaint, and in February 2018 the motion to dismiss was granted with leave to amend. The Company believes that the plaintiffs’ allegations are without merit, and intends to vigorously defend against the claims.  In July 2017, a putative shareholder derivative action was filed in California Superior Court (Mortman v. Gunst, et. al., No. RG17867679) against certain of the Company’s officers and directors and naming the Company as a nominal defendant. The action is based on allegations similar to those in the securities class action litigation described above. The Company believes the likelihood of an unfavorable outcome from these actions is remote.

21—FAIR VALUE MEASUREMENTS
ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined under ASC 820 as the exit price associated with the sale of an asset or transfer of a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes the following three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value:
Level 1—Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3—Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

F-29

NATUS MEDICAL INCORPORATED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
Years Ended December 31, 2017, 2016 and 2015

The Company does not have any financial assets or liabilities measured at fair value on a recurring basis.
The following financial instruments are not measured at fair value on the consolidated balance sheet as of December 31, 2017 and 2016, but require disclosure of fair values: cash and cash equivalents, accounts receivable, and accounts payable. The carrying value of these financial instruments approximates fair values because of the relatively short maturity.
During the third quarter of 2014, the Company listed the facility in Mundelein, Illinois for sale. This asset was measured at fair value less cost to sell as of September 30, 2014 based on market price and Level 2 inputs. The book value of this asset on June 30, 2014 was $3.6 million. The Company expensed $2.2 million during the third quarter of 2014 for this impairment. As of December 31, 2017 the Company is carrying the asset as held for sale its fair value of $1.4 million.
The Company also has contingent consideration associated with earnouts from acquisitions. Contingent consideration liabilities are classified as Level 3 liabilities, as the Company use unobservable inputs to value them, which is a probability-based income approach. Contingent considerations are classified as accrued liabilities on the consolidated balance sheets. Subsequent changes in the fair value of contingent consideration liabilities are recorded within the income statement as an operating expense.
Contingent consideration associated with earnouts from acquisitions is as follows (in thousands):
 
December 31, 2016
 
Additions
 
Payments
 
Adjustments
 
December 31, 2017
Liabilities:
 
 
 
 
 
 
 
 
 
Contingent consideration
$
3,043

 
$
693

 
$
(2,966
)
 
$
(623
)
 
$
147

Total
$
3,043

 
$
693

 
$
(2,966
)
 
$
(623
)
 
$
147

The significant unobservable inputs used in the fair value measurement of contingent consideration related to the acquisitions are annualized revenue forecasts developed by the Company considering the probability of achievement of those revenue forecasts. Significant increases (decreases) in these unobservable inputs in isolation would result in a significantly lower (higher) fair value measurement.
The Company's Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spread, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets. See Note 4 to these Consolidated Financial Statements for further information regarding the Company's financial instruments.

ITEM 16.    Form 10-K Summary
Not Applicable.



F-30


EXHIBIT INDEX 
 
 
 
 
Incorporated By Reference
Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
 
 
S-1
 
3.1.1

 
333-44138
 
8/18/2000
 
 
8-K
 
3.1

 
000-33001
 
9/13/2012
 
 
8-A
 
3.1.2

 
000-33001
 
9/6/2002
 
 
8-K
 
3.1

 
000-33001
 
6/18/2008
 
 
10-Q
 
3.1

 
000-33001
 
5/9/2012
 
 
S-1
 
10.1

 
333-44138
 
8/18/2000
 
 
8-K
 
10.1

 
000-33001
 
1/4/2006
 
 
S-1
 
10.3.1

 
333-44138
 
8/18/2000
 
 
10-Q
 
10.2

 
000-33001
 
8/9/2006
 
 
10-K
 
10.2.3

 
000-33001
 
3/14/2008
 
 
10-Q
 
10.02

 
000-33001
 
5/9/2008
 
 
S-1
 
10.4.1

 
333-44138
 
8/18/2000
 
 
S-1
 
10.15

 
333-44138
 
2/9/2001
 
 
S-1
 
10.15.1

 
333-44138
 
2/9/2001
 
 
8-K
 
10.2

 
000-33001
 
1/4/2006
 
 
14-A
 

 
000-33001
 
4/20/2011
 
 
10-Q
 
10.1

 
000-33001
 
11/7/2011
 
 
10-Q
 
10.2

 
000-33001
 
11/7/2011
 
 
10-Q
 
10.3

 
000-33001
 
11/7/2011
 
 
14-A
 

 
000-33001
 
4/20/2011
 
 
14-A
 

 
000-33001
 
4/20/2011
 
 
10-K
 
10.10

 
000-33001
 
3/10/2009






 
 
 
 
Incorporated By Reference
Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
 
 
10-K
 
 
 
000-33001
 
3/16/2015
 
 
8-K
 
99.1

 
000-33001
 
4/22/2013
 
 
10-Q
 
10.1

 
000-33001
 
8/8/2013
 
 
8-K
 
10.1

 
000-33001
 
10/9/2015
 
 
10-Q
 
 
 
000-33001
 
2/29/2016
 
 
10-Q
 
10.2

 
000-33001
 
11/3/2016
 
 
10-Q
 
10.1

 
000-33001
 
11/3/2016
 
 
10-Q
 
10.3

 
000-33001
 
11/3/2016
 
 
8-K
 
16.1

 
000-33001
 
3/28/2014
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101.INS#
 
XBRL Instance Document
 
 
 
 
 
 
 
 
101.SCH#
 
XBRL Taxonomy Extension Schema Document
 
 
 
 
 
 
 
 
101.CAL#
 
XBRL Taxonomy Extension Label Calculation Linkbase Document
 
 
 
 
 
 
 
 



 
 
 
 
Incorporated By Reference
Exhibit No.
 
Exhibit
 
Filing
 
Exhibit No.
 
File No.
 
File Date
101.DEF#
 
XBRL Taxonomy Extension Definition Document
 
 
 
 
 
 
 
 
101.LAB#
 
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
 
 
 
 
 
101.PRE#
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 
 
 
 
 
 

*    Indicates a management contract or compensatory plan or arrangement
#     Previously filed with Annual Report on Form 10-K for year ended December 31, 2017


EX-31.5 2 exhibit31312311710-ka3.htm EXHIBIT 31.5 Exhibit


Exhibit 31.5
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Jonathan A. Kennedy, certify that:
1. I have reviewed this report on Form 10-K of Natus Medical Incorporated, (the "Registrant");
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and
5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.
 
 
 
 
 
 
 
 
Date:
July 20, 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
/s/ Jonathan A. Kennedy
 
 
 
 
 
 
Jonathan A. Kennedy
 
 
 
 
 
 
President and Chief Executive Officer


EX-31.6 3 exhibit31412311710-ka3.htm EXHIBIT 31.6 Exhibit


Exhibit 31.6
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Sharon R. Villaverde, certify that:
1. I have reviewed this report on Form 10-K of Natus Medical Incorporated, (the "Registrant");
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and
5. The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.
 
 
 
 
 
 
 
 
Date:
July 20, 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
/s/ Sharon R. Villaverde
 
 
 
 
 
 
Sharon R. Villaverde
 
 
 
 
 
 
Interim Chief Financial Officer
 
 
 
 
 
 
 


EX-32.3 4 exhibit32212311710-ka3.htm EXHIBIT 32.3 Exhibit


EXHIBIT 32.3
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO TITLE 18, UNITED STATES CODE, SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Natus Medical Incorporated (the “Company”) on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jonathan A. Kennedy, President and Chief Executive Officer of the Company, certify, pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
/s/ Jonathan A. Kennedy
Print Name: Jonathan A. Kennedy
Title: President and Chief Executive Officer
Date:
July 20, 2018
In connection with the Annual Report of Natus Medical Incorporated (the “Company”) on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sharon R. Villaverde, Interim Chief Financial Officer of the Company, certify, pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
/s/ Sharon R. Villaverde
Print Name: Sharon R. Villaverde
Title: Interim Chief Financial Officer
Date:
July 20, 2018


EX-101.INS 5 baby-20171231.xml XBRL INSTANCE DOCUMENT 0000878526 2017-01-01 2017-12-31 0000878526 2018-02-21 0000878526 2017-06-30 0000878526 2014-12-31 0000878526 2016-01-01 2016-12-31 0000878526 us-gaap:AllowanceForDoubtfulAccountsMember 2016-01-01 2016-12-31 0000878526 2015-01-01 2015-12-31 0000878526 us-gaap:AllowanceForDoubtfulAccountsMember 2017-12-31 0000878526 us-gaap:AllowanceForDoubtfulAccountsMember 2015-01-01 2015-12-31 0000878526 us-gaap:AllowanceForDoubtfulAccountsMember 2017-01-01 2017-12-31 0000878526 us-gaap:AllowanceForDoubtfulAccountsMember 2015-12-31 0000878526 us-gaap:AllowanceForDoubtfulAccountsMember 2016-12-31 0000878526 2015-12-31 0000878526 2016-12-31 0000878526 2017-12-31 0000878526 us-gaap:AllowanceForDoubtfulAccountsMember 2014-12-31 0000878526 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0000878526 us-gaap:CommonStockMember 2014-12-31 0000878526 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000878526 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0000878526 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000878526 us-gaap:CommonStockMember 2016-12-31 0000878526 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0000878526 us-gaap:RetainedEarningsMember 2016-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000878526 us-gaap:CommonStockMember 2015-12-31 0000878526 us-gaap:CommonStockMember 2017-12-31 0000878526 us-gaap:RetainedEarningsMember 2014-12-31 0000878526 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0000878526 us-gaap:RetainedEarningsMember 2017-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000878526 us-gaap:RetainedEarningsMember 2015-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000878526 us-gaap:RestrictedStockMember baby:EmployeesMember 2017-01-01 2017-12-31 0000878526 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000878526 us-gaap:BuildingMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000878526 us-gaap:BuildingMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000878526 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2017-01-01 2017-12-31 0000878526 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000878526 us-gaap:RestrictedStockMember us-gaap:DirectorMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-01-01 2017-12-31 0000878526 baby:DemonstrationAndLoanedEquipmentMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000878526 us-gaap:ComputerEquipmentMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000878526 us-gaap:RestrictedStockMember us-gaap:ExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-01-01 2017-12-31 0000878526 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0000878526 us-gaap:RestrictedStockMember us-gaap:ExecutiveOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-01-01 2017-12-31 0000878526 2014-01-01 2014-12-31 0000878526 us-gaap:RestrictedStockMember us-gaap:ExecutiveOfficerMember 2017-01-01 2017-12-31 0000878526 us-gaap:ComputerEquipmentMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0000878526 baby:OtometricsMember 2017-01-03 0000878526 baby:NicViewMember 2015-01-02 0000878526 baby:IntegraMember 2016-01-01 2016-12-31 0000878526 baby:RetCamMember 2016-07-06 0000878526 baby:GlobalNeuroDiagnosticsMember 2015-01-23 0000878526 baby:RetCamMember 2016-07-06 2016-07-06 0000878526 baby:NicViewMember 2015-01-02 2015-01-02 0000878526 baby:NeuroQuestMember 2016-03-02 0000878526 baby:MonarchMedicalDiagnosticsLLCMember 2015-11-13 2015-11-13 0000878526 baby:IntegraMember 2017-10-06 2017-10-06 0000878526 baby:OtometricsMember us-gaap:ProFormaMember 2016-01-01 2016-12-31 0000878526 baby:IntegraMember 2017-10-06 0000878526 baby:RetCamMember 2016-07-07 2016-09-30 0000878526 baby:MonarchMedicalDiagnosticsLLCMember 2015-11-13 0000878526 baby:OtometricsMember us-gaap:ProFormaMember 2017-01-01 2017-12-31 0000878526 baby:IntegraMember 2017-01-01 2017-12-31 0000878526 baby:OtometricsMember 2017-01-03 2017-12-31 0000878526 baby:GlobalNeuroDiagnosticsMember 2015-01-23 2015-01-23 0000878526 baby:OtometricsMember 2017-01-03 2017-01-03 0000878526 baby:NeuroQuestMember 2016-03-02 2016-03-02 0000878526 baby:MonarchMedicalDiagnosticsLLCMember 2016-01-11 2016-01-11 0000878526 baby:OtometricsMember 2016-01-01 2016-12-31 0000878526 baby:OtometricsMember 2017-01-01 2017-12-31 0000878526 baby:DevelopedInvestmentGradeBondsMember 2017-12-31 0000878526 baby:USInvestmentGradeBondsMember 2017-12-31 0000878526 baby:USInvestmentGradeBondsMember 2016-12-31 0000878526 baby:DevelopedInvestmentGradeBondsMember 2016-12-31 0000878526 baby:DevelopedInvestmentGradeBondsMember 2017-12-31 0000878526 baby:USInvestmentGradeBondsMember 2017-12-31 0000878526 baby:DevelopedInvestmentGradeBondsMember 2016-12-31 0000878526 baby:USInvestmentGradeBondsMember 2016-12-31 0000878526 us-gaap:ComputerEquipmentMember 2016-12-31 0000878526 us-gaap:LandMember 2017-12-31 0000878526 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2016-12-31 0000878526 us-gaap:BuildingMember 2017-12-31 0000878526 us-gaap:FurnitureAndFixturesMember 2017-12-31 0000878526 us-gaap:BuildingMember 2016-12-31 0000878526 us-gaap:FurnitureAndFixturesMember 2016-12-31 0000878526 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2017-12-31 0000878526 baby:DemonstrationAndLoanedEquipmentMember 2017-12-31 0000878526 us-gaap:ComputerEquipmentMember 2017-12-31 0000878526 baby:DemonstrationAndLoanedEquipmentMember 2016-12-31 0000878526 us-gaap:LandMember 2016-12-31 0000878526 us-gaap:PatentsMember 2017-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2017-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2016-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2017-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2016-12-31 0000878526 us-gaap:TradeNamesMember 2016-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2016-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2017-12-31 0000878526 us-gaap:TradeNamesMember 2017-12-31 0000878526 us-gaap:PatentsMember 2016-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2015-01-01 2015-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2015-01-01 2015-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2017-01-01 2017-12-31 0000878526 us-gaap:PatentsMember 2017-01-01 2017-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2017-01-01 2017-12-31 0000878526 us-gaap:PatentsMember 2016-01-01 2016-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2016-01-01 2016-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2016-01-01 2016-12-31 0000878526 us-gaap:TradeNamesMember 2016-01-01 2016-12-31 0000878526 us-gaap:TradeNamesMember 2017-01-01 2017-12-31 0000878526 us-gaap:DevelopedTechnologyRightsMember 2016-01-01 2016-12-31 0000878526 us-gaap:TradeNamesMember 2015-01-01 2015-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2015-01-01 2015-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2017-01-01 2017-12-31 0000878526 us-gaap:PatentsMember 2015-01-01 2015-12-31 0000878526 us-gaap:ComputerSoftwareIntangibleAssetMember 2017-01-01 2017-12-31 0000878526 baby:CreditAgreementMember baby:CitibankNationalAssociationMember 2017-12-31 0000878526 baby:CreditAgreementMember baby:CitibankNationalAssociationMember 2017-07-01 2017-09-30 0000878526 baby:CreditAgreementMember baby:CitibankNationalAssociationMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-01-01 2017-12-31 0000878526 baby:CreditAgreementMember baby:CitibankNationalAssociationMember us-gaap:MaximumMember 2017-12-31 0000878526 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2017-12-31 0000878526 baby:CreditAgreementMember baby:CitibankNationalAssociationMember us-gaap:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-01-01 2017-12-31 0000878526 baby:CreditAgreementMember baby:CitibankNationalAssociationMember us-gaap:MinimumMember 2017-12-31 0000878526 baby:CreditAgreementMember baby:CitibankNationalAssociationMember 2017-09-30 0000878526 baby:CertainNeoBLUEPhototherapyProductsMember 2017-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0000878526 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0000878526 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-12-31 0000878526 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-12-31 0000878526 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0000878526 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-12-31 0000878526 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-12-31 0000878526 us-gaap:CostOfSalesMember 2015-01-01 2015-12-31 0000878526 us-gaap:CostOfSalesMember 2016-01-01 2016-12-31 0000878526 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-12-31 0000878526 us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000878526 us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-12-31 0000878526 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-12-31 0000878526 us-gaap:RestrictedStockMember 2016-12-31 0000878526 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0000878526 us-gaap:RestrictedStockMember 2017-12-31 0000878526 us-gaap:EmployeeStockMember 2017-12-31 0000878526 us-gaap:EmployeeStockOptionMember 2017-12-31 0000878526 us-gaap:RestrictedStockUnitsRSUMember 2015-12-31 0000878526 us-gaap:EmployeeStockMember 2017-01-01 2017-12-31 0000878526 us-gaap:EmployeeStockOptionMember us-gaap:DirectorMember 2017-01-01 2017-12-31 0000878526 us-gaap:RestrictedStockMember 2015-12-31 0000878526 baby:PersonnelRelatedMember 2016-01-01 2016-12-31 0000878526 us-gaap:FacilityClosingMember 2015-01-01 2015-12-31 0000878526 us-gaap:FacilityClosingMember 2016-01-01 2016-12-31 0000878526 baby:PersonnelRelatedMember 2017-12-31 0000878526 us-gaap:FacilityClosingMember 2014-12-31 0000878526 us-gaap:FacilityClosingMember 2016-12-31 0000878526 baby:PersonnelRelatedMember 2015-12-31 0000878526 us-gaap:FacilityClosingMember 2017-01-01 2017-12-31 0000878526 us-gaap:FacilityClosingMember 2015-12-31 0000878526 baby:PersonnelRelatedMember 2017-01-01 2017-12-31 0000878526 baby:PersonnelRelatedMember 2015-01-01 2015-12-31 0000878526 baby:PersonnelRelatedMember 2014-12-31 0000878526 baby:PersonnelRelatedMember 2016-12-31 0000878526 us-gaap:FacilityClosingMember 2017-12-31 0000878526 us-gaap:ResearchMember 2017-12-31 0000878526 country:DK 2017-12-31 0000878526 country:FR 2017-12-31 0000878526 us-gaap:MaximumMember 2017-01-01 2017-12-31 0000878526 2017-10-01 2017-12-31 0000878526 us-gaap:ForeignCountryMember 2017-12-31 0000878526 country:CA 2017-12-31 0000878526 country:DE 2017-12-31 0000878526 baby:IncomeTaxProvisionMember 2017-01-01 2017-12-31 0000878526 us-gaap:MinimumMember 2017-01-01 2017-12-31 0000878526 baby:NewbornCareProductsMember 2017-01-01 2017-12-31 0000878526 baby:ServicesMember baby:NewbornCareProductsMember 2017-01-01 2017-12-31 0000878526 baby:SuppliesMember baby:OtometricsProductsMember 2015-01-01 2015-12-31 0000878526 baby:ForeignCountriesMember 2016-12-31 0000878526 baby:DevicesAndSystemsMember baby:NeurologyProductsMember 2015-01-01 2015-12-31 0000878526 baby:SuppliesMember baby:OtometricsProductsMember 2016-01-01 2016-12-31 0000878526 us-gaap:NonUsMember 2017-01-01 2017-12-31 0000878526 baby:SuppliesMember baby:NeurologyProductsMember 2016-01-01 2016-12-31 0000878526 baby:OtometricsProductsMember 2016-01-01 2016-12-31 0000878526 baby:ForeignCountriesMember 2017-12-31 0000878526 baby:OtometricsProductsMember 2015-01-01 2015-12-31 0000878526 baby:DevicesAndSystemsMember baby:NeurologyProductsMember 2016-01-01 2016-12-31 0000878526 baby:SuppliesMember baby:NewbornCareProductsMember 2017-01-01 2017-12-31 0000878526 country:IE 2017-12-31 0000878526 baby:DevicesAndSystemsMember baby:NeurologyProductsMember 2017-01-01 2017-12-31 0000878526 baby:NeurologyProductsMember 2016-01-01 2016-12-31 0000878526 baby:DevicesAndSystemsMember baby:OtometricsProductsMember 2017-01-01 2017-12-31 0000878526 baby:SuppliesMember baby:NewbornCareProductsMember 2016-01-01 2016-12-31 0000878526 baby:ServicesMember baby:OtometricsProductsMember 2015-01-01 2015-12-31 0000878526 baby:DevicesAndSystemsMember baby:NewbornCareProductsMember 2017-01-01 2017-12-31 0000878526 baby:ServicesMember baby:OtometricsProductsMember 2016-01-01 2016-12-31 0000878526 baby:DevicesAndSystemsMember baby:NewbornCareProductsMember 2016-01-01 2016-12-31 0000878526 country:US 2016-01-01 2016-12-31 0000878526 baby:ServicesMember baby:NeurologyProductsMember 2015-01-01 2015-12-31 0000878526 baby:ServicesMember baby:NeurologyProductsMember 2016-01-01 2016-12-31 0000878526 baby:OtometricsProductsMember 2017-01-01 2017-12-31 0000878526 baby:ServicesMember baby:OtometricsProductsMember 2017-01-01 2017-12-31 0000878526 country:US 2017-01-01 2017-12-31 0000878526 baby:SuppliesMember baby:OtometricsProductsMember 2017-01-01 2017-12-31 0000878526 baby:DevicesAndSystemsMember baby:NewbornCareProductsMember 2015-01-01 2015-12-31 0000878526 us-gaap:NonUsMember 2015-01-01 2015-12-31 0000878526 baby:ServicesMember baby:NewbornCareProductsMember 2016-01-01 2016-12-31 0000878526 us-gaap:NonUsMember 2016-01-01 2016-12-31 0000878526 baby:DevicesAndSystemsMember baby:OtometricsProductsMember 2015-01-01 2015-12-31 0000878526 baby:DevicesAndSystemsMember baby:OtometricsProductsMember 2016-01-01 2016-12-31 0000878526 country:AR 2016-12-31 0000878526 country:US 2017-12-31 0000878526 baby:SuppliesMember baby:NeurologyProductsMember 2017-01-01 2017-12-31 0000878526 baby:NewbornCareProductsMember 2015-01-01 2015-12-31 0000878526 country:CA 2016-12-31 0000878526 baby:ServicesMember baby:NewbornCareProductsMember 2015-01-01 2015-12-31 0000878526 baby:SuppliesMember baby:NeurologyProductsMember 2015-01-01 2015-12-31 0000878526 baby:ServicesMember baby:NeurologyProductsMember 2017-01-01 2017-12-31 0000878526 baby:NewbornCareProductsMember 2016-01-01 2016-12-31 0000878526 baby:NeurologyProductsMember 2017-01-01 2017-12-31 0000878526 baby:SuppliesMember baby:NewbornCareProductsMember 2015-01-01 2015-12-31 0000878526 country:DK 2016-12-31 0000878526 baby:NeurologyProductsMember 2015-01-01 2015-12-31 0000878526 country:US 2015-01-01 2015-12-31 0000878526 country:AR 2017-12-31 0000878526 country:US 2016-12-31 0000878526 country:IE 2016-12-31 0000878526 baby:MundeleinFacilityMember 2014-07-01 2014-09-30 0000878526 baby:MundeleinFacilityMember 2017-12-31 0000878526 baby:MundeleinFacilityMember 2014-06-30 0000878526 baby:ContingentConsiderationMember 2017-01-01 2017-12-31 0000878526 baby:ContingentConsiderationMember 2017-12-31 0000878526 baby:ContingentConsiderationMember 2016-12-31 xbrli:pure iso4217:USD iso4217:USD xbrli:shares xbrli:shares baby:Segment 292000 1704000 0 338000 11745000 2938000 3916000 112000 1620000 3159000 13155000 3452000 3407000 112000 2069000 4115000 27490000 10945000 7705000 244000 2117000 6479000 3200000 1000000 1500000 500000 7200000 12500000 3000000 4600000 14800000 181000000 12678000 23934000 0 0 621000 0 -1184000 -190000 0 0 711000 0 543000 726000 0 0 3883000 3290000 3290000 5157000 50000 1058000 133000 3916000 0 0 314000 -784000 -495000 -1521000 64660000 91975000 10625 10.16 1.75 2061000 1905000 1818000 1093000 431000 431000 13900000 P1Y 3900000 16600000 20500000 400000 0 0 0 21619 20937 35929 false --12-31 FY 2017 2017-12-31 10-K 0000878526 33160428 Yes Large Accelerated Filer 1236474075 NATUS MEDICAL INC No Yes BABY 18700000 25242000 86638000 126809000 37895000 51738000 1191000 2280000 32019000 36439000 -45020000 -23595000 P5Y P5Y P5Y P5Y P9Y 4341000 4341000 4107000 4107000 7052000 7052000 7104000 7104000 6953000 156000 4725000 1264000 808000 9008000 219000 6453000 1515000 821000 9445000 232000 7341000 1332000 540000 4182000 8978000 7447000 8983000 19171000 0 2000 565000 649012000 709919000 405799000 305628000 1400000 34019000 9542000 24477000 9542000 24477000 0 0 0 0 0 0 0 0 0 0 0 79000 25000 54000 0 0 0 34098000 9567000 24531000 0 0 0 247570000 88950000 12364000 0 21655000 0 0.54 -0.49 0.53 -0.49 17385000 -15965000 432400000 491994000 539100000 500970000 4300000 600000 500000 -664000 -1284000 -2966000 3043000 147000 1300000 500000 2000000 1100000 5604000 26851000 16069000 7655000 745000 15193000 90913000 4800000 1200000 1300000 4900000 19500000 22182000 100000 2000000 1100000 1748000 300000 112000 2256000 149247000 2200000 66558000 82469000 213551000 88950000 15911000 131082000 -124601000 117270 0.001 0.001 120000000 120000000 32920246 33134101 32920246 33134101 312986000 316577000 29546000 37423000 1132000 2836000 2327000 6380000 145492000 144632000 213376000 13497000 -1388000 10110000 2239000 15069000 12764000 17720000 14373000 23953000 1984000 692000 1079000 1625000 2424000 0.0275 0.0175 140000000 155000000 0.0334 -3410000 -1534000 6345000 0 717000 560000 -152000 -3522000 14915000 10709000 -3235000 -2064000 1490000 12678000 24314000 3684000 19407000 132000 161000 23346000 15157000 1885000 4039000 -385000 -378000 -1333000 27615000 21478000 11231000 23909000 15616000 6557000 3958000 2512000 4466000 2389000 1085000 16157000 11969000 3700000 3706000 5862000 5900000 8698000 0 380000 1300000 1500000 2500000 4200000 3700000 4100000 15987000 16879000 30098000 3600000 1.17 1.31 -0.62 1.14 1.29 -0.62 -2295000 -6758000 10782000 0.35 0.35 0.35 16064000 22816000 P2Y3M P1Y9M 10800000 900000 1000 200000 200000 300000 7104000 0 0 7104000 0 623000 623000 693000 693000 2966000 2966000 3043000 3043000 147000 147000 P6Y P10Y P14Y P13Y P10Y 71899000 17610000 34683000 2251000 10220000 7135000 99081000 28972000 42048000 2495000 12293000 13273000 55324000 27014000 18564000 22210000 23634000 25836000 152354000 38087000 62563000 2620000 16978000 32106000 276820000 108074000 101045000 2778000 15610000 49313000 77165000 20477000 27880000 369000 6758000 21681000 172582000 79052000 57939000 150000 3317000 32124000 -1400000 -1415000 -400000 -359000 1013000 1000000 5000 29000 21000 46363000 50877000 74424000 107466000 113112000 172998000 8900000 2700000 2400000 3500000 1700000 39355000 15500000 -1059000 5140000 6705000 54746000 227537000 234933000 281214000 0 0 1674000 2200000 20507000 68000 -18059000 31902000 54835000 23209000 52409000 54903000 5150000 14485000 12309000 25443000 -5878000 980000 980000 -1760000 -6838000 -3101000 18343000 19216000 1802000 204000 -530000 606000 0 0 2880000 149000 855000 936000 0 0 16564000 1249000 188000 -318000 3897000 485000 2048000 935000 911000 1498000 10164000 16344000 5740000 3270000 -4965000 -1385000 15272000 -19723000 30473000 -6177000 -6967000 5421000 -1543000 2437000 -4032000 -1118000 13879000 -7232000 12232000 7668000 -7581000 -858000 11387000 -5492000 77165000 172582000 352000 430000 5081000 0 41000 4464000 34908000 43488000 49587000 71529000 15073000 20446000 28245000 44699000 1507000 3788000 27000 315000 425000 231638000 287822000 649012000 709919000 79941000 92137000 6125000 17934000 155000000 75000000 225000000.0 150000000 140000000 154283000 0 0 0 0 140000000 154283000 0 0 0 0 140000000 154283000 47800000 832000 118417000 5826000 -19478000 -53264000 -160935000 36852000 72687000 19726000 37924000 37924000 42594000 42594000 -20293000 -20293000 289000 134000 148000 17333000 700000 2121000 4941000 17000 2530000 7024000 22071000 948000 1591000 5068000 1158000 3178000 10128000 -1064000 -357000 -3567000 1 174064000 179673000 272497000 -1000000 53473000 55260000 8717000 30078000 7038000 2457000 3392000 4609000 5732000 6850000 4400000 5300000 6700000 1200000 500000 30000 500000 1400000 718000 2718000 20688000 25931000 0 -168000 -45000 -8378000 -8400000 -5003000 -5000000 21470000 21500000 -8378000 -8378000 -5171000 -5171000 21425000 21425000 8013000 21995000 676000 117000 76000 4200000 3000 22000 11525000 19289000 2268000 629000 473000 156000 2563000 1990000 573000 724000 631000 93000 0 533000 354000 4341000 4107000 7052000 1100000 11400000 2700000 4600000 10600000 149200000 46400000 14284000 15849000 190888000 1126000 210000 0 4068000 3186000 4066000 0 34019000 0 0.001 0.001 10000000 10000000 0 0 0 0 0 0 22004000 18340000 33056000 32564000 0 140000000 60000000 10258000 3630000 3466000 0 0 34019000 0 16000000 0 2753000 10386000 10670000 10995000 5400000 0 222000 1159000 10670000 10995000 3096000 2649000 6204000 10729000 2711000 5370000 10729000 2934000 5370000 49352000 11393000 5219000 9100000 18398000 2856000 2386000 58510000 11932000 5096000 9760000 25612000 2815000 3295000 1056000 1303000 1006000 17333000 22071000 P5Y P40Y P30Y P5Y P3Y P10Y P3Y P3Y 2.44 2.75 0 16000000 45000000 30434000 33443000 51822000 2145000 156000 1536000 725000 914000 0 368000 368000 0 1676000 1676000 0 495000 343000 152000 20000 -39000 59000 -124000 -124000 0 -436000 -436000 0 -182000 -182000 0 149408000 129115000 114200000 375865000 168776000 72669000 0 8320000 15913000 0 60205000 49982000 0 237301000 138564000 0 242050000 133815000 381892000 168200000 72562000 0 11641000 23134000 0 58681000 47674000 0 238522000 143370000 0 250694000 131198000 500970000 171315000 77573000 86920000 11886000 22325000 0 59955000 43732000 27264000 243156000 143630000 114184000 270860000 230110000 87675000 84834000 126166000 6953000 9008000 9445000 P4Y P4Y P3Y P1Y P4Y 0.85 16083 25006 35.87 34.47 265449 55176 34.94 35.16 506389 363808 24144 34.82 34.39 37.46 37.17 391947 35929 32.41 33.65 0.15 29903 779298 790573 15.14 17700000 3400000 3100000 2592 1317 0 933096 795085 15.02 15.18 18200000 10300000 900000 9000000 900000 14300000 18300000 1300000 795085 15.18 14.06 16.31 13.83 0.00 1.00 0.50 0.25 900000 P10Y P6Y P1Y2M P1Y2M 0.85 32649158 33153500 32920246 33134101 102112 97231 193212 34019000 0 35467 45515 48470 199620 191492 249366 0 631663 151142 134102 134102 1251000 1251000 1360000 1360000 1581000 1581000 0 0 0 6953000 6953000 9008000 9008000 9445000 9445000 9008000 9008000 2269000 2269000 1885000 1885000 281915 545109 60800 11526000 11526000 19289000 19289000 2268000 2268000 352715000 -31471000 315296000 68890000 390710000 -39849000 323745000 106814000 417374000 -45020000 312986000 149408000 422097000 -23595000 316577000 129115000 4200000 400000 4160000 8155000 3395000 6300000 6314000 5898000 5900000 7017000 7000000 185000 400000 600000 600000 100000 200000 -10000 3302000 70000 1712000 600000 53000 281000 174000 747000 1100000 664000 475000 1393000 900000 0 2400000 2500000 4000000 2200000 3151000 4324000 3972000 4686000 3706000 4182000 5862000 8978000 821000 1496000 0 1123000 2156000 10017000 0 1134000 266000 1627000 0 5221000 1496000 1123000 10017000 32460000 32564000 893000 596000 0 33241000 33056000 32564000 32348000 32460000 32564000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the components of gross and net intangible asset balances (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="30" rowspan="1"></td></tr><tr><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross<br clear="none"/>Carrying<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br clear="none"/>Impairment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br clear="none"/>Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Net Book<br clear="none"/>Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross<br clear="none"/>Carrying<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br clear="none"/>Impairment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br clear="none"/>Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Net Book<br clear="none"/>Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">101,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(1,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(42,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">57,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">62,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(34,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">27,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Customer related</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">108,074</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(50</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(28,972</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">79,052</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">38,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(17,610</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">20,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Trade names</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">49,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(3,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(13,273</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">32,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">32,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(3,290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(7,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">21,681</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Internally developed software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">15,610</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(12,293</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">3,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">16,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(10,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">6,758</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Patents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">2,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(133</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(2,495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">2,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(2,251</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">369</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Total Definite-lived intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">276,820</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(5,157</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(99,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">172,582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">152,354</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(3,290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(71,899</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">77,165</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ACCRUED&#160;LIABILITIES</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consist of (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation and related benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,816</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued federal, state, and local taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,160</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warranty reserve</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued amounts due to customers</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,424</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued selling expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,704</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued travel</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,718</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">718</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pro forma financial information is presented for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of the earliest period presented, nor is it intended to be a projection of future results. </font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Unaudited Pro forma Financial Information</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.51461988304094%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended&#160; December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">500,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">491,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,965</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,385</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Earnings (loss) per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.53</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted average shares used in the calculation of earnings per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,056</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BUSINESS COMBINATIONS</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assets acquired and liabilities assumed at the date of acquisition are recorded in the Consolidated Financial Statements at the respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets is recorded as goodwill.</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The determination of estimated fair value of acquired assets and liabilities requires management to make significant estimates and assumptions. The Company determines the fair value by applying established valuation techniques, based on information that management believes to be relevant to this determination. The Company also utilizes independent third parties to assist in the valuation of goodwill and intangible assets.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations from acquisitions are included in the Consolidated Financial Statements from the date of the acquisition.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Integra</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 6, 2017, the Company acquired certain neurosurgery business assets from Integra LifeSciences (&#8220;Integra&#8221; or &#8220;Neurosurgery&#8221;) for </font><font style="font-family:inherit;font-size:10pt;">$46.4 million</font><font style="font-family:inherit;font-size:10pt;"> in cash. As part of the acquisition, the Company acquired a global product line, including the manufacturing facility it leases from a third party and the U.S. rights related to four other product lines. The total purchase price has been preliminarily allocated to </font><font style="font-family:inherit;font-size:10pt;">$12.5 million</font><font style="font-family:inherit;font-size:10pt;"> of tangible assets, </font><font style="font-family:inherit;font-size:10pt;">$19.5 million</font><font style="font-family:inherit;font-size:10pt;"> of intangible assets with an associated weighted average life of </font><font style="font-family:inherit;font-size:10pt;">9</font><font style="font-family:inherit;font-size:10pt;"> years being amortized on the straight line method, and </font><font style="font-family:inherit;font-size:10pt;">$15.5 million</font><font style="font-family:inherit;font-size:10pt;"> of goodwill, offset by </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> of net liabilities. Purchase price allocation is considered preliminary at this time although no material adjustments are anticipated. Pro form financial information for the Integra acquisition is not presented as the data necessary to present pro forma net income and pro forma earnings per share is not available. However, pro forma revenue assuming the acquisition occurred on January 1, 2016 would be </font><font style="font-family:inherit;font-size:10pt;">$539.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$432.4 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended December 31, 2017 and 2016, respectively. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Otometrics</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 3, 2017, the Company acquired the Otometrics business from GN Store Nord A/S for a cash purchase price of </font><font style="font-family:inherit;font-size:10pt;">$149.2 million</font><font style="font-family:inherit;font-size:10pt;">, which includes a </font><font style="font-family:inherit;font-size:10pt;">$4.2 million</font><font style="font-family:inherit;font-size:10pt;"> net working capital adjustment. Otometrics is a manufacturer of hearing diagnostics and balance assessment equipment, disposables and software. Otometrics provides computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms to hearing and balance care professionals worldwide. Otometrics has a complete product and brand portfolio known for its sophisticated design technology in the hearing and balance assessment markets. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the purchase price allocation of the fair value of the assets acquired and liabilities assumed at the date of acquisition, (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.28460038986355%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,851</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,256</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,355</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,748</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,655</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(16,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(745</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred income tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">149,247</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The goodwill recorded represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. The goodwill recorded as part of the acquisition of Otometrics is not amortized and includes the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expected synergies and other benefits that the Company believes will result from combining the operations of Otometrics with the operations of Natus;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any intangible assets that did not qualify for separate recognition, as well as future, yet unidentified projects and products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The value of the going-concern element of Otometrics's existing businesses (the higher rate of return on the assembled collection of net assets versus if Natus has acquired all of the net assets separately). </font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management worked with an independent valuation firm to determine fair values of the identifiable intangible assets. The Company used a combination of income approaches including relief from royalty and multi-period excess earnings methods. The valuation models were based on estimates of future operating projections of the acquired business and rights to sell products as well as judgments on the discount rates used and other variables. The Company determined the forecasts based on a number of factors, included their best estimate of near-term net sales expectations and long-term projections, which included review of internal and independent market analyses. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Otometrics's revenue of </font><font style="font-family:inherit;font-size:10pt;">$114.2 million</font><font style="font-family:inherit;font-size:10pt;"> and loss from operations of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> are included in the condensed consolidated statement of operations for the period from January 3, 2017 (acquisition date) to </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unaudited pro forma financial results presented below for the </font><font style="font-family:inherit;font-size:10pt;">twelve months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, include the effects of pro forma adjustments as if the acquisition occurred on January 1, 2016. The pro forma results were prepared using the acquisition method of accounting and combine the historical results of Natus and Otometrics for the </font><font style="font-family:inherit;font-size:10pt;">twelve months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, including the effects of the business combination, primarily amortization expense related to the fair value of identifiable intangible assets acquired, interest expense associated with the financing obtained by Natus in connection with the acquisition, and the elimination of acquisition-related costs incurred. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pro forma financial information is presented for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of the earliest period presented, nor is it intended to be a projection of future results. </font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Unaudited Pro forma Financial Information</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.51461988304094%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended&#160; December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">500,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">491,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,965</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,385</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Earnings (loss) per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.53</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted average shares used in the calculation of earnings per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,056</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pro forma results for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> were adjusted to exclude </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> of nonrecurring expense related to the fair value adjustment of acquisition-date inventory.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pro forma results for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> were adjusted to include </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> of amortization of intangible assets, and </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;"> of interest expense.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RetCam</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 6, 2016, the Company acquired the portfolio of RetCam Imaging Systems (&#8220;RetCam&#8221;) from Clarity Medical Systems, Inc. for </font><font style="font-family:inherit;font-size:10pt;">$10.6 million</font><font style="font-family:inherit;font-size:10pt;"> in cash. RetCam is an imaging system used to diagnose and monitor a range of ophthalmic maladies in premature infants. The purchase agreement also included a holdback of </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> which was paid on February 16, 2017. Subsequent to the acquisition, an additional </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> was paid by the Company to Clarity Medical Systems as a result of a working capital adjustment. Results of operations for RetCam are included in the consolidated financial statements from the date of acquisition. The total purchase price was allocated </font><font style="font-family:inherit;font-size:10pt;">$7.2 million</font><font style="font-family:inherit;font-size:10pt;"> to tangible assets, </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;"> to intangible assets with an assigned weighted average life of </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;"> years being amortized on the straight line method, and </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> to goodwill, offset by </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> to net liabilities. Pro forma financial information for the RetCam acquisition is not presented as it is not considered material. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NeuroQuest</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 2, 2016, the Company acquired NeuroQuest, LLC (&#8220;NeuroQuest&#8221;) through an asset purchase. NeuroQuest complements the Global Neuro-Diagnostics (&#8220;GND&#8221;) and Monarch Medical Diagnostics, LLC (&#8220;Monarch&#8221;) acquisitions which offer patients a convenient way to complete routine-electroencephalography and extended video electronencephalography (&#8220;VEEG&#8221;) testing. The cash consideration for NeuroQuest was </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;">. The purchase agreement included a consideration holdback of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> which was paid on April 30, 2017. The total purchase price was allocated to </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> of tangible assets, </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> of intangible assets with an assigned weighted average life of </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;"> years being amortized on the straight line method, and </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;"> of goodwill, offset by </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> of net liabilities. Pro forma financial information for the NeuroQuest acquisition is not presented as it is not considered material. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Monarch</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company acquired Monarch Medical Diagnostics, LLC (&#8220;Monarch&#8221;) through an asset purchase on November 13, 2015. Monarch's service compliments the Global Neuro-Diagnostics acquisition which offers patients a more convenient way to complete routine diagnostic electroencephalography and video electromyography testing which can be performed at the home, hospital or physician's office. The service also provides comprehensive reporting and support to the physician. The cash consideration for Monarch was </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">. The purchase agreement also included contingent consideration which was paid on January 11, 2016 of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. The total purchase price was allocated to </font><font style="font-family:inherit;font-size:10pt;">$112,000</font><font style="font-family:inherit;font-size:10pt;"> of tangible assets, </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> of intangible assets with an assigned weighted average life of </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;"> years being amortized on the straight line method, and </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> of goodwill. Pro forma financial information for the Monarch acquisition is not presented as it is not considered material. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Global Neuro-Diagnostics</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company acquired GND through an equity purchase on January 23, 2015. GND's service offers patients a more convenient way to complete routine EEG and EMG testing which can be performed at the home, hospital or physician's office. The service also provides comprehensive reporting and support to the physician. The cash consideration for GND was </font><font style="font-family:inherit;font-size:10pt;">$11.4 million</font><font style="font-family:inherit;font-size:10pt;">, which consists primarily of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> of tangible assets, </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;"> of intangible assets with an assigned weighted average life of </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;"> years being amortized on the straight line method, and </font><font style="font-family:inherit;font-size:10pt;">$8.9 million</font><font style="font-family:inherit;font-size:10pt;"> of goodwill, offset by </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> of net liabilities. The purchase agreement also included an earn-out condition which was originally estimated to be </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">. The earn-out condition was subsequently not achieved. Pro forma financial information for the GND acquisition is not presented as it is not considered material.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NicView</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 2, 2015, the Company purchased the assets of NicView. NicView provides streaming video for families with babies in the neonatal intensive care unit. The cash consideration for NicView was </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> was allocated to tangible assets and </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;"> to goodwill, offset by </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> allocated to net liabilities. The asset purchase agreement included an earn-out condition contingent upon orders received in and installed by February 28, 2016. The Company settled this earnout for </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> in March 2016. Pro forma financial information for the NicView acquisition is not presented as it is not considered material.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Equivalents and Short-term Investments</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All highly liquid investments purchased with an original maturity of three months or less are classified as cash equivalents.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS</font></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"></font><font style="font-family:inherit;font-size:10pt;">The Company has invested its excess cash in highly liquid marketable securities such as corporate debt instruments, U.S. government agency securities and asset-backed securities. Investments with maturities greater than one year are classified as current because management considers all investments to be available for current operations. </font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"></font><font style="font-family:inherit;font-size:10pt;">The Company's investments are designed to provide liquidity, preserve capital and maximize total return on invested assets with a focus on high credit-quality securities. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's investments have been classified and accounted for as available-for-sale. Such investments are recorded at fair value, and unrealized holding gains and losses are reported as a separate component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses on sales of investments, if any, are determined on the specific identification method and are reclassified from accumulated other comprehensive income (loss) to results of operations as other income (expense). </font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"></font><font style="font-family:inherit;font-size:10pt;">The Company, to date, has not determined that any of the unrealized losses on its investments are considered to be other-than-temporary. The Company reviews its investment portfolio to determine if any security is other-than-temporarily impaired, which would require the Company to record an impairment charge in the period any such determination is made. In making this judgment, the Company evaluates, among other things: the duration and extent to which the fair value of a security is less than its cost; the financial condition of the issuer and any changes thereto; and the Company's intent and ability to hold its investment for a period of time sufficient to allow for any anticipated recovery in market value, or whether the Company will more likely than not be required to sell the security before recovery of its aggregated cost basis.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and short-term investments consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.18518518518519%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">213,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Short-term investments:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. investment grade bonds</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Developed investment grade bonds</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total short-term investments</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and short-term investments</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88,950</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">247,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"></font><font style="font-family:inherit;font-size:10pt;">Short-term investments by investment type are as follows (in thousands):</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="32" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregated Cost Basis </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregated Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregated Cost Basis </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregated Fair Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. investment grade bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Developed investment grade bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,567</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,542</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,098</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments by contractual maturity are as follows (in thousands):</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.53216374269006%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Investments</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,364</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total short-term investment</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 21 to these Consolidated Financial Statements for additional discussion regarding the fair value of the Company's short-term investments.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#8212;The Company has entered into noncancelable operating leases for some of the facilities including related office equipment located in the U.S. and Europe through 2024. Minimum lease payments under noncancelable operating leases as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands): </font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,038</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,392</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,457</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,078</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense, which is recorded on the straight-line method from commencement over the period of the lease, totaled </font><font style="font-family:inherit;font-size:10pt;">$6.7 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$5.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Purchase commitments</font><font style="font-family:inherit;font-size:10pt;">&#8212;The Company has various purchase obligations for goods or services totaling </font><font style="font-family:inherit;font-size:10pt;">$47.8 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, which are expected to be paid within the next year. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Indemnifications</font><font style="font-family:inherit;font-size:10pt;">&#8212;Under the bylaws, the Company has agreed to indemnify the officers and directors for certain events or occurrences arising as a result of the officer or director serving in such capacity. The Company has a director and officer liability insurance policy that limits the exposure under these indemnifications and enables them to recover a portion of any future loss arising out of them. In addition, the Company entered into indemnification agreements with other parties in the ordinary course of business. The Company has determined that these agreements fall within the scope of ASC 460, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Guarantees</font><font style="font-family:inherit;font-size:10pt;">. In some cases liability insurance is obtained to provide coverage that limits its exposure for these other indemnified matters. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. The Company believes the estimated fair value of these indemnification agreements is minimal and have not recorded a liability for these agreements as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal matters</font><font style="font-family:inherit;font-size:10pt;">&#8212;The Company may from time to time become a party to various legal proceedings or claims that arise in the ordinary course of business. The Company does not believe that any current legal or administrative proceedings are likely to have a material effect on business, financial condition, or results of operations. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, a putative class action lawsuit (Badger v. Natus Medical Incorporation, et al., No. 17-cv-00458-JSW) alleging violations of federal securities laws was filed in the United States District Court for the Northern District of California, naming as defendants the Company and certain officers and a director. In July 2017, plaintiffs filed an amended complaint with a new lead plaintiff (Costabile v. Natus Medical Incorporation, et al., No. 17-cv-00458-JSW) alleging violations of federal securities laws based on allegedly false and misleading statements. The defendants moved to dismiss the Amended Complaint, and in February 2018 the motion to dismiss was granted with leave to amend. The Company believes that the plaintiffs&#8217; allegations are without merit, and intends to vigorously defend against the claims.&#160; In July 2017, a&#160;putative shareholder derivative action was filed in California Superior Court (Mortman v. Gunst, et. al., No. RG17867679) against certain of the Company&#8217;s officers and directors and naming the Company as a nominal defendant. The action is based on allegations similar to those in the securities class action litigation described above. The Company believes the likelihood of an unfavorable outcome from these actions is remote.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EMPLOYEE BENEFIT PLAN</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company offers pre-tax and after-tax 401(k) savings plan options under which eligible U.S. employees may elect to have a portion of their salary deferred and contributed to the plan. Employer matching contributions are determined by management and are discretionary. Employer matching contributions were </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> respectively, in the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. For new hires, employer contributions vest ratably over the first two years of employment.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Comprehensive Income</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company reports by major components and as a single total the change in net assets during the period from non-owner sources as defined in ASC Topic 220, Comprehensive Income. The consolidated statement of comprehensive income has been included with the consolidated statements of operations. Accumulated other comprehensive income consists of translation gains and losses on foreign subsidiary financial statements as well as unrealized gains and losses on investments.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DEBT AND CREDIT ARRANGEMENTS</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a Credit Agreement with JP Morgan Chase Bank ("JP Morgan") and Citibank, NA (&#8220;Citibank&#8221;). The Credit Agreement provides for an aggregate </font><font style="font-family:inherit;font-size:10pt;">$150 million</font><font style="font-family:inherit;font-size:10pt;"> of secured revolving credit facility. In the third quarter of 2017, the Company exercised the right to increase the amount available under the facility by </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">, bringing the aggregate revolving credit facility to </font><font style="font-family:inherit;font-size:10pt;">$225.0 million</font><font style="font-family:inherit;font-size:10pt;">. The Credit Agreement contains covenants relating to maintenance of books and records, financial reporting and notification, compliance with laws, maintenance of properties and insurance, and limitations on guaranties, investments, issuance of debt, lease obligations and capital expenditures, and is secured by virtually all of the Company's assets. The Credit Agreement provides for events of default, including failure to pay any principal or interest when due, failure to perform or observe covenants, bankruptcy or insolvency events and the occurrence of a material adverse effect. The Company has no other significant credit facilities. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the customary restrictive covenants listed above, the Credit Agreement also contains financial covenants that require the Company to maintain a certain leverage ratio and fixed charge coverage ratio, each as defined in the Credit Agreement:</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><font style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Leverage Ratio, as defined, to be no higher than </font><font style="font-family:inherit;font-size:10pt;text-transform:default;">2.75</font><font style="font-family:inherit;font-size:10pt;"> to 1.00.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;text-align:justify;text-indent:36px;"><font style="padding-bottom:8px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:12px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">Interest Coverage Ratio, as defined, to be at least </font><font style="font-family:inherit;font-size:10pt;text-transform:default;">1.75</font><font style="font-family:inherit;font-size:10pt;"> to 1.00 at all times.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company was in compliance with the Leverage Ratio at </font><font style="font-family:inherit;font-size:10pt;">2.44</font><font style="font-family:inherit;font-size:10pt;"> to 1.00 and the Interest Coverage Ratio at </font><font style="font-family:inherit;font-size:10pt;">10.16</font><font style="font-family:inherit;font-size:10pt;"> to 1.00. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$155 million</font><font style="font-family:inherit;font-size:10pt;"> outstanding under the Credit Agreement. </font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of the Credit Agreement, the outstanding principal balance will bear interest at either (a) a fluctuating rate per annum equal to the Applicable Rate, as defined in the Credit Agreement, depending on the leverage ratio plus the higher of (i) the federal funds rate plus one-half of one percent per annum; (ii) the prime rate in effect on such a day; and (iii) the LIBOR rate plus one percent, or (b) a fluctuating rate per annum of LIBOR Rate plus the Applicable Rate, which ranges between </font><font style="font-family:inherit;font-size:10pt;">1.75%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">2.75%</font><font style="font-family:inherit;font-size:10pt;">. The effective interest rate during the twelve months ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">3.34%</font><font style="font-family:inherit;font-size:10pt;">. The Credit Agreement matures on September 23, 2021, at which time all principal amounts outstanding under the Credit Agreement will be due and payable.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt consists of (in thousands):</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving credit facility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(717</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Less: current portion of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,283</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of long-term debt as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,283</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,283</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of the total debt approximated fair market value.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SHARE-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-Based Compensation Expense</font><font style="font-family:inherit;font-size:10pt;">&#8212;The Company accounts for share-based compensation in accordance with ASC Topic 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">. Share-based compensation was recognized as follows in the consolidated statement of income (in thousands):</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketing and selling</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,341</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,453</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,725</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,445</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,953</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Awards Plans</font><font style="font-family:inherit;font-size:10pt;">&#8212;Natus' 2011 Stock Awards Plan (the &#8220;Plan&#8221;) provides for the granting of the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incentive stock options to employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-statutory stock options to employees, directors and consultants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock awards and restricted stock units;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock bonuses; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock appreciation rights.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">779,298</font><font style="font-family:inherit;font-size:10pt;"> shares available for future awards under the plan.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Plan, stock options may be issued at not less than the fair market value of the common stock on the date of grant, as determined by the Board of Directors. Options issued under the Plan become exercisable as determined by the Board of Directors and expire no more than </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> years after the date of grant. Most options vest ratably over </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Option Activity</font><font style="font-family:inherit;font-size:10pt;">&#8212;Stock option activity under the stock awards plans for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> is summarized as follows: </font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise&#160;Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2016 (816,691 shares exercisable at a weighted average exercise price of $14.54 per share)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">933,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(134,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,317</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,592</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2017 (790,573 shares exercisable at a weighted average exercise price of $15.14 per share)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">795,085</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, unrecognized compensation related to the unvested portion of stock options was approximately </font><font style="font-family:inherit;font-size:10pt;">$1.0 thousand</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized at the beginning of 2018. The intrinsic value of options exercised, representing the difference between the closing stock price of common stock on the date of the exercise and the exercise price, in the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$17.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were: (i)&#160;</font><font style="font-family:inherit;font-size:10pt;">795,085</font><font style="font-family:inherit;font-size:10pt;"> options vested and expected to vest with a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$15.18</font><font style="font-family:inherit;font-size:10pt;">, an intrinsic value of </font><font style="font-family:inherit;font-size:10pt;">$18.3 million</font><font style="font-family:inherit;font-size:10pt;">, and a weighted average remaining contractual term of </font><font style="font-family:inherit;font-size:10pt;">1.2</font><font style="font-family:inherit;font-size:10pt;"> years; and (ii)&#160;</font><font style="font-family:inherit;font-size:10pt;">790,573</font><font style="font-family:inherit;font-size:10pt;"> options exercisable with a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$15.14</font><font style="font-family:inherit;font-size:10pt;">, an intrinsic value of </font><font style="font-family:inherit;font-size:10pt;">$18.2 million</font><font style="font-family:inherit;font-size:10pt;">, and a weighted average remaining contractual term of </font><font style="font-family:inherit;font-size:10pt;">1.2</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expected life of options is based primarily on historical share option exercise experience of the employees for options granted by the Company. All options are treated as a single group in the determination of expected life, as the Company does not currently expect substantially different exercise or post-vesting termination behavior among the employee population. The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the awards in effect at the time of grant. Expected volatility is based primarily on historical volatility data of the Company's common stock. The Company has no history or expectation of paying dividends on common stock.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense associated with options is based on awards ultimately expected to vest. At the time of an option grant, the Company estimates the expected future rate of forfeitures based on historical experience. These estimates are revised, if necessary, in subsequent periods if actual forfeiture rates differ from those estimates. If the actual forfeiture rate is lower than estimated the Company will record additional expense and if the actual forfeiture is higher than estimated the Company will record a recovery of prior expense.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Stock Awards Activity</font><font style="font-family:inherit;font-size:10pt;">&#8212;The following table summarizes the activity for restricted stock awards during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">: </font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">506,389</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,449</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(391,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,083</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.87</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363,808</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, unrecognized compensation related to the unvested portion of stock awards was </font><font style="font-family:inherit;font-size:10pt;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">2.3</font><font style="font-family:inherit;font-size:10pt;"> years. The fair market value of outstanding restricted stock awards at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$13.9 million</font><font style="font-family:inherit;font-size:10pt;">. For the restricted stock awards units that vested during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the total intrinsic value was </font><font style="font-family:inherit;font-size:10pt;">$14.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$10.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Stock Units Activity</font><font style="font-family:inherit;font-size:10pt;">&#8212;The following table summarizes restricted stock units activity for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">: </font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Awarded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,006</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,144</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, unrecognized compensation related to the unvested portion of stock units was </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">1.8</font><font style="font-family:inherit;font-size:10pt;"> years. The aggregate intrinsic value of outstanding restricted stock units at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">. For the restricted stock units that vested during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the total intrinsic value was </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employee Stock Purchase Plan</font><font style="font-family:inherit;font-size:10pt;">&#8212;Under Natus' 2011 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), U.S. employees can elect to have salary withholdings of up to </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;"> of eligible compensation to a maximum of </font><font style="font-family:inherit;font-size:10pt;">$10,625</font><font style="font-family:inherit;font-size:10pt;"> per offering period, to purchase shares of common stock on April&#160;30 and October&#160;31 of each year. The purchase price for shares acquired under the ESPP is </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the fair market value on the last day of the offering period. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">117,270</font><font style="font-family:inherit;font-size:10pt;"> shares reserved for future issuance under the ESPP. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the ESPP does not have a &#8220;look back&#8221; feature, the compensation expense associated with the Plan is not measured by the use of the Black-Scholes pricing model, but rather by measuring the difference between the fair market value of common stock on the last day of the offering period and the purchase price for the offering period, which is </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the fair market value. Compensation expense associated with the ESPP for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, was </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic and Diluted Net Income per Share</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Natus computes net income per share as defined in ASC Topic 260, Earnings per Share. Basic net income per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalents outstanding during the period. Common stock equivalents are options granted and shares of restricted stock issued under the stock awards plans and are calculated under the treasury stock method. Common equivalent shares from unexercised stock options and restricted stock are excluded from the computation when there is a loss as the effect is anti-dilutive, or if the exercise price of such options is greater than the average market price of the stock for the period.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EARNINGS PER SHARE</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of basic and diluted EPS are as follows (in thousands, except per share amounts):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,460</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,348</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of stock based awards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted Shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,056</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,241</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic earnings per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted earnings per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.62</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares excluded from calculation of diluted EPS</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FAIR VALUE MEASUREMENTS</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined under ASC 820 as the exit price associated with the sale of an asset or transfer of a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes the following three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1</font><font style="font-family:inherit;font-size:10pt;">&#8212;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2&#8212;</font><font style="font-family:inherit;font-size:10pt;">Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3</font><font style="font-family:inherit;font-size:10pt;">&#8212;Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not have any financial assets or liabilities measured at fair value on a recurring basis.</font></div><div style="line-height:120%;padding-bottom:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following financial instruments are not measured at fair value on the consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, but require disclosure of fair values: cash and cash equivalents, accounts receivable, and accounts payable. The carrying value of these financial instruments approximates fair values because of the relatively short maturity. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the third quarter of 2014, the Company listed the facility in Mundelein, Illinois for sale. This asset was measured at fair value less cost to sell as of September&#160;30, 2014 based on market price and Level 2 inputs. The book value of this asset on June&#160;30, 2014 was </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;">. The Company expensed </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> during the third quarter of 2014 for this impairment. As of December&#160;31, 2017 the Company is carrying the asset as held for sale its fair value of </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also has contingent consideration associated with earnouts from acquisitions. Contingent consideration liabilities are classified as Level 3 liabilities, as the Company use unobservable inputs to value them, which is a probability-based income approach. Contingent considerations are classified as accrued liabilities on the consolidated balance sheets. Subsequent changes in the fair value of contingent consideration liabilities are recorded within the income statement as an operating expense.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration associated with earnouts from acquisitions is as follows (in thousands): </font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Contingent consideration</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">693</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,966</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">147</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The significant unobservable inputs used in the fair value measurement of contingent consideration related to the acquisitions are annualized revenue forecasts developed by the Company considering the probability of achievement of those revenue forecasts. Significant increases (decreases) in these unobservable inputs in isolation would result in a significantly lower (higher) fair value measurement.</font></div><div style="line-height:120%;padding-bottom:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spread, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets. See Note 4 to these Consolidated Financial Statements for further information regarding the Company's financial instruments.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration associated with earnouts from acquisitions is as follows (in thousands): </font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Contingent consideration</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">693</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,966</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">147</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments include cash and cash equivalents, investments, accounts receivable, and accounts payable. Cash is reported at its fair value on the balance sheet dates. The recorded carrying amounts of investments, accounts receivable and accounts payable approximate the fair values due to the short-term maturities.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The functional currency of the Company's subsidiaries outside of North America is generally the local currency of the country where the subsidiary is located. Accordingly, foreign currency translation adjustments relating to the translation of foreign subsidiary financial statements are included as a component of accumulated other comprehensive loss. The Company recorded </font><font style="font-family:inherit;font-size:10pt;">$21.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$(5.0) million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$(8.4) million</font><font style="font-family:inherit;font-size:10pt;"> of foreign currency translation gains (losses) for the years ended December&#160;31, 2017, 2016 and 2015, respectively.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gains and losses from transactions denominated in currencies other than the functional currencies are included in other income and expense. In 2017, 2016, and 2015, net foreign currency transaction gains (losses) were </font><font style="font-family:inherit;font-size:10pt;">$1.0</font><font style="font-family:inherit;font-size:10pt;"> million, </font><font style="font-family:inherit;font-size:10pt;">$(0.4)</font><font style="font-family:inherit;font-size:10pt;"> million, and </font><font style="font-family:inherit;font-size:10pt;">$(1.4)</font><font style="font-family:inherit;font-size:10pt;"> million, respectively. Foreign currency gains and losses result primarily from fluctuations in the exchange rate between the U.S.&#160;Dollar, Canadian Dollar, Euro, Argentine Peso, British Pound, and Danish Kroner.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying value of intangible assets and goodwill</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company amortizes intangible assets with finite lives over the useful lives; any future changes that would limit the useful lives or any determination that these assets are carried at amounts greater than the estimated fair value could result in additional charges. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill is not amortized but is subject to an annual impairment analysis, which is performed as of October&#160;1st; this assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, 2016 and 2015, the Company performed a qualitative assessment to test goodwill for impairment. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on the qualitative assessment, the Company determined that the fair value was more likely than not to be greater than its carrying amount, and no further analysis was needed.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the fair value was less than its carrying amount, the Company would perform a two-step impairment test on goodwill. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. The Company uses a projected discounted cash flow model to determine the fair value of a reporting unit. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit. If the carrying amount of the reporting unit&#8217;s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the assignment of definite lives to trade names in the second quarter of 2015 (See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 6 - Intangible Assets</font><font style="font-family:inherit;font-size:10pt;">), the Company tested indefinite lived intangibles for impairment by comparing the carrying value of those assets to be fair value as of the assessment date. The Company used the relief from royalty method to determine the fair value of the assets. This analysis is dependent upon a number of quantitative and qualitative factors including estimates of forecasted revenue, royalty rate, and taxes. The discount rate applied also has an impact on the estimates of fair value, as use of a higher rate will result in a lower estimate of fair value.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GOODWILL</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amount of goodwill and the changes in those balances are as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:48px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.98245614035088%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisitions/Purchase Accounting Adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,705</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,112</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisitions/Purchase Accounting Adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,998</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long lived assets</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continually monitors events and changes in circumstances that could indicate that carrying amounts of its long-lived assets, including property and equipment and intangible assets, may not be recoverable. When such events or changes in circumstances occur, the Company assess the recoverability by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the future undiscounted cash flows are less than the carrying amount of these assets, the Company will recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income before provision for income tax is as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,209</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,835</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,902</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income before provision for income tax</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,150</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,903</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,409</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of income tax expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,388</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. State and local</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,764</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,069</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,239</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,953</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,373</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. State and local</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,333</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(378</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(385</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,522</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(152</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,490</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,064</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,235</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,443</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,485</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,958</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,557</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accruals deductible in different periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,969</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,157</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee benefits</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,085</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,389</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,478</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,615</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,862</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,706</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,616</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,909</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basis difference in fixed and intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,934</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,678</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign earnings to be repatriated</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(380</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,314</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,678</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,231</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax expense in the accompanying statements of income differs from the provision calculated by applying the U.S. federal statutory income tax rate of </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> to income before taxes due to the following:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal statutory tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(318</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,249</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign taxes at rates less than U.S. rates</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred charges on sales of U.S. intellectual property</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,878</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,498</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(911</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(935</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertain tax position</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lapse of statute</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,521</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(495</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(784</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change of valuation allowance on foreign tax credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnout adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(190</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,184</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repatriation tax net of foreign tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax asset re-measurement</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,883</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax audits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">726</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Withholding taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,880</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Return to provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">711</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AMT on acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">936</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,443</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,485</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the &#8220;Act&#8221;) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;"> effective for tax years beginning after December 31, 2017, the transition of U.S. international taxation from a worldwide tax system to a modified territorial system, and a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017. On December 22, 2017, Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;) was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. The Company has calculated its best estimate of the impact of the Act in its year end income tax provision in accordance with its understanding of the Act and guidance available as of the date of this filing. As a result, the Company has recorded </font><font style="font-family:inherit;font-size:10pt;">$20.5 million</font><font style="font-family:inherit;font-size:10pt;"> as an additional income tax expense in the fourth quarter of 2017, the period in which the legislation was enacted. The provisional amount related to the re-measurement of certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future was </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">. The provisional amount related to the one-time transition tax on the mandatory deemed repatriation of foreign earnings, net of foreign tax credits was </font><font style="font-family:inherit;font-size:10pt;">$16.6 million</font><font style="font-family:inherit;font-size:10pt;"> based on cumulative foreign earnings of </font><font style="font-family:inherit;font-size:10pt;">$181.0 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with SAB 118, the Company has determined that the </font><font style="font-family:inherit;font-size:10pt;">$16.6 million</font><font style="font-family:inherit;font-size:10pt;"> of current tax expense recorded in connection with the transition tax on the mandatory deemed repatriation of foreign earnings was a provisional amount and a reasonable estimate at December 31, 2017. Additional work is necessary to do a more detailed analysis of historical foreign earnings as well as potential correlative adjustments. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2017, the Company has not assessed the impact of the changes arising from the Act that are effective in tax year 2018 and onward and will be included in the 2018 as interpreted guidance is further released. The Company has also not yet made a policy election with respect to its treatment of potential global intangible low-taxed income (&#8220;GILTI&#8221;). Companies can either account for taxes on GILTI as incurred or recognize deferred taxes when basis differences exist that are expected to affect the amount of the GILTI inclusion upon reversal. The Company is still in the process of analyzing the provisions of the Act associated with GILTI and the expected impact of GILTI on the Company in the future.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had deferred tax assets attributable to U.S. state net operating loss carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">, which will begin to expire in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had U.S. state R&amp;D credit carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">, which will begin to expire in 2021. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$4.2 million</font><font style="font-family:inherit;font-size:10pt;"> of U.S. foreign tax credit carryforwards that can be used to offset future U.S. tax liabilities related to foreign source taxable income. The foreign tax credits will start to expire in 2022.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, certain foreign subsidiaries had deferred tax assets attributable to net operating loss carryforwards as follows: </font><font style="font-family:inherit;font-size:10pt;">$0.03 million</font><font style="font-family:inherit;font-size:10pt;"> in Germany, </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> in France, </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in Canada, and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in Denmark. These foreign net operating loss carryforwards, if not utilized to offset taxable income in future periods, will expire in various amounts beginning in 2028. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, valuation allowances of </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;"> were recorded at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. The increase of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> in valuation allowance was primarily due to a valuation allowance recorded against the Company's current year generation of the Foreign Tax Credit in U.S. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The realizability of the deferred tax assets is primarily dependent on the Company's ability to generate sufficient taxable income in future periods. The Company's management weighed the aggregate effect of all positive evidence and negative evidence in determining the likelihood of realization of the deferred tax assets. The factors used by management to collect evidence included historical earnings of the applicable taxing jurisdiction, the cash refund opportunity to utilize the tax losses, and the future forecast of profitability in the jurisdiction. Weighing all the positive and negative evidence, the Company has recorded a valuation allowance related primarily to net operating losses in certain foreign jurisdictions and U.S. foreign tax credits where it is more likely than not that the tax benefit of the net operating losses and tax credits will not be realized. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no changes to the position on the Company's permanent reinvestment of its earnings from foreign operations, with the exception of Excel-Tech and Natus Ireland. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company intends to distribute all of the earnings from Excel-Tech and Natus Ireland in excess of their operational needs. The Company has recorded a deferred tax liability of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> accordingly for </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> Canadian withholding tax on the expected Excel-Tech distribution to Natus Ireland. Natus Ireland has </font><font style="font-family:inherit;font-size:10pt;">0%</font><font style="font-family:inherit;font-size:10pt;"> withholding tax under domestic exemption and therefore, no liability has been recorded. The Company intends on permanently reinvesting the earnings of its remaining foreign subsidiaries. The other remaining foreign subsidiaries have both the intent and ability to indefinitely reinvest its undistributed earnings. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Uncertain Tax Positions</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits (excluding interest and penalties) is as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for tax positions related to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for tax positions related to the current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lapse of statutes of limitations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for tax positions related to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for tax positions related to the current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lapse of statutes of limitations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(475</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange difference</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,898</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for tax positions related to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for tax positions related to the current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,712</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lapse of statutes of limitations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange difference</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, unrecognized tax benefits increased by </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> of tax expense in the income tax provision were recorded. The increase was primarily attributable to the increase in uncertain tax positions related to the current year in certain jurisdictions. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unrecognized tax benefits for the tax years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively which include </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively that would impact the effective tax rate if recognized.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company expects a range from </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized tax benefit that will impact the effective tax rate in the next </font><font style="font-family:inherit;font-size:10pt;">12 months</font><font style="font-family:inherit;font-size:10pt;"> due to the lapse of statute of limitations provided that no taxing authority conducts a new examination.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had cumulatively accrued </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> for estimated interest and penalties related to uncertain tax positions. The Company records interest and penalties related to recognized tax positions as a component of income tax expense (benefit), which totaled approximately </font><font style="font-family:inherit;font-size:10pt;">$(0.01) million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is currently unaware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation in this estimate over the next </font><font style="font-family:inherit;font-size:10pt;">12 months</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's tax returns remain open to examination as follows: U.S. federal, </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">; U.S. states, generally </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">; and significant foreign jurisdictions, generally </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records net deferred tax assets to the extent it is more likely than not that the assets will be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. To the extent that previously reserved deferred tax assets are estimated to be realizable, the Company adjusts the valuation allowance which reduces the provision for income taxes.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes the tax benefit of uncertain tax positions in the financial statements as defined in ASC Topic 740, Income Tax. When the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than </font><font style="font-family:inherit;font-size:10pt;">50 percent</font><font style="font-family:inherit;font-size:10pt;"> likely of being ultimately realized upon settlement, as defined in ASC 740-10-05.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INTANGIBLE ASSETS</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the components of gross and net intangible asset balances (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="30" rowspan="1"></td></tr><tr><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross<br clear="none"/>Carrying<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br clear="none"/>Impairment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br clear="none"/>Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Net Book<br clear="none"/>Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Gross<br clear="none"/>Carrying<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br clear="none"/>Impairment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br clear="none"/>Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Net Book<br clear="none"/>Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">101,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(1,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(42,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">57,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">62,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(34,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">27,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Customer related</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">108,074</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(50</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(28,972</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">79,052</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">38,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(17,610</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">20,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Trade names</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">49,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(3,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(13,273</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">32,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">32,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(3,290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(7,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">21,681</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Internally developed software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">15,610</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(12,293</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">3,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">16,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(10,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">6,758</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Patents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">2,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(133</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(2,495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">2,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(2,251</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">369</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">Total Definite-lived intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">276,820</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(5,157</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(99,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">172,582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">152,354</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(3,290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(71,899</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">77,165</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finite lived intangible assets are amortized over their weighted average lives, which are </font><font style="font-family:inherit;font-size:10pt;">13</font><font style="font-family:inherit;font-size:10pt;"> years for patents, </font><font style="font-family:inherit;font-size:10pt;">14</font><font style="font-family:inherit;font-size:10pt;"> years for technology, </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years for customer-related intangibles, </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years for trade names, and </font><font style="font-family:inherit;font-size:10pt;">6</font><font style="font-family:inherit;font-size:10pt;"> years for internally developed software. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Internally developed software consists of </font><font style="font-family:inherit;font-size:10pt;">$14.8 million</font><font style="font-family:inherit;font-size:10pt;"> relating to costs incurred for development of internal use computer software and </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> for development of software to be sold.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense related to intangible assets with finite lives was as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer related</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,945</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,452</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,938</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,479</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Internally developed software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,117</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,069</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total amortization</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,745</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected annual amortization expense related to amortizable intangible assets is as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,836</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,210</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total expected amortization expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INVENTORIES</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consist of (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials and subassemblies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,788</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,908</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,975</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,660</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Non-current Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,446</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,073</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,529</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,587</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company has classified </font><font style="font-family:inherit;font-size:10pt;">$20.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$15.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of inventories as non-current. This inventory consists of service components used to repair products held by customers pursuant to warranty obligations and extended service contracts, including service components for products that the Company no longer sells, inventory purchased for lifetime buys, and inventory that is turning at a slow rate. The Company believes that these inventories will be utilized for the intended purpose.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories are carried at the lower of cost or market, with cost being determined using the first-in, first-out method. The carrying value of the Company's inventories is reduced for any difference between cost and estimated market value of inventories that is determined to be obsolete or unmarketable, based upon assumptions about future demand and market conditions. Adjustments to the value of inventory establish a new cost basis and are considered permanent even if circumstances later suggest that increased carrying amounts are recoverable. If demand is higher than expected, Natus may sell inventory that had previously been impaired.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Short-term Investments</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All highly liquid investments purchased with an original maturity of three months or less are classified as cash equivalents. Investments with maturities greater than one year are classified as current because management considers all investments to be available for current operations. Cash equivalents and investments are stated at amounts that approximate fair value based on quoted market prices. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's investments have been classified and accounted for as available-for-sale. Such investments are recorded at fair value and unrealized holding gains and losses are reported as a separate component of comprehensive income until realized. Realized gains and losses on sales of investments, if any, are determined on the specific identification method and are reclassified from accumulated other comprehensive loss to results of operations as other income (expense). </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments by contractual maturity are as follows (in thousands):</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.53216374269006%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Investments</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,364</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total short-term investment</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#8220;ASU 2014-09&#8221;), which supersedes nearly all existing revenue recognition guidance. The standard's core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard creates a five-step model to achieve its core principle: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction's price to the separate performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. In addition, entities must disclose sufficient information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Qualitative and quantitative disclosures are required about: (i) the entity's contracts with customers; (ii) the significant judgments, and changes in judgments, made in applying the guidance to those contracts; and (iii) any assets recognized from the costs to obtain or fulfill a contract with a customer. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 616) - Deferral of the Effective Date, which deferred the effective date of ASU 2014-09 to interim and annual periods beginning January 1, 2018. The standard allows entities to apply the standard retrospectively to each prior period presented (&#8220;full retrospective adoption&#8221;) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application (&#8220;modified retrospective adoption&#8221;). The Company adopted the modified retrospective approach of this guidance on January 1, 2018 and has determined that its adoption will not have a material effect on its financial position or results of operations. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This standard requires a lessee to recognize the lease assets and lease liabilities arising from operating leases in the statement of financial position. Qualitative along with specific quantitative disclosures are required by lessees to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 including interim periods within those fiscal years. The Company is currently evaluating the impact that will result from adopting ASU 2016-02. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). This update modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Because these amendments eliminate a step from the goodwill impairment test, they should reduce the cost and complexity of evaluating goodwill for impairment. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company will adopt ASU 2017-04 to goodwill impairment testing on the effective date.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. This update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This guidance is effective for annual periods beginning after December 15, 2017, including interim periods within that year, and must be applied prospectively to an award modified on or after the adoption date. The Company will adopt this guidance and will apply to all future share-based modifications.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Natus Medical Incorporated (&#8220;Natus&#8221;, the &#8220;Company&#8221;) was incorporated in California in May 1987 and reincorporated in Delaware in August 2000. Natus is a leading provider of newborn care, neurology, and hearing and balance assessment healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn&#8217;s environment, software systems for managing and tracking disorders and diseases for public health laboratories, computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms for hearing and balance care professionals. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain reclassifications to the prior periods have been made to conform to the current period presentation. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Consolidated Financial Statements and the reported amount of revenue and expenses during the reporting period. Such estimates include allowances for potentially uncollectible accounts receivable, valuation of inventory, intangible assets, goodwill, share-based compensation, deferred income taxes, reserves for warranty obligations, and the provision for income taxes. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue, net of discounts, is recognized from sales of medical devices and supplies, including sales to distributors, when the following conditions have been met: a purchase order has been received, title has transferred, the selling price is fixed or determinable, and collection of the resulting receivable is reasonably assured. Terms of sale for most domestic sales are FOB origin, reflecting that title and risk of loss are assumed by the purchaser at the shipping point; however, terms of sale for some neurology, sleep-diagnostic, and head cooling systems are FOB destination, reflecting that title and risk of loss are assumed by the purchaser upon delivery. Terms of sales to international distributors are generally EXW, reflecting that goods are shipped &#8220;ex works,&#8221; in which title and risk of loss are assumed by the distributor at the shipping point. For products shipped under FOB origin or EXW terms, delivery is generally considered to have occurred when the product is shipped. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue. The Company generally does not provide rights of return on products.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For products containing embedded software, the Company has determined that the hardware and software components function together to deliver the products&#8217; essential functionality, and therefore, the revenue from the sale of these products does not fall within the scope of the software revenue recognition rules. The Company's revenue recognition policies for sales of these products are substantially the same as for other tangible products.</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from sales of certain products that remain within the scope of the software revenue recognition rules under ASC Subtopic 985-605 is not significant.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from extended service and maintenance agreements, for both medical devices and data management systems, is recognized ratably over the service period. Revenue from installation or training services is deferred until such time service is provided. Hearing screening and ambulatory EEG monitoring revenue is recorded when the procedure is performed at the estimated net realizable value based on contractual agreements with payers&#160;and historical collections.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain revenue transactions include multiple element arrangements. The Company allocates revenue in these arrangements to each unit of accounting using the relative selling price method. The selling prices used during the allocation process are based on vendor specific objective evidence (&#8220;VSOE&#8221;) if available, third party evidence (&#8220;TPE&#8221;) if VSOE is not available, or estimated selling price (&#8220;ESP&#8221;) if neither VSOE or TPE is available.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Group purchasing organization (&#8220;GPOs&#8221;) negotiate volume purchase prices for member hospitals, group practices, and other clinics. The Company's agreements with GPOs typically contain preferential terms for the GPO and its members, including provisions for some, if not all, of the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of marketing fees by Natus to the GPO, usually based on purchasing experience of group members; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-recourse cancellation provisions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Natus does not sell products to GPOs. Hospitals, group practices, and other clinics that are members of a GPO purchase products directly from the Company under the terms negotiated by the GPO. Negotiated pricing and discounts are recognized as a reduction of the selling price of products at the time of the sale. Revenue from sales to members of GPOs is otherwise consistent with general revenue recognition policies as previously described.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories are carried at the lower of cost or market, with cost being determined using the first-in, first-out method. The carrying value of the Company's inventories is reduced for any difference between cost and estimated market value of inventories that is determined to be obsolete or unmarketable, based upon assumptions about future demand and market conditions. Adjustments to the value of inventory establish a new cost basis and are considered permanent even if circumstances later suggest that increased carrying amounts are recoverable. If demand is higher than expected, Natus may sell inventory that had previously been impaired.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying value of intangible assets and goodwill</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company amortizes intangible assets with finite lives over the useful lives; any future changes that would limit the useful lives or any determination that these assets are carried at amounts greater than the estimated fair value could result in additional charges. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill is not amortized but is subject to an annual impairment analysis, which is performed as of October&#160;1st; this assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, 2016 and 2015, the Company performed a qualitative assessment to test goodwill for impairment. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on the qualitative assessment, the Company determined that the fair value was more likely than not to be greater than its carrying amount, and no further analysis was needed.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the fair value was less than its carrying amount, the Company would perform a two-step impairment test on goodwill. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. The Company uses a projected discounted cash flow model to determine the fair value of a reporting unit. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit. If the carrying amount of the reporting unit&#8217;s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the assignment of definite lives to trade names in the second quarter of 2015 (See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 6 - Intangible Assets</font><font style="font-family:inherit;font-size:10pt;">), the Company tested indefinite lived intangibles for impairment by comparing the carrying value of those assets to be fair value as of the assessment date. The Company used the relief from royalty method to determine the fair value of the assets. This analysis is dependent upon a number of quantitative and qualitative factors including estimates of forecasted revenue, royalty rate, and taxes. The discount rate applied also has an impact on the estimates of fair value, as use of a higher rate will result in a lower estimate of fair value. </font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long lived assets</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continually monitors events and changes in circumstances that could indicate that carrying amounts of its long-lived assets, including property and equipment and intangible assets, may not be recoverable. When such events or changes in circumstances occur, the Company assess the recoverability by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the future undiscounted cash flows are less than the carrying amount of these assets, the Company will recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability for product warranties</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company provides a warranty for products that is generally&#160;one year&#160;in length. In some cases, regulations may require the Company to provide repair or remediation beyond the typical warranty period. If any products contain defects, the Company may be required to incur additional repair and remediation costs.&#160;Service for domestic customers is provided by Company-owned service centers that perform all service, repair, and calibration services. Service for international customers is provided by a combination of Company-owned facilities and vendors on a contract basis.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management&#8217;s best estimate of probable liability. The Company considers a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of the reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-based compensation</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes share-based compensation expense associated with employee stock options under the single-option straight line method over the requisite service period, which is generally a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year vesting period and </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year contractual term pursuant to ASC Topic 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">. See Note 14 of the Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For employee stock options, the value of each option is estimated on the date of grant using the Black-Scholes option pricing model, which was developed for use in estimating the value of freely traded options. Similar to other option pricing models, the Black-Scholes method requires the input of highly subjective assumptions, including stock price volatility. Changes in the subjective input assumptions can materially affect the estimated fair value of the employee stock options.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes share-based compensation associated with Restricted Stock Awards (&#8220;RSA&#8221;) and Restricted Stock Units (&#8220;RSU&#8221;). RSAs and RSUs vest ratably over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year period for employees. RSAs and RSUs for executives vest over a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year period; </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> on the second anniversary of the awarded date and </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> on each of the third and fourth anniversaries. RSAs and RSUs for non employees (Board of Directors) vest over a </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year period; </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> on the first anniversary. The value is estimated based on the market value of Natus common stock on the date of issuance pursuant to ASC Topic 718, Compensation-Stock Compensation.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company issues new shares of common stock upon the exercise of stock options and the vesting of RSAs and RSUs.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeitures of employee stock options and awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share-based compensation expense is recorded net of estimated forfeitures, such that expense is recorded only for those share-based awards that are expected to vest.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Equivalents and Short-term Investments</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All highly liquid investments purchased with an original maturity of three months or less are classified as cash equivalents. Investments with maturities greater than one year are classified as current because management considers all investments to be available for current operations. Cash equivalents and investments are stated at amounts that approximate fair value based on quoted market prices. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's investments have been classified and accounted for as available-for-sale. Such investments are recorded at fair value and unrealized holding gains and losses are reported as a separate component of comprehensive income until realized. Realized gains and losses on sales of investments, if any, are determined on the specific identification method and are reclassified from accumulated other comprehensive loss to results of operations as other income (expense). </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Allowance for Doubtful Accounts</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimates the allowance for potentially uncollectible accounts receivable based on historical collection experience within the markets in which the Company operates and other customer-specific information, such as bankruptcy filings or customer liquidity problems. When all internal efforts have been exhausted to collect the receivable, it is written off and relieved from the reserve.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments include cash and cash equivalents, investments, accounts receivable, and accounts payable. Cash is reported at its fair value on the balance sheet dates. The recorded carrying amounts of investments, accounts receivable and accounts payable approximate the fair values due to the short-term maturities.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over estimated useful lives of the respective assets, which are </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years for office furniture and equipment, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years or the length of the license for computer software and hardware, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years for demonstration and loaned equipment, and </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">40</font><font style="font-family:inherit;font-size:10pt;"> years for buildings. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life. Land is not depreciated. Costs associated with acquiring and installing software to be used for internal purposes are capitalized and amortized on a straight-line basis over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research&#160;&amp; Development Costs</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs incurred in research and development are charged to operations as incurred. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records net deferred tax assets to the extent it is more likely than not that the assets will be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. To the extent that previously reserved deferred tax assets are estimated to be realizable, the Company adjusts the valuation allowance which reduces the provision for income taxes.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes the tax benefit of uncertain tax positions in the financial statements as defined in ASC Topic 740, Income Tax. When the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than </font><font style="font-family:inherit;font-size:10pt;">50 percent</font><font style="font-family:inherit;font-size:10pt;"> likely of being ultimately realized upon settlement, as defined in ASC 740-10-05.</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The functional currency of the Company's subsidiaries outside of North America is generally the local currency of the country where the subsidiary is located. Accordingly, foreign currency translation adjustments relating to the translation of foreign subsidiary financial statements are included as a component of accumulated other comprehensive loss. The Company recorded </font><font style="font-family:inherit;font-size:10pt;">$21.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$(5.0) million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$(8.4) million</font><font style="font-family:inherit;font-size:10pt;"> of foreign currency translation gains (losses) for the years ended December&#160;31, 2017, 2016 and 2015, respectively.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gains and losses from transactions denominated in currencies other than the functional currencies are included in other income and expense. In 2017, 2016, and 2015, net foreign currency transaction gains (losses) were </font><font style="font-family:inherit;font-size:10pt;">$1.0</font><font style="font-family:inherit;font-size:10pt;"> million, </font><font style="font-family:inherit;font-size:10pt;">$(0.4)</font><font style="font-family:inherit;font-size:10pt;"> million, and </font><font style="font-family:inherit;font-size:10pt;">$(1.4)</font><font style="font-family:inherit;font-size:10pt;"> million, respectively. Foreign currency gains and losses result primarily from fluctuations in the exchange rate between the U.S.&#160;Dollar, Canadian Dollar, Euro, Argentine Peso, British Pound, and Danish Kroner.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Comprehensive Income</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company reports by major components and as a single total the change in net assets during the period from non-owner sources as defined in ASC Topic 220, Comprehensive Income. The consolidated statement of comprehensive income has been included with the consolidated statements of operations. Accumulated other comprehensive income consists of translation gains and losses on foreign subsidiary financial statements as well as unrealized gains and losses on investments.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic and Diluted Net Income per Share</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Natus computes net income per share as defined in ASC Topic 260, Earnings per Share. Basic net income per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalents outstanding during the period. Common stock equivalents are options granted and shares of restricted stock issued under the stock awards plans and are calculated under the treasury stock method. Common equivalent shares from unexercised stock options and restricted stock are excluded from the computation when there is a loss as the effect is anti-dilutive, or if the exercise price of such options is greater than the average market price of the stock for the period.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330). This standard requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is estimated selling prices in the ordinary course of business, less reasonable predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted ASU 2015-11in January 2017 and no impact was recorded by the Company. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805). This update is to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisition (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. ASU 2017-01 is effective for annual periods beginning after December 15, 2017, including interim periods within those periods, and must be applied prospectively. The Company will apply this guidance to business combinations that occur on or after the effective date.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#8220;ASU 2014-09&#8221;), which supersedes nearly all existing revenue recognition guidance. The standard's core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard creates a five-step model to achieve its core principle: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction's price to the separate performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. In addition, entities must disclose sufficient information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Qualitative and quantitative disclosures are required about: (i) the entity's contracts with customers; (ii) the significant judgments, and changes in judgments, made in applying the guidance to those contracts; and (iii) any assets recognized from the costs to obtain or fulfill a contract with a customer. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 616) - Deferral of the Effective Date, which deferred the effective date of ASU 2014-09 to interim and annual periods beginning January 1, 2018. The standard allows entities to apply the standard retrospectively to each prior period presented (&#8220;full retrospective adoption&#8221;) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application (&#8220;modified retrospective adoption&#8221;). The Company adopted the modified retrospective approach of this guidance on January 1, 2018 and has determined that its adoption will not have a material effect on its financial position or results of operations. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This standard requires a lessee to recognize the lease assets and lease liabilities arising from operating leases in the statement of financial position. Qualitative along with specific quantitative disclosures are required by lessees to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 including interim periods within those fiscal years. The Company is currently evaluating the impact that will result from adopting ASU 2016-02. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). This update modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Because these amendments eliminate a step from the goodwill impairment test, they should reduce the cost and complexity of evaluating goodwill for impairment. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company will adopt ASU 2017-04 to goodwill impairment testing on the effective date.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. This update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This guidance is effective for annual periods beginning after December 15, 2017, including interim periods within that year, and must be applied prospectively to an award modified on or after the adoption date. The Company will adopt this guidance and will apply to all future share-based modifications.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER INCOME (EXPENSE), NET</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net consists of (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,081</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(430</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(352</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency gain (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">676</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,567</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,064</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LONG-TERM OTHER LIABILITIES</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term other liabilities consist of (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent tax obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,039</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,885</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term other liabilities consist of (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent tax obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-current deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,039</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,885</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,013</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RESERVE FOR PRODUCT WARRANTIES</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company provides a warranty for products that is generally </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> year in length and in some cases, regulations may require them to provide repair or remediation beyond the typical warranty period. If any of the products contain defects, the Company may be required to incur additional repair and remediation costs. Service for domestic customers is provided by Company-owned service centers that perform all service, repair and calibration services. Service for international customers is provided by a combination of Company-owned facilities and vendors on a contract basis.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management's best estimate of probable liability. The Company considers a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has accrued </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;"> to bring certain NeoBLUE</font><font style="font-family:inherit;font-size:11pt;">&#174; </font><font style="font-family:inherit;font-size:10pt;">phototherapy products into U.S. regulatory compliance. The Company's estimate of the costs associated with bringing the NeoBLUE</font><font style="font-family:inherit;font-size:11pt;">&#174; </font><font style="font-family:inherit;font-size:10pt;">phototherapy products into compliance is primarily based upon the number of units outstanding that may require the repair, costs associated with shipping and repairing the product, and the assumption that the FDA will approve the Company's plan for compliance. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The details of activity in the warranty reserve are as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance&#160;at</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">of Period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assumed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Through</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Acquisitions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Charged&#160;to</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Reductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">at&#160;End</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">of&#160;Period</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,670</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,159</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,204</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,386</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,711</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,649</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,670</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,753</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,729</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,096</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,386</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimates the Company uses in projecting future product warranty costs may prove to be incorrect. Any future determination that product warranty reserves are understated could result in increases to cost of sales and reductions in operating profits and results of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PROPERTY AND EQUIPMENT</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consist of (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,096</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,295</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,398</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer software and hardware</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Demonstration and loaned equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,932</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,439</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense of property and equipment was </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$4.2 million</font><font style="font-family:inherit;font-size:10pt;"> in the years ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over estimated useful lives of the respective assets, which are </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years for office furniture and equipment, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years or the length of the license for computer software and hardware, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years for demonstration and loaned equipment, and </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">40</font><font style="font-family:inherit;font-size:10pt;"> years for buildings. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life. Land is not depreciated. Costs associated with acquiring and installing software to be used for internal purposes are capitalized and amortized on a straight-line basis over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consist of (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,096</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,295</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,398</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer software and hardware</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Demonstration and loaned equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,932</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,439</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Allowance for Doubtful Accounts</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company estimates the allowance for potentially uncollectible accounts receivable based on historical collection experience within the markets in which the Company operates and other customer-specific information, such as bankruptcy filings or customer liquidity problems. When all internal efforts have been exhausted to collect the receivable, it is written off and relieved from the reserve.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research&#160;&amp; Development Costs</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs incurred in research and development are charged to operations as incurred. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RESTRUCTURING RESERVE</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has historically incurred an ongoing level of restructuring-type activities to maintain a competitive cost structure, including manufacturing and workforce optimization resulting from acquisitions.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance of the restructuring reserve is included in accrued liabilities on the accompanying consolidated balance sheets. Employee termination benefits are included as a part of restructuring expenses.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity in the restructuring reserves for these plans for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">,&#160;</font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.00779727095517%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Personnel</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Related</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Facility</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Related</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,061</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reversals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(473</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(156</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December&#160;31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,093</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">725</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,818</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reversals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,990</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(573</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,563</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December&#160;31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reversals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(631</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(93</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(724</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue, net of discounts, is recognized from sales of medical devices and supplies, including sales to distributors, when the following conditions have been met: a purchase order has been received, title has transferred, the selling price is fixed or determinable, and collection of the resulting receivable is reasonably assured. Terms of sale for most domestic sales are FOB origin, reflecting that title and risk of loss are assumed by the purchaser at the shipping point; however, terms of sale for some neurology, sleep-diagnostic, and head cooling systems are FOB destination, reflecting that title and risk of loss are assumed by the purchaser upon delivery. Terms of sales to international distributors are generally EXW, reflecting that goods are shipped &#8220;ex works,&#8221; in which title and risk of loss are assumed by the distributor at the shipping point. For products shipped under FOB origin or EXW terms, delivery is generally considered to have occurred when the product is shipped. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue. The Company generally does not provide rights of return on products.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For products containing embedded software, the Company has determined that the hardware and software components function together to deliver the products&#8217; essential functionality, and therefore, the revenue from the sale of these products does not fall within the scope of the software revenue recognition rules. The Company's revenue recognition policies for sales of these products are substantially the same as for other tangible products.</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from sales of certain products that remain within the scope of the software revenue recognition rules under ASC Subtopic 985-605 is not significant.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from extended service and maintenance agreements, for both medical devices and data management systems, is recognized ratably over the service period. Revenue from installation or training services is deferred until such time service is provided. Hearing screening and ambulatory EEG monitoring revenue is recorded when the procedure is performed at the estimated net realizable value based on contractual agreements with payers&#160;and historical collections.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain revenue transactions include multiple element arrangements. The Company allocates revenue in these arrangements to each unit of accounting using the relative selling price method. The selling prices used during the allocation process are based on vendor specific objective evidence (&#8220;VSOE&#8221;) if available, third party evidence (&#8220;TPE&#8221;) if VSOE is not available, or estimated selling price (&#8220;ESP&#8221;) if neither VSOE or TPE is available.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Group purchasing organization (&#8220;GPOs&#8221;) negotiate volume purchase prices for member hospitals, group practices, and other clinics. The Company's agreements with GPOs typically contain preferential terms for the GPO and its members, including provisions for some, if not all, of the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of marketing fees by Natus to the GPO, usually based on purchasing experience of group members; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-recourse cancellation provisions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Natus does not sell products to GPOs. Hospitals, group practices, and other clinics that are members of a GPO purchase products directly from the Company under the terms negotiated by the GPO. Negotiated pricing and discounts are recognized as a reduction of the selling price of products at the time of the sale. Revenue from sales to members of GPOs is otherwise consistent with general revenue recognition policies as previously described.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consist of (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation and related benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,816</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued federal, state, and local taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,160</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warranty reserve</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued amounts due to customers</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,424</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued selling expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,704</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued travel</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,718</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">718</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,738</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the purchase price allocation of the fair value of the assets acquired and liabilities assumed at the date of acquisition, (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.28460038986355%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,851</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,256</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,355</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,748</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,655</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(16,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(745</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred income tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total purchase price</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">149,247</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and short-term investments consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.18518518518519%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88,950</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">213,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Short-term investments:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. investment grade bonds</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Developed investment grade bonds</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total short-term investments</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and short-term investments</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88,950</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:30px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">247,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of income tax expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,388</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. State and local</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,764</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,069</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,239</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,953</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,373</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. State and local</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,333</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(378</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(385</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,522</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(152</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,490</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,064</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,235</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,443</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,485</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt consists of (in thousands):</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving credit facility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(717</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Less: current portion of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,283</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant components of deferred tax assets and liabilities as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,958</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,557</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accruals deductible in different periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,969</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,157</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee benefits</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,085</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,389</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,478</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,615</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,862</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,706</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,616</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,909</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basis difference in fixed and intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,934</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,678</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign earnings to be repatriated</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(380</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,314</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,678</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,231</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of basic and diluted EPS are as follows (in thousands, except per share amounts):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,460</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,348</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of stock based awards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted Shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,056</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,241</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic earnings per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted earnings per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.62</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares excluded from calculation of diluted EPS</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax expense in the accompanying statements of income differs from the provision calculated by applying the U.S. federal statutory income tax rate of </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> to income before taxes due to the following:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal statutory tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(318</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,249</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign taxes at rates less than U.S. rates</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred charges on sales of U.S. intellectual property</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,878</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,498</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(911</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(935</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertain tax position</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lapse of statute</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,521</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(495</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(784</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change of valuation allowance on foreign tax credit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnout adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(190</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,184</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Repatriation tax net of foreign tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax asset re-measurement</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,883</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax audits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">726</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Withholding taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,880</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Return to provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">711</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AMT on acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">936</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,443</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,485</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation was recognized as follows in the consolidated statement of income (in thousands):</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketing and selling</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,341</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,453</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,725</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,445</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,953</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense related to intangible assets with finite lives was as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer related</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,945</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,452</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,938</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,479</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Internally developed software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,117</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,069</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total amortization</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,745</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Minimum lease payments under noncancelable operating leases as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands): </font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year Ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,038</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,392</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,457</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,078</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amount of goodwill and the changes in those balances are as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:48px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.98245614035088%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisitions/Purchase Accounting Adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,705</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,112</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisitions/Purchase Accounting Adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,998</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income before provision for income tax is as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,209</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,835</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,902</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income before provision for income tax</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,150</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,903</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,409</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consist of (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials and subassemblies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,788</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,908</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,975</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,660</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Non-current Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,446</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,073</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,529</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,587</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of long-term debt as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,283</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154,283</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net consists of (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,081</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(430</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(352</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency gain (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">676</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,567</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,064</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The details of activity in the warranty reserve are as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance&#160;at</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">of Period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assumed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Through</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Acquisitions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Charged&#160;to</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Reductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">at&#160;End</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">of&#160;Period</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,670</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,159</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,204</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,995</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,386</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,711</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,649</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,670</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,753</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,729</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,096</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,386</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity in the restructuring reserves for these plans for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">,&#160;</font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.00779727095517%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Personnel</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Related</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Facility</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Related</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,061</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reversals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(473</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(156</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December&#160;31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,093</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">725</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,818</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reversals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,990</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(573</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,563</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December&#160;31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reversals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(631</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(93</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(724</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue and long-lived asset information by geographic region is as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Revenue:</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,694</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,050</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign countries</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,110</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,198</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,892</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375,865</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue by End Market:</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Neuro</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Devices and Systems</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,776</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplies</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,955</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Services</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,886</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Neurology Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,156</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238,522</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,301</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Newborn Care</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Devices and Systems</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,573</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,562</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,669</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,982</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Services</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,913</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Newborn Care Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Otometrics</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Devices and Systems</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,920</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplies</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,264</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Services</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Otometrics Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,892</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375,865</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net:</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,128</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,024</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canada</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Argentina</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,121</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ireland</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denmark</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,158</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Other foreign countries</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">948</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes restricted stock units activity for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">: </font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;text-indent:36px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Awarded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,006</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,144</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Option Activity</font><font style="font-family:inherit;font-size:10pt;">&#8212;Stock option activity under the stock awards plans for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> is summarized as follows: </font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise&#160;Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2016 (816,691 shares exercisable at a weighted average exercise price of $14.54 per share)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">933,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(134,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,317</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,592</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2017 (790,573 shares exercisable at a weighted average exercise price of $15.14 per share)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">795,085</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the activity for restricted stock awards during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">: </font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">506,389</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,449</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(391,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,083</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.87</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363,808</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits (excluding interest and penalties) is as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January&#160;1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for tax positions related to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for tax positions related to the current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lapse of statutes of limitations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for tax positions related to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for tax positions related to the current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lapse of statutes of limitations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(475</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange difference</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,898</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for tax positions related to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for tax positions related to the current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,712</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lapse of statutes of limitations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange difference</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SCHEDULE II:&#160;VALUATION AND QUALIFYING ACCOUNTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the years ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">, </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> and </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance&#160;at<br clear="none"/>Beginning<br clear="none"/>of Period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions<br clear="none"/>Charged&#160;to<br clear="none"/>Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance<br clear="none"/>at&#160;End<br clear="none"/>of&#160;Period</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December&#160;31, 2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,182</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,017</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,221</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December&#160;31, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,972</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(266</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,706</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December&#160;31, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,496</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,134</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,686</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected annual amortization expense related to amortizable intangible assets is as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-left:36px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.73684210526315%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,836</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,210</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total expected amortization expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">172,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SEGMENT, CUSTOMER, AND GEOGRAPHIC INFORMATION</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in one reportable segment, which is presented as the aggregation of the Neurology, Newborn Care, and Otometrics operating segments. Through the </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> reportable segment the Company is organized on the basis of the healthcare products and services provided which are used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, and sleep disorders.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">End-users customer base includes hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Most of the Company's international sales are to distributors who resell products to end users or sub-distributors. The Company's foreign countries&#8217; revenue is determined based on the customer&#8217;s billing address.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue and long-lived asset information by geographic region is as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Revenue:</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,694</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,050</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign countries</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,110</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,198</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,892</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375,865</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue by End Market:</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Neuro</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Devices and Systems</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168,776</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplies</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,955</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Services</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,886</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,641</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,320</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Neurology Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,156</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238,522</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,301</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Newborn Care</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Devices and Systems</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,573</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,562</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,669</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,982</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Services</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,913</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Newborn Care Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Otometrics</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Devices and Systems</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,920</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplies</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,264</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Services</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Otometrics Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114,184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,892</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375,865</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net:</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,128</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,024</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canada</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Argentina</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,121</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ireland</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denmark</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,158</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Other foreign countries</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">948</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, no single customer or foreign country contributed to more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of revenue.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-based compensation</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes share-based compensation expense associated with employee stock options under the single-option straight line method over the requisite service period, which is generally a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year vesting period and </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year contractual term pursuant to ASC Topic 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">. See Note 14 of the Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For employee stock options, the value of each option is estimated on the date of grant using the Black-Scholes option pricing model, which was developed for use in estimating the value of freely traded options. Similar to other option pricing models, the Black-Scholes method requires the input of highly subjective assumptions, including stock price volatility. Changes in the subjective input assumptions can materially affect the estimated fair value of the employee stock options.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes share-based compensation associated with Restricted Stock Awards (&#8220;RSA&#8221;) and Restricted Stock Units (&#8220;RSU&#8221;). RSAs and RSUs vest ratably over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year period for employees. RSAs and RSUs for executives vest over a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year period; </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> on the second anniversary of the awarded date and </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> on each of the third and fourth anniversaries. RSAs and RSUs for non employees (Board of Directors) vest over a </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year period; </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> on the first anniversary. The value is estimated based on the market value of Natus common stock on the date of issuance pursuant to ASC Topic 718, Compensation-Stock Compensation.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company issues new shares of common stock upon the exercise of stock options and the vesting of RSAs and RSUs.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeitures of employee stock options and awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share-based compensation expense is recorded net of estimated forfeitures, such that expense is recorded only for those share-based awards that are expected to vest.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability for product warranties</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company provides a warranty for products that is generally&#160;one year&#160;in length. In some cases, regulations may require the Company to provide repair or remediation beyond the typical warranty period. If any products contain defects, the Company may be required to incur additional repair and remediation costs.&#160;Service for domestic customers is provided by Company-owned service centers that perform all service, repair, and calibration services. Service for international customers is provided by a combination of Company-owned facilities and vendors on a contract basis.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management&#8217;s best estimate of probable liability. The Company considers a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of the reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock</font><font style="font-family:inherit;font-size:10pt;">&#8212;The Company has </font><font style="font-family:inherit;font-size:10pt;">120,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock authorized at a par value or </font><font style="font-family:inherit;font-size:10pt;">$0.001</font><font style="font-family:inherit;font-size:10pt;"> per share.</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Preferred Stock</font><font style="font-family:inherit;font-size:10pt;">&#8212;The Company has </font><font style="font-family:inherit;font-size:10pt;">10,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of preferred stock authorized at a par value of </font><font style="font-family:inherit;font-size:10pt;">$0.001</font><font style="font-family:inherit;font-size:10pt;"> per share. In accordance with the terms of the amended and restated certificate of incorporation, the Board of Directors is authorized to provide for the issuance of one or more series of preferred stock, including increases or decreases to the series. The Board of Directors has the authority to set the rights, preferences, and terms of such shares. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, no shares of preferred stock were issued and outstanding.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments by investment type are as follows (in thousands):</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="32" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregated Cost Basis </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregated Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregated Cost Basis </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregated Fair Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. investment grade bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Developed investment grade bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,567</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,542</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total short-term investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,098</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Consolidated Financial Statements and the reported amount of revenue and expenses during the reporting period. Such estimates include allowances for potentially uncollectible accounts receivable, valuation of inventory, intangible assets, goodwill, share-based compensation, deferred income taxes, reserves for warranty obligations, and the provision for income taxes. Actual results could differ from those estimates.</font></div></div> EX-101.SCH 6 baby-20171231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2108100 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 2402409 - Disclosure - Business Combinations - Global Neuro-Diagnostics Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Business Combinations - Integra Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2402408 - Disclosure - Business Combinations - Monarch Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2402407 - Disclosure - Business Combinations - NeuroQuest Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2402410 - Disclosure - Business Combinations - NicView Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Business Combinations - Otometrics Acquisition Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Business Combinations - RetCam Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Business Combinations - Schedule of Pro Forma Financial (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Business Combinations - Summary of Purchase Price Allocation of Fair Value of Assets Acquired and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Cash, Cash Equivalents, and Short-term Investments link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Cash, Cash Equivalents, and Short-term Investments - Investments Classified by Contractual Maturity Date (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Cash, Cash Equivalents, and Short-term Investments - Schedule of cash, cash equivalents and short-term investments (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Cash, Cash Equivalents, and Short-term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Cash, Cash Equivalents, and Short-term Investments - Unrealized Gain (Loss) on Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Commitments And Contingencies link:presentationLink link:calculationLink link:definitionLink 2423402 - Disclosure - Commitments And Contingencies - Minimum Lease Payment under Non Cancelable Operating Lease (Details) link:presentationLink link:calculationLink link:definitionLink 2423403 - Disclosure - Commitments And Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2323301 - Disclosure - Commitments And Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Operations and Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Debt and Credit Arrangements link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Debt and Credit Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Debt and Credit Arrangements - Schedule of Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Debt and Credit Arrangements - Schedule of Maturities of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Debt and Credit Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Earnings Per Share - Components of Basic and Diluted EPS (Detail) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Employee Benefit Plan link:presentationLink link:calculationLink link:definitionLink 2420401 - Disclosure - Employee Benefit Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2425403 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2425402 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2325301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Goodwill link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Income Taxes - Component of Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2419404 - Disclosure - Income Taxes - Components of Deferred Tax Asset and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Income Taxes - Income Loss before Provision (Benefit) for Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 2419405 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2419406 - Disclosure - Income Taxes - Reconciliation of Income tax Expense from Continuous Operation (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2419407 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Intangible Assets - Components of Gross and Net Intangible Asset Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Intangible Assets - Expected Annual Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Intangible Assets - Schedule of Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Inventories - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Long-Term Other Liabilities link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Long-Term Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Long-Term Other Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Organization and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Other Income (Expense), Net link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Other Income (Expense), Net (Details) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Other Income (Expense), Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Reserve for Product Warranties link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Reserve for Product Warranties (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Reserve for Product Warranties (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Restructuring Reserve link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Restructuring Reserve (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Restructuring Reserve (Tables) link:presentationLink link:calculationLink link:definitionLink 2126100 - Schedule - Schedule II: Valuation And Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 2426401 - Schedule - Schedule II: Valuation And Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Segment, Customer and Geographic Information link:presentationLink link:calculationLink link:definitionLink 2421403 - Disclosure - Segment, Customer and Geographic Information (Details) link:presentationLink link:calculationLink link:definitionLink 2421402 - Disclosure - Segment, Customer and Geographic Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2321301 - Disclosure - Segment, Customer and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Share-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Share-Based Compensation - Restricted Stock Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Share-Based Compensation - Restricted Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Share-Based Compensation - Share-based Compensation Expense Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Share-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 baby-20171231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 baby-20171231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 baby-20171231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Other Liabilities Disclosure [Abstract] Contingent tax obligations Liability for Uncertainty in Income Taxes, Noncurrent Non-current deferred revenue Deferred Revenue, Noncurrent Other Other Sundry Liabilities, Noncurrent Total Other Liabilities, Noncurrent Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Table] Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Table] Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Activity [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted Stock Awards [Member] Restricted Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Unvested, beginning of period, Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted, Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested, Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited, Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unvested, end of period, Shares Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Unvested, beginning of period, Weighted - average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted, Weighted - average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested, Weighted - average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited, Weighted - average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Unvested, end of period, Weighted - average grant date fair value Restructuring and Related Activities [Abstract] Detail of Activity in the Restructuring Reserve Restructuring and Related Costs [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents [Member] Patents [Member] Technology [Member] Developed Technology Rights [Member] Customer related [Member] Customer Relationships [Member] Trade names [Member] Trade Names [Member] Internally developed software [Member] Computer Software, Intangible Asset [Member] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Weighted average life of intangible assets Finite-Lived Intangible Asset, Useful Life Costs incurred for development of internal use computer software Costs Incurred for Development of Internal Use Computer Software Costs incurred for development of internal use computer software. Costs incurred for development of software to be sold Capitalized Software Development Costs for Software Sold to Customers Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] 2018 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Total expected amortization expense Finite-Lived Intangible Assets, Net Property, Plant and Equipment [Abstract] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] NeuroQuest [Member] NeuroQuest [Member] NeuroQuest [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Purchase price paid in cash to acquire entity Payments to Acquire Businesses, Gross Contingent consideration Business Combination, Contingent Consideration, Liability Tangible assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Intangible assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Identifiable intangible assets acquired, average useful life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Goodwill Goodwill Liabilities assumed in acquisition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term investments Short-term Investments Accounts receivable, net of allowance for doubtful accounts of $8,978 and $4,182 Accounts Receivable, Net, Current Inventories Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Deferred income tax Deferred Income Tax Assets, Net Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued liabilities Accrued Liabilities, Current Deferred revenue Deferred Revenue, Current Total current liabilities Liabilities, Current Long-term liabilities: Liabilities, Noncurrent [Abstract] Other liabilities Long-term debt Long-term Debt Deferred income tax Deferred Income Tax Liabilities, Net Total liabilities Liabilities Commitments and contingencies (Note 20) Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock, $0.001 par value; 120,000,000 shares authorized; shares issued and outstanding 33,134,101 in 2017 and 32,920,246 in 2016 Common Stock, Value, Issued Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding in 2017 and in 2016 Preferred Stock, Value, Issued Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Cash and Cash Equivalents [Abstract] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] U.S. investment grade bonds US Investment Grade Bonds [Member] US Investment Grade Bonds [Member] Developed investment grade bonds Developed Investment Grade Bonds [Member] Developed Investment Grade Bonds [Member] Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Aggregated Cost Basis Available-for-sale Securities, Amortized Cost Basis Gross Unrealized Gains Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Aggregated Fair Value Available-for-sale Securities Schedule of Purchase Price Allocation Schedule of Business Acquisitions, by Acquisition [Table Text Block] Pro Forma Financial Information Business Acquisition, Pro Forma Information [Table Text Block] Fair Value Disclosures [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Contingent Consideration [Member] Contingent Consideration [Member] Contingent Consideration [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Contingent consideration, beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Adjustments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Contingent consideration, ending balance Segment Reporting [Abstract] Number of reporting segments Number of Reportable Segments Revenue and long-lived asset information by geographic region Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Intangible Assets Intangible Assets Disclosure [Text Block] Share-Based Compensation Expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Stock Options Activity Share-based Compensation, Stock Options, Activity [Table Text Block] Restricted Stock Awards Activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Restricted Stock Units Activity Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Integra [Member] Integra [Member] Integra [Member] Revenue Business Acquisition, Pro Forma Revenue Payables and Accruals [Abstract] Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] RetCam [Member] RetCam [Member] RetCam [Member] Adjustments to consideration transferred Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Equity [Abstract] Common Stock, shares authorized Common Stock, Shares Authorized Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Preferred stock authorized Preferred Stock, Shares Authorized Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock issued Preferred Stock, Shares Issued Preferred stock outstanding Preferred Stock, Shares Outstanding Income Tax Disclosure [Abstract] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Beginning-Unrecognized Tax Benefits Unrecognized Tax Benefits Increases for tax positions related to prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Increases for tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Lapse of statutes of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Foreign exchange difference Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation Foreign exchange difference Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Ending-Unrecognized Tax Benefits Debt Disclosure [Abstract] Revolving credit facility Long-term Debt, Gross Debt Issuance Costs, Net Debt Issuance Costs, Net Less: current portion of long-term debt Long-term Debt, Current Maturities Total long-term debt Long-term Debt, Excluding Current Maturities Inventory Disclosure [Abstract] Non-current Inventories Inventory, Noncurrent Defined Contribution Plan [Abstract] Employer matching contributions Defined Contribution Plan, Employer Discretionary Contribution Amount Goodwill Goodwill Disclosure [Text Block] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Raw materials and subassemblies Inventory, Raw Materials and Supplies, Net of Reserves Work in process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total Inventories Inventory Current and Noncurrent Inventory current and noncurrent. Less: Non-current Inventories Trade Names [Member] Internally Developed Software [Member] Software Development [Member] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Impairment of Intangible Assets Defined Lived (excluding Goodwill) Impairment of Intangible Assets Defined Lived (excluding Goodwill) Impairment of Intangible Assets Defined Lived (excluding Goodwill) Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Long-Term Other Liabilities Other Liabilities Disclosure [Text Block] Statement of Cash Flows [Abstract] Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Net Income (Loss) Attributable to Parent Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Provision for losses on accounts receivable Valuation Allowances and Reserves, Period Increase (Decrease) Excess tax benefit on the exercise of stock options Excess Tax Benefit from Share-based Compensation, Operating Activities Depreciation and amortization Depreciation, Depletion and Amortization Gain on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Impairment of intangible assets Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Warranty reserve Product Warranty Expense Stock-based compensation Share-based Compensation Changes in operating assets and liabilities, net of assets and liabilities acquired in acquisitions: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued liabilities Increase (Decrease) in Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Deferred taxes Increase (Decrease) in Deferred Income Taxes Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Acquisition of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Acquisition of intangible assets Payments to Acquire Intangible Assets Purchases of short-term investments Payments to Acquire Short-term Investments Sales of short-term investments Proceeds from Sale of Short-term Investments Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from stock option exercises and ESPP Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Excess tax benefit on the exercise of stock options Excess Tax Benefit from Share-based Compensation, Financing Activities Repurchase of company stock Payments for Repurchase of Common Stock Taxes paid related to net share settlement of equity awards Payments Related to Tax Withholding for Share-based Compensation Proceeds from short-term borrowings Proceeds from Short-term Debt Proceeds from long-term borrowings Proceeds from Issuance of Long-term Debt Deferred debt issuance costs Payments of Debt Issuance Costs Contingent consideration earn-out Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Payments on borrowings Repayments of Debt Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Exchange rate effect on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Cash paid for income taxes Income Taxes Paid Non-cash investing activities: Other Noncash Investing and Financing Items [Abstract] Property and equipment included in accounts payable Noncash or Part Noncash Acquisition, Fixed Assets Acquired Inventory transferred to property and equipment Property, Plant and Equipment, Gross, Period Increase (Decrease) Restricted Stock Units [Member] Restricted Stock Units (RSUs) [Member] Unvested, beginning of period, Shares Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Awarded, units Release, units Forfeited, units Commitments and Contingencies Disclosure [Abstract] Minimum Future Leases Payments Receivable Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Accounting Policies [Abstract] Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Table] Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Table] Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Table] Employee Stock Option [Member] Employee Stock Option [Member] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Employees [Member] Employees [Member] Employees [Member] Executives RSAs and RSUs [Member] Executive Officer [Member] Director [Member] Director [Member] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] Vest on second anniversary of the vesting start date [Member] Share-based Compensation Award, Tranche One [Member] On each of the third and fourth anniversaries of the vesting date[Member] Share-based Compensation Award, Tranche Two [Member] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Office furniture and equipment [Member] Furniture and Fixtures [Member] Computer software and hardware [Member] Computer Equipment [Member] Demonstration and loaned equipment [Member] Demonstration and Loaned Equipment [Member] Demonstration and loaned equipment. Buildings [Member] Building [Member] Software for internal purposes [Member] Software and Software Development Costs [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items] Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items] Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items] Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share based compensation, expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Estimated useful lives of property and equipment Property, Plant and Equipment, Useful Life Recorded foreign currency translation gains (losses) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Net foreign currency transaction gains (losses) Foreign Currency Transaction Gain (Loss), before Tax Due in one year or less Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Due after one year through five years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis Total short-term investment Commitments And Contingencies Commitments and Contingencies Disclosure [Text Block] Monarch Medical Diagnostics, LLC [Member] Monarch Medical Diagnostics, LLC [Member] Monarch Medical Diagnostics, LLC [Member] Contingent consideration Business Combination, Contingent Consideration, Earn-Out Receivable, Financing Activities Business Combination, Contingent Consideration, Earn-Out Receivable, Financing Activities Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Product Warranties Disclosures [Abstract] Product warranty period Standard Product Warranty Period Standard product warranty period. Product Warranty Liability [Table] Product Warranty Liability [Table] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Certain NeoBLUE Phototherapy Products [Member] Certain NeoBLUE Phototherapy Products [Member] Certain NeoBLUE Phototherapy Products [Member] Product Warranty Liability [Line Items] Product Warranty Liability [Line Items] Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward] Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward] Balance at Beginning of Period Standard and Extended Product Warranty Accrual Assumed Through Acquisitions Standard and Extended Product Warranty Accrual, Additions from Business Acquisition Additions Charged to Expense Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Reductions Standard and Extended Product Warranty Accrual, Decrease for Payments Balance at End of Period 2018 Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months 2019 Long-term Debt, Maturities, Repayments of Principal in Year Two 2020 Long-term Debt, Maturities, Repayments of Principal in Year Three Thereafter Long-term Debt, Maturities, Repayments of Principal in Year Four Long-term Debt Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, beginning of period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Cancelled (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Outstanding, end of period (shares) Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cancelled (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding, end of period (in dollars per share) Inventories Schedule of Inventory, Current [Table Text Block] 2018 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2019 Operating Leases, Future Minimum Payments, Due in Two Years 2020 Operating Leases, Future Minimum Payments, Due in Three Years 2021 Operating Leases, Future Minimum Payments, Due in Four Years 2022 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total minimum lease payments Operating Leases, Future Minimum Payments Due Long-Term Other Liabilities Other Noncurrent Liabilities [Table Text Block] Restructuring Reserve Restructuring and Related Activities Disclosure [Text Block] Cash, Cash Equivalents and Short-term Investments Cash, Cash Equivalents and Investments [Table Text Block] Unrealized Gain (Loss) on Investments Unrealized Gain (Loss) on Investments [Table Text Block] Investments Classified by Contractual Maturity Date Investments Classified by Contractual Maturity Date [Table Text Block] Inventories Inventory Disclosure [Text Block] U.S. Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Income before provision for income tax Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Goodwill Schedule of Goodwill [Table Text Block] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Personnel Related [Member] Personnel Related [Member] Personnel Related [Member] Facility Closing [Member] Facility Closing [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Beginning balance Restructuring Reserve Restructuring Restructuring Charges Additions Restructuring Charges, Excluding Reversals Restructuring Charges, Excluding Reversals Reversals Restructuring Reserve, Accrual Adjustment Payments Payments for Restructuring Ending balance Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of revenue [Member] Cost of Sales [Member] Marketing and sales [Member] Selling and Marketing Expense [Member] Research and development [Member] Research and Development Expense [Member] General and administrative [Member] General and Administrative Expense [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Total expense Allocated Share-based Compensation Expense Earnings Per Share [Abstract] Earnings Per Share Earnings Per Share [Text Block] Income Statement [Abstract] Revenue Revenues Cost of revenue Cost of Revenue Intangibles amortization Cost of Goods Sold, Amortization Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Marketing and selling Selling and Marketing Expense Research and development Research and Development Expense General and administrative General and Administrative Expense Intangibles amortization Amortization of Intangible Assets Total operating expenses Operating Expenses Income from operations Operating Income (Loss) Other income (expense), net Nonoperating Income (Expense) Provision for income tax Income Tax Expense (Benefit) Net income (loss) Net income (loss) per share: Basic Earnings Per Share, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Weighted average shares used in the calculation of net income (loss) per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Other Comprehensive income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized losses on available-for-sale investments Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Foreign currency translation adjustment Total other comprehensive income Other Comprehensive Income (Loss), Net of Tax Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Land [Member] Land [Member] Leasehold improvements [Member] Leaseholds and Leasehold Improvements [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and Equipment, Gross Property, Plant and Equipment, Gross Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Total Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Other Income and Expenses [Abstract] Other Income (Expense), Net Other Income and Other Expense Disclosure [Text Block] Otometrics [Member] Otometrics [Member] Otometrics [Member] Net income (loss) Business Acquisition, Pro Forma Net Income (Loss) Earnings (loss) per share: Earnings Per Share, Pro Forma [Abstract] Basic (USD per share) Business Acquisition, Pro Forma Earnings Per Share, Basic Diluted (USD per share) Business Acquisition, Pro Forma Earnings Per Share, Diluted Weighted average shares used in the calculation of earnings per share: Weighted Average Number of Shares Outstanding, Basic [Abstract] Basic (shares) Weighted Average Basic Shares Outstanding, Pro Forma Diluted (shares) Pro Forma Weighted Average Shares Outstanding, Diluted Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Accrued liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Deferred revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Deferred income tax Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent Total purchase price Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Weighted average common shares Dilutive effect of stock based awards Weighted Average Number Diluted Shares Outstanding Adjustment Diluted Shares (in dollars per share) Basic earnings per share (in dollars per share) Diluted earnings per share (in dollars per share) Shares excluded from calculations of diluted EPS Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Components of Basic and Diluted EPS Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Reserve for Product Warranties Product Warranty Disclosure [Text Block] Reserves for Product Warranties Schedule of Product Warranty Liability [Table Text Block] Organization and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Document and Entity Information [Abstract] Document and entity information [abstract]. Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Public Float Entity Public Float Compensation and related benefits Employee-related Liabilities, Current Accrued federal, state, and local taxes Taxes Payable, Current Warranty reserve Product Warranty Accrual, Current Accrued amounts due to customers Customer Refund Liability, Current Accrued professional fees Accrued Professional Fees, Current Accrued selling expenses Accrued Selling Expense, Current Accrued Selling Expense, Current Accrued travel Accrued Travel, Current Accrued Travel, Current Deferred rent Deferred Rent Credit, Current Other Other Accrued Liabilities, Current Total Components of Gross and Net Intangible Asset Balances Schedule of Finite and Indefinite Lived Intangible Assets [Table Text Block] Schedule of finite and indefinite lived intangible assets. Amortization expense related to intangible assets with definite lives Schedule of Finite-Lived Intangible Assets [Table Text Block] Expected annual amortization expense related to amortizable intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Income Taxes Income Tax Disclosure [Text Block] Goodwill [Roll Forward] Goodwill [Roll Forward] Beginning Balance Acquisitions/Purchase Accounting Adjustments Goodwill, Translation and Purchase Accounting Adjustments Foreign currency translation Goodwill, Foreign Currency Translation Gain (Loss) Ending Balance Finite-Lived Intangible Assets, Net [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total amortization Amortization of Intangible Assets, Production and Nonproduction Amortization of Intangible Assets, Production and Nonproduction Global Neuro-Diagnostics [Member] Global Neuro-Diagnostics [Member] Global Neuro-Diagnostics [Member] Net liabilities Business Combination, Consideration Transferred, Liabilities Incurred Fair Value Measurements Fair Value Disclosures [Text Block] Other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Valuation and Qualifying Accounts [Abstract] Schedule II: of Valuation and Qualifying Accounts Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] NicView [Member] NicView [Member] NicView [Member] Changes in fair value of contingent consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Cash, Cash Equivalents, and Short-term Investments Cash, Cash Equivalents, and Short-term Investments [Text Block] Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Allowance for Doubtful Accounts [Member] Allowance for Doubtful Accounts [Member] Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and Qualifying Accounts Disclosure [Line Items] Movement in Valuation Allowances and Reserves [Roll Forward] Movement in Valuation Allowances and Reserves [Roll Forward] Balance at Beginning of Period Valuation Allowances and Reserves, Balance Additions Charged to Expense Valuation Allowances and Reserves, Additions for Charges to Cost and Expense Deductions Valuation Allowances and Reserves, Deductions Balance at End of Period Business Combinations Business Combination Disclosure [Text Block] Employee Stock Purchase Plan [Member] Employee Stock [Member] Shares available for future awards Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share based compensation, vesting period Unrecognized compensation expense related to unvested portion of stock options Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Weighted average vested options Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Weighted average exercise price of vested stock Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Intrinsic value of options vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted average shares exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Intrinsic value of options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Weighted average remaining contractual term, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Unrecognized compensation of unvested awards Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Weighted average period of recognition of unrecognized compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Fair market value of outstanding awards Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Fair Value Aggregate intrinsic value of outstanding restricted stock units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Employee maximum withholding rate (percent) Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate Eligible compensation of employees Maximum Eligible Compensation Maximum eligible compensation. Purchase price for shares acquired Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Shares reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Offering price, percentage of fair market value Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date Compensation expense associated with the ESPP Employee Stock Ownership Plan (ESOP), Compensation Expense Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States [Member] UNITED STATES Foreign countries [Member] Non-US [Member] Canada [Member] CANADA Argentina [Member] ARGENTINA Ireland [Member] IRELAND Denmark [Member] DENMARK Other Foreign countries [Member] Foreign Countries [Member] Foreign countries. Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Neurology Products [Member] Neurology Products [Member] Neurology Products [Member] Newborn Care Products [Member] Newborn Care Products [Member] Newborn Care Products [Member] OtometricsProducts [Member] OtometricsProducts [Member] OtometricsProducts [Member] Devices and Systems [Member] Devices and Systems [Member] Devices and systems. Supplies [Member] Supplies [Member] Supplies [Member] Services [Member] Services [Member] Services [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Long-lived assets Long-Lived Assets Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Long Lived Assets Held-for-sale by Asset Type [Axis] Long Lived Assets Held-for-sale by Asset Type [Axis] Long Lived Assets Held-for-sale, Name [Domain] Long Lived Assets Held-for-sale, Name [Domain] Mundelein Facility [Member] Mundelein Facility [Member] Mundelein Illinois Facility. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Book value of asset Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Impairment of asset Impairment of Long-Lived Assets to be Disposed of Asset held-for-sale at fair value Assets Held-for-sale, Long Lived, Fair Value Disclosure Property, Plant and Equipment, Net [Abstract] Depreciation expense Depreciation Schedule Of Income Taxes [Table] Schedule Of Income Taxes [Table] Schedule Of Income Taxes [Table] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Research Tax Credit Carryforward [Member] Research Tax Credit Carryforward [Member] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Significant foreign jurisdictions [Member] Foreign Tax Authority [Member] Germany [Member] GERMANY France [Member] FRANCE Income Tax Provision [Member] Income Tax Provision [Member] Income Tax Provision [Member] Schedule Of Income Taxes [Line Items] Schedule Of Income Taxes [Line Items] Schedule Of Income Taxes [Line Items] Statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Provisional income tax expense as a result of Tax Cuts 2017 Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Provisional Income Tax Expense (Benefit) Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Provisional Income Tax Expense (Benefit) Provisional income tax expense from re-remeasurement of deferred tax assets and liabilities Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Asset, Provisional Income Tax Expense Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Asset, Provisional Income Tax Expense Provisional income tax related to one-time transition tax on mandatory deemed repatriation of foreign earnings Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Income Tax Expense Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Income Tax Expense Undistributed earnings Cumulative Earnings (Deficit), Foreign Cumulative Earnings (Deficit), Foreign Tax net operating loss carryforwards Operating Loss Carryforwards Tax credits carryforwards Tax Credit Carryforward, Amount Valuation allowances Deferred Tax Assets, Valuation Allowance Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Deferred tax liabilities related to foreign earnings Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Liability Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Liability Increase in unrecognized tax benefits Unrecognized Tax Benefits, Period Increase (Decrease) Unrecognized Tax Benefits Unrecognized tax would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Lapse of statutes of limitations Interest and penalties related to uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Total Interest and penalties related to uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Property and Equipment Property, Plant and Equipment [Table Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Revenue recognition Revenue Recognition, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Carrying value of intangible assets and goodwill Goodwill and Intangible Assets, Policy [Policy Text Block] Long lived assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Liability for product warranties Standard Product Warranty, Policy [Policy Text Block] Share-based compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Short-term Investments Investment, Policy [Policy Text Block] Allowance for Doubtful Accounts Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Research & Development Costs Research, Development, and Computer Software, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Comprehensive Income Comprehensive Income, Policy [Policy Text Block] Basic and Diluted Net Income per Share Earnings Per Share, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Debt and Credit Arrangements Debt Disclosure [Text Block] Segment, Customer and Geographic Information Segment Reporting Disclosure [Text Block] Schedule of Long-term Debt Instruments Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-term Debt [Table Text Block] Income (loss) before provision (benefit) for income tax Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Summary of components of income tax expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Reconciliation of effective income tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Uncertain Tax Positions Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Share-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Current Current Income Tax Expense (Benefit), Continuing Operations [Abstract] U.S. Federal Current Federal Tax Expense (Benefit) U.S. State and local Current State and Local Tax Expense (Benefit) Non-U.S. Current Foreign Tax Expense (Benefit) Total current tax expense Current Income Tax Expense (Benefit) Deferred Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] U.S. Federal Deferred Federal Income Tax Expense (Benefit) U.S. State and local Deferred State and Local Income Tax Expense (Benefit) Non-U.S. Deferred Foreign Income Tax Expense (Benefit) Total deferred tax expense (benefit) Deferred Income Tax Expense (Benefit) Total expense Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Common Stock, shares issued Common Stock, Shares, Issued Common Stock, shares outstanding Common Stock, Shares, Outstanding Preferred stock, shares authorized Preferred stock, issued Preferred stock, outstanding Federal statutory tax expense Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount State tax expense Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Foreign taxes at rates less than U.S. rates Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Deferred charges on sales of U.S. intellectual property Effective Income Tax Rate Reconciliation, Disposition of Asset, Amount Equity compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount Uncertain tax position Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Lapse of statute Income Tax Reconciliation Lapse Of Statute And Audit Settlement On Uncertain Tax Position Income tax reconciliation lapse of statute and audit settlement on uncertain tax position. Change of valuation allowance on foreign tax credit Income Tax Reconciliation Change Of Valuation Allowance On Foreign Tax Credit Income tax reconciliation change of valuation allowance on foreign tax credit. Earnout adjustment Effective Income Tax Rate Reconciliation, Other Reconciling Items, Earnout Adjustment Effective Income Tax Rate Reconciliation, Other Reconciling Items, Earnout Adjustment Repatriation tax net of foreign tax credits Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount Net deferred tax asset re-measurement Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act of 2017, Amount Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act of 2017, Amount Withholding taxes Effective Income Tax Rate Reconciliation, Tax Audit Effective Income Tax Rate Reconciliation, Tax Audit Withholding taxes Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Return to provision Effective Income Tax Rate Reconciliation, Return To Provision Effective Income Tax Rate Reconciliation, Return To Provision AMT on acquisition Effective, Income Tax Rate Reconciliation, Alternative Minimum Tax On Acquisitions Effective, Income Tax Rate Reconciliation, Alternative Minimum Tax On Acquisitions Other Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Pro Forma [Member] Pro Forma [Member] Inventory purchase commitment Other Payments to Acquire Businesses Income from operations Acquisition related costs Business Combination, Acquisition Related Costs Amortization of intangible assets Business Combination, Separately Recognized Transactions, Additional Disclosures, Amortization Of Intangible Assets Business Combination, Separately Recognized Transactions, Additional Disclosures, Amortization Of Intangible Assets Interest expense Business Combination, Separately Recognized Transactions, Additional Disclosures, Interest Business Combination, Separately Recognized Transactions, Additional Disclosures, Interest Deferred tax assets: Deferred Tax Assets, Net [Abstract] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Accruals deductible in different periods Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Employee benefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits Total deferred tax assets Deferred Tax Assets, Gross Valuation allowance Total net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Basis difference in fixed and intangible assets Deferred Tax Liabilities Basis Difference In Fixed And Intangible Assets Deferred tax liabilities basis difference in fixed and intangible assets. Foreign Earnings Repatriated Deferred Tax Liabilities, Undistributed Foreign Earnings Total deferred tax liabilities Deferred Tax Liabilities, Gross Deferred tax liabilities, net Deferred Tax Liabilities, Net Total net deferred tax assets Deferred Tax Assets, Net Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Retained Earnings Retained Earnings [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance Beginning balance (shares) Shares, Issued Tax benefit of options exercises Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation Vesting of restricted stock units Vesting Of Restricted Stock Units Vesting of restricted stock units. Vesting of restricted stock units (shares) Vesting Of Restricted Stock Units Shares Vesting of restricted stock units shares. Net issuance of restricted stock awards Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Net issuance of restricted stock awards (shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Employee stock purchase plan (shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Stock-based compensation expense Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Stock-based compensation expense (shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Repurchase of company stock Stock Repurchased During Period, Value Repurchase of company stock (shares) Stock Repurchased During Period, Shares Taxes paid related to net share settlement of equity awards Adjustments Related to Tax Withholding for Share-based Compensation Taxes paid related to net share settlement of equity awards (shares) Shares Paid for Tax Withholding for Share Based Compensation Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options (shares) Other comprehensive income Ending balance Ending balance (shares) Rent expense Operating Leases, Rent Expense, Net Purchase commitments for inventory, total Long-term Purchase Commitment, Amount Other expense, net Nonoperating Income (Expense) [Abstract] Interest income Investment Income, Interest Interest expense Interest Expense Foreign currency gain (loss) Other Other Nonoperating Income (Expense) Total other income (expense), net Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) [Member] London Interbank Offered Rate (LIBOR) [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Credit Agreement [Member] Credit Agreement [Member] Credit Agreement [Member] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Citibank, National Association [Member] Citibank, National Association [Member] Citibank, National Association [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving credit facility [Member] Revolving Credit Facility [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Line of Credit [Member] Line of Credit [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Revolving credit facility with Wells Fargo Bank Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Increase (Decrease), Net Line of Credit Facility, Increase (Decrease), Net Ratio of Indebtedness to Net Capital Ratio of Indebtedness to Net Capital Ratio of Interest Coverage Ratio of Interest Coverage Ratio of Interest Coverage Available amount under credit facility Long-term Line of Credit Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Employee Benefit Plan Compensation and Employee Benefit Plans [Text Block] Schedule of Cash and Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Cash and cash equivalents: Cash and Cash Equivalents, at Carrying Value [Abstract] Cash and Cash Equivalents, at Carrying Value Short-term investments: Short-term Investments [Abstract] Total short-term investment Total cash, cash equivalents and short-term investments Available-for-sale Securities, Current EX-101.PRE 10 baby-20171231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 chart-73c62e9208d152b1b2b.jpg begin 644 chart-73c62e9208d152b1b2b.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2017
Feb. 21, 2018
Jun. 30, 2017
Document and Entity Information [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2017    
Document Fiscal Year Focus 2017    
Document Fiscal Period Focus FY    
Trading Symbol BABY    
Entity Registrant Name NATUS MEDICAL INC    
Entity Central Index Key 0000878526    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer Yes    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Large Accelerated Filer    
Entity Common Stock, Shares Outstanding   33,160,428  
Entity Public Float     $ 1,236,474,075
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 88,950 $ 213,551
Short-term investments 0 34,019
Accounts receivable, net of allowance for doubtful accounts of $8,978 and $4,182 126,809 86,638
Inventories 71,529 49,587
Prepaid expenses and other current assets 18,340 22,004
Total current assets 305,628 405,799
Property and equipment, net 22,071 17,333
Intangible assets, net 172,582 77,165
Goodwill 172,998 113,112
Deferred income tax 10,709 14,915
Other assets 25,931 20,688
Total assets 709,919 649,012
Current liabilities:    
Accounts payable 25,242 18,700
Accrued liabilities 51,738 37,895
Deferred revenue 15,157 23,346
Total current liabilities 92,137 79,941
Long-term liabilities:    
Other liabilities 21,995 8,013
Long-term debt 154,283 140,000
Deferred income tax 19,407 3,684
Total liabilities 287,822 231,638
Commitments and contingencies (Note 20)
Stockholders’ equity:    
Common stock, $0.001 par value; 120,000,000 shares authorized; shares issued and outstanding 33,134,101 in 2017 and 32,920,246 in 2016 316,577 312,986
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding in 2017 and in 2016 0 0
Retained earnings 129,115 149,408
Accumulated other comprehensive loss (23,595) (45,020)
Total stockholders’ equity 422,097 417,374
Total liabilities and stockholders’ equity $ 709,919 $ 649,012
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 8,978 $ 4,182
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common Stock, shares authorized 120,000,000 120,000,000
Common Stock, shares issued 33,134,101 32,920,246
Common Stock, shares outstanding 33,134,101 32,920,246
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, issued 0 0
Preferred stock, outstanding 0 0
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Operations and Comprehensive Income - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Income Statement [Abstract]      
Revenue $ 500,970 $ 381,892 $ 375,865
Cost of revenue 213,376 144,632 145,492
Intangibles amortization 6,380 2,327 2,836
Gross profit 281,214 234,933 227,537
Operating expenses:      
Marketing and selling 126,166 84,834 87,675
Research and development 51,822 33,443 30,434
General and administrative 74,424 50,877 46,363
Intangibles amortization 19,171 8,983 7,447
Restructuring 914 1,536 2,145
Total operating expenses 272,497 179,673 174,064
Income from operations 8,717 55,260 53,473
Other income (expense), net (3,567) (357) (1,064)
Income before provision for income tax 5,150 54,903 52,409
Provision for income tax 25,443 12,309 14,485
Net income (loss) $ (20,293) $ 42,594 $ 37,924
Net income (loss) per share:      
Basic $ (0.62) $ 1.31 $ 1.17
Diluted (in dollars per share) $ (0.62) $ 1.29 $ 1.14
Weighted average shares used in the calculation of net income (loss) per share:      
Basic (shares) 32,564 32,460 32,348
Diluted (shares) 32,564 33,056 33,241
Other Comprehensive income:      
Unrealized losses on available-for-sale investments $ (45) $ (168) $ 0
Foreign currency translation adjustment 21,470 (5,003) (8,378)
Total other comprehensive income 21,425 (5,171) (8,378)
Comprehensive income $ 1,132 $ 37,423 $ 29,546
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Retained Earnings
Accumulated Other Comprehensive Loss
Beginning balance at Dec. 31, 2014 $ 352,715 $ 315,296 $ 68,890 $ (31,471)
Beginning balance (shares) at Dec. 31, 2014   32,649,158    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Tax benefit of options exercises 7,104 $ 7,104    
Vesting of restricted stock units 0      
Vesting of restricted stock units (shares)   21,619    
Net issuance of restricted stock awards 0      
Net issuance of restricted stock awards (shares)   199,620    
Employee stock purchase plan 1,251 $ 1,251    
Employee stock purchase plan (shares)   35,467    
Stock-based compensation expense 6,953 $ 6,953    
Repurchase of company stock (11,526) $ (11,526)    
Repurchase of company stock (shares)   (281,915)    
Taxes paid related to net share settlement of equity awards (4,341) $ (4,341)    
Taxes paid related to net share settlement of equity awards (shares)   (102,112)    
Exercise of stock options 9,008 $ 9,008    
Exercise of stock options (shares)   631,663    
Other comprehensive income (8,378)     (8,378)
Net loss 37,924   37,924  
Ending balance at Dec. 31, 2015 390,710 $ 323,745 106,814 (39,849)
Ending balance (shares) at Dec. 31, 2015   33,153,500    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Vesting of restricted stock units 0      
Vesting of restricted stock units (shares)   20,937    
Net issuance of restricted stock awards 0      
Net issuance of restricted stock awards (shares)   191,492    
Employee stock purchase plan 1,360 $ 1,360    
Employee stock purchase plan (shares)   45,515    
Stock-based compensation expense 9,008 $ 9,008    
Repurchase of company stock (19,289) $ (19,289)    
Repurchase of company stock (shares)   (545,109)    
Taxes paid related to net share settlement of equity awards (4,107) $ (4,107)    
Taxes paid related to net share settlement of equity awards (shares)   (97,231)    
Exercise of stock options 2,269 $ 2,269    
Exercise of stock options (shares)   151,142    
Other comprehensive income (5,171)     (5,171)
Net loss 42,594   42,594  
Ending balance at Dec. 31, 2016 417,374 $ 312,986 149,408 (45,020)
Ending balance (shares) at Dec. 31, 2016   32,920,246    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Vesting of restricted stock units 0      
Vesting of restricted stock units (shares)   35,929    
Net issuance of restricted stock awards 0      
Net issuance of restricted stock awards (shares)   249,366    
Employee stock purchase plan 1,581 $ 1,581    
Employee stock purchase plan (shares)   48,470    
Stock-based compensation expense 9,445 $ 9,445    
Stock-based compensation expense (shares)   0    
Repurchase of company stock (2,268) $ (2,268)    
Repurchase of company stock (shares)   (60,800)    
Taxes paid related to net share settlement of equity awards (7,052) $ (7,052)    
Taxes paid related to net share settlement of equity awards (shares)   (193,212)    
Exercise of stock options $ 1,885 $ 1,885    
Exercise of stock options (shares) 134,102 134,102    
Other comprehensive income $ 21,425     21,425
Net loss (20,293)   (20,293)  
Ending balance at Dec. 31, 2017 $ 422,097 $ 316,577 $ 129,115 $ (23,595)
Ending balance (shares) at Dec. 31, 2017   33,134,101    
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Operating activities:      
Net loss $ (20,293) $ 42,594 $ 37,924
Adjustments to reconcile net income to net cash provided by operating activities:      
Provision for losses on accounts receivable 10,017 1,123 1,496
Excess tax benefit on the exercise of stock options   0 (7,104)
Depreciation and amortization 30,098 16,879 15,987
Gain on disposal of property and equipment (21) (29) (5)
Impairment of intangible assets 1,674 0 0
Warranty reserve 5,370 2,934 10,729
Stock-based compensation 9,445 9,008 6,953
Changes in operating assets and liabilities, net of assets and liabilities acquired in acquisitions:      
Accounts receivable (30,473) 19,723 (15,272)
Inventories 7,581 (7,668) (12,232)
Other assets 5,492 (11,387) 858
Accounts payable (1,385) (4,965) 3,270
Accrued liabilities 5,421 (6,967) (6,177)
Deferred revenue (7,232) 13,879 (1,118)
Deferred taxes 4,032 (2,437) 1,543
Net cash provided by operating activities 19,726 72,687 36,852
Investing activities:      
Acquisition of businesses, net of cash acquired (190,888) (15,849) (14,284)
Acquisition of property and equipment (4,066) (3,186) (4,068)
Acquisition of intangible assets 0 (210) (1,126)
Purchases of short-term investments 0 (34,019) 0
Sales of short-term investments 34,019 0 0
Net cash used in investing activities (160,935) (53,264) (19,478)
Financing activities:      
Proceeds from stock option exercises and ESPP 3,466 3,630 10,258
Excess tax benefit on the exercise of stock options 0 0 7,104
Repurchase of company stock (2,268) (19,289) (11,525)
Taxes paid related to net share settlement of equity awards (7,052) (4,107) (4,341)
Proceeds from short-term borrowings 0 16,000 0
Proceeds from long-term borrowings 60,000 140,000 0
Deferred debt issuance costs (354) (533) 0
Contingent consideration earn-out (2,966) (1,284) (664)
Payments on borrowings (45,000) (16,000) 0
Net cash provided by financing activities 5,826 118,417 832
Exchange rate effect on cash and cash equivalents 10,782 (6,758) (2,295)
Net increase (decrease) in cash and cash equivalents (124,601) 131,082 15,911
Cash and cash equivalents, beginning of year 213,551 82,469 66,558
Cash and cash equivalents, end of year 88,950 213,551 82,469
Supplemental disclosure of cash flow information:      
Cash paid for interest 4,464 41 0
Cash paid for income taxes 5,740 16,344 10,164
Non-cash investing activities:      
Property and equipment included in accounts payable 148 134 289
Inventory transferred to property and equipment $ 1,006 $ 1,303 $ 1,056
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Significant Accounting Policies
12 Months Ended
Dec. 31, 2017
Accounting Policies [Abstract]  
Organization and Significant Accounting Policies
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES
Organization
Natus Medical Incorporated (“Natus”, the “Company”) was incorporated in California in May 1987 and reincorporated in Delaware in August 2000. Natus is a leading provider of newborn care, neurology, and hearing and balance assessment healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, software systems for managing and tracking disorders and diseases for public health laboratories, computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms for hearing and balance care professionals.
Basis of Presentation and Principles of Consolidation
The accompanying Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain reclassifications to the prior periods have been made to conform to the current period presentation.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Consolidated Financial Statements and the reported amount of revenue and expenses during the reporting period. Such estimates include allowances for potentially uncollectible accounts receivable, valuation of inventory, intangible assets, goodwill, share-based compensation, deferred income taxes, reserves for warranty obligations, and the provision for income taxes. Actual results could differ from those estimates.
Revenue recognition
Revenue, net of discounts, is recognized from sales of medical devices and supplies, including sales to distributors, when the following conditions have been met: a purchase order has been received, title has transferred, the selling price is fixed or determinable, and collection of the resulting receivable is reasonably assured. Terms of sale for most domestic sales are FOB origin, reflecting that title and risk of loss are assumed by the purchaser at the shipping point; however, terms of sale for some neurology, sleep-diagnostic, and head cooling systems are FOB destination, reflecting that title and risk of loss are assumed by the purchaser upon delivery. Terms of sales to international distributors are generally EXW, reflecting that goods are shipped “ex works,” in which title and risk of loss are assumed by the distributor at the shipping point. For products shipped under FOB origin or EXW terms, delivery is generally considered to have occurred when the product is shipped. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue. The Company generally does not provide rights of return on products.
For products containing embedded software, the Company has determined that the hardware and software components function together to deliver the products’ essential functionality, and therefore, the revenue from the sale of these products does not fall within the scope of the software revenue recognition rules. The Company's revenue recognition policies for sales of these products are substantially the same as for other tangible products. 
Revenue from sales of certain products that remain within the scope of the software revenue recognition rules under ASC Subtopic 985-605 is not significant.
Revenue from extended service and maintenance agreements, for both medical devices and data management systems, is recognized ratably over the service period. Revenue from installation or training services is deferred until such time service is provided. Hearing screening and ambulatory EEG monitoring revenue is recorded when the procedure is performed at the estimated net realizable value based on contractual agreements with payers and historical collections.
Certain revenue transactions include multiple element arrangements. The Company allocates revenue in these arrangements to each unit of accounting using the relative selling price method. The selling prices used during the allocation process are based on vendor specific objective evidence (“VSOE”) if available, third party evidence (“TPE”) if VSOE is not available, or estimated selling price (“ESP”) if neither VSOE or TPE is available.
Group purchasing organization (“GPOs”) negotiate volume purchase prices for member hospitals, group practices, and other clinics. The Company's agreements with GPOs typically contain preferential terms for the GPO and its members, including provisions for some, if not all, of the following:
Payment of marketing fees by Natus to the GPO, usually based on purchasing experience of group members; and
Non-recourse cancellation provisions.
Natus does not sell products to GPOs. Hospitals, group practices, and other clinics that are members of a GPO purchase products directly from the Company under the terms negotiated by the GPO. Negotiated pricing and discounts are recognized as a reduction of the selling price of products at the time of the sale. Revenue from sales to members of GPOs is otherwise consistent with general revenue recognition policies as previously described.
Inventory
Inventories are carried at the lower of cost or market, with cost being determined using the first-in, first-out method. The carrying value of the Company's inventories is reduced for any difference between cost and estimated market value of inventories that is determined to be obsolete or unmarketable, based upon assumptions about future demand and market conditions. Adjustments to the value of inventory establish a new cost basis and are considered permanent even if circumstances later suggest that increased carrying amounts are recoverable. If demand is higher than expected, Natus may sell inventory that had previously been impaired.
Carrying value of intangible assets and goodwill
The Company amortizes intangible assets with finite lives over the useful lives; any future changes that would limit the useful lives or any determination that these assets are carried at amounts greater than the estimated fair value could result in additional charges.
Goodwill is not amortized but is subject to an annual impairment analysis, which is performed as of October 1st; this assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired.
In 2017, 2016 and 2015, the Company performed a qualitative assessment to test goodwill for impairment. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on the qualitative assessment, the Company determined that the fair value was more likely than not to be greater than its carrying amount, and no further analysis was needed.
If the fair value was less than its carrying amount, the Company would perform a two-step impairment test on goodwill. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. The Company uses a projected discounted cash flow model to determine the fair value of a reporting unit. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit. If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.
Prior to the assignment of definite lives to trade names in the second quarter of 2015 (See Note 6 - Intangible Assets), the Company tested indefinite lived intangibles for impairment by comparing the carrying value of those assets to be fair value as of the assessment date. The Company used the relief from royalty method to determine the fair value of the assets. This analysis is dependent upon a number of quantitative and qualitative factors including estimates of forecasted revenue, royalty rate, and taxes. The discount rate applied also has an impact on the estimates of fair value, as use of a higher rate will result in a lower estimate of fair value.
Long lived assets
The Company continually monitors events and changes in circumstances that could indicate that carrying amounts of its long-lived assets, including property and equipment and intangible assets, may not be recoverable. When such events or changes in circumstances occur, the Company assess the recoverability by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the future undiscounted cash flows are less than the carrying amount of these assets, the Company will recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets.
Liability for product warranties
The Company provides a warranty for products that is generally one year in length. In some cases, regulations may require the Company to provide repair or remediation beyond the typical warranty period. If any products contain defects, the Company may be required to incur additional repair and remediation costs. Service for domestic customers is provided by Company-owned service centers that perform all service, repair, and calibration services. Service for international customers is provided by a combination of Company-owned facilities and vendors on a contract basis.
A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management’s best estimate of probable liability. The Company considers a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of the reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.
Share-based compensation
The Company recognizes share-based compensation expense associated with employee stock options under the single-option straight line method over the requisite service period, which is generally a four-year vesting period and ten-year contractual term pursuant to ASC Topic 718, Compensation-Stock Compensation. See Note 14 of the Consolidated Financial Statements.
For employee stock options, the value of each option is estimated on the date of grant using the Black-Scholes option pricing model, which was developed for use in estimating the value of freely traded options. Similar to other option pricing models, the Black-Scholes method requires the input of highly subjective assumptions, including stock price volatility. Changes in the subjective input assumptions can materially affect the estimated fair value of the employee stock options.
The Company recognizes share-based compensation associated with Restricted Stock Awards (“RSA”) and Restricted Stock Units (“RSU”). RSAs and RSUs vest ratably over a three-year period for employees. RSAs and RSUs for executives vest over a four-year period; 50% on the second anniversary of the awarded date and 25% on each of the third and fourth anniversaries. RSAs and RSUs for non employees (Board of Directors) vest over a one-year period; 100% on the first anniversary. The value is estimated based on the market value of Natus common stock on the date of issuance pursuant to ASC Topic 718, Compensation-Stock Compensation.
The Company issues new shares of common stock upon the exercise of stock options and the vesting of RSAs and RSUs.
Forfeitures of employee stock options and awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share-based compensation expense is recorded net of estimated forfeitures, such that expense is recorded only for those share-based awards that are expected to vest.
Cash Equivalents and Short-term Investments
All highly liquid investments purchased with an original maturity of three months or less are classified as cash equivalents. Investments with maturities greater than one year are classified as current because management considers all investments to be available for current operations. Cash equivalents and investments are stated at amounts that approximate fair value based on quoted market prices.
The Company's investments have been classified and accounted for as available-for-sale. Such investments are recorded at fair value and unrealized holding gains and losses are reported as a separate component of comprehensive income until realized. Realized gains and losses on sales of investments, if any, are determined on the specific identification method and are reclassified from accumulated other comprehensive loss to results of operations as other income (expense).
Allowance for Doubtful Accounts
The Company estimates the allowance for potentially uncollectible accounts receivable based on historical collection experience within the markets in which the Company operates and other customer-specific information, such as bankruptcy filings or customer liquidity problems. When all internal efforts have been exhausted to collect the receivable, it is written off and relieved from the reserve.
Fair Value of Financial Instruments
Financial instruments include cash and cash equivalents, investments, accounts receivable, and accounts payable. Cash is reported at its fair value on the balance sheet dates. The recorded carrying amounts of investments, accounts receivable and accounts payable approximate the fair values due to the short-term maturities.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over estimated useful lives of the respective assets, which are three to ten years for office furniture and equipment, three to five years or the length of the license for computer software and hardware, three to five years for demonstration and loaned equipment, and 30 to 40 years for buildings. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life. Land is not depreciated. Costs associated with acquiring and installing software to be used for internal purposes are capitalized and amortized on a straight-line basis over three years.
Research & Development Costs
Costs incurred in research and development are charged to operations as incurred.
Income Taxes
The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
The Company records net deferred tax assets to the extent it is more likely than not that the assets will be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. To the extent that previously reserved deferred tax assets are estimated to be realizable, the Company adjusts the valuation allowance which reduces the provision for income taxes.
The Company recognizes the tax benefit of uncertain tax positions in the financial statements as defined in ASC Topic 740, Income Tax. When the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50 percent likely of being ultimately realized upon settlement, as defined in ASC 740-10-05. 
On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740, Income Taxes. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements.
Foreign Currency
The functional currency of the Company's subsidiaries outside of North America is generally the local currency of the country where the subsidiary is located. Accordingly, foreign currency translation adjustments relating to the translation of foreign subsidiary financial statements are included as a component of accumulated other comprehensive loss. The Company recorded $21.5 million, $(5.0) million, and $(8.4) million of foreign currency translation gains (losses) for the years ended December 31, 2017, 2016 and 2015, respectively.
Gains and losses from transactions denominated in currencies other than the functional currencies are included in other income and expense. In 2017, 2016, and 2015, net foreign currency transaction gains (losses) were $1.0 million, $(0.4) million, and $(1.4) million, respectively. Foreign currency gains and losses result primarily from fluctuations in the exchange rate between the U.S. Dollar, Canadian Dollar, Euro, Argentine Peso, British Pound, and Danish Kroner.
Comprehensive Income
The Company reports by major components and as a single total the change in net assets during the period from non-owner sources as defined in ASC Topic 220, Comprehensive Income. The consolidated statement of comprehensive income has been included with the consolidated statements of operations. Accumulated other comprehensive income consists of translation gains and losses on foreign subsidiary financial statements as well as unrealized gains and losses on investments.
Basic and Diluted Net Income per Share
Natus computes net income per share as defined in ASC Topic 260, Earnings per Share. Basic net income per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalents outstanding during the period. Common stock equivalents are options granted and shares of restricted stock issued under the stock awards plans and are calculated under the treasury stock method. Common equivalent shares from unexercised stock options and restricted stock are excluded from the computation when there is a loss as the effect is anti-dilutive, or if the exercise price of such options is greater than the average market price of the stock for the period.
Recent Adopted Accounting Pronouncements
In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330). This standard requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is estimated selling prices in the ordinary course of business, less reasonable predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted ASU 2015-11in January 2017 and no impact was recorded by the Company.
In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805). This update is to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisition (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. ASU 2017-01 is effective for annual periods beginning after December 15, 2017, including interim periods within those periods, and must be applied prospectively. The Company will apply this guidance to business combinations that occur on or after the effective date.
Recent Issued Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance. The standard's core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard creates a five-step model to achieve its core principle: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction's price to the separate performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. In addition, entities must disclose sufficient information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Qualitative and quantitative disclosures are required about: (i) the entity's contracts with customers; (ii) the significant judgments, and changes in judgments, made in applying the guidance to those contracts; and (iii) any assets recognized from the costs to obtain or fulfill a contract with a customer. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 616) - Deferral of the Effective Date, which deferred the effective date of ASU 2014-09 to interim and annual periods beginning January 1, 2018. The standard allows entities to apply the standard retrospectively to each prior period presented (“full retrospective adoption”) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application (“modified retrospective adoption”). The Company adopted the modified retrospective approach of this guidance on January 1, 2018 and has determined that its adoption will not have a material effect on its financial position or results of operations.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This standard requires a lessee to recognize the lease assets and lease liabilities arising from operating leases in the statement of financial position. Qualitative along with specific quantitative disclosures are required by lessees to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 including interim periods within those fiscal years. The Company is currently evaluating the impact that will result from adopting ASU 2016-02.
    
In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). This update modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Because these amendments eliminate a step from the goodwill impairment test, they should reduce the cost and complexity of evaluating goodwill for impairment. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company will adopt ASU 2017-04 to goodwill impairment testing on the effective date.
In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. This update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This guidance is effective for annual periods beginning after December 15, 2017, including interim periods within that year, and must be applied prospectively to an award modified on or after the adoption date. The Company will adopt this guidance and will apply to all future share-based modifications.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations
12 Months Ended
Dec. 31, 2017
Business Combinations [Abstract]  
Business Combinations
BUSINESS COMBINATIONS
The assets acquired and liabilities assumed at the date of acquisition are recorded in the Consolidated Financial Statements at the respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets is recorded as goodwill. 
The determination of estimated fair value of acquired assets and liabilities requires management to make significant estimates and assumptions. The Company determines the fair value by applying established valuation techniques, based on information that management believes to be relevant to this determination. The Company also utilizes independent third parties to assist in the valuation of goodwill and intangible assets.
The results of operations from acquisitions are included in the Consolidated Financial Statements from the date of the acquisition.
Integra
On October 6, 2017, the Company acquired certain neurosurgery business assets from Integra LifeSciences (“Integra” or “Neurosurgery”) for $46.4 million in cash. As part of the acquisition, the Company acquired a global product line, including the manufacturing facility it leases from a third party and the U.S. rights related to four other product lines. The total purchase price has been preliminarily allocated to $12.5 million of tangible assets, $19.5 million of intangible assets with an associated weighted average life of 9 years being amortized on the straight line method, and $15.5 million of goodwill, offset by $1.1 million of net liabilities. Purchase price allocation is considered preliminary at this time although no material adjustments are anticipated. Pro form financial information for the Integra acquisition is not presented as the data necessary to present pro forma net income and pro forma earnings per share is not available. However, pro forma revenue assuming the acquisition occurred on January 1, 2016 would be $539.1 million and $432.4 million for the years ended December 31, 2017 and 2016, respectively.
Otometrics
On January 3, 2017, the Company acquired the Otometrics business from GN Store Nord A/S for a cash purchase price of $149.2 million, which includes a $4.2 million net working capital adjustment. Otometrics is a manufacturer of hearing diagnostics and balance assessment equipment, disposables and software. Otometrics provides computer-based audiological, otoneurologic and vestibular instrumentation and sound rooms to hearing and balance care professionals worldwide. Otometrics has a complete product and brand portfolio known for its sophisticated design technology in the hearing and balance assessment markets.
The following table summarizes the purchase price allocation of the fair value of the assets acquired and liabilities assumed at the date of acquisition, (in thousands):
Cash and cash equivalents
$
5,604

Accounts receivable
26,851

Inventories
22,182

Property and equipment
2,256

Intangible assets
90,913

Goodwill
39,355

Other assets
1,748

Accounts payable
(7,655
)
Accrued liabilities
(16,069
)
Deferred revenue
(745
)
Deferred income tax
(15,193
)
Total purchase price
$
149,247


The goodwill recorded represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. The goodwill recorded as part of the acquisition of Otometrics is not amortized and includes the following:
The expected synergies and other benefits that the Company believes will result from combining the operations of Otometrics with the operations of Natus;
Any intangible assets that did not qualify for separate recognition, as well as future, yet unidentified projects and products; and
The value of the going-concern element of Otometrics's existing businesses (the higher rate of return on the assembled collection of net assets versus if Natus has acquired all of the net assets separately).
Management worked with an independent valuation firm to determine fair values of the identifiable intangible assets. The Company used a combination of income approaches including relief from royalty and multi-period excess earnings methods. The valuation models were based on estimates of future operating projections of the acquired business and rights to sell products as well as judgments on the discount rates used and other variables. The Company determined the forecasts based on a number of factors, included their best estimate of near-term net sales expectations and long-term projections, which included review of internal and independent market analyses.
Otometrics's revenue of $114.2 million and loss from operations of $1.0 million are included in the condensed consolidated statement of operations for the period from January 3, 2017 (acquisition date) to December 31, 2017.
The unaudited pro forma financial results presented below for the twelve months ended December 31, 2017 and December 31, 2016, include the effects of pro forma adjustments as if the acquisition occurred on January 1, 2016. The pro forma results were prepared using the acquisition method of accounting and combine the historical results of Natus and Otometrics for the twelve months ended December 31, 2017 and December 31, 2016, including the effects of the business combination, primarily amortization expense related to the fair value of identifiable intangible assets acquired, interest expense associated with the financing obtained by Natus in connection with the acquisition, and the elimination of acquisition-related costs incurred.
The pro forma financial information is presented for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of the earliest period presented, nor is it intended to be a projection of future results.
Unaudited Pro forma Financial Information
(in thousands)
 
Year Ended  December 31,
 
2017
 
2016
Revenue
$
500,970

 
$
491,994

Net income (loss)
$
(15,965
)
 
$
17,385

 
 
 
 
Earnings (loss) per share:
 
 
 
Basic
$
(0.49
)
 
$
0.54

Diluted
$
(0.49
)
 
$
0.53

Weighted average shares used in the calculation of earnings per share:
 
 
 
Basic
32,564

 
32,460

Diluted
32,564

 
33,056


The pro forma results for the year ended December 31, 2017 were adjusted to exclude $4.3 million of nonrecurring expense related to the fair value adjustment of acquisition-date inventory.
The pro forma results for the year ended December 31, 2016 were adjusted to include $3.0 million of amortization of intangible assets, and $4.6 million of interest expense.
RetCam
On July 6, 2016, the Company acquired the portfolio of RetCam Imaging Systems (“RetCam”) from Clarity Medical Systems, Inc. for $10.6 million in cash. RetCam is an imaging system used to diagnose and monitor a range of ophthalmic maladies in premature infants. The purchase agreement also included a holdback of $2.0 million which was paid on February 16, 2017. Subsequent to the acquisition, an additional $1.1 million was paid by the Company to Clarity Medical Systems as a result of a working capital adjustment. Results of operations for RetCam are included in the consolidated financial statements from the date of acquisition. The total purchase price was allocated $7.2 million to tangible assets, $4.9 million to intangible assets with an assigned weighted average life of 5 years being amortized on the straight line method, and $1.7 million to goodwill, offset by $2.0 million to net liabilities. Pro forma financial information for the RetCam acquisition is not presented as it is not considered material.
NeuroQuest
On March 2, 2016, the Company acquired NeuroQuest, LLC (“NeuroQuest”) through an asset purchase. NeuroQuest complements the Global Neuro-Diagnostics (“GND”) and Monarch Medical Diagnostics, LLC (“Monarch”) acquisitions which offer patients a convenient way to complete routine-electroencephalography and extended video electronencephalography (“VEEG”) testing. The cash consideration for NeuroQuest was $4.6 million. The purchase agreement included a consideration holdback of $0.5 million which was paid on April 30, 2017. The total purchase price was allocated to $0.5 million of tangible assets, $1.3 million of intangible assets with an assigned weighted average life of 5 years being amortized on the straight line method, and $3.5 million of goodwill, offset by $0.1 million of net liabilities. Pro forma financial information for the NeuroQuest acquisition is not presented as it is not considered material.
Monarch
The Company acquired Monarch Medical Diagnostics, LLC (“Monarch”) through an asset purchase on November 13, 2015. Monarch's service compliments the Global Neuro-Diagnostics acquisition which offers patients a more convenient way to complete routine diagnostic electroencephalography and video electromyography testing which can be performed at the home, hospital or physician's office. The service also provides comprehensive reporting and support to the physician. The cash consideration for Monarch was $2.7 million. The purchase agreement also included contingent consideration which was paid on January 11, 2016 of $1.0 million. The total purchase price was allocated to $112,000 of tangible assets, $1.2 million of intangible assets with an assigned weighted average life of 5 years being amortized on the straight line method, and $2.4 million of goodwill. Pro forma financial information for the Monarch acquisition is not presented as it is not considered material.
Global Neuro-Diagnostics
The Company acquired GND through an equity purchase on January 23, 2015. GND's service offers patients a more convenient way to complete routine EEG and EMG testing which can be performed at the home, hospital or physician's office. The service also provides comprehensive reporting and support to the physician. The cash consideration for GND was $11.4 million, which consists primarily of $1.5 million of tangible assets, $4.8 million of intangible assets with an assigned weighted average life of 5 years being amortized on the straight line method, and $8.9 million of goodwill, offset by $0.5 million of net liabilities. The purchase agreement also included an earn-out condition which was originally estimated to be $3.2 million. The earn-out condition was subsequently not achieved. Pro forma financial information for the GND acquisition is not presented as it is not considered material.
NicView
On January 2, 2015, the Company purchased the assets of NicView. NicView provides streaming video for families with babies in the neonatal intensive care unit. The cash consideration for NicView was $1.1 million, of which $0.3 million was allocated to tangible assets and $2.7 million to goodwill, offset by $0.6 million allocated to net liabilities. The asset purchase agreement included an earn-out condition contingent upon orders received in and installed by February 28, 2016. The Company settled this earnout for $1.3 million in March 2016. Pro forma financial information for the NicView acquisition is not presented as it is not considered material.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash, Cash Equivalents, and Short-term Investments
12 Months Ended
Dec. 31, 2017
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents, and Short-term Investments
CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS
The Company has invested its excess cash in highly liquid marketable securities such as corporate debt instruments, U.S. government agency securities and asset-backed securities. Investments with maturities greater than one year are classified as current because management considers all investments to be available for current operations.

The Company's investments are designed to provide liquidity, preserve capital and maximize total return on invested assets with a focus on high credit-quality securities.

The Company's investments have been classified and accounted for as available-for-sale. Such investments are recorded at fair value, and unrealized holding gains and losses are reported as a separate component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses on sales of investments, if any, are determined on the specific identification method and are reclassified from accumulated other comprehensive income (loss) to results of operations as other income (expense).

The Company, to date, has not determined that any of the unrealized losses on its investments are considered to be other-than-temporary. The Company reviews its investment portfolio to determine if any security is other-than-temporarily impaired, which would require the Company to record an impairment charge in the period any such determination is made. In making this judgment, the Company evaluates, among other things: the duration and extent to which the fair value of a security is less than its cost; the financial condition of the issuer and any changes thereto; and the Company's intent and ability to hold its investment for a period of time sufficient to allow for any anticipated recovery in market value, or whether the Company will more likely than not be required to sell the security before recovery of its aggregated cost basis.    

Cash, cash equivalents and short-term investments consisted of the following (in thousands):

    
 
December 31, 2017
 
December 31, 2016
Cash and cash equivalents:
 
 
 
Cash
88,950

 
213,551

Short-term investments:
 
 
 
U.S. investment grade bonds

 
24,477

Developed investment grade bonds

 
9,542

Total short-term investments

 
34,019

Total cash, cash equivalents and short-term investments
88,950

 
247,570



Short-term investments by investment type are as follows (in thousands):
  
 
December 31, 2017
 
December 31, 2016
 
Aggregated Cost Basis
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Aggregated Fair Value
 
Aggregated Cost Basis
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Aggregated Fair Value
U.S. investment grade bonds

 

 

 

 
24,531

 

 
(54
)
 
24,477

Developed investment grade bonds

 

 

 

 
9,567

 

 
(25
)
 
9,542

Total short-term investments
$

 
$

 
$

 
$

 
$
34,098

 
$

 
$
(79
)
 
$
34,019



Short-term investments by contractual maturity are as follows (in thousands):

 
December 31, 2017
 
December 31, 2016
 
Investments
 
Investments
Due in one year or less
$

 
$
21,655

Due after one year through five years

 
12,364

Total short-term investment
$

 
$
34,019



See Note 21 to these Consolidated Financial Statements for additional discussion regarding the fair value of the Company's short-term investments.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories
12 Months Ended
Dec. 31, 2017
Inventory Disclosure [Abstract]  
Inventories
INVENTORIES
Inventories consist of (in thousands): 
 
December 31,
 
2017
 
2016
Raw materials and subassemblies
$
44,699

 
$
28,245

Work in process
3,788

 
1,507

Finished goods
43,488

 
34,908

Total Inventories
91,975

 
64,660

Less: Non-current Inventories
(20,446
)
 
(15,073
)
Inventories
$
71,529

 
$
49,587


At December 31, 2017 and 2016, the Company has classified $20.4 million and $15.1 million, respectively, of inventories as non-current. This inventory consists of service components used to repair products held by customers pursuant to warranty obligations and extended service contracts, including service components for products that the Company no longer sells, inventory purchased for lifetime buys, and inventory that is turning at a slow rate. The Company believes that these inventories will be utilized for the intended purpose.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Property and Equipment
12 Months Ended
Dec. 31, 2017
Property, Plant and Equipment [Abstract]  
Property and Equipment
PROPERTY AND EQUIPMENT
Property and equipment consist of (in thousands): 
 
December 31,
 
2017
 
2016
Land
$
2,815

 
$
2,856

Buildings
5,096

 
5,219

Leasehold improvements
3,295

 
2,386

Office furniture and equipment
25,612

 
18,398

Computer software and hardware
9,760

 
9,100

Demonstration and loaned equipment
11,932

 
11,393

 
58,510

 
49,352

Accumulated depreciation
(36,439
)
 
(32,019
)
Total
$
22,071

 
$
17,333


Depreciation expense of property and equipment was $4.1 million, $3.7 million, and $4.2 million in the years ending December 31, 2017, 2016 and 2015, respectively.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets
12 Months Ended
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets
INTANGIBLE ASSETS
The following table summarizes the components of gross and net intangible asset balances (in thousands): 
 
December 31, 2017
 
December 31, 2016
 
Gross
Carrying
Amount
 
Accumulated
Impairment
 
Accumulated
Amortization
 
Net Book
Value
 
Gross
Carrying
Amount
 
Accumulated
Impairment
 
Accumulated
Amortization
 
Net Book
Value
Technology
$
101,045

 
(1,058
)
 
$
(42,048
)
 
$
57,939

 
$
62,563

 

 
$
(34,683
)
 
$
27,880

Customer related
108,074

 
(50
)
 
(28,972
)
 
79,052

 
38,087

 

 
(17,610
)
 
20,477

Trade names
49,313

 
(3,916
)
 
(13,273
)
 
32,124

 
32,106

 
(3,290
)
 
(7,135
)
 
21,681

Internally developed software
15,610

 

 
(12,293
)
 
3,317

 
16,978

 

 
(10,220
)
 
6,758

Patents
2,778

 
(133
)
 
(2,495
)
 
150

 
2,620

 

 
(2,251
)
 
369

Total Definite-lived intangible assets
276,820

 
(5,157
)
 
(99,081
)
 
172,582

 
152,354

 
(3,290
)
 
(71,899
)
 
77,165


Finite lived intangible assets are amortized over their weighted average lives, which are 13 years for patents, 14 years for technology, 10 years for customer-related intangibles, 10 years for trade names, and 6 years for internally developed software.
Internally developed software consists of $14.8 million relating to costs incurred for development of internal use computer software and $2.2 million for development of software to be sold.
Amortization expense related to intangible assets with finite lives was as follows (in thousands): 
 
Years Ended December 31,
 
2017
 
2016
 
2015
Technology
$
7,705

 
$
3,407

 
$
3,916

Customer related
10,945

 
3,452

 
2,938

Trade names
6,479

 
4,115

 
3,159

Internally developed software
2,117

 
2,069

 
1,620

Patents
244

 
112

 
112

Total amortization
$
27,490

 
$
13,155

 
$
11,745


Expected annual amortization expense related to amortizable intangible assets is as follows (in thousands): 
2018
$
27,014

2019
25,836

2020
23,634

2021
22,210

2022
18,564

Thereafter
55,324

Total expected amortization expense
$
172,582

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill
12 Months Ended
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill
GOODWILL
The carrying amount of goodwill and the changes in those balances are as follows (in thousands): 
As of December 31, 2015
$
107,466

Acquisitions/Purchase Accounting Adjustments
6,705

Foreign currency translation
(1,059
)
As of December 31, 2016
$
113,112

Acquisitions/Purchase Accounting Adjustments
54,746

Foreign currency translation
5,140

As of December 31, 2017
$
172,998

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accrued Liabilities
12 Months Ended
Dec. 31, 2017
Payables and Accruals [Abstract]  
Accrued Liabilities
ACCRUED LIABILITIES
Accrued liabilities consist of (in thousands): 
 
December 31,
 
2017
 
2016
Compensation and related benefits
$
22,816

 
$
16,064

Accrued federal, state, and local taxes
8,155

 
4,160

Warranty reserve
10,995

 
10,670

Accrued amounts due to customers
2,424

 
1,625

Accrued professional fees
2,280

 
1,191

Accrued selling expenses
1,704

 
292

Contingent consideration
147

 
3,043

Accrued travel
338

 

Deferred rent
161

 
132

Other
2,718

 
718

Total
$
51,738

 
$
37,895

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Long-Term Other Liabilities
12 Months Ended
Dec. 31, 2017
Other Liabilities Disclosure [Abstract]  
Long-Term Other Liabilities
LONG-TERM OTHER LIABILITIES
Long-term other liabilities consist of (in thousands): 
 
December 31,
 
2017
 
2016
Contingent tax obligations
$
17,934

 
$
6,125

Non-current deferred revenue
4,039

 
1,885

Other
22

 
3

Total
$
21,995

 
$
8,013

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt and Credit Arrangements
12 Months Ended
Dec. 31, 2017
Debt Disclosure [Abstract]  
Debt and Credit Arrangements
DEBT AND CREDIT ARRANGEMENTS
The Company has a Credit Agreement with JP Morgan Chase Bank ("JP Morgan") and Citibank, NA (“Citibank”). The Credit Agreement provides for an aggregate $150 million of secured revolving credit facility. In the third quarter of 2017, the Company exercised the right to increase the amount available under the facility by $75.0 million, bringing the aggregate revolving credit facility to $225.0 million. The Credit Agreement contains covenants relating to maintenance of books and records, financial reporting and notification, compliance with laws, maintenance of properties and insurance, and limitations on guaranties, investments, issuance of debt, lease obligations and capital expenditures, and is secured by virtually all of the Company's assets. The Credit Agreement provides for events of default, including failure to pay any principal or interest when due, failure to perform or observe covenants, bankruptcy or insolvency events and the occurrence of a material adverse effect. The Company has no other significant credit facilities.
In addition to the customary restrictive covenants listed above, the Credit Agreement also contains financial covenants that require the Company to maintain a certain leverage ratio and fixed charge coverage ratio, each as defined in the Credit Agreement:
Leverage Ratio, as defined, to be no higher than 2.75 to 1.00.
Interest Coverage Ratio, as defined, to be at least 1.75 to 1.00 at all times.
As of December 31, 2017, the Company was in compliance with the Leverage Ratio at 2.44 to 1.00 and the Interest Coverage Ratio at 10.16 to 1.00.
As of December 31, 2017, the Company had $155 million outstanding under the Credit Agreement.
Pursuant to the terms of the Credit Agreement, the outstanding principal balance will bear interest at either (a) a fluctuating rate per annum equal to the Applicable Rate, as defined in the Credit Agreement, depending on the leverage ratio plus the higher of (i) the federal funds rate plus one-half of one percent per annum; (ii) the prime rate in effect on such a day; and (iii) the LIBOR rate plus one percent, or (b) a fluctuating rate per annum of LIBOR Rate plus the Applicable Rate, which ranges between 1.75% to 2.75%. The effective interest rate during the twelve months ended December 31, 2017 was 3.34%. The Credit Agreement matures on September 23, 2021, at which time all principal amounts outstanding under the Credit Agreement will be due and payable.

Long-term debt consists of (in thousands):
 
December 31,
 
2017
 
2016
Revolving credit facility
$
155,000

 
$
140,000

Debt issuance costs
(717
)
 

Less: current portion of long-term debt

 

Total long-term debt
$
154,283

 
$
140,000


Maturities of long-term debt as of December 31, 2017 are as follows (in thousands):
 
December 31,
 
2017
 
2016
2018
$

 
$

2019

 

2020

 

Thereafter
154,283

 
140,000

Total
$
154,283

 
$
140,000


As of December 31, 2017, the carrying value of the total debt approximated fair market value.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Reserve for Product Warranties
12 Months Ended
Dec. 31, 2017
Product Warranties Disclosures [Abstract]  
Reserve for Product Warranties
RESERVE FOR PRODUCT WARRANTIES
The Company provides a warranty for products that is generally one year in length and in some cases, regulations may require them to provide repair or remediation beyond the typical warranty period. If any of the products contain defects, the Company may be required to incur additional repair and remediation costs. Service for domestic customers is provided by Company-owned service centers that perform all service, repair and calibration services. Service for international customers is provided by a combination of Company-owned facilities and vendors on a contract basis.
A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management's best estimate of probable liability. The Company considers a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.
As of December 31, 2017, the Company has accrued $5.4 million to bring certain NeoBLUE® phototherapy products into U.S. regulatory compliance. The Company's estimate of the costs associated with bringing the NeoBLUE® phototherapy products into compliance is primarily based upon the number of units outstanding that may require the repair, costs associated with shipping and repairing the product, and the assumption that the FDA will approve the Company's plan for compliance.
The details of activity in the warranty reserve are as follows (in thousands): 
 
Balance at
Beginning
of Period
 
Assumed
Through
Acquisitions
 
Additions
Charged to
Expense
 
Reductions
 
Balance
at End
of Period
December 31, 2017
$
10,670

 
$
1,159

 
$
5,370

 
$
(6,204
)
 
$
10,995

December 31, 2016
$
10,386

 
$
222

 
$
2,711

 
$
(2,649
)
 
$
10,670

December 31, 2015
$
2,753

 
$

 
$
10,729

 
$
(3,096
)
 
$
10,386


The estimates the Company uses in projecting future product warranty costs may prove to be incorrect. Any future determination that product warranty reserves are understated could result in increases to cost of sales and reductions in operating profits and results of operations.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity
12 Months Ended
Dec. 31, 2017
Equity [Abstract]  
Stockholders' Equity
STOCKHOLDERS’ EQUITY
Common Stock—The Company has 120,000,000 shares of common stock authorized at a par value or $0.001 per share. 
Preferred Stock—The Company has 10,000,000 shares of preferred stock authorized at a par value of $0.001 per share. In accordance with the terms of the amended and restated certificate of incorporation, the Board of Directors is authorized to provide for the issuance of one or more series of preferred stock, including increases or decreases to the series. The Board of Directors has the authority to set the rights, preferences, and terms of such shares. As of December 31, 2017, no shares of preferred stock were issued and outstanding.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Earnings Per Share
12 Months Ended
Dec. 31, 2017
Earnings Per Share [Abstract]  
Earnings Per Share
EARNINGS PER SHARE
The components of basic and diluted EPS are as follows (in thousands, except per share amounts): 
 
December 31,
 
2017
 
2016
 
2015
Net income (loss)
$
(20,293
)
 
$
42,594

 
$
37,924

Weighted average common shares
32,564

 
32,460

 
32,348

Dilutive effect of stock based awards

 
596

 
893

Diluted Shares
32,564

 
33,056

 
33,241

Basic earnings per share
$
(0.62
)
 
$
1.31

 
$
1.17

Diluted earnings per share
$
(0.62
)
 
$
1.29

 
$
1.14

Shares excluded from calculation of diluted EPS
565

 
2

 

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Compensation
12 Months Ended
Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation
SHARE-BASED COMPENSATION
Share-Based Compensation Expense—The Company accounts for share-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation. Share-based compensation was recognized as follows in the consolidated statement of income (in thousands):
 
December 31,
 
2017
 
2016
 
2015
Cost of revenue
$
232

 
$
219

 
$
156

Marketing and selling
540

 
821

 
808

Research and development
1,332

 
1,515

 
1,264

General and administrative
7,341

 
6,453

 
4,725

Total expense
9,445

 
9,008

 
6,953


Stock Awards Plans—Natus' 2011 Stock Awards Plan (the “Plan”) provides for the granting of the following:
Incentive stock options to employees;
Non-statutory stock options to employees, directors and consultants;
Restricted stock awards and restricted stock units;
Stock bonuses; and
Stock appreciation rights.
As of December 31, 2017, there were 779,298 shares available for future awards under the plan.
Under the Plan, stock options may be issued at not less than the fair market value of the common stock on the date of grant, as determined by the Board of Directors. Options issued under the Plan become exercisable as determined by the Board of Directors and expire no more than six years after the date of grant. Most options vest ratably over four years.
Stock Option Activity—Stock option activity under the stock awards plans for the year ended December 31, 2017 is summarized as follows:  
 
Number of
Shares
 
Weighted
Average
Exercise Price
Outstanding, December 31, 2016 (816,691 shares exercisable at a weighted average exercise price of $14.54 per share)
933,096

 
$
15.02

Granted

 
$

Exercised
(134,102
)
 
$
14.06

Forfeited
(1,317
)
 
$
13.83

Expired
(2,592
)
 
$
16.31

Outstanding, December 31, 2017 (790,573 shares exercisable at a weighted average exercise price of $15.14 per share)
795,085

 
$
15.18


As of December 31, 2017, unrecognized compensation related to the unvested portion of stock options was approximately $1.0 thousand, which is expected to be recognized at the beginning of 2018. The intrinsic value of options exercised, representing the difference between the closing stock price of common stock on the date of the exercise and the exercise price, in the years ended December 31, 2017, 2016 and 2015 was $3.1 million, $3.4 million, and $17.7 million, respectively.
As of December 31, 2017, there were: (i) 795,085 options vested and expected to vest with a weighted average exercise price of $15.18, an intrinsic value of $18.3 million, and a weighted average remaining contractual term of 1.2 years; and (ii) 790,573 options exercisable with a weighted average exercise price of $15.14, an intrinsic value of $18.2 million, and a weighted average remaining contractual term of 1.2 years.
The expected life of options is based primarily on historical share option exercise experience of the employees for options granted by the Company. All options are treated as a single group in the determination of expected life, as the Company does not currently expect substantially different exercise or post-vesting termination behavior among the employee population. The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the awards in effect at the time of grant. Expected volatility is based primarily on historical volatility data of the Company's common stock. The Company has no history or expectation of paying dividends on common stock.
Share-based compensation expense associated with options is based on awards ultimately expected to vest. At the time of an option grant, the Company estimates the expected future rate of forfeitures based on historical experience. These estimates are revised, if necessary, in subsequent periods if actual forfeiture rates differ from those estimates. If the actual forfeiture rate is lower than estimated the Company will record additional expense and if the actual forfeiture is higher than estimated the Company will record a recovery of prior expense.
Restricted Stock Awards Activity—The following table summarizes the activity for restricted stock awards during the year ended December 31, 2017:  
 
Shares
 
Weighted
Average
Grant
Date Fair
Value
Unvested at December 31, 2016
506,389

 
$
34.82

Granted
265,449

 
$
34.94

Vested
(391,947
)
 
$
32.41

Forfeited
(16,083
)
 
$
35.87

Unvested at December 31, 2017
363,808

 
$
37.46


As of December 31, 2017, unrecognized compensation related to the unvested portion of stock awards was $10.8 million, which is expected to be recognized over a weighted average period of 2.3 years. The fair market value of outstanding restricted stock awards at December 31, 2017 was $13.9 million. For the restricted stock awards units that vested during the years ended December 31, 2017, 2016, and 2015, the total intrinsic value was $14.3 million, $9.0 million, and $10.3 million, respectively.
Restricted Stock Units Activity—The following table summarizes restricted stock units activity for the year ended December 31, 2017:  
 
Shares
 
Weighted
Average
Grant
Date Fair
Value
Outstanding at December 31, 2016
29,903

 
$
34.39

Awarded
55,176

 
$
35.16

Released
(35,929
)
 
$
33.65

Forfeited
(25,006
)
 
$
34.47

Outstanding at December 31, 2017
24,144

 
$
37.17

As of December 31, 2017, unrecognized compensation related to the unvested portion of stock units was $0.9 million, which is expected to be recognized over a weighted average period of 1.8 years. The aggregate intrinsic value of outstanding restricted stock units at December 31, 2017 was $0.9 million. For the restricted stock units that vested during the years ended December 31, 2017, 2016, and 2015, the total intrinsic value was $1.3 million, $0.9 million, and $0.9 million, respectively.
Employee Stock Purchase Plan—Under Natus' 2011 Employee Stock Purchase Plan (the “ESPP”), U.S. employees can elect to have salary withholdings of up to 15% of eligible compensation to a maximum of $10,625 per offering period, to purchase shares of common stock on April 30 and October 31 of each year. The purchase price for shares acquired under the ESPP is 85% of the fair market value on the last day of the offering period. As of December 31, 2017, there were 117,270 shares reserved for future issuance under the ESPP.
Because the ESPP does not have a “look back” feature, the compensation expense associated with the Plan is not measured by the use of the Black-Scholes pricing model, but rather by measuring the difference between the fair market value of common stock on the last day of the offering period and the purchase price for the offering period, which is 85% of the fair market value. Compensation expense associated with the ESPP for the years ended December 31, 2017, 2016 and 2015, respectively, was $0.3 million, $0.2 million, and $0.2 million.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restructuring Reserve
12 Months Ended
Dec. 31, 2017
Restructuring and Related Activities [Abstract]  
Restructuring Reserve
RESTRUCTURING RESERVE
The Company has historically incurred an ongoing level of restructuring-type activities to maintain a competitive cost structure, including manufacturing and workforce optimization resulting from acquisitions.
The balance of the restructuring reserve is included in accrued liabilities on the accompanying consolidated balance sheets. Employee termination benefits are included as a part of restructuring expenses.
Activity in the restructuring reserves for these plans for the years ended December 31, 20172016 and 2015 is as follows (in thousands): 
 
Personnel
Related
 
Facility
Related
 
Total
Balance as of December 31, 2014
$
368

 

 
$
368

Additions
1,905

 
156

 
2,061

Reversals
(124
)
 

 
(124
)
Payments
(473
)
 
(156
)
 
(629
)
Balance as of December 31, 2015
1,676

 

 
1,676

Additions
1,093

 
725

 
1,818

Reversals
(436
)
 

 
(436
)
Payments
(1,990
)
 
(573
)
 
(2,563
)
Balance as of December 31, 2016
343

 
152

 
495

Additions
431

 

 
431

Reversals
(182
)
 

 
(182
)
Payments
(631
)
 
(93
)
 
(724
)
Balance as of December 31, 2017
$
(39
)
 
59

 
$
20

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Income (Expense), Net
12 Months Ended
Dec. 31, 2017
Other Income and Expenses [Abstract]  
Other Income (Expense), Net
OTHER INCOME (EXPENSE), NET
Other income (expense), net consists of (in thousands): 
 
Years Ended December 31,
 
2017
 
2016
 
2015
Interest income
$
425

 
$
315

 
$
27

Interest expense
(5,081
)
 
(430
)
 
(352
)
Foreign currency gain (loss)
1,013

 
(359
)
 
(1,415
)
Other
76

 
117

 
676

Total other income (expense), net
$
(3,567
)
 
$
(357
)
 
$
(1,064
)
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes
12 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
Income Taxes
INCOME TAXES
Income before provision for income tax is as follows (in thousands): 
 
Years Ended December 31,
 
2017
 
2016
 
2015
U.S.
$
(18,059
)
 
$
68

 
$
20,507

Foreign
23,209

 
54,835

 
31,902

Income before provision for income tax
$
5,150

 
$
54,903

 
$
52,409



The components of income tax expense for the years ended December 31, 2017, 2016 and 2015 (in thousands): 
 
Years Ended December 31,
 
2017
 
2016
 
2015
Current
 
 
 
 
 
U.S. Federal
$
10,110

 
$
(1,388
)
 
$
13,497

U.S. State and local
1,079

 
692

 
1,984

Non-U.S.
12,764

 
15,069

 
2,239

Total current tax expense
23,953

 
14,373

 
17,720

Deferred
 
 
 
 
 
U.S. Federal
6,345

 
(1,534
)
 
(3,410
)
U.S. State and local
(1,333
)
 
(378
)
 
(385
)
Non-U.S.
(3,522
)
 
(152
)
 
560

Total deferred tax benefit
1,490

 
(2,064
)
 
(3,235
)
Total income tax expense
$
25,443

 
$
12,309

 
$
14,485


Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities as of December 31, 2017 and 2016 are as follows (in thousands): 
 
December 31,
 
2017
 
2016
Deferred tax assets:
 
 
 
Net operating loss carryforwards
$
3,958

 
$
6,557

Credit carryforwards
4,466

 
2,512

Accruals deductible in different periods
11,969

 
16,157

Employee benefits
1,085

 
2,389

Total deferred tax assets
21,478

 
27,615

Valuation allowance
(5,862
)
 
(3,706
)
Total net deferred tax assets
$
15,616

 
$
23,909

Deferred tax liabilities:
 
Basis difference in fixed and intangible assets
(23,934
)
 
(12,678
)
Foreign earnings to be repatriated
(380
)
 

Total deferred tax liabilities
(24,314
)
 
(12,678
)
Total net deferred tax assets
$
(8,698
)
 
$
11,231


The income tax expense in the accompanying statements of income differs from the provision calculated by applying the U.S. federal statutory income tax rate of 35% in 2017, 2016, and 2015 to income before taxes due to the following: 
 
Years Ended December 31,
 
2017
 
2016
 
2015
Federal statutory tax expense
$
1,802

 
$
19,216

 
$
18,343

State tax expense
(318
)
 
188

 
1,249

Foreign taxes at rates less than U.S. rates
(3,101
)
 
(6,838
)
 
(1,760
)
Deferred charges on sales of U.S. intellectual property
980

 
980

 
(5,878
)
Equity compensation
606

 
(530
)
 
204

Tax credits
(1,498
)
 
(911
)
 
(935
)
Uncertain tax position
2,048

 
485

 
3,897

Lapse of statute
(1,521
)
 
(495
)
 
(784
)
Change of valuation allowance on foreign tax credit
314

 

 

Earnout adjustment
(190
)
 
(1,184
)
 

Repatriation tax net of foreign tax credits
16,564

 

 

Net deferred tax asset re-measurement

3,883

 

 

Tax audits
726

 
543

 

Withholding taxes
2,880

 

 

Return to provision
711

 

 

AMT on acquisition
621

 

 

Other
936

 
855

 
149

Total expense
$
25,443

 
$
12,309

 
$
14,485


On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017, the transition of U.S. international taxation from a worldwide tax system to a modified territorial system, and a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017. On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. The Company has calculated its best estimate of the impact of the Act in its year end income tax provision in accordance with its understanding of the Act and guidance available as of the date of this filing. As a result, the Company has recorded $20.5 million as an additional income tax expense in the fourth quarter of 2017, the period in which the legislation was enacted. The provisional amount related to the re-measurement of certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future was $3.9 million. The provisional amount related to the one-time transition tax on the mandatory deemed repatriation of foreign earnings, net of foreign tax credits was $16.6 million based on cumulative foreign earnings of $181.0 million.
In accordance with SAB 118, the Company has determined that the $16.6 million of current tax expense recorded in connection with the transition tax on the mandatory deemed repatriation of foreign earnings was a provisional amount and a reasonable estimate at December 31, 2017. Additional work is necessary to do a more detailed analysis of historical foreign earnings as well as potential correlative adjustments. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete.
As of December 31, 2017, the Company has not assessed the impact of the changes arising from the Act that are effective in tax year 2018 and onward and will be included in the 2018 as interpreted guidance is further released. The Company has also not yet made a policy election with respect to its treatment of potential global intangible low-taxed income (“GILTI”). Companies can either account for taxes on GILTI as incurred or recognize deferred taxes when basis differences exist that are expected to affect the amount of the GILTI inclusion upon reversal. The Company is still in the process of analyzing the provisions of the Act associated with GILTI and the expected impact of GILTI on the Company in the future.
At December 31, 2017, the Company had deferred tax assets attributable to U.S. state net operating loss carryforwards of $1.2 million, which will begin to expire in 2018. At December 31, 2017, the Company had U.S. state R&D credit carryforwards of $0.4 million, which will begin to expire in 2021. At December 31, 2017, the Company had $4.2 million of U.S. foreign tax credit carryforwards that can be used to offset future U.S. tax liabilities related to foreign source taxable income. The foreign tax credits will start to expire in 2022.
At December 31, 2017, certain foreign subsidiaries had deferred tax assets attributable to net operating loss carryforwards as follows: $0.03 million in Germany, $1.4 million in France, $0.5 million in Canada, and $0.5 million in Denmark. These foreign net operating loss carryforwards, if not utilized to offset taxable income in future periods, will expire in various amounts beginning in 2028.
A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, valuation allowances of $5.9 million and $3.7 million were recorded at December 31, 2017 and 2016, respectively. The increase of $2.2 million in valuation allowance was primarily due to a valuation allowance recorded against the Company's current year generation of the Foreign Tax Credit in U.S.
The realizability of the deferred tax assets is primarily dependent on the Company's ability to generate sufficient taxable income in future periods. The Company's management weighed the aggregate effect of all positive evidence and negative evidence in determining the likelihood of realization of the deferred tax assets. The factors used by management to collect evidence included historical earnings of the applicable taxing jurisdiction, the cash refund opportunity to utilize the tax losses, and the future forecast of profitability in the jurisdiction. Weighing all the positive and negative evidence, the Company has recorded a valuation allowance related primarily to net operating losses in certain foreign jurisdictions and U.S. foreign tax credits where it is more likely than not that the tax benefit of the net operating losses and tax credits will not be realized.
There are no changes to the position on the Company's permanent reinvestment of its earnings from foreign operations, with the exception of Excel-Tech and Natus Ireland. As of December 31, 2017, the Company intends to distribute all of the earnings from Excel-Tech and Natus Ireland in excess of their operational needs. The Company has recorded a deferred tax liability of $0.4 million accordingly for 5% Canadian withholding tax on the expected Excel-Tech distribution to Natus Ireland. Natus Ireland has 0% withholding tax under domestic exemption and therefore, no liability has been recorded. The Company intends on permanently reinvesting the earnings of its remaining foreign subsidiaries. The other remaining foreign subsidiaries have both the intent and ability to indefinitely reinvest its undistributed earnings.
Uncertain Tax Positions
A reconciliation of the beginning and ending amount of unrecognized tax benefits (excluding interest and penalties) is as follows (in thousands): 
Balance at January 1, 2015
$
3,395

Increases for tax positions related to prior years
281

Increases for tax positions related to the current year
3,302

Lapse of statutes of limitations
(664
)
Balance at January 1, 2016
$
6,314

Increases for tax positions related to prior years
174

Increases for tax positions related to the current year
70

Lapse of statutes of limitations
(475
)
Foreign exchange difference
(185
)
Balance at January 1, 2017
$
5,898

Increases for tax positions related to prior years
747

Increases for tax positions related to the current year
1,712

Lapse of statutes of limitations
(1,393
)
Foreign exchange difference
53

Balance at December 31, 2017
$
7,017


For the year ended December 31, 2017, unrecognized tax benefits increased by $1.1 million and $0.6 million of tax expense in the income tax provision were recorded. The increase was primarily attributable to the increase in uncertain tax positions related to the current year in certain jurisdictions.
The unrecognized tax benefits for the tax years ended December 31, 2017, 2016 and 2015 were $7.0 million, $5.9 million and $6.3 million, respectively which include $4.0 million, $2.5 million and $2.4 million, respectively that would impact the effective tax rate if recognized.
The Company expects a range from zero to $0.9 million of unrecognized tax benefit that will impact the effective tax rate in the next 12 months due to the lapse of statute of limitations provided that no taxing authority conducts a new examination.
At December 31, 2017, 2016 and 2015, the Company had cumulatively accrued $0.6 million, $0.6 million, and $0.4 million for estimated interest and penalties related to uncertain tax positions. The Company records interest and penalties related to recognized tax positions as a component of income tax expense (benefit), which totaled approximately $(0.01) million, $0.2 million, and $0.1 million for the years ended December 31, 2017, 2016, and 2015, respectively.
The Company is currently unaware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation in this estimate over the next 12 months.
The Company's tax returns remain open to examination as follows: U.S. federal, 2014 through 2017; U.S. states, generally 2013 through 2017; and significant foreign jurisdictions, generally 2013 through 2017.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Employee Benefit Plan
12 Months Ended
Dec. 31, 2017
Defined Contribution Plan [Abstract]  
Employee Benefit Plan
EMPLOYEE BENEFIT PLAN
The Company offers pre-tax and after-tax 401(k) savings plan options under which eligible U.S. employees may elect to have a portion of their salary deferred and contributed to the plan. Employer matching contributions are determined by management and are discretionary. Employer matching contributions were $2.5 million, $1.5 million, and $1.3 million respectively, in the years ended December 31, 2017, 2016, and 2015. For new hires, employer contributions vest ratably over the first two years of employment.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment, Customer and Geographic Information
12 Months Ended
Dec. 31, 2017
Segment Reporting [Abstract]  
Segment, Customer and Geographic Information
SEGMENT, CUSTOMER, AND GEOGRAPHIC INFORMATION
The Company operates in one reportable segment, which is presented as the aggregation of the Neurology, Newborn Care, and Otometrics operating segments. Through the one reportable segment the Company is organized on the basis of the healthcare products and services provided which are used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, and sleep disorders.
End-users customer base includes hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Most of the Company's international sales are to distributors who resell products to end users or sub-distributors. The Company's foreign countries’ revenue is determined based on the customer’s billing address.
Revenue and long-lived asset information by geographic region is as follows (in thousands): 
 
Years Ended December 31,
 
2017
 
2016
 
2015
Consolidated Revenue:
 
United States
$
270,860

 
$
250,694

 
$
242,050

Foreign countries
230,110

 
131,198

 
133,815

 
$
500,970

 
$
381,892

 
$
375,865

Revenue by End Market:
 
Neuro
 
Devices and Systems
$
171,315

 
$
168,200

 
$
168,776

Supplies
59,955

 
58,681

 
60,205

Services
11,886

 
11,641

 
8,320

Total Neurology Revenue
$
243,156

 
$
238,522

 
$
237,301

Newborn Care
 
Devices and Systems
$
77,573

 
$
72,562

 
$
72,669

Supplies
43,732

 
47,674

 
49,982

Services
22,325

 
23,134

 
15,913

Total Newborn Care Revenue
$
143,630

 
$
143,370

 
$
138,564

Otometrics
 
Devices and Systems
$
86,920

 
$

 
$

Supplies
27,264

 

 

Services

 

 

Total Otometrics Revenue
$
114,184

 
$

 
$

Total Revenue
$
500,970

 
$
381,892

 
$
375,865

 
 
 
 
 
 
Property and equipment, net:
 
United States
$
10,128

 
$
7,024

 
 
Canada
5,068

 
4,941

 
 
Argentina
1,591

 
2,121

 
 
Ireland
3,178

 
2,530

 
 
Denmark
1,158

 
17

 
 
Other foreign countries
948

 
700

 
 
 
$
22,071

 
$
17,333

 
 

During the years ended December 31, 2017, 2016 and 2015, no single customer or foreign country contributed to more than 10% of revenue.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments And Contingencies
12 Months Ended
Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments And Contingencies
COMMITMENTS AND CONTINGENCIES
Leases—The Company has entered into noncancelable operating leases for some of the facilities including related office equipment located in the U.S. and Europe through 2024. Minimum lease payments under noncancelable operating leases as of December 31, 2017 are as follows (in thousands):  
 
Operating
Leases
Year Ending December 31,
 
2018
$
7,038

2019
5,732

2020
4,609

2021
3,392

2022
2,457

Thereafter
6,850

Total minimum lease payments
$
30,078

 
Rent expense, which is recorded on the straight-line method from commencement over the period of the lease, totaled $6.7 million, $5.3 million and $4.4 million in 2017, 2016, and 2015, respectively.
Purchase commitments—The Company has various purchase obligations for goods or services totaling $47.8 million at December 31, 2017, which are expected to be paid within the next year.
Indemnifications—Under the bylaws, the Company has agreed to indemnify the officers and directors for certain events or occurrences arising as a result of the officer or director serving in such capacity. The Company has a director and officer liability insurance policy that limits the exposure under these indemnifications and enables them to recover a portion of any future loss arising out of them. In addition, the Company entered into indemnification agreements with other parties in the ordinary course of business. The Company has determined that these agreements fall within the scope of ASC 460, Guarantees. In some cases liability insurance is obtained to provide coverage that limits its exposure for these other indemnified matters. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. The Company believes the estimated fair value of these indemnification agreements is minimal and have not recorded a liability for these agreements as of December 31, 2017.
Legal matters—The Company may from time to time become a party to various legal proceedings or claims that arise in the ordinary course of business. The Company does not believe that any current legal or administrative proceedings are likely to have a material effect on business, financial condition, or results of operations.
In January 2017, a putative class action lawsuit (Badger v. Natus Medical Incorporation, et al., No. 17-cv-00458-JSW) alleging violations of federal securities laws was filed in the United States District Court for the Northern District of California, naming as defendants the Company and certain officers and a director. In July 2017, plaintiffs filed an amended complaint with a new lead plaintiff (Costabile v. Natus Medical Incorporation, et al., No. 17-cv-00458-JSW) alleging violations of federal securities laws based on allegedly false and misleading statements. The defendants moved to dismiss the Amended Complaint, and in February 2018 the motion to dismiss was granted with leave to amend. The Company believes that the plaintiffs’ allegations are without merit, and intends to vigorously defend against the claims.  In July 2017, a putative shareholder derivative action was filed in California Superior Court (Mortman v. Gunst, et. al., No. RG17867679) against certain of the Company’s officers and directors and naming the Company as a nominal defendant. The action is based on allegations similar to those in the securities class action litigation described above. The Company believes the likelihood of an unfavorable outcome from these actions is remote.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements
12 Months Ended
Dec. 31, 2017
Fair Value Disclosures [Abstract]  
Fair Value Measurements
FAIR VALUE MEASUREMENTS
ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined under ASC 820 as the exit price associated with the sale of an asset or transfer of a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes the following three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value:
Level 1—Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3—Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
The Company does not have any financial assets or liabilities measured at fair value on a recurring basis.
The following financial instruments are not measured at fair value on the consolidated balance sheet as of December 31, 2017 and 2016, but require disclosure of fair values: cash and cash equivalents, accounts receivable, and accounts payable. The carrying value of these financial instruments approximates fair values because of the relatively short maturity.
During the third quarter of 2014, the Company listed the facility in Mundelein, Illinois for sale. This asset was measured at fair value less cost to sell as of September 30, 2014 based on market price and Level 2 inputs. The book value of this asset on June 30, 2014 was $3.6 million. The Company expensed $2.2 million during the third quarter of 2014 for this impairment. As of December 31, 2017 the Company is carrying the asset as held for sale its fair value of $1.4 million.
The Company also has contingent consideration associated with earnouts from acquisitions. Contingent consideration liabilities are classified as Level 3 liabilities, as the Company use unobservable inputs to value them, which is a probability-based income approach. Contingent considerations are classified as accrued liabilities on the consolidated balance sheets. Subsequent changes in the fair value of contingent consideration liabilities are recorded within the income statement as an operating expense.
Contingent consideration associated with earnouts from acquisitions is as follows (in thousands):
 
December 31, 2016
 
Additions
 
Payments
 
Adjustments
 
December 31, 2017
Liabilities:
 
 
 
 
 
 
 
 
 
Contingent consideration
$
3,043

 
$
693

 
$
(2,966
)
 
$
(623
)
 
$
147

Total
$
3,043

 
$
693

 
$
(2,966
)
 
$
(623
)
 
$
147


The significant unobservable inputs used in the fair value measurement of contingent consideration related to the acquisitions are annualized revenue forecasts developed by the Company considering the probability of achievement of those revenue forecasts. Significant increases (decreases) in these unobservable inputs in isolation would result in a significantly lower (higher) fair value measurement.
The Company's Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spread, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming those securities traded in active markets. See Note 4 to these Consolidated Financial Statements for further information regarding the Company's financial instruments.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Schedule II: Valuation And Qualifying Accounts
12 Months Ended
Dec. 31, 2017
Valuation and Qualifying Accounts [Abstract]  
Schedule II: of Valuation and Qualifying Accounts
SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS
For the years ended December 31, 2017, 2016 and 2015
(In thousands) 
 
Balance at
Beginning
of Period
 
Additions
Charged to
Expense
 
Deductions
 
Balance
at End
of Period
Year ended December 31, 2017
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
4,182

 
$
10,017

 
$
(5,221
)
 
$
8,978

Valuation allowance
3,706

 
2,156

 

 
5,862

Year ended December 31, 2016
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
4,686

 
$
1,123

 
$
(1,627
)
 
$
4,182

Valuation allowance
3,972

 

 
(266
)
 
3,706

Year ended December 31, 2015
 
 
 
 
 
 
 
Allowance for doubtful accounts
$
4,324

 
$
1,496

 
$
(1,134
)
 
$
4,686

Valuation allowance
3,151

 
821

 

 
3,972

XML 40 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2017
Accounting Policies [Abstract]  
Principles of Consolidation
Principles of Consolidation
The accompanying Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the Consolidated Financial Statements and the reported amount of revenue and expenses during the reporting period. Such estimates include allowances for potentially uncollectible accounts receivable, valuation of inventory, intangible assets, goodwill, share-based compensation, deferred income taxes, reserves for warranty obligations, and the provision for income taxes. Actual results could differ from those estimates.
Revenue recognition
Revenue recognition
Revenue, net of discounts, is recognized from sales of medical devices and supplies, including sales to distributors, when the following conditions have been met: a purchase order has been received, title has transferred, the selling price is fixed or determinable, and collection of the resulting receivable is reasonably assured. Terms of sale for most domestic sales are FOB origin, reflecting that title and risk of loss are assumed by the purchaser at the shipping point; however, terms of sale for some neurology, sleep-diagnostic, and head cooling systems are FOB destination, reflecting that title and risk of loss are assumed by the purchaser upon delivery. Terms of sales to international distributors are generally EXW, reflecting that goods are shipped “ex works,” in which title and risk of loss are assumed by the distributor at the shipping point. For products shipped under FOB origin or EXW terms, delivery is generally considered to have occurred when the product is shipped. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue. The Company generally does not provide rights of return on products.
For products containing embedded software, the Company has determined that the hardware and software components function together to deliver the products’ essential functionality, and therefore, the revenue from the sale of these products does not fall within the scope of the software revenue recognition rules. The Company's revenue recognition policies for sales of these products are substantially the same as for other tangible products. 
Revenue from sales of certain products that remain within the scope of the software revenue recognition rules under ASC Subtopic 985-605 is not significant.
Revenue from extended service and maintenance agreements, for both medical devices and data management systems, is recognized ratably over the service period. Revenue from installation or training services is deferred until such time service is provided. Hearing screening and ambulatory EEG monitoring revenue is recorded when the procedure is performed at the estimated net realizable value based on contractual agreements with payers and historical collections.
Certain revenue transactions include multiple element arrangements. The Company allocates revenue in these arrangements to each unit of accounting using the relative selling price method. The selling prices used during the allocation process are based on vendor specific objective evidence (“VSOE”) if available, third party evidence (“TPE”) if VSOE is not available, or estimated selling price (“ESP”) if neither VSOE or TPE is available.
Group purchasing organization (“GPOs”) negotiate volume purchase prices for member hospitals, group practices, and other clinics. The Company's agreements with GPOs typically contain preferential terms for the GPO and its members, including provisions for some, if not all, of the following:
Payment of marketing fees by Natus to the GPO, usually based on purchasing experience of group members; and
Non-recourse cancellation provisions.
Natus does not sell products to GPOs. Hospitals, group practices, and other clinics that are members of a GPO purchase products directly from the Company under the terms negotiated by the GPO. Negotiated pricing and discounts are recognized as a reduction of the selling price of products at the time of the sale. Revenue from sales to members of GPOs is otherwise consistent with general revenue recognition policies as previously described.
Inventory
Inventory
Inventories are carried at the lower of cost or market, with cost being determined using the first-in, first-out method. The carrying value of the Company's inventories is reduced for any difference between cost and estimated market value of inventories that is determined to be obsolete or unmarketable, based upon assumptions about future demand and market conditions. Adjustments to the value of inventory establish a new cost basis and are considered permanent even if circumstances later suggest that increased carrying amounts are recoverable. If demand is higher than expected, Natus may sell inventory that had previously been impaired.
Carrying value of intangible assets and goodwill
Carrying value of intangible assets and goodwill
The Company amortizes intangible assets with finite lives over the useful lives; any future changes that would limit the useful lives or any determination that these assets are carried at amounts greater than the estimated fair value could result in additional charges.
Goodwill is not amortized but is subject to an annual impairment analysis, which is performed as of October 1st; this assessment is also performed whenever there is a change in circumstances that indicates the carrying value of goodwill may be impaired.
In 2017, 2016 and 2015, the Company performed a qualitative assessment to test goodwill for impairment. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on the qualitative assessment, the Company determined that the fair value was more likely than not to be greater than its carrying amount, and no further analysis was needed.
If the fair value was less than its carrying amount, the Company would perform a two-step impairment test on goodwill. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit to its carrying value, including goodwill. The Company uses a projected discounted cash flow model to determine the fair value of a reporting unit. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. The fair value of a reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit. If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment charge is recognized in an amount equal to that excess.
Prior to the assignment of definite lives to trade names in the second quarter of 2015 (See Note 6 - Intangible Assets), the Company tested indefinite lived intangibles for impairment by comparing the carrying value of those assets to be fair value as of the assessment date. The Company used the relief from royalty method to determine the fair value of the assets. This analysis is dependent upon a number of quantitative and qualitative factors including estimates of forecasted revenue, royalty rate, and taxes. The discount rate applied also has an impact on the estimates of fair value, as use of a higher rate will result in a lower estimate of fair value.
Long lived assets
Long lived assets
The Company continually monitors events and changes in circumstances that could indicate that carrying amounts of its long-lived assets, including property and equipment and intangible assets, may not be recoverable. When such events or changes in circumstances occur, the Company assess the recoverability by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the future undiscounted cash flows are less than the carrying amount of these assets, the Company will recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets.
Liability for product warranties
Liability for product warranties
The Company provides a warranty for products that is generally one year in length. In some cases, regulations may require the Company to provide repair or remediation beyond the typical warranty period. If any products contain defects, the Company may be required to incur additional repair and remediation costs. Service for domestic customers is provided by Company-owned service centers that perform all service, repair, and calibration services. Service for international customers is provided by a combination of Company-owned facilities and vendors on a contract basis.
A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management’s best estimate of probable liability. The Company considers a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of the reserve. The reserve is reduced as costs are incurred to honor existing warranty and regulatory obligations.
Share-based compensation
Share-based compensation
The Company recognizes share-based compensation expense associated with employee stock options under the single-option straight line method over the requisite service period, which is generally a four-year vesting period and ten-year contractual term pursuant to ASC Topic 718, Compensation-Stock Compensation. See Note 14 of the Consolidated Financial Statements.
For employee stock options, the value of each option is estimated on the date of grant using the Black-Scholes option pricing model, which was developed for use in estimating the value of freely traded options. Similar to other option pricing models, the Black-Scholes method requires the input of highly subjective assumptions, including stock price volatility. Changes in the subjective input assumptions can materially affect the estimated fair value of the employee stock options.
The Company recognizes share-based compensation associated with Restricted Stock Awards (“RSA”) and Restricted Stock Units (“RSU”). RSAs and RSUs vest ratably over a three-year period for employees. RSAs and RSUs for executives vest over a four-year period; 50% on the second anniversary of the awarded date and 25% on each of the third and fourth anniversaries. RSAs and RSUs for non employees (Board of Directors) vest over a one-year period; 100% on the first anniversary. The value is estimated based on the market value of Natus common stock on the date of issuance pursuant to ASC Topic 718, Compensation-Stock Compensation.
The Company issues new shares of common stock upon the exercise of stock options and the vesting of RSAs and RSUs.
Forfeitures of employee stock options and awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share-based compensation expense is recorded net of estimated forfeitures, such that expense is recorded only for those share-based awards that are expected to vest.
Cash Equivalents
Cash Equivalents and Short-term Investments
All highly liquid investments purchased with an original maturity of three months or less are classified as cash equivalents.
Short-term Investments
Short-term Investments
All highly liquid investments purchased with an original maturity of three months or less are classified as cash equivalents. Investments with maturities greater than one year are classified as current because management considers all investments to be available for current operations. Cash equivalents and investments are stated at amounts that approximate fair value based on quoted market prices.
The Company's investments have been classified and accounted for as available-for-sale. Such investments are recorded at fair value and unrealized holding gains and losses are reported as a separate component of comprehensive income until realized. Realized gains and losses on sales of investments, if any, are determined on the specific identification method and are reclassified from accumulated other comprehensive loss to results of operations as other income (expense).
Allowance for Doubtful Accounts
Allowance for Doubtful Accounts
The Company estimates the allowance for potentially uncollectible accounts receivable based on historical collection experience within the markets in which the Company operates and other customer-specific information, such as bankruptcy filings or customer liquidity problems. When all internal efforts have been exhausted to collect the receivable, it is written off and relieved from the reserve.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
Financial instruments include cash and cash equivalents, investments, accounts receivable, and accounts payable. Cash is reported at its fair value on the balance sheet dates. The recorded carrying amounts of investments, accounts receivable and accounts payable approximate the fair values due to the short-term maturities.
Property and Equipment
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over estimated useful lives of the respective assets, which are three to ten years for office furniture and equipment, three to five years or the length of the license for computer software and hardware, three to five years for demonstration and loaned equipment, and 30 to 40 years for buildings. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life. Land is not depreciated. Costs associated with acquiring and installing software to be used for internal purposes are capitalized and amortized on a straight-line basis over three years.
Research & Development Costs
Research & Development Costs
Costs incurred in research and development are charged to operations as incurred.
Income Taxes
Income Taxes
The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
The Company records net deferred tax assets to the extent it is more likely than not that the assets will be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. To the extent that previously reserved deferred tax assets are estimated to be realizable, the Company adjusts the valuation allowance which reduces the provision for income taxes.
The Company recognizes the tax benefit of uncertain tax positions in the financial statements as defined in ASC Topic 740, Income Tax. When the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50 percent likely of being ultimately realized upon settlement, as defined in ASC 740-10-05.
Foreign Currency
Foreign Currency
The functional currency of the Company's subsidiaries outside of North America is generally the local currency of the country where the subsidiary is located. Accordingly, foreign currency translation adjustments relating to the translation of foreign subsidiary financial statements are included as a component of accumulated other comprehensive loss. The Company recorded $21.5 million, $(5.0) million, and $(8.4) million of foreign currency translation gains (losses) for the years ended December 31, 2017, 2016 and 2015, respectively.
Gains and losses from transactions denominated in currencies other than the functional currencies are included in other income and expense. In 2017, 2016, and 2015, net foreign currency transaction gains (losses) were $1.0 million, $(0.4) million, and $(1.4) million, respectively. Foreign currency gains and losses result primarily from fluctuations in the exchange rate between the U.S. Dollar, Canadian Dollar, Euro, Argentine Peso, British Pound, and Danish Kroner.
Comprehensive Income
Comprehensive Income
The Company reports by major components and as a single total the change in net assets during the period from non-owner sources as defined in ASC Topic 220, Comprehensive Income. The consolidated statement of comprehensive income has been included with the consolidated statements of operations. Accumulated other comprehensive income consists of translation gains and losses on foreign subsidiary financial statements as well as unrealized gains and losses on investments.
Basic and Diluted Net Income per Share
Basic and Diluted Net Income per Share
Natus computes net income per share as defined in ASC Topic 260, Earnings per Share. Basic net income per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalents outstanding during the period. Common stock equivalents are options granted and shares of restricted stock issued under the stock awards plans and are calculated under the treasury stock method. Common equivalent shares from unexercised stock options and restricted stock are excluded from the computation when there is a loss as the effect is anti-dilutive, or if the exercise price of such options is greater than the average market price of the stock for the period.
Recent Accounting Pronouncements
Recent Issued Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance. The standard's core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard creates a five-step model to achieve its core principle: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction's price to the separate performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. In addition, entities must disclose sufficient information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Qualitative and quantitative disclosures are required about: (i) the entity's contracts with customers; (ii) the significant judgments, and changes in judgments, made in applying the guidance to those contracts; and (iii) any assets recognized from the costs to obtain or fulfill a contract with a customer. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 616) - Deferral of the Effective Date, which deferred the effective date of ASU 2014-09 to interim and annual periods beginning January 1, 2018. The standard allows entities to apply the standard retrospectively to each prior period presented (“full retrospective adoption”) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application (“modified retrospective adoption”). The Company adopted the modified retrospective approach of this guidance on January 1, 2018 and has determined that its adoption will not have a material effect on its financial position or results of operations.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This standard requires a lessee to recognize the lease assets and lease liabilities arising from operating leases in the statement of financial position. Qualitative along with specific quantitative disclosures are required by lessees to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 including interim periods within those fiscal years. The Company is currently evaluating the impact that will result from adopting ASU 2016-02.
    
In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). This update modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Because these amendments eliminate a step from the goodwill impairment test, they should reduce the cost and complexity of evaluating goodwill for impairment. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company will adopt ASU 2017-04 to goodwill impairment testing on the effective date.
In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. This update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This guidance is effective for annual periods beginning after December 15, 2017, including interim periods within that year, and must be applied prospectively to an award modified on or after the adoption date. The Company will adopt this guidance and will apply to all future share-based modifications.
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations (Tables)
12 Months Ended
Dec. 31, 2017
Business Combinations [Abstract]  
Schedule of Purchase Price Allocation
The following table summarizes the purchase price allocation of the fair value of the assets acquired and liabilities assumed at the date of acquisition, (in thousands):
Cash and cash equivalents
$
5,604

Accounts receivable
26,851

Inventories
22,182

Property and equipment
2,256

Intangible assets
90,913

Goodwill
39,355

Other assets
1,748

Accounts payable
(7,655
)
Accrued liabilities
(16,069
)
Deferred revenue
(745
)
Deferred income tax
(15,193
)
Total purchase price
$
149,247

Pro Forma Financial Information
The pro forma financial information is presented for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of the earliest period presented, nor is it intended to be a projection of future results.
Unaudited Pro forma Financial Information
(in thousands)
 
Year Ended  December 31,
 
2017
 
2016
Revenue
$
500,970

 
$
491,994

Net income (loss)
$
(15,965
)
 
$
17,385

 
 
 
 
Earnings (loss) per share:
 
 
 
Basic
$
(0.49
)
 
$
0.54

Diluted
$
(0.49
)
 
$
0.53

Weighted average shares used in the calculation of earnings per share:
 
 
 
Basic
32,564

 
32,460

Diluted
32,564

 
33,056

XML 42 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash, Cash Equivalents, and Short-term Investments (Tables)
12 Months Ended
Dec. 31, 2017
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents and Short-term Investments
Cash, cash equivalents and short-term investments consisted of the following (in thousands):

    
 
December 31, 2017
 
December 31, 2016
Cash and cash equivalents:
 
 
 
Cash
88,950

 
213,551

Short-term investments:
 
 
 
U.S. investment grade bonds

 
24,477

Developed investment grade bonds

 
9,542

Total short-term investments

 
34,019

Total cash, cash equivalents and short-term investments
88,950

 
247,570

Unrealized Gain (Loss) on Investments
Short-term investments by investment type are as follows (in thousands):
  
 
December 31, 2017
 
December 31, 2016
 
Aggregated Cost Basis
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Aggregated Fair Value
 
Aggregated Cost Basis
 
Gross Unrealized Gains
 
Gross Unrealized Losses
 
Aggregated Fair Value
U.S. investment grade bonds

 

 

 

 
24,531

 

 
(54
)
 
24,477

Developed investment grade bonds

 

 

 

 
9,567

 

 
(25
)
 
9,542

Total short-term investments
$

 
$

 
$

 
$

 
$
34,098

 
$

 
$
(79
)
 
$
34,019

Investments Classified by Contractual Maturity Date
Short-term investments by contractual maturity are as follows (in thousands):

 
December 31, 2017
 
December 31, 2016
 
Investments
 
Investments
Due in one year or less
$

 
$
21,655

Due after one year through five years

 
12,364

Total short-term investment
$

 
$
34,019

XML 43 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories (Tables)
12 Months Ended
Dec. 31, 2017
Inventory Disclosure [Abstract]  
Inventories
Inventories consist of (in thousands): 
 
December 31,
 
2017
 
2016
Raw materials and subassemblies
$
44,699

 
$
28,245

Work in process
3,788

 
1,507

Finished goods
43,488

 
34,908

Total Inventories
91,975

 
64,660

Less: Non-current Inventories
(20,446
)
 
(15,073
)
Inventories
$
71,529

 
$
49,587

XML 44 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Property and Equipment (Tables)
12 Months Ended
Dec. 31, 2017
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and equipment consist of (in thousands): 
 
December 31,
 
2017
 
2016
Land
$
2,815

 
$
2,856

Buildings
5,096

 
5,219

Leasehold improvements
3,295

 
2,386

Office furniture and equipment
25,612

 
18,398

Computer software and hardware
9,760

 
9,100

Demonstration and loaned equipment
11,932

 
11,393

 
58,510

 
49,352

Accumulated depreciation
(36,439
)
 
(32,019
)
Total
$
22,071

 
$
17,333

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets (Tables)
12 Months Ended
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Components of Gross and Net Intangible Asset Balances
The following table summarizes the components of gross and net intangible asset balances (in thousands): 
 
December 31, 2017
 
December 31, 2016
 
Gross
Carrying
Amount
 
Accumulated
Impairment
 
Accumulated
Amortization
 
Net Book
Value
 
Gross
Carrying
Amount
 
Accumulated
Impairment
 
Accumulated
Amortization
 
Net Book
Value
Technology
$
101,045

 
(1,058
)
 
$
(42,048
)
 
$
57,939

 
$
62,563

 

 
$
(34,683
)
 
$
27,880

Customer related
108,074

 
(50
)
 
(28,972
)
 
79,052

 
38,087

 

 
(17,610
)
 
20,477

Trade names
49,313

 
(3,916
)
 
(13,273
)
 
32,124

 
32,106

 
(3,290
)
 
(7,135
)
 
21,681

Internally developed software
15,610

 

 
(12,293
)
 
3,317

 
16,978

 

 
(10,220
)
 
6,758

Patents
2,778

 
(133
)
 
(2,495
)
 
150

 
2,620

 

 
(2,251
)
 
369

Total Definite-lived intangible assets
276,820

 
(5,157
)
 
(99,081
)
 
172,582

 
152,354

 
(3,290
)
 
(71,899
)
 
77,165

Amortization expense related to intangible assets with definite lives
Amortization expense related to intangible assets with finite lives was as follows (in thousands): 
 
Years Ended December 31,
 
2017
 
2016
 
2015
Technology
$
7,705

 
$
3,407

 
$
3,916

Customer related
10,945

 
3,452

 
2,938

Trade names
6,479

 
4,115

 
3,159

Internally developed software
2,117

 
2,069

 
1,620

Patents
244

 
112

 
112

Total amortization
$
27,490

 
$
13,155

 
$
11,745

Expected annual amortization expense related to amortizable intangible assets
Expected annual amortization expense related to amortizable intangible assets is as follows (in thousands): 
2018
$
27,014

2019
25,836

2020
23,634

2021
22,210

2022
18,564

Thereafter
55,324

Total expected amortization expense
$
172,582

XML 46 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill (Tables)
12 Months Ended
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill
The carrying amount of goodwill and the changes in those balances are as follows (in thousands): 
As of December 31, 2015
$
107,466

Acquisitions/Purchase Accounting Adjustments
6,705

Foreign currency translation
(1,059
)
As of December 31, 2016
$
113,112

Acquisitions/Purchase Accounting Adjustments
54,746

Foreign currency translation
5,140

As of December 31, 2017
$
172,998

XML 47 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accrued Liabilities (Tables)
12 Months Ended
Dec. 31, 2017
Payables and Accruals [Abstract]  
Accrued Liabilities
Accrued liabilities consist of (in thousands): 
 
December 31,
 
2017
 
2016
Compensation and related benefits
$
22,816

 
$
16,064

Accrued federal, state, and local taxes
8,155

 
4,160

Warranty reserve
10,995

 
10,670

Accrued amounts due to customers
2,424

 
1,625

Accrued professional fees
2,280

 
1,191

Accrued selling expenses
1,704

 
292

Contingent consideration
147

 
3,043

Accrued travel
338

 

Deferred rent
161

 
132

Other
2,718

 
718

Total
$
51,738

 
$
37,895

XML 48 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Long-Term Other Liabilities (Tables)
12 Months Ended
Dec. 31, 2017
Other Liabilities Disclosure [Abstract]  
Long-Term Other Liabilities
Long-term other liabilities consist of (in thousands): 
 
December 31,
 
2017
 
2016
Contingent tax obligations
$
17,934

 
$
6,125

Non-current deferred revenue
4,039

 
1,885

Other
22

 
3

Total
$
21,995

 
$
8,013

XML 49 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt and Credit Arrangements (Tables)
12 Months Ended
Dec. 31, 2017
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments
Long-term debt consists of (in thousands):
 
December 31,
 
2017
 
2016
Revolving credit facility
$
155,000

 
$
140,000

Debt issuance costs
(717
)
 

Less: current portion of long-term debt

 

Total long-term debt
$
154,283

 
$
140,000

Schedule of Maturities of Long-term Debt
Maturities of long-term debt as of December 31, 2017 are as follows (in thousands):
 
December 31,
 
2017
 
2016
2018
$

 
$

2019

 

2020

 

Thereafter
154,283

 
140,000

Total
$
154,283

 
$
140,000

XML 50 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Reserve for Product Warranties (Tables)
12 Months Ended
Dec. 31, 2017
Product Warranties Disclosures [Abstract]  
Reserves for Product Warranties
The details of activity in the warranty reserve are as follows (in thousands): 
 
Balance at
Beginning
of Period
 
Assumed
Through
Acquisitions
 
Additions
Charged to
Expense
 
Reductions
 
Balance
at End
of Period
December 31, 2017
$
10,670

 
$
1,159

 
$
5,370

 
$
(6,204
)
 
$
10,995

December 31, 2016
$
10,386

 
$
222

 
$
2,711

 
$
(2,649
)
 
$
10,670

December 31, 2015
$
2,753

 
$

 
$
10,729

 
$
(3,096
)
 
$
10,386

XML 51 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Earnings Per Share (Tables)
12 Months Ended
Dec. 31, 2017
Earnings Per Share [Abstract]  
Components of Basic and Diluted EPS
The components of basic and diluted EPS are as follows (in thousands, except per share amounts): 
 
December 31,
 
2017
 
2016
 
2015
Net income (loss)
$
(20,293
)
 
$
42,594

 
$
37,924

Weighted average common shares
32,564

 
32,460

 
32,348

Dilutive effect of stock based awards

 
596

 
893

Diluted Shares
32,564

 
33,056

 
33,241

Basic earnings per share
$
(0.62
)
 
$
1.31

 
$
1.17

Diluted earnings per share
$
(0.62
)
 
$
1.29

 
$
1.14

Shares excluded from calculation of diluted EPS
565

 
2

 

XML 52 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation Expense
Share-based compensation was recognized as follows in the consolidated statement of income (in thousands):
 
December 31,
 
2017
 
2016
 
2015
Cost of revenue
$
232

 
$
219

 
$
156

Marketing and selling
540

 
821

 
808

Research and development
1,332

 
1,515

 
1,264

General and administrative
7,341

 
6,453

 
4,725

Total expense
9,445

 
9,008

 
6,953

Stock Options Activity
Stock Option Activity—Stock option activity under the stock awards plans for the year ended December 31, 2017 is summarized as follows:  
 
Number of
Shares
 
Weighted
Average
Exercise Price
Outstanding, December 31, 2016 (816,691 shares exercisable at a weighted average exercise price of $14.54 per share)
933,096

 
$
15.02

Granted

 
$

Exercised
(134,102
)
 
$
14.06

Forfeited
(1,317
)
 
$
13.83

Expired
(2,592
)
 
$
16.31

Outstanding, December 31, 2017 (790,573 shares exercisable at a weighted average exercise price of $15.14 per share)
795,085

 
$
15.18

Restricted Stock Awards Activity
The following table summarizes the activity for restricted stock awards during the year ended December 31, 2017:  
 
Shares
 
Weighted
Average
Grant
Date Fair
Value
Unvested at December 31, 2016
506,389

 
$
34.82

Granted
265,449

 
$
34.94

Vested
(391,947
)
 
$
32.41

Forfeited
(16,083
)
 
$
35.87

Unvested at December 31, 2017
363,808

 
$
37.46

Restricted Stock Units Activity
The following table summarizes restricted stock units activity for the year ended December 31, 2017:  
 
Shares
 
Weighted
Average
Grant
Date Fair
Value
Outstanding at December 31, 2016
29,903

 
$
34.39

Awarded
55,176

 
$
35.16

Released
(35,929
)
 
$
33.65

Forfeited
(25,006
)
 
$
34.47

Outstanding at December 31, 2017
24,144

 
$
37.17

XML 53 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restructuring Reserve (Tables)
12 Months Ended
Dec. 31, 2017
Restructuring and Related Activities [Abstract]  
Detail of Activity in the Restructuring Reserve
Activity in the restructuring reserves for these plans for the years ended December 31, 20172016 and 2015 is as follows (in thousands): 
 
Personnel
Related
 
Facility
Related
 
Total
Balance as of December 31, 2014
$
368

 

 
$
368

Additions
1,905

 
156

 
2,061

Reversals
(124
)
 

 
(124
)
Payments
(473
)
 
(156
)
 
(629
)
Balance as of December 31, 2015
1,676

 

 
1,676

Additions
1,093

 
725

 
1,818

Reversals
(436
)
 

 
(436
)
Payments
(1,990
)
 
(573
)
 
(2,563
)
Balance as of December 31, 2016
343

 
152

 
495

Additions
431

 

 
431

Reversals
(182
)
 

 
(182
)
Payments
(631
)
 
(93
)
 
(724
)
Balance as of December 31, 2017
$
(39
)
 
59

 
$
20

XML 54 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Income (Expense), Net (Tables)
12 Months Ended
Dec. 31, 2017
Other Income and Expenses [Abstract]  
Other income (expense), net
Other income (expense), net consists of (in thousands): 
 
Years Ended December 31,
 
2017
 
2016
 
2015
Interest income
$
425

 
$
315

 
$
27

Interest expense
(5,081
)
 
(430
)
 
(352
)
Foreign currency gain (loss)
1,013

 
(359
)
 
(1,415
)
Other
76

 
117

 
676

Total other income (expense), net
$
(3,567
)
 
$
(357
)
 
$
(1,064
)
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
Income (loss) before provision (benefit) for income tax
Income before provision for income tax is as follows (in thousands): 
 
Years Ended December 31,
 
2017
 
2016
 
2015
U.S.
$
(18,059
)
 
$
68

 
$
20,507

Foreign
23,209

 
54,835

 
31,902

Income before provision for income tax
$
5,150

 
$
54,903

 
$
52,409

Summary of components of income tax expense
The components of income tax expense for the years ended December 31, 2017, 2016 and 2015 (in thousands): 
 
Years Ended December 31,
 
2017
 
2016
 
2015
Current
 
 
 
 
 
U.S. Federal
$
10,110

 
$
(1,388
)
 
$
13,497

U.S. State and local
1,079

 
692

 
1,984

Non-U.S.
12,764

 
15,069

 
2,239

Total current tax expense
23,953

 
14,373

 
17,720

Deferred
 
 
 
 
 
U.S. Federal
6,345

 
(1,534
)
 
(3,410
)
U.S. State and local
(1,333
)
 
(378
)
 
(385
)
Non-U.S.
(3,522
)
 
(152
)
 
560

Total deferred tax benefit
1,490

 
(2,064
)
 
(3,235
)
Total income tax expense
$
25,443

 
$
12,309

 
$
14,485

Deferred tax assets and liabilities
Significant components of deferred tax assets and liabilities as of December 31, 2017 and 2016 are as follows (in thousands): 
 
December 31,
 
2017
 
2016
Deferred tax assets:
 
 
 
Net operating loss carryforwards
$
3,958

 
$
6,557

Credit carryforwards
4,466

 
2,512

Accruals deductible in different periods
11,969

 
16,157

Employee benefits
1,085

 
2,389

Total deferred tax assets
21,478

 
27,615

Valuation allowance
(5,862
)
 
(3,706
)
Total net deferred tax assets
$
15,616

 
$
23,909

Deferred tax liabilities:
 
Basis difference in fixed and intangible assets
(23,934
)
 
(12,678
)
Foreign earnings to be repatriated
(380
)
 

Total deferred tax liabilities
(24,314
)
 
(12,678
)
Total net deferred tax assets
$
(8,698
)
 
$
11,231

Reconciliation of effective income tax rate
The income tax expense in the accompanying statements of income differs from the provision calculated by applying the U.S. federal statutory income tax rate of 35% in 2017, 2016, and 2015 to income before taxes due to the following: 
 
Years Ended December 31,
 
2017
 
2016
 
2015
Federal statutory tax expense
$
1,802

 
$
19,216

 
$
18,343

State tax expense
(318
)
 
188

 
1,249

Foreign taxes at rates less than U.S. rates
(3,101
)
 
(6,838
)
 
(1,760
)
Deferred charges on sales of U.S. intellectual property
980

 
980

 
(5,878
)
Equity compensation
606

 
(530
)
 
204

Tax credits
(1,498
)
 
(911
)
 
(935
)
Uncertain tax position
2,048

 
485

 
3,897

Lapse of statute
(1,521
)
 
(495
)
 
(784
)
Change of valuation allowance on foreign tax credit
314

 

 

Earnout adjustment
(190
)
 
(1,184
)
 

Repatriation tax net of foreign tax credits
16,564

 

 

Net deferred tax asset re-measurement

3,883

 

 

Tax audits
726

 
543

 

Withholding taxes
2,880

 

 

Return to provision
711

 

 

AMT on acquisition
621

 

 

Other
936

 
855

 
149

Total expense
$
25,443

 
$
12,309

 
$
14,485

Uncertain Tax Positions
A reconciliation of the beginning and ending amount of unrecognized tax benefits (excluding interest and penalties) is as follows (in thousands): 
Balance at January 1, 2015
$
3,395

Increases for tax positions related to prior years
281

Increases for tax positions related to the current year
3,302

Lapse of statutes of limitations
(664
)
Balance at January 1, 2016
$
6,314

Increases for tax positions related to prior years
174

Increases for tax positions related to the current year
70

Lapse of statutes of limitations
(475
)
Foreign exchange difference
(185
)
Balance at January 1, 2017
$
5,898

Increases for tax positions related to prior years
747

Increases for tax positions related to the current year
1,712

Lapse of statutes of limitations
(1,393
)
Foreign exchange difference
53

Balance at December 31, 2017
$
7,017

XML 56 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment, Customer and Geographic Information (Tables)
12 Months Ended
Dec. 31, 2017
Segment Reporting [Abstract]  
Revenue and long-lived asset information by geographic region
Revenue and long-lived asset information by geographic region is as follows (in thousands): 
 
Years Ended December 31,
 
2017
 
2016
 
2015
Consolidated Revenue:
 
United States
$
270,860

 
$
250,694

 
$
242,050

Foreign countries
230,110

 
131,198

 
133,815

 
$
500,970

 
$
381,892

 
$
375,865

Revenue by End Market:
 
Neuro
 
Devices and Systems
$
171,315

 
$
168,200

 
$
168,776

Supplies
59,955

 
58,681

 
60,205

Services
11,886

 
11,641

 
8,320

Total Neurology Revenue
$
243,156

 
$
238,522

 
$
237,301

Newborn Care
 
Devices and Systems
$
77,573

 
$
72,562

 
$
72,669

Supplies
43,732

 
47,674

 
49,982

Services
22,325

 
23,134

 
15,913

Total Newborn Care Revenue
$
143,630

 
$
143,370

 
$
138,564

Otometrics
 
Devices and Systems
$
86,920

 
$

 
$

Supplies
27,264

 

 

Services

 

 

Total Otometrics Revenue
$
114,184

 
$

 
$

Total Revenue
$
500,970

 
$
381,892

 
$
375,865

 
 
 
 
 
 
Property and equipment, net:
 
United States
$
10,128

 
$
7,024

 
 
Canada
5,068

 
4,941

 
 
Argentina
1,591

 
2,121

 
 
Ireland
3,178

 
2,530

 
 
Denmark
1,158

 
17

 
 
Other foreign countries
948

 
700

 
 
 
$
22,071

 
$
17,333

 
 
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments And Contingencies (Tables)
12 Months Ended
Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]  
Minimum Future Leases Payments Receivable
Minimum lease payments under noncancelable operating leases as of December 31, 2017 are as follows (in thousands):  
 
Operating
Leases
Year Ending December 31,
 
2018
$
7,038

2019
5,732

2020
4,609

2021
3,392

2022
2,457

Thereafter
6,850

Total minimum lease payments
$
30,078

XML 58 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2017
Fair Value Disclosures [Abstract]  
Changes in fair value of contingent consideration
Contingent consideration associated with earnouts from acquisitions is as follows (in thousands):
 
December 31, 2016
 
Additions
 
Payments
 
Adjustments
 
December 31, 2017
Liabilities:
 
 
 
 
 
 
 
 
 
Contingent consideration
$
3,043

 
$
693

 
$
(2,966
)
 
$
(623
)
 
$
147

Total
$
3,043

 
$
693

 
$
(2,966
)
 
$
(623
)
 
$
147

XML 59 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Recorded foreign currency translation gains (losses) $ 21,470 $ (5,003) $ (8,378)  
Net foreign currency transaction gains (losses) $ 1,013 $ (359) $ (1,415) $ (1,400)
Office furniture and equipment [Member] | Minimum [Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Estimated useful lives of property and equipment 3 years      
Office furniture and equipment [Member] | Maximum [Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Estimated useful lives of property and equipment 10 years      
Computer software and hardware [Member] | Minimum [Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Estimated useful lives of property and equipment 3 years      
Computer software and hardware [Member] | Maximum [Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Estimated useful lives of property and equipment 5 years      
Demonstration and loaned equipment [Member] | Maximum [Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Estimated useful lives of property and equipment 5 years      
Buildings [Member] | Minimum [Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Estimated useful lives of property and equipment 30 years      
Buildings [Member] | Maximum [Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Estimated useful lives of property and equipment 40 years      
Software for internal purposes [Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Estimated useful lives of property and equipment 3 years      
Employee Stock Option [Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Vesting period 4 years      
Share based compensation, expiration period 10 years      
Employee Stock Option [Member] | Director [Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Vesting period 4 years      
Share based compensation, expiration period 6 years      
Restricted Stock Awards [Member] | Employees [Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Vesting period 3 years      
Restricted Stock Awards [Member] | Executives RSAs and RSUs [Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Vesting period 4 years      
Restricted Stock Awards [Member] | Executives RSAs and RSUs [Member] | Vest on second anniversary of the vesting start date [Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Vesting percentage 50.00%      
Restricted Stock Awards [Member] | Executives RSAs and RSUs [Member] | On each of the third and fourth anniversaries of the vesting date[Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Vesting percentage 25.00%      
Restricted Stock Awards [Member] | Director [Member] | On each of the third and fourth anniversaries of the vesting date[Member]        
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Line Items]        
Vesting period 1 year      
Vesting percentage 100.00%      
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations - Integra Acquisition (Details) - USD ($)
$ in Thousands
12 Months Ended
Oct. 06, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]        
Goodwill   $ 172,998 $ 113,112 $ 107,466
Integra [Member]        
Business Acquisition [Line Items]        
Purchase price paid in cash to acquire entity $ 46,400      
Tangible assets acquired 12,500      
Intangible assets acquired $ 19,500      
Identifiable intangible assets acquired, average useful life 9 years      
Goodwill $ 15,500      
Liabilities assumed in acquisition $ 1,100      
Revenue   $ 539,100 $ 432,400  
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations - Otometrics Acquisition Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Jan. 03, 2017
Dec. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]          
Revenue     $ 500,970 $ 381,892 $ 375,865
Income from operations     (8,717) (55,260) $ (53,473)
Otometrics [Member]          
Business Acquisition [Line Items]          
Purchase price paid in cash to acquire entity $ 149,200        
Inventory purchase commitment $ 4,200        
Revenue   $ 114,200      
Income from operations   $ 1,000      
Pro Forma [Member] | Otometrics [Member]          
Business Acquisition [Line Items]          
Acquisition related costs     $ 4,300    
Amortization of intangible assets       3,000  
Interest expense       $ 4,600  
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations - Summary of Purchase Price Allocation of Fair Value of Assets Acquired and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Jan. 03, 2017
Dec. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]        
Goodwill $ 172,998   $ 113,112 $ 107,466
Otometrics [Member]        
Business Acquisition [Line Items]        
Cash and cash equivalents   $ 5,604    
Accounts receivable   26,851    
Inventories   22,182    
Property and equipment   2,256    
Intangible assets   90,913    
Goodwill   39,355    
Other assets   1,748    
Accounts payable   (7,655)    
Accrued liabilities   (16,069)    
Deferred revenue   (745)    
Deferred income tax   (15,193)    
Total purchase price   $ 149,247    
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations - Schedule of Pro Forma Financial (Details) - Otometrics [Member] - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Business Acquisition [Line Items]    
Revenue $ 500,970 $ 491,994
Net income (loss) $ (15,965) $ 17,385
Earnings (loss) per share:    
Basic (USD per share) $ (0.49) $ 0.54
Diluted (USD per share) $ (0.49) $ 0.53
Weighted average shares used in the calculation of earnings per share:    
Basic (shares) 32,564 32,460
Diluted (shares) 32,564 33,056
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations - RetCam Acquisition (Details) - USD ($)
$ in Thousands
3 Months Ended
Jul. 06, 2016
Sep. 30, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]          
Contingent consideration     $ 147 $ 3,043  
Goodwill     $ 172,998 $ 113,112 $ 107,466
RetCam [Member]          
Business Acquisition [Line Items]          
Purchase price paid in cash to acquire entity $ 10,600        
Contingent consideration 2,000        
Adjustments to consideration transferred   $ 1,100      
Tangible assets acquired 7,200        
Intangible assets acquired $ 4,900        
Identifiable intangible assets acquired, average useful life 5 years        
Goodwill $ 1,700        
Liabilities assumed in acquisition $ 2,000        
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations - NeuroQuest Acquisition (Details) - USD ($)
$ in Thousands
Mar. 02, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]        
Contingent consideration   $ 147 $ 3,043  
Goodwill   $ 172,998 $ 113,112 $ 107,466
NeuroQuest [Member]        
Business Acquisition [Line Items]        
Purchase price paid in cash to acquire entity $ 4,600      
Contingent consideration 500      
Tangible assets acquired 500      
Intangible assets acquired $ 1,300      
Identifiable intangible assets acquired, average useful life 5 years      
Goodwill $ 3,500      
Liabilities assumed in acquisition $ 100      
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations - Monarch Acquisition (Details) - USD ($)
$ in Thousands
Jan. 11, 2016
Nov. 13, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]          
Goodwill     $ 172,998 $ 113,112 $ 107,466
Monarch Medical Diagnostics, LLC [Member]          
Business Acquisition [Line Items]          
Purchase price paid in cash to acquire entity   $ 2,700      
Contingent consideration $ 1,000        
Property and equipment   112      
Intangible assets acquired   $ 1,200      
Identifiable intangible assets acquired, average useful life   5 years      
Goodwill   $ 2,400      
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations - Global Neuro-Diagnostics Acquisition (Details) - USD ($)
$ in Thousands
Jan. 23, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]        
Goodwill   $ 172,998 $ 113,112 $ 107,466
Global Neuro-Diagnostics [Member]        
Business Acquisition [Line Items]        
Purchase price paid in cash to acquire entity $ 11,400      
Tangible assets acquired 1,500      
Intangible assets acquired $ 4,800      
Identifiable intangible assets acquired, average useful life 5 years      
Goodwill $ 8,900      
Net liabilities 500      
Contingent consideration $ 3,200      
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations - NicView Acquisition (Details) - USD ($)
$ in Thousands
Jan. 02, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]        
Goodwill   $ 172,998 $ 113,112 $ 107,466
Contingent consideration   $ 147 $ 3,043  
NicView [Member]        
Business Acquisition [Line Items]        
Purchase price paid in cash to acquire entity $ 1,100      
Property and equipment 300      
Goodwill 2,700      
Net liabilities 600      
Contingent consideration $ 1,300      
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash, Cash Equivalents, and Short-term Investments - Schedule of cash, cash equivalents and short-term investments (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Cash and cash equivalents:        
Cash and Cash Equivalents, at Carrying Value $ 88,950 $ 213,551 $ 82,469 $ 66,558
Short-term investments:        
Total short-term investment 0 34,019    
Total cash, cash equivalents and short-term investments 88,950 247,570    
U.S. investment grade bonds        
Short-term investments:        
Total short-term investment 0 24,477    
Developed investment grade bonds        
Short-term investments:        
Total short-term investment $ 0 $ 9,542    
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash, Cash Equivalents, and Short-term Investments - Unrealized Gain (Loss) on Investments (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]    
Aggregated Cost Basis $ 0 $ 34,098
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 (79)
Aggregated Fair Value 0 34,019
U.S. investment grade bonds    
Schedule of Available-for-sale Securities [Line Items]    
Aggregated Cost Basis 0 24,531
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 (54)
Aggregated Fair Value 0 24,477
Developed investment grade bonds    
Schedule of Available-for-sale Securities [Line Items]    
Aggregated Cost Basis 0 9,567
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 (25)
Aggregated Fair Value $ 0 $ 9,542
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash, Cash Equivalents, and Short-term Investments - Investments Classified by Contractual Maturity Date (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Cash and Cash Equivalents [Abstract]    
Due in one year or less $ 0 $ 21,655
Due after one year through five years 0 12,364
Total short-term investment $ 0 $ 34,019
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Inventory Disclosure [Abstract]    
Raw materials and subassemblies $ 44,699 $ 28,245
Work in process 3,788 1,507
Finished goods 43,488 34,908
Total Inventories 91,975 64,660
Less: Non-current Inventories (20,446) (15,073)
Inventories $ 71,529 $ 49,587
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories - Narrative (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Inventory Disclosure [Abstract]    
Non-current Inventories $ 20,446 $ 15,073
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.10.0.1
Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Property, Plant and Equipment [Line Items]    
Property and Equipment, Gross $ 58,510 $ 49,352
Accumulated depreciation (36,439) (32,019)
Total 22,071 17,333
Land [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, Gross 2,815 2,856
Buildings [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, Gross 5,096 5,219
Leasehold improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, Gross 3,295 2,386
Office furniture and equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, Gross 25,612 18,398
Computer software and hardware [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, Gross 9,760 9,100
Demonstration and loaned equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, Gross $ 11,932 $ 11,393
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.10.0.1
Property and Equipment - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Property, Plant and Equipment, Net [Abstract]      
Depreciation expense $ 4.1 $ 3.7 $ 4.2
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets - Narrative (Details)
$ in Millions
12 Months Ended
Dec. 31, 2017
USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]  
Costs incurred for development of internal use computer software $ 14.8
Costs incurred for development of software to be sold $ 2.2
Patents [Member]  
Acquired Finite-Lived Intangible Assets [Line Items]  
Weighted average life of intangible assets 13 years
Technology [Member]  
Acquired Finite-Lived Intangible Assets [Line Items]  
Weighted average life of intangible assets 14 years
Customer related [Member]  
Acquired Finite-Lived Intangible Assets [Line Items]  
Weighted average life of intangible assets 10 years
Trade names [Member]  
Acquired Finite-Lived Intangible Assets [Line Items]  
Weighted average life of intangible assets 10 years
Internally developed software [Member]  
Acquired Finite-Lived Intangible Assets [Line Items]  
Weighted average life of intangible assets 6 years
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets - Components of Gross and Net Intangible Asset Balances (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 276,820 $ 152,354
Impairment of Intangible Assets Defined Lived (excluding Goodwill) (5,157) (3,290)
Accumulated Amortization (99,081) (71,899)
Total expected amortization expense 172,582 77,165
Technology [Member]    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 101,045 62,563
Impairment of Intangible Assets Defined Lived (excluding Goodwill) (1,058)  
Accumulated Amortization (42,048) (34,683)
Total expected amortization expense 57,939 27,880
Customer related [Member]    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 108,074 38,087
Impairment of Intangible Assets Defined Lived (excluding Goodwill) (50)  
Accumulated Amortization (28,972) (17,610)
Total expected amortization expense 79,052 20,477
Trade Names [Member]    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 49,313 32,106
Impairment of Intangible Assets Defined Lived (excluding Goodwill) (3,916) (3,290)
Accumulated Amortization (13,273) (7,135)
Total expected amortization expense 32,124 21,681
Internally Developed Software [Member]    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 15,610 16,978
Accumulated Amortization (12,293) (10,220)
Total expected amortization expense 3,317 6,758
Patents [Member]    
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 2,778 2,620
Impairment of Intangible Assets Defined Lived (excluding Goodwill) (133)  
Accumulated Amortization (2,495) (2,251)
Total expected amortization expense $ 150 $ 369
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets - Schedule of Amortization Expense (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]      
Total amortization $ 27,490 $ 13,155 $ 11,745
Technology [Member]      
Finite-Lived Intangible Assets [Line Items]      
Total amortization 7,705 3,407 3,916
Customer related [Member]      
Finite-Lived Intangible Assets [Line Items]      
Total amortization 10,945 3,452 2,938
Trade names [Member]      
Finite-Lived Intangible Assets [Line Items]      
Total amortization 6,479 4,115 3,159
Internally Developed Software [Member]      
Finite-Lived Intangible Assets [Line Items]      
Total amortization 2,117 2,069 1,620
Patents [Member]      
Finite-Lived Intangible Assets [Line Items]      
Total amortization $ 244 $ 112 $ 112
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets - Expected Annual Amortization Expense (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]    
2018 $ 27,014  
2019 25,836  
2020 23,634  
2021 22,210  
2022 18,564  
Thereafter 55,324  
Total expected amortization expense $ 172,582 $ 77,165
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.10.0.1
Goodwill (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Goodwill [Roll Forward]    
Beginning Balance $ 113,112 $ 107,466
Acquisitions/Purchase Accounting Adjustments 54,746 6,705
Foreign currency translation 5,140 (1,059)
Ending Balance $ 172,998 $ 113,112
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.10.0.1
Accrued Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Payables and Accruals [Abstract]    
Compensation and related benefits $ 22,816 $ 16,064
Accrued federal, state, and local taxes 8,155 4,160
Warranty reserve 10,995 10,670
Accrued amounts due to customers 2,424 1,625
Accrued professional fees 2,280 1,191
Accrued selling expenses 1,704 292
Contingent consideration 147 3,043
Accrued travel 338 0
Deferred rent 161 132
Other 2,718 718
Total $ 51,738 $ 37,895
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.10.0.1
Long-Term Other Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Other Liabilities Disclosure [Abstract]    
Contingent tax obligations $ 17,934 $ 6,125
Non-current deferred revenue 4,039 1,885
Other 22 3
Total $ 21,995 $ 8,013
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt and Credit Arrangements - Narrative (Details)
3 Months Ended 12 Months Ended
Sep. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Revolving credit facility [Member] | Line of Credit [Member]    
Debt Instrument [Line Items]    
Revolving credit facility with Wells Fargo Bank   $ 150,000,000
Available amount under credit facility   $ 155,000,000
Credit Agreement [Member] | Citibank, National Association [Member]    
Debt Instrument [Line Items]    
Revolving credit facility with Wells Fargo Bank $ 225,000,000.0  
Line of Credit Facility, Increase (Decrease), Net $ 75,000,000  
Ratio of Indebtedness to Net Capital   2.44
Ratio of Interest Coverage   10.16
Debt Instrument, Interest Rate, Effective Percentage   3.34%
Maximum [Member] | Credit Agreement [Member] | Citibank, National Association [Member]    
Debt Instrument [Line Items]    
Ratio of Indebtedness to Net Capital   2.75
Minimum [Member] | Credit Agreement [Member] | Citibank, National Association [Member]    
Debt Instrument [Line Items]    
Ratio of Interest Coverage   1.75
London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member] | Credit Agreement [Member] | Citibank, National Association [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Basis Spread on Variable Rate   2.75%
London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member] | Credit Agreement [Member] | Citibank, National Association [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Basis Spread on Variable Rate   1.75%
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt and Credit Arrangements - Schedule of Long Term Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Debt Disclosure [Abstract]    
Revolving credit facility $ 155,000 $ 140,000
Debt Issuance Costs, Net (717) 0
Less: current portion of long-term debt 0 0
Total long-term debt $ 154,283 $ 140,000
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt and Credit Arrangements - Schedule of Maturities of Long-term Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Debt Disclosure [Abstract]    
2018 $ 0 $ 0
2019 0 0
2020 0 0
Thereafter 154,283 140,000
Long-term Debt $ 154,283 $ 140,000
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.10.0.1
Reserve for Product Warranties (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Product Warranties Disclosures [Abstract]      
Product warranty period 1 year    
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]      
Balance at Beginning of Period $ 10,670 $ 10,386 $ 2,753
Assumed Through Acquisitions 1,159 222 0
Additions Charged to Expense 5,370 2,711 10,729
Reductions (6,204) (2,649) (3,096)
Balance at End of Period 10,995 $ 10,670 $ 10,386
Certain NeoBLUE Phototherapy Products [Member]      
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]      
Balance at End of Period $ 5,400    
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Details) - $ / shares
Dec. 31, 2017
Dec. 31, 2016
Equity [Abstract]    
Common Stock, shares authorized 120,000,000 120,000,000
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock authorized 10,000,000 10,000,000
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock issued 0 0
Preferred stock outstanding 0 0
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.10.0.1
Earnings Per Share - Components of Basic and Diluted EPS (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Earnings Per Share [Abstract]      
Net loss $ (20,293) $ 42,594 $ 37,924
Weighted average common shares 32,564 32,460 32,348
Dilutive effect of stock based awards 0 596 893
Diluted Shares (in dollars per share) 32,564 33,056 33,241
Basic earnings per share (in dollars per share) $ (0.62) $ 1.31 $ 1.17
Diluted earnings per share (in dollars per share) $ (0.62) $ 1.29 $ 1.14
Shares excluded from calculations of diluted EPS 565 2 0
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Compensation - Share-based Compensation Expense Allocation (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total expense $ 9,445 $ 9,008 $ 6,953
Cost of revenue [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total expense 232 219 156
Marketing and sales [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total expense 540 821 808
Research and development [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total expense 1,332 1,515 1,264
General and administrative [Member]      
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]      
Total expense $ 7,341 $ 6,453 $ 4,725
XML 90 R79.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Compensation - Narrative (Details) - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares available for future awards 779,298    
Unrecognized compensation expense related to unvested portion of stock options $ 1,000    
Intrinsic value of options exercised $ 3,100,000 $ 3,400,000 $ 17,700,000
Weighted average vested options 795,085    
Weighted average exercise price of vested stock $ 15.18    
Intrinsic value of options vested and expected to vest $ 14,300,000    
Weighted average remaining contractual term 1 year 2 months    
Weighted average exercise price (in dollars per share) $ 15.14    
Intrinsic value of options exercisable $ 18,200,000    
Weighted average remaining contractual term, exercisable 1 year 2 months    
Compensation expense associated with the ESPP $ 300,000 200,000 200,000
Employee Stock Option [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share based compensation, expiration period 10 years    
Share based compensation, vesting period 4 years    
Intrinsic value of options vested and expected to vest $ 18,300,000    
Restricted Stock Awards [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Intrinsic value of options vested and expected to vest   9,000,000 10,300,000
Weighted average shares exercisable 790,573    
Unrecognized compensation of unvested awards $ 10,800,000    
Weighted average period of recognition of unrecognized compensation expense 2 years 3 months    
Fair market value of outstanding awards $ 13,900,000    
Restricted Stock Units [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Intrinsic value of options vested and expected to vest 1,300,000 $ 900,000 $ 900,000
Unrecognized compensation of unvested awards $ 900,000    
Weighted average period of recognition of unrecognized compensation expense 1 year 9 months    
Aggregate intrinsic value of outstanding restricted stock units $ 900,000    
Employee Stock Purchase Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Employee maximum withholding rate (percent) 15.00%    
Eligible compensation of employees $ 10,625    
Purchase price for shares acquired 85.00%    
Shares reserved for future issuance 117,270    
Offering price, percentage of fair market value 85.00%    
Director [Member] | Employee Stock Option [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share based compensation, expiration period 6 years    
Share based compensation, vesting period 4 years    
XML 91 R80.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Compensation - Stock Option Activity (Details)
12 Months Ended
Dec. 31, 2017
$ / shares
shares
Number of Shares  
Outstanding, beginning of period (shares) | shares 933,096
Granted (shares) | shares 0
Exercised (shares) | shares (134,102)
Cancelled (shares) | shares (1,317)
Expired (shares) | shares (2,592)
Outstanding, end of period (shares) | shares 795,085
Weighted Average Exercise Price  
Outstanding, beginning of period (in dollars per share) | $ / shares $ 15.02
Granted (in dollars per share) | $ / shares 0.00
Exercised (in dollars per share) | $ / shares 14.06
Cancelled (in dollars per share) | $ / shares 13.83
Expired (in dollars per share) | $ / shares 16.31
Outstanding, end of period (in dollars per share) | $ / shares $ 15.18
XML 92 R81.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Compensation - Restricted Stock Award Activity (Details) - Restricted Stock Awards [Member]
12 Months Ended
Dec. 31, 2017
$ / shares
shares
Shares  
Unvested, beginning of period, Shares | shares 506,389
Granted, Shares | shares 265,449
Vested, Shares | shares (391,947)
Forfeited, Shares | shares (16,083)
Unvested, end of period, Shares | shares 363,808
Weighted Average Grant Date Fair Value  
Unvested, beginning of period, Weighted - average grant date fair value | $ / shares $ 34.82
Granted, Weighted - average grant date fair value | $ / shares 34.94
Vested, Weighted - average grant date fair value | $ / shares 32.41
Forfeited, Weighted - average grant date fair value | $ / shares 35.87
Unvested, end of period, Weighted - average grant date fair value | $ / shares $ 37.46
XML 93 R82.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Compensation - Restricted Unit Activity (Details) - Restricted Stock Units [Member]
12 Months Ended
Dec. 31, 2017
$ / shares
shares
Shares  
Unvested, beginning of period, Shares | shares 29,903
Awarded, units | shares 55,176
Release, units | shares (35,929)
Forfeited, units | shares (25,006)
Unvested, end of period, Shares | shares 24,144
Weighted Average Grant Date Fair Value  
Unvested, beginning of period, Weighted - average grant date fair value | $ / shares $ 34.39
Granted, Weighted - average grant date fair value | $ / shares 35.16
Vested, Weighted - average grant date fair value | $ / shares 33.65
Forfeited, Weighted - average grant date fair value | $ / shares 34.47
Unvested, end of period, Weighted - average grant date fair value | $ / shares $ 37.17
XML 94 R83.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restructuring Reserve (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Restructuring Reserve [Roll Forward]      
Beginning balance $ 495 $ 1,676 $ 368
Restructuring 914 1,536 2,145
Additions 431 1,818 2,061
Reversals (182) (436) (124)
Payments (724) (2,563) (629)
Ending balance 20 495 1,676
Personnel Related [Member]      
Restructuring Reserve [Roll Forward]      
Beginning balance 343 1,676 368
Additions 431 1,093 1,905
Reversals (182) (436) (124)
Payments (631) (1,990) (473)
Ending balance (39) 343 1,676
Facility Closing [Member]      
Restructuring Reserve [Roll Forward]      
Beginning balance 152 0 0
Restructuring 0 725 156
Reversals 0 0 0
Payments (93) (573) (156)
Ending balance $ 59 $ 152 $ 0
XML 95 R84.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Income (Expense), Net (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Other expense, net        
Interest income $ 425 $ 315 $ 27  
Interest expense (5,081) (430) (352)  
Foreign currency gain (loss) 1,013 (359) (1,415) $ (1,400)
Other 76 117 676  
Total other income (expense), net $ (3,567) $ (357) $ (1,064)  
XML 96 R85.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Income Loss before Provision (Benefit) for Income Tax (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Income Tax Disclosure [Abstract]      
U.S. $ (18,059) $ 68 $ 20,507
Foreign 23,209 54,835 31,902
Income before provision for income tax $ 5,150 $ 54,903 $ 52,409
XML 97 R86.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Component of Income Tax Expense (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Current      
U.S. Federal $ 10,110 $ (1,388) $ 13,497
U.S. State and local 1,079 692 1,984
Non-U.S. 12,764 15,069 2,239
Total current tax expense 23,953 14,373 17,720
Deferred      
U.S. Federal 6,345 (1,534) (3,410)
U.S. State and local (1,333) (378) (385)
Non-U.S. (3,522) (152) 560
Total deferred tax expense (benefit) 1,490 (2,064) (3,235)
Total expense $ 25,443 $ 12,309 $ 14,485
XML 98 R87.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Components of Deferred Tax Asset and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Deferred tax assets:    
Net operating loss carryforwards $ 3,958 $ 6,557
Credit carryforwards 4,466 2,512
Accruals deductible in different periods 11,969 16,157
Employee benefits 1,085 2,389
Total deferred tax assets 21,478 27,615
Valuation allowance (5,862) (3,706)
Total net deferred tax assets 15,616 23,909
Deferred tax liabilities:    
Basis difference in fixed and intangible assets (23,934) (12,678)
Foreign Earnings Repatriated (380) 0
Total deferred tax liabilities (24,314) (12,678)
Deferred tax liabilities, net $ (8,698)  
Total net deferred tax assets   $ 11,231
XML 99 R88.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Narrative (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Schedule Of Income Taxes [Line Items]          
Statutory tax rate   35.00% 35.00% 35.00%  
Provisional income tax expense as a result of Tax Cuts 2017 $ 20,500,000        
Provisional income tax expense from re-remeasurement of deferred tax assets and liabilities 3,900,000        
Provisional income tax related to one-time transition tax on mandatory deemed repatriation of foreign earnings 16,600,000        
Undistributed earnings 181,000,000 $ 181,000,000      
Tax net operating loss carryforwards 1,200,000 1,200,000      
Valuation allowances 5,862,000 5,862,000 $ 3,706,000    
Increase in valuation allowance   2,200,000      
Deferred tax liabilities related to foreign earnings 400,000 400,000      
Increase in unrecognized tax benefits   1,100,000      
Increases for tax positions related to the current year   1,712,000 70,000 $ 3,302,000  
Unrecognized Tax Benefits 7,017,000 7,017,000 5,898,000 6,314,000 $ 3,395,000
Unrecognized tax would impact effective tax rate 4,000,000 4,000,000 2,500,000 2,400,000  
Lapse of statutes of limitations   1,393,000 475,000 664,000  
Interest and penalties related to uncertain tax positions 600,000 600,000 600,000 400,000  
Total Interest and penalties related to uncertain tax positions   (10,000) $ 200,000 $ 100,000  
Income Tax Provision [Member]          
Schedule Of Income Taxes [Line Items]          
Increases for tax positions related to the current year   600,000      
Minimum [Member]          
Schedule Of Income Taxes [Line Items]          
Lapse of statutes of limitations   0      
Maximum [Member]          
Schedule Of Income Taxes [Line Items]          
Lapse of statutes of limitations   900,000      
Germany [Member]          
Schedule Of Income Taxes [Line Items]          
Tax net operating loss carryforwards 30,000 30,000      
France [Member]          
Schedule Of Income Taxes [Line Items]          
Tax net operating loss carryforwards 1,400,000 1,400,000      
Canada [Member]          
Schedule Of Income Taxes [Line Items]          
Tax net operating loss carryforwards 500,000 500,000      
Denmark [Member]          
Schedule Of Income Taxes [Line Items]          
Tax net operating loss carryforwards 500,000 500,000      
Significant foreign jurisdictions [Member]          
Schedule Of Income Taxes [Line Items]          
Tax credits carryforwards 4,200,000 4,200,000      
Research Tax Credit Carryforward [Member]          
Schedule Of Income Taxes [Line Items]          
Tax credits carryforwards $ 400,000 $ 400,000      
XML 100 R89.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Reconciliation of Income tax Expense from Continuous Operation (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Income Tax Disclosure [Abstract]      
Federal statutory tax expense $ 1,802 $ 19,216 $ 18,343
State tax expense (318) 188 1,249
Foreign taxes at rates less than U.S. rates (3,101) (6,838) (1,760)
Deferred charges on sales of U.S. intellectual property 980 980 (5,878)
Equity compensation 606 (530) 204
Tax credits (1,498) (911) (935)
Uncertain tax position 2,048 485 3,897
Lapse of statute (1,521) (495) (784)
Change of valuation allowance on foreign tax credit 314 0 0
Earnout adjustment (190) (1,184) 0
Repatriation tax net of foreign tax credits 16,564 0 0
Net deferred tax asset re-measurement 3,883 0 0
Withholding taxes 726 543 0
Withholding taxes 2,880 0 0
Return to provision 711 0 0
AMT on acquisition 621 0 0
Other 936 855 149
Total expense $ 25,443 $ 12,309 $ 14,485
XML 101 R90.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Beginning-Unrecognized Tax Benefits $ 5,898 $ 6,314 $ 3,395
Increases for tax positions related to prior years 747 174 281
Increases for tax positions related to the current year 1,712 70 3,302
Lapse of statutes of limitations (1,393) (475) (664)
Foreign exchange difference   (185)  
Foreign exchange difference 53    
Ending-Unrecognized Tax Benefits $ 7,017 $ 5,898 $ 6,314
XML 102 R91.htm IDEA: XBRL DOCUMENT v3.10.0.1
Employee Benefit Plan (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Defined Contribution Plan [Abstract]      
Employer matching contributions $ 2.5 $ 1.5 $ 1.3
XML 103 R92.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment, Customer and Geographic Information - Narrative (Details)
12 Months Ended
Dec. 31, 2017
Segment
Segment Reporting [Abstract]  
Number of reporting segments 1
XML 104 R93.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment, Customer and Geographic Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Segment Reporting Information [Line Items]      
Revenue $ 500,970 $ 381,892 $ 375,865
Long-lived assets 22,071 17,333  
Neurology Products [Member]      
Segment Reporting Information [Line Items]      
Revenue 243,156 238,522 237,301
Neurology Products [Member] | Devices and Systems [Member]      
Segment Reporting Information [Line Items]      
Revenue 171,315 168,200 168,776
Neurology Products [Member] | Supplies [Member]      
Segment Reporting Information [Line Items]      
Revenue 59,955 58,681 60,205
Neurology Products [Member] | Services [Member]      
Segment Reporting Information [Line Items]      
Revenue 11,886 11,641 8,320
Newborn Care Products [Member]      
Segment Reporting Information [Line Items]      
Revenue 143,630 143,370 138,564
Newborn Care Products [Member] | Devices and Systems [Member]      
Segment Reporting Information [Line Items]      
Revenue 77,573 72,562 72,669
Newborn Care Products [Member] | Supplies [Member]      
Segment Reporting Information [Line Items]      
Revenue 43,732 47,674 49,982
Newborn Care Products [Member] | Services [Member]      
Segment Reporting Information [Line Items]      
Revenue 22,325 23,134 15,913
OtometricsProducts [Member]      
Segment Reporting Information [Line Items]      
Revenue 114,184 0 0
OtometricsProducts [Member] | Devices and Systems [Member]      
Segment Reporting Information [Line Items]      
Revenue 86,920 0 0
OtometricsProducts [Member] | Supplies [Member]      
Segment Reporting Information [Line Items]      
Revenue 27,264 0 0
OtometricsProducts [Member] | Services [Member]      
Segment Reporting Information [Line Items]      
Revenue 0 0 0
United States [Member]      
Segment Reporting Information [Line Items]      
Revenue 270,860 250,694 242,050
Long-lived assets 10,128 7,024  
Foreign countries [Member]      
Segment Reporting Information [Line Items]      
Revenue 230,110 131,198 $ 133,815
Canada [Member]      
Segment Reporting Information [Line Items]      
Long-lived assets 5,068 4,941  
Argentina [Member]      
Segment Reporting Information [Line Items]      
Long-lived assets 1,591 2,121  
Ireland [Member]      
Segment Reporting Information [Line Items]      
Long-lived assets 3,178 2,530  
Denmark [Member]      
Segment Reporting Information [Line Items]      
Long-lived assets 1,158 17  
Other Foreign countries [Member]      
Segment Reporting Information [Line Items]      
Long-lived assets $ 948 $ 700  
XML 105 R94.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments And Contingencies - Minimum Lease Payment under Non Cancelable Operating Lease (Details)
$ in Thousands
Dec. 31, 2017
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2018 $ 7,038
2019 5,732
2020 4,609
2021 3,392
2022 2,457
Thereafter 6,850
Total minimum lease payments $ 30,078
XML 106 R95.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments And Contingencies - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]      
Rent expense $ 6.7 $ 5.3 $ 4.4
Purchase commitments for inventory, total $ 47.8    
XML 107 R96.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Narrative (Details) - Mundelein Facility [Member] - USD ($)
$ in Millions
3 Months Ended
Sep. 30, 2014
Dec. 31, 2017
Jun. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Book value of asset     $ 3.6
Impairment of asset $ 2.2    
Asset held-for-sale at fair value   $ 1.4  
XML 108 R97.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2017
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Contingent consideration, beginning balance $ 3,043
Additions 693
Payments (2,966)
Adjustments (623)
Contingent consideration, ending balance 147
Contingent Consideration [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Contingent consideration, beginning balance 3,043
Additions 693
Payments (2,966)
Adjustments (623)
Contingent consideration, ending balance $ 147
XML 109 R98.htm IDEA: XBRL DOCUMENT v3.10.0.1
Schedule II: Valuation And Qualifying Accounts (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Period $ 3,706 $ 3,972 $ 3,151
Additions Charged to Expense 2,156 0 821
Deductions 0 (266) 0
Balance at End of Period 5,862 3,706 3,972
Allowance for Doubtful Accounts [Member]      
Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Period 4,182 4,686 4,324
Additions Charged to Expense 10,017 1,123 1,496
Deductions (5,221) (1,627) (1,134)
Balance at End of Period $ 8,978 $ 4,182 $ 4,686
EXCEL 110 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 112 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 114 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 236 426 1 false 72 0 false 5 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.natus.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.natus.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.natus.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Operations and Comprehensive Income Sheet http://www.natus.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncome Consolidated Statements of Operations and Comprehensive Income Statements 4 false false R5.htm 1003000 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.natus.com/role/ConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 1004000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.natus.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101100 - Disclosure - Organization and Significant Accounting Policies Sheet http://www.natus.com/role/OrganizationAndSignificantAccountingPolicies Organization and Significant Accounting Policies Notes 7 false false R8.htm 2102100 - Disclosure - Business Combinations Sheet http://www.natus.com/role/BusinessCombinations Business Combinations Notes 8 false false R9.htm 2103100 - Disclosure - Cash, Cash Equivalents, and Short-term Investments Sheet http://www.natus.com/role/CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments Notes 9 false false R10.htm 2104100 - Disclosure - Inventories Sheet http://www.natus.com/role/Inventories Inventories Notes 10 false false R11.htm 2105100 - Disclosure - Property and Equipment Sheet http://www.natus.com/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 2106100 - Disclosure - Intangible Assets Sheet http://www.natus.com/role/IntangibleAssets Intangible Assets Notes 12 false false R13.htm 2107100 - Disclosure - Goodwill Sheet http://www.natus.com/role/Goodwill Goodwill Notes 13 false false R14.htm 2108100 - Disclosure - Accrued Liabilities Sheet http://www.natus.com/role/AccruedLiabilities Accrued Liabilities Notes 14 false false R15.htm 2109100 - Disclosure - Long-Term Other Liabilities Sheet http://www.natus.com/role/LongTermOtherLiabilities Long-Term Other Liabilities Notes 15 false false R16.htm 2111100 - Disclosure - Debt and Credit Arrangements Sheet http://www.natus.com/role/DebtAndCreditArrangements Debt and Credit Arrangements Notes 16 false false R17.htm 2112100 - Disclosure - Reserve for Product Warranties Sheet http://www.natus.com/role/ReserveForProductWarranties Reserve for Product Warranties Notes 17 false false R18.htm 2114100 - Disclosure - Stockholders' Equity Sheet http://www.natus.com/role/StockholdersEquity Stockholders' Equity Notes 18 false false R19.htm 2115100 - Disclosure - Earnings Per Share Sheet http://www.natus.com/role/EarningsPerShare Earnings Per Share Notes 19 false false R20.htm 2116100 - Disclosure - Share-Based Compensation Sheet http://www.natus.com/role/ShareBasedCompensation Share-Based Compensation Notes 20 false false R21.htm 2117100 - Disclosure - Restructuring Reserve Sheet http://www.natus.com/role/RestructuringReserve Restructuring Reserve Notes 21 false false R22.htm 2118100 - Disclosure - Other Income (Expense), Net Sheet http://www.natus.com/role/OtherIncomeExpenseNet Other Income (Expense), Net Notes 22 false false R23.htm 2119100 - Disclosure - Income Taxes Sheet http://www.natus.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 2120100 - Disclosure - Employee Benefit Plan Sheet http://www.natus.com/role/EmployeeBenefitPlan Employee Benefit Plan Notes 24 false false R25.htm 2121100 - Disclosure - Segment, Customer and Geographic Information Sheet http://www.natus.com/role/SegmentCustomerAndGeographicInformation Segment, Customer and Geographic Information Notes 25 false false R26.htm 2123100 - Disclosure - Commitments And Contingencies Sheet http://www.natus.com/role/CommitmentsAndContingencies Commitments And Contingencies Notes 26 false false R27.htm 2125100 - Disclosure - Fair Value Measurements Sheet http://www.natus.com/role/FairValueMeasurements Fair Value Measurements Notes 27 false false R28.htm 2126100 - Schedule - Schedule II: Valuation And Qualifying Accounts Sheet http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccounts Schedule II: Valuation And Qualifying Accounts Uncategorized 28 false false R29.htm 2201201 - Disclosure - Organization and Significant Accounting Policies (Policies) Sheet http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesPolicies Organization and Significant Accounting Policies (Policies) Uncategorized 29 false false R30.htm 2302301 - Disclosure - Business Combinations (Tables) Sheet http://www.natus.com/role/BusinessCombinationsTables Business Combinations (Tables) Uncategorized 30 false false R31.htm 2303301 - Disclosure - Cash, Cash Equivalents, and Short-term Investments (Tables) Sheet http://www.natus.com/role/CashCashEquivalentsAndShortTermInvestmentsTables Cash, Cash Equivalents, and Short-term Investments (Tables) Uncategorized 31 false false R32.htm 2304301 - Disclosure - Inventories (Tables) Sheet http://www.natus.com/role/InventoriesTables Inventories (Tables) Uncategorized 32 false false R33.htm 2305301 - Disclosure - Property and Equipment (Tables) Sheet http://www.natus.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Uncategorized 33 false false R34.htm 2306301 - Disclosure - Intangible Assets (Tables) Sheet http://www.natus.com/role/IntangibleAssetsTables Intangible Assets (Tables) Uncategorized 34 false false R35.htm 2307301 - Disclosure - Goodwill (Tables) Sheet http://www.natus.com/role/GoodwillTables Goodwill (Tables) Uncategorized 35 false false R36.htm 2308301 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.natus.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Uncategorized 36 false false R37.htm 2309301 - Disclosure - Long-Term Other Liabilities (Tables) Sheet http://www.natus.com/role/LongTermOtherLiabilitiesTables Long-Term Other Liabilities (Tables) Uncategorized 37 false false R38.htm 2311301 - Disclosure - Debt and Credit Arrangements (Tables) Sheet http://www.natus.com/role/DebtAndCreditArrangementsTables Debt and Credit Arrangements (Tables) Uncategorized 38 false false R39.htm 2312301 - Disclosure - Reserve for Product Warranties (Tables) Sheet http://www.natus.com/role/ReserveForProductWarrantiesTables Reserve for Product Warranties (Tables) Uncategorized 39 false false R40.htm 2315301 - Disclosure - Earnings Per Share (Tables) Sheet http://www.natus.com/role/EarningsPerShareTables Earnings Per Share (Tables) Uncategorized 40 false false R41.htm 2316301 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.natus.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Uncategorized 41 false false R42.htm 2317301 - Disclosure - Restructuring Reserve (Tables) Sheet http://www.natus.com/role/RestructuringReserveTables Restructuring Reserve (Tables) Uncategorized 42 false false R43.htm 2318301 - Disclosure - Other Income (Expense), Net (Tables) Sheet http://www.natus.com/role/OtherIncomeExpenseNetTables Other Income (Expense), Net (Tables) Uncategorized 43 false false R44.htm 2319301 - Disclosure - Income Taxes (Tables) Sheet http://www.natus.com/role/IncomeTaxesTables Income Taxes (Tables) Uncategorized 44 false false R45.htm 2321301 - Disclosure - Segment, Customer and Geographic Information (Tables) Sheet http://www.natus.com/role/SegmentCustomerAndGeographicInformationTables Segment, Customer and Geographic Information (Tables) Uncategorized 45 false false R46.htm 2323301 - Disclosure - Commitments And Contingencies (Tables) Sheet http://www.natus.com/role/CommitmentsAndContingenciesTables Commitments And Contingencies (Tables) Uncategorized 46 false false R47.htm 2325301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.natus.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Uncategorized 47 false false R48.htm 2401402 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details) Sheet http://www.natus.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails Organization and Significant Accounting Policies - Narrative (Details) Uncategorized 48 false false R49.htm 2402402 - Disclosure - Business Combinations - Integra Acquisition (Details) Sheet http://www.natus.com/role/BusinessCombinationsIntegraAcquisitionDetails Business Combinations - Integra Acquisition (Details) Uncategorized 49 false false R50.htm 2402403 - Disclosure - Business Combinations - Otometrics Acquisition Narrative (Details) Sheet http://www.natus.com/role/BusinessCombinationsOtometricsAcquisitionNarrativeDetails Business Combinations - Otometrics Acquisition Narrative (Details) Uncategorized 50 false false R51.htm 2402404 - Disclosure - Business Combinations - Summary of Purchase Price Allocation of Fair Value of Assets Acquired and Liabilities (Details) Sheet http://www.natus.com/role/BusinessCombinationsSummaryOfPurchasePriceAllocationOfFairValueOfAssetsAcquiredAndLiabilitiesDetails Business Combinations - Summary of Purchase Price Allocation of Fair Value of Assets Acquired and Liabilities (Details) Uncategorized 51 false false R52.htm 2402405 - Disclosure - Business Combinations - Schedule of Pro Forma Financial (Details) Sheet http://www.natus.com/role/BusinessCombinationsScheduleOfProFormaFinancialDetails Business Combinations - Schedule of Pro Forma Financial (Details) Uncategorized 52 false false R53.htm 2402406 - Disclosure - Business Combinations - RetCam Acquisition (Details) Sheet http://www.natus.com/role/BusinessCombinationsRetcamAcquisitionDetails Business Combinations - RetCam Acquisition (Details) Uncategorized 53 false false R54.htm 2402407 - Disclosure - Business Combinations - NeuroQuest Acquisition (Details) Sheet http://www.natus.com/role/BusinessCombinationsNeuroquestAcquisitionDetails Business Combinations - NeuroQuest Acquisition (Details) Uncategorized 54 false false R55.htm 2402408 - Disclosure - Business Combinations - Monarch Acquisition (Details) Sheet http://www.natus.com/role/BusinessCombinationsMonarchAcquisitionDetails Business Combinations - Monarch Acquisition (Details) Uncategorized 55 false false R56.htm 2402409 - Disclosure - Business Combinations - Global Neuro-Diagnostics Acquisition (Details) Sheet http://www.natus.com/role/BusinessCombinationsGlobalNeuroDiagnosticsAcquisitionDetails Business Combinations - Global Neuro-Diagnostics Acquisition (Details) Uncategorized 56 false false R57.htm 2402410 - Disclosure - Business Combinations - NicView Acquisition (Details) Sheet http://www.natus.com/role/BusinessCombinationsNicviewAcquisitionDetails Business Combinations - NicView Acquisition (Details) Uncategorized 57 false false R58.htm 2403402 - Disclosure - Cash, Cash Equivalents, and Short-term Investments - Schedule of cash, cash equivalents and short-term investments (Details) Sheet http://www.natus.com/role/CashCashEquivalentsAndShortTermInvestmentsScheduleOfCashCashEquivalentsAndShortTermInvestmentsDetails Cash, Cash Equivalents, and Short-term Investments - Schedule of cash, cash equivalents and short-term investments (Details) Uncategorized 58 false false R59.htm 2403403 - Disclosure - Cash, Cash Equivalents, and Short-term Investments - Unrealized Gain (Loss) on Investments (Details) Sheet http://www.natus.com/role/CashCashEquivalentsAndShortTermInvestmentsUnrealizedGainLossOnInvestmentsDetails Cash, Cash Equivalents, and Short-term Investments - Unrealized Gain (Loss) on Investments (Details) Uncategorized 59 false false R60.htm 2403404 - Disclosure - Cash, Cash Equivalents, and Short-term Investments - Investments Classified by Contractual Maturity Date (Details) Sheet http://www.natus.com/role/CashCashEquivalentsAndShortTermInvestmentsInvestmentsClassifiedByContractualMaturityDateDetails Cash, Cash Equivalents, and Short-term Investments - Investments Classified by Contractual Maturity Date (Details) Uncategorized 60 false false R61.htm 2404402 - Disclosure - Inventories (Details) Sheet http://www.natus.com/role/InventoriesDetails Inventories (Details) Uncategorized 61 false false R62.htm 2404403 - Disclosure - Inventories - Narrative (Details) Sheet http://www.natus.com/role/InventoriesNarrativeDetails Inventories - Narrative (Details) Uncategorized 62 false false R63.htm 2405402 - Disclosure - Property and Equipment (Details) Sheet http://www.natus.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Uncategorized 63 false false R64.htm 2405403 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://www.natus.com/role/PropertyAndEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Uncategorized 64 false false R65.htm 2406402 - Disclosure - Intangible Assets - Narrative (Details) Sheet http://www.natus.com/role/IntangibleAssetsNarrativeDetails Intangible Assets - Narrative (Details) Uncategorized 65 false false R66.htm 2406403 - Disclosure - Intangible Assets - Components of Gross and Net Intangible Asset Balances (Details) Sheet http://www.natus.com/role/IntangibleAssetsComponentsOfGrossAndNetIntangibleAssetBalancesDetails Intangible Assets - Components of Gross and Net Intangible Asset Balances (Details) Uncategorized 66 false false R67.htm 2406404 - Disclosure - Intangible Assets - Schedule of Amortization Expense (Details) Sheet http://www.natus.com/role/IntangibleAssetsScheduleOfAmortizationExpenseDetails Intangible Assets - Schedule of Amortization Expense (Details) Uncategorized 67 false false R68.htm 2406405 - Disclosure - Intangible Assets - Expected Annual Amortization Expense (Details) Sheet http://www.natus.com/role/IntangibleAssetsExpectedAnnualAmortizationExpenseDetails Intangible Assets - Expected Annual Amortization Expense (Details) Uncategorized 68 false false R69.htm 2407402 - Disclosure - Goodwill (Details) Sheet http://www.natus.com/role/GoodwillDetails Goodwill (Details) Uncategorized 69 false false R70.htm 2408402 - Disclosure - Accrued Liabilities (Details) Sheet http://www.natus.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Uncategorized 70 false false R71.htm 2409402 - Disclosure - Long-Term Other Liabilities (Details) Sheet http://www.natus.com/role/LongTermOtherLiabilitiesDetails Long-Term Other Liabilities (Details) Uncategorized 71 false false R72.htm 2411402 - Disclosure - Debt and Credit Arrangements - Narrative (Details) Sheet http://www.natus.com/role/DebtAndCreditArrangementsNarrativeDetails Debt and Credit Arrangements - Narrative (Details) Uncategorized 72 false false R73.htm 2411403 - Disclosure - Debt and Credit Arrangements - Schedule of Long Term Debt (Details) Sheet http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfLongTermDebtDetails Debt and Credit Arrangements - Schedule of Long Term Debt (Details) Uncategorized 73 false false R74.htm 2411404 - Disclosure - Debt and Credit Arrangements - Schedule of Maturities of Long-term Debt (Details) Sheet http://www.natus.com/role/DebtAndCreditArrangementsScheduleOfMaturitiesOfLongTermDebtDetails Debt and Credit Arrangements - Schedule of Maturities of Long-term Debt (Details) Uncategorized 74 false false R75.htm 2412402 - Disclosure - Reserve for Product Warranties (Details) Sheet http://www.natus.com/role/ReserveForProductWarrantiesDetails Reserve for Product Warranties (Details) Uncategorized 75 false false R76.htm 2414401 - Disclosure - Stockholders' Equity (Details) Sheet http://www.natus.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Uncategorized 76 false false R77.htm 2415402 - Disclosure - Earnings Per Share - Components of Basic and Diluted EPS (Detail) Sheet http://www.natus.com/role/EarningsPerShareComponentsOfBasicAndDilutedEpsDetail Earnings Per Share - Components of Basic and Diluted EPS (Detail) Uncategorized 77 false false R78.htm 2416402 - Disclosure - Share-Based Compensation - Share-based Compensation Expense Allocation (Details) Sheet http://www.natus.com/role/ShareBasedCompensationShareBasedCompensationExpenseAllocationDetails Share-Based Compensation - Share-based Compensation Expense Allocation (Details) Uncategorized 78 false false R79.htm 2416403 - Disclosure - Share-Based Compensation - Narrative (Details) Sheet http://www.natus.com/role/ShareBasedCompensationNarrativeDetails Share-Based Compensation - Narrative (Details) Uncategorized 79 false false R80.htm 2416404 - Disclosure - Share-Based Compensation - Stock Option Activity (Details) Sheet http://www.natus.com/role/ShareBasedCompensationStockOptionActivityDetails Share-Based Compensation - Stock Option Activity (Details) Uncategorized 80 false false R81.htm 2416405 - Disclosure - Share-Based Compensation - Restricted Stock Award Activity (Details) Sheet http://www.natus.com/role/ShareBasedCompensationRestrictedStockAwardActivityDetails Share-Based Compensation - Restricted Stock Award Activity (Details) Uncategorized 81 false false R82.htm 2416406 - Disclosure - Share-Based Compensation - Restricted Unit Activity (Details) Sheet http://www.natus.com/role/ShareBasedCompensationRestrictedUnitActivityDetails Share-Based Compensation - Restricted Unit Activity (Details) Uncategorized 82 false false R83.htm 2417402 - Disclosure - Restructuring Reserve (Details) Sheet http://www.natus.com/role/RestructuringReserveDetails Restructuring Reserve (Details) Uncategorized 83 false false R84.htm 2418402 - Disclosure - Other Income (Expense), Net (Details) Sheet http://www.natus.com/role/OtherIncomeExpenseNetDetails Other Income (Expense), Net (Details) Uncategorized 84 false false R85.htm 2419402 - Disclosure - Income Taxes - Income Loss before Provision (Benefit) for Income Tax (Details) Sheet http://www.natus.com/role/IncomeTaxesIncomeLossBeforeProvisionBenefitForIncomeTaxDetails Income Taxes - Income Loss before Provision (Benefit) for Income Tax (Details) Uncategorized 85 false false R86.htm 2419403 - Disclosure - Income Taxes - Component of Income Tax Expense (Details) Sheet http://www.natus.com/role/IncomeTaxesComponentOfIncomeTaxExpenseDetails Income Taxes - Component of Income Tax Expense (Details) Uncategorized 86 false false R87.htm 2419404 - Disclosure - Income Taxes - Components of Deferred Tax Asset and Liabilities (Details) Sheet http://www.natus.com/role/IncomeTaxesComponentsOfDeferredTaxAssetAndLiabilitiesDetails Income Taxes - Components of Deferred Tax Asset and Liabilities (Details) Uncategorized 87 false false R88.htm 2419405 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.natus.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Uncategorized 88 false false R89.htm 2419406 - Disclosure - Income Taxes - Reconciliation of Income tax Expense from Continuous Operation (Details) Sheet http://www.natus.com/role/IncomeTaxesReconciliationOfIncomeTaxExpenseFromContinuousOperationDetails Income Taxes - Reconciliation of Income tax Expense from Continuous Operation (Details) Uncategorized 89 false false R90.htm 2419407 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) Sheet http://www.natus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails Income Taxes - Unrecognized Tax Benefits (Details) Uncategorized 90 false false R91.htm 2420401 - Disclosure - Employee Benefit Plan (Details) Sheet http://www.natus.com/role/EmployeeBenefitPlanDetails Employee Benefit Plan (Details) Uncategorized 91 false false R92.htm 2421402 - Disclosure - Segment, Customer and Geographic Information - Narrative (Details) Sheet http://www.natus.com/role/SegmentCustomerAndGeographicInformationNarrativeDetails Segment, Customer and Geographic Information - Narrative (Details) Uncategorized 92 false false R93.htm 2421403 - Disclosure - Segment, Customer and Geographic Information (Details) Sheet http://www.natus.com/role/SegmentCustomerAndGeographicInformationDetails Segment, Customer and Geographic Information (Details) Uncategorized 93 false false R94.htm 2423402 - Disclosure - Commitments And Contingencies - Minimum Lease Payment under Non Cancelable Operating Lease (Details) Sheet http://www.natus.com/role/CommitmentsAndContingenciesMinimumLeasePaymentUnderNonCancelableOperatingLeaseDetails Commitments And Contingencies - Minimum Lease Payment under Non Cancelable Operating Lease (Details) Uncategorized 94 false false R95.htm 2423403 - Disclosure - Commitments And Contingencies - Narrative (Details) Sheet http://www.natus.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments And Contingencies - Narrative (Details) Uncategorized 95 false false R96.htm 2425402 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.natus.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Uncategorized 96 false false R97.htm 2425403 - Disclosure - Fair Value Measurements (Details) Sheet http://www.natus.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Uncategorized 97 false false R98.htm 2426401 - Schedule - Schedule II: Valuation And Qualifying Accounts (Details) Sheet http://www.natus.com/role/ScheduleIiValuationAndQualifyingAccountsDetails Schedule II: Valuation And Qualifying Accounts (Details) Uncategorized 98 false false All Reports Book All Reports baby-20171231.xml baby-20171231.xsd baby-20171231_cal.xml baby-20171231_def.xml baby-20171231_lab.xml baby-20171231_pre.xml http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 116 0000878526-18-000125-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000878526-18-000125-xbrl.zip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�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

V&8I/ ME,+X;%J ZC!3ZGGCA!H18'"?B<,EN".4 V#D2-:48G0HD,LPZ0M:/:/"QK

,Q*/"&M>8HE67_A'5I-/V.)H^8[W(Y 7:^(&Q"LFT:X'XZ@H/D?5?N%S^NM2X\Z\._A0G(#.-GA&([ M*.27%+9%NYCHDL1QSG)LE"QF5T8AOU$"H6%1L'-BE%[JZ&VBG4I5(Y$+362Z MJ%Q3W H3*?6]:9G9JD2+G]I50F 3B#+D$NA $"P;;9897SI5E-1!*@HL(6$] MM0JP9QW[.D>5MP$.O/*M*RJ_&=<:CO6>6N_57"=9431.:ZJS6AA]L*T5)#%Z MIU3N&F#QLIH2FNL9(Z,2WP+3N<3(>[)?@[Q>!IJ)H&-&J1_0Z21MZ1Q M-D3W]&DT=$2B3S,-Y%3,_T W5XB2?IW$%<'G:.\L]F[TF6=,=I)F=37;%*KD MFU+3T]!2]-B/+:?1M> RKZP.KI(.!7X\ZS::'TI>66GI]1_/!HU.N:O3F:J0 M.451U9FHJ/J02P7@ '5D">679(Y6V[&+$1>SHTAO6>O@Y.?56C/AFNBCA.#% M@3X-6U"7=%"<@@+'A4I,Y8'T1%.N-DR;ZDL^049L6Z,VI@6*-U>L<75SGWA9 M!\(_.HV2CEXDLYP<^76/ 2S:RO8&DE*N(U./3PF_\3@@4+:^V 7>7LK @0ZJP'\S[" M@NK\1@C3\F\9BLGYG6*B.AX=4IL_N#0F(5/6JGM)6_P M68]+OD@.C!!ASYH5SIE1$ M]1E82T;CL"FBO:?.8I=VZF&=C,C_N]GG41?19M'H@6C;?+"0J\VW8<+5;ULU*,F:R:RIL PZRD7M\M$G09^0K^6'5]X.J%- MKF#>6"H.;4).2#FTI;Q1#0J1:\Q6IQ9!VC/Q51^B6H?>@K>V2'&>)_5=FGD3 M/">TDII-JJ#GQ2QQ>>(F#OP(;C-VSQ7Y:=TD.K5@&*W+8ZJ[%OXC3J8@(4@2W0$KI?P1$*\-3CT)7AG1+Q/&6* MU/I[ DYF!LA_>W%WJ03DXNXW^LNYX]A6.D/(.A.*K-UN?I"0KB2XV%2>%@?@ MP!6$;UV*(4V4<=8FK13.[!$'D^OCFLDH7F3) :)GEU#$\ M&9$ T[:H#-:2E. .3$ Q2@]A4@?H,=I/FS:=8.Y8 M?^S*5%S%M=FJX*Z_,S]!+X0;.K.#Y9T(F'*XXY()Q"7'XJR1 8SC)AJ &:IRYK M-O$7+YB(%CUUPH-PY1'ZH$)\,!,A\+OD6;2.L:IG.^3AS8@7=!6.!5H7S:O% MDE3)QM$'K2J%:BO%2E-,Y$U?PN39P)P8#25H99ZR!A&?O3O*!"C*NBA#NR+DIRPHN2AY>$J;^U,,E?BA71(<4H@X)>A($>Q^NB1L4:>-U25!OI M>UD$9R_KF0AFUQ+#SL72,[N-WWJ(2IE#V,]/4LH.9CZ5T]\J7Y'\RDB)=*02 M2<,][>/NI"F,+ &SHI_UHM;)(1ZY:[11MUN_"06#1\;XQO/FT,Z/0+P*!#:< M5!!7*5BI5%:]9N]#[NU2JO!11:?-4;+ >K$)Q3,L]&BR>E;W4S0S47&ZG'\A ME_YGY/:0W$J@#@YQ=U67>.H42'65X2JKQY-/BT47J-RF^#D@>7/RF5%ED*)2 MV*VD>C.,5GV( KU.GL!&::(@'>>#=V:'JW)-HGA.]1I88W*=T2O'K@(Q%":=B\+&,VRB%!-,RB-23Z-;X=X\G"9/"B][_) .#%F]Z,^1C %4ZYQJ M(]]Z%:AKS^ -&SCAC$S8!WV;$ DDFKIB$$WA:\0QO02-M3-#2CH=0<(]POI( ML)_(%6.@TMY;_!(N_,$DDH-%"],ZY^4[9?3\G"LY&"&;E""_CU!61)N\A&JFL8^" MOS)J_CG:^![)7+2M8#.H#Q]HE8+6VJLP^-I?YHR&:@FKJ")YW2X*(4I?+?F M.%+AS<>Y6E,M (X$]8,1U2R@I(;^FP@>A;K+JQ#5;CS=J*EI :PMW14SHW.#V*.=6G/D- M5O00%2Y&F0R@]I&N"M?#MECW;T@(&%4@X>@6F0)>8(TE.9:Z50'B>_G[1>R! M)Z2ZJ2-D\OQ;LB2NR,U2/6I:J"QA@= .Z5RDK3F;,2RBR10E2P(*D>\FP2/T M)8,>%J@1+R^[.*BBCO\-#\$>XQ2LSP0S^T[4KOEHU"%:KV-4MH[;[9LT0"6Q6:= MUC/9" KV.1=U\KD[_2+?$:!I94E%''HB7J]01?5#C/6]6%':./)# ML'^*_["=$H? 7'R)''[-X_60DLP758J]9,"TL1Y;&*U-ADH0HJ%OSHX)D,'N M^0\W!4L"!:(%SU2-)S(>8GZK-I='@,B0W,&5VN=456!6>M(V_^LTTC<=6YO7 M%8%-3F?'(C=_H:2)REUVFRN9'*G/TV!AS!?"#&737C0?1([(MB2P')T9JG1\ MT7R9+:?%*3_Z]2]8&_.GOTB?+'61QF!^0*.'@"BTLBP2*)I$B0/'Y$F()D8% M@PS3FT=+.>Q-7?_R2$HYBM 5C;6%W5ERG"!%=V^=)]BP+B5^6BS&_L 73H12 MY#C)V2<86(MBMG3/-X_GA+]J 2WVA:2.JDQN80KYNP20TW31QD&V&DMOS'_) MV=)*/6Y:'AFH5RG?85%V"Y5B;EFP6YM>23B:_CMDL_:MAV3VYUD=-,P#L((2 M6H=@54JH[PP^?+3NQN!3(&?\2AI(^JM92BBOIM9[ BBND^%%.II<5J^"0 O$ M**5/1*8VAW.Y8$O1U/NDN4SY\QL1,6RO1G\K%QLNKC#9&]!&R!O;Y&Y M55/"Z5M3%WXU"9OZWNL#$35QR+OW^&H]$RRTF6R"T^FMD_&%.@_U[[_^)8G. M'QA;?/P2/C#P7>GF*SUI?N%/OHKXC'[\,DV3D]G A.O4JX2K[[*8/N.UK_ \ MK'Z\!TFZ](!O__N__M=?TW>C 155'' __70C:B"S!Z1_.'7LY\"4;L5ZXY@N7D?U4>$SMYZHKJJQG;/_/LE3$(6 MIRE2P\,NSZ=_ %*7;#-^A,*!?4/OK@VVH MKF8.1U[/,"QKY/1LMZ?V^@-;'XZLP5!]]^LSL; )U9N030C]0A[053+#\4ZH MG]!%LO;9B5]O_F]TA3Y]&7S]?80N1O_OV^C+]>@'!7T9W$+>I5=OK=D>O+6\*B*3_*/Z["2"?=Y\3LR"C=$3 M7M/8;U8W7IQ!DRA:_.:7=^J[\G-&/9?EY\-1\1 &^?2CYUVZJJ7:KJ[;])5= MZ_U/M^S8-_W 6@'B>48^+O_8Y!WV:AM+3%=_,0N'+2S^Y9VFOT,I=1"K#ZL? M_Y@'ZS_3K;=8O$RU0LM[_].3&VT\8=M-GU^OG7CYJ==+?;GRX$UE+%/4Y7'%H; M_)3BZ\5J[UXGU4*L+0BAS;^CTF!"_ZV6_SF*E%L%W'9B5=,I^9!KNP7Q9^G1 MC7:7 >U+5N#$DSC1. ,COD')<[,FL_@/(*5@C,:ZJ;%0]\=I&% ;KJZH+; : M)U:S@=6 U9IA-:L>G4II\M,M]O^Z2UG='7/%DO3C?_L^(9.)4)J61RB5[A+K MMQ.^77]7,W1W4EP46OT/+^J\R5O[VKS[$Z/D/*[4,/6]T77;=;8K\ MB-KXO[R+DYB\^W'UGDTP1(=5(,B9;LL98W\M#W(&Y S(&9 S1U%#YQ8B$7[C M3Q4SAWM3+76:%@>JQSCT^AL.?UV/#I8U M%[7@[;PIM/QAYW!+%7N+-*+P1MT6):BO#L-)XY?E"W@"/'4>3S;HI_I/AO=T M(IX7!$MG%=Z44QZ2W?6X];":05DM2 I6PWH*#H4/U?'+97F+?*U(=KDP%,NN MR5HXAF;M]H@A&E536EZSLF[QM+)'@+ :7 Y!6 !5$* @0(5C M2A"@7,]55-L4AZ =%J$;GOF/94^CK;]_O>'9(4W'7G0K^[QN'7E[NJ,ZK>]1]OGKE]\^W(RN?D=5M[+/GWK]3Y\_ MW7P:7;_*!8+W*/N<, *2=+:(CFSV&%WT*).J1=D3E5E2ZWD#LCV8[\E-1&]B M9EXZANV:NJ9:NFUH')N8N5QZF#E&ESI9"78YM/$ZR"0X;_,D1^PSGOJ;BD#G MKO,Q'_2X@!6PB?*KM>MGT$-MQ@1FN*ZW!1,6Q ![K-HI7/M*675N35).9IF MHG 3.)82:+3N()-?WY2N _-4/ZP=Q43UL!.G'%!1*-5<-J=,81]=4SR/7]SG M+=*(P@S@R;8QVUR&-%VAQ) ,NUU9S;Z:.R\!%'.VFDW+ 7T_E?I'Y_26) M%U'CC0MOV/,/2?\>#@=.7]-=RS95R['&;%ZUZEAFO^_VO;[9/T?Z-Z1*/V,8 M2)6&5&F)LH4%NQQ2I0]2J) J_0JM(%6ZS0":G2HOAAD"H-J=*U44F&L ^D2H,G"ZG2715#D"H-J=(GI4KO MD?N\F2_]+4V"PL__B=,4Q_GC<8VRK9XW<*R^XXT]QQH8(WU57OB^R]LF^F! V2&<74(YJG MR7T8T,W"Z&'!+VB2I.Q[QD,9RJ=_%V%*Z)N1&4SH/>F/4?XX9Y)N3:@Y75827*)/$\1HF4S*GZU( MQT"&Z6+8T0W]K)3_NB0\6\DM62XF8 L)&[9XLP#=/BZ?^R%YB.D7V>+:*LUILB]9HCN\O('RN8:Z+N'MVFUAL6_/UM&R.X6X\7R=ZX%TU>8W8;5#QG9GBYN M@OUE/0)[[#V)@X3>A/X4ES1-J7Q"MS@+LTN98=A;,U)*&#T)HQ-E@JA@=**, M@WT_+>B?FQ4:C,R,C]C8/S]GU"IR*MHKIF"TK':&OMN*$2]1;\%3&6,S=O7R M@9A>22E);T.I2R4UOJ-\%N?_FU'>S'+$>&J&<\+N2^]V6Y8U+%?S>(DV)4E9 M.A*PW7ZQO71#<[:#U;NQI;&;IB'E$;;!$:;60/4"*[0FZ0JH;$'T']@OJX*5 M?Q7!7?DE*L'%2EG"F-V5O1F>)45<%K LWK%:Y0:%*=H*G[XQSA9$8T0(*PU; MXG":Q'0]Y'N8L=RR]2Y5.%PM;R/9[/*E4&R.$;63&;'D&R[B>&LZ-]J:57O, M[9^*T"G=P25$N-S^?ZQ+$]%?171/^6@GRDVW*6,BGYK)3!=\(4G_\Q^C4^ZN M/7,8'?,G/J\_GR9YB3 \?UQK,2K3$_3'Y?7E)N]3@,^I'(A]\D0(4+FQ*3+8 M9BT@EF6)3]47W:F'D*KIDBA+R$I*DS4-*OU&7SNEMUO(TV*>Q.7;Q04#!"-' M$8=,1!=YEE-14KT]5;O/;)*%QE5V4"Z;AO,YN[:21NRG2SHNEE>)RE(69EDQ MFY=2N'P2^VX\I'J'LCC"0>+I94-8[>I:M:JNWJNDU?V>58XZBK M7(H'EY?@Y24IKQ3N3 :JWG97O?5QQ&S*-5UQOJ\5U.PZ M"75/6%!!R-510_9;&7OD=5X#J 74OL)O/>9(DM>Y[5QKNYFF27$W%7)M/9^Z M]5EX]H)4@&IWH+H,]0L)B,$4IW=4D*QV/4^$7.=B)#5@%C#; +==L1,I4!+ M<$U[82**7NH0KK9[%(MI!5D)#]:6HH!=B3(2)"1("-!1NZ@Y86MZ"J_3JTG$W0-Z;843O\ (E0H$1](+4$VMKQ') ?24@NU.-3*[WKWV^8G.WM,.SMW61."..J+V->%' MLEIDGN$VQWQR,%+='C18>2##0(;Q:R!75YM9$& @P$" @0"K78 ICJ:!" ,1 M!B),!-8#$7;$X8.NV&9S62RGGC$(S'W<#AE PIU7PHD;O!55P(E]-M!H)K,, M;-3\&8! YZ9-'@XTUQR?Z_FI*.24(\E$&%%'O5&KP5[GHG-/W8ZH0#(-[#?Q MV1&$V1%LY^J:WAS?"<]#(-) I G$CB#2#G5%'5V @C%1V >D&4@S@=@1I-EA M!P>&HGH-)J!QK5H0A>>@,*%;LDZ.DRPY)*$D!ZQ-)^K*S7H2=@$ MN##VDS2EEUZB'KW?XN+E6"N\GM[RXGZ+D275 "O*QB3-\G)0C)\4$1L.DQ51 MSM9&'Y$2-@P/E6-KLG(\5H:CQ8"U=-5^D/TXF1,VXZV:'S9A$VNJW[";E2-4 M%C]@8Z]>Y[7@^3#+MP=3/AMC29^4/WZ+Z(][<3#Z=Q'.V=ROXP9:]OON6!^- M/=T<>]9@;'OCGCFT![K7]_I.SS9;/]#RV]77;Z.KFS]1[\L0C?[^QZ=OOX^^ MW,B,RB6'E!Q*ENQ13:*KF%R:\3U/;*>24,^'\^S!Z#7CM4.' M46TX:](5EV,NK>A[?VH,%,Z*:CHK DG3!4EC\3NL$7WO3Y4T76\&U2_"B"WM MD E'J]7J;]C6-0<0ZNCURS$A1)0MKEL9@\YM-2)TC5O"9UL0 4[Q+J>8G69/ MDRA X:P\2V?G?K6H%JX$/2O"#$7GV/FS[?8:>(8-:*GV@$OGFKG6=G!UW1GZ M.IF$/D&3(HW#,MOK2?X*V(,,4)9B:]QZ'HJR\> BB:-\I(.$YBJ&YP(DP$?: MB[ L0;G(28JR9)(_X(66F>(T8!_ G'N-=I[BV/PZ(;7=G -?"7RE@\"EJ0 N M\)7VH]^0S)(XRZN*DU*%10F.2]GW@;P&D7H.4 MX=741:Z]D#HJW1TL2+ @-P^+7<72P(0$_ZRMZ.)53L(?>J:G&!8_.Q(&1';8 MM>OY?C$KHK)E04#F*?'#TLL#ZW.OIE*V8AHU]GP2%]HK,/^-V"5A>> MK1.EN+ZH'*).DD%8CF(8 HR'D8+Q. 9!H WEVX?AZR@)(M_G),X(:W,WW]X( M[P%GZ,7K'B5=S$L-T5]%VZ(SQ]Q0X;0NX]+AO"Y&05XTT[FN#96]# EZI R= M(1(S9N2SU*W]J]#63D%GW.RM[62.(B2W/=XZN.XX$J4DF[/^L?CRBK^K> MG5+WZK#ZC:H:__&0[JJ>HP\#4E)]@QY"BB;LTVU-F<8HKZ,[CZF= M33^NH%3UUJ?/",H7"EFOPQA':%ZD\R1;],SW\3RD5Y:OP&ZT\4*4B9YIHEN< MT066;RH:,LN-XV8T/C/^]C(8#S$5!WIOI*FF8[B&9_6V[5J>9XP\ MLH#.]>=C/C$ZAD/G M^HZ>L O&AZ*Q&G2N/Y4KH7,]]),^Y"P-.MO"5!%-7;0(7=*X'7VE?^D'G M>C[&(W2N!W\+.AERAA1TKH?.]?( L#46)'2N!_^LU>B"SO4=:]K62=<..M>? M0#SH7 ^=Z\56B.U#''2NYXXXZ%P/G>LE*-B!SO4-TDP4]@&_6]#J0NA<+ZFH M@\[UT+E^MP&XNW/]D3WXMG;?NR(^">_9D[*;% >$7O UI^_7\WVZ!WFV_O=> M1"4BCGTR3M(AW;-\4D3+7U7M_?;HTZB4LNQ:ZU%MN4( IAH@ODOH6E'$6)+U M]TTW6>Q#_CAG^G3)7@P+,TQU$/TOPF6G>)*'Y6R#TC2OZCVHLHVF5,%'_ZG2D6DCRZBG/VH5$-E,^TL+&'WNAZ28#-N M<51:+NNA$&LJ+Y4MT\P5V2KI1.V8M*!_1B&^I79"N0%)99DP$Z?<778YZ\[, M/)GRV&_YH&Q*J.ERB4:S>90\DJK;>1A7E+XE,9F$BW;IJT=2/L%HCM/\!1\L M1V/(O0\+,?FX'%BT=1.J1O/TGS."YI24J\_K^4:$4[_^NL<;O1(F.BJ8V>(Y M1PQZF&TULTJS%TW.H4%YQJ-!N7ZIJH[C.6P.DV5I#K\&Y9K&I4.Y99^W2;29DD/R,^UNH6KR^L, ;!PWKPC MP;$PIM8.];@> 0K=@@*HA1?<=E#6%/2.V-6M=1&6P>5OWE.4,M];"Y$ M+VDYTC$,FUO3&[EYAET'^6@BYJ.=I_;KG*"LB.CJFEX_%0&< $ZP+<"V -M" M7/%U:BVK].4Z/;JP\O"_CIB6=+5RFN*IW)J-B[+%=:MXT.0UH^"L107\AB4! M'CJ#A_9J"%U1;6ZUAFU!!%1#[Z+L%:$OG^$(AKR\WJ- T[D%Y=^D2KL[$T! M1H9HJ3#V79,!45&P!#%/"2Q#4&Z@W"!<]_RZ;_BQOIF!K>M\93J-]3GN!OX@ M]-$,%TEI2EYPC!4"W !NH-U>AYNM0U-'.9HZRFYU[IE7>\C):0?]0$VQ'1BV M"T&6<]N@D/59)Q4[D38%X)0M BKN:(YFU&(G8-GY\"AD,SY%ELIOT)LH6URW MZ@(-U>)L1D>'[%[ V0SKC6$JW&K)&D+(B";$;(93SQW-NIW:+H1DH= @PQ1 M0&'L.\AFA%B>D)8A*#=0;A"N@VS&4X"G*9[';WH\9'Q \ /R&5\%G 7IPP W M82W*UNDW7;%L !QD- J4T7B(IP-Y'4^O,TQ^8.YT5@<$:&2(@<&O?0"@#= &RNUUM#D<^X0#W.J,8LIN=.Z9_NC4PXX& M9<<@*6XCJN9HO4O"J'+:-' )2KZFJ&P3D;G_PQQQ3NFS]_9:_?_ZQ MR#[<83S_>$6R/"W\O$@IJ_7BX(I$."=!S\_#^S /238,,S]*LB(E-Y02_2CQ M__KUO_[V\_KZ>Q(7Y(KXR5UZXZ[#O.0+,L<^@ZP[YFV -7,S7#4T?O?GVV)YOTO0EG M)$-?R .Z2F9XM^3=N#P*8_)A2DI!K^GJ^^=(8VO(Z"8I(SESR@7$11 MFF<*"K/E2_Z'!&B2)C.4X8B4GON,!$P(H(#409D5X9^U'! MWFQQ09ZP^^9I>%OD24I_\# E,I/<490*2OHOV?5/]/ED?">! K*PYP*&_8/>8KC;$+2M/R:/B(C4<0> M,$_I2ME+3<+O]'V2E"X^)^DLC!D@E?(5J(2)B,]6P5Z279V2K(AR=GWU,/;; MBC(X2]B5CPAG#'3!);JA=RNIP]Z:OEJ*9DF64TE(&9_*S 4Q<$K0^&N?+B"\ M"V.%WFE2/I,^(I_B?/$J;#5IF/W%;D=175W&GD0ICVX?R[4MR9(B=AE[U6DX MGY?OFH1Q_A.:)@\L:8S2X<7*,KHHNN=%2H7QW:."LHB0^8<@Q'=QPA9;T6-* M,"-*4A(P>\QR,EN_0,#>*L:,6GS>HIA3N@PS%C1U9_(=_20I']ERNH[[2?Z M/,JIH3\]X&TV%K5]5R[1F/[3/$T"*LRSU5*H8J046/,%XT_Z%M7.*2NJ,-9; MOR;%3!;2Z^CUE#HE;!+?+QCOKR&V>!2[(\@H9?&2<[6>D]?")6F3E9=234>I4:\(MFES.+VR=XSA8O# MF+$&"X,&C-!9,LD?*!4KV;4D%1-L2VG%*#M=L!:E=/!0=T:1Q,[V MT:2(*W&6)W>$7I&6LKABIDWNR%;)6\Y/B&09O3BD$%M>3BF4/U8B@=V$4 FR M6.&2*TKU4'([DS"5\,S6MU]O\83N.'H(\VE8L2=5-_/E!>M72%]J69065 P\ M8:'_S;;^<,X,&ZJ(*D&W5%G/%E3*@>(VRW'YJM'C8O6S,CC-KDPJ>N'X+F1" M?S?_[<\([H&NHN#SQ9 M7AA3"$41KHRFE-E?E4A;7)6QNP>DLLCH'N9A1'%7ZM39^M;T-PO93^__?]3+ M*N_@TQW!7U,0I7@:/0;-:TH@9) M*868NEX(4&;"S$H5QNQ?:M1%X7]*$^\>1_2.M]0N"9CR8:(ZI2Y004FZIG?) MS6B.'ZF^7".Z-)RH&4 7QW9@;5/*K;H&"U@OJ5T:VKAZL:6A@&;,6)Y3^I&H MXC&H_3!G'WCSW Z@T83L;E-YT>8?%DV;D47M>;BIZ^_>TO-KK^E23%?.A>,)$EZAZF J[9XDS*_??N:/2%-3.X2:A/D5 HD$37NU_[G M@G=*UZX\N:8N5C8/J0"D4O2N>B(3$^Q7E;E4&1$^I5#HOS!>GDL2MA*4/\Z9 MW*C,^X4B9>)S89)5KAQ; >-:>D7YF)#>HEK1$_>[E*E9B="ETZ>4.\]8*(J4 MI?9=N>$?7]WR,G1%]7L4+3;XEW?JN_)S-L?^\O-BH[;PP&OA(+1K\[ MK<+W F4_,=B='/X%0 &@A ?4ER3^P.SJ(J4:T&=Q-XR[#SE=,W1KH*G6V.N-!M9P:'DCLV\/+=<=ZGK/U6Q! M3M=JA=F"C"A:TW')#8Q5+DH7D>XP9=WLAY?&ZOZ/].J-Q+U4-YMD4U^AVL:# MGMQ$W7*/S97$23K#T9/+T_V M6?P#SS/RXK&U+.$( Q>8[W#F M,\[ ?&]0\MSLR+,>!A)N@=5>9[6].\]#C=NN@S+JF),XJT(D9<[0(DOFEKJQ MD_"@C@O- SB.)*(LOGL.BA$$; 0!41-ZT6-9BNJS:\/ M@.B;?ZJH.;5_E.Q6SC)2.R$!B\TK]'IJY%3''"R3)D(Y_DZ@'SR[SE4TB]ND M!5$8H&Y=#2JYQ8@P%4H*0 1XU'L1]I]E0FC^R*JQ2'I/ZH!0>YJ$:JKB-3#8 M1Q3F )]1 @75*G39#K^Z^;:C"]RDRDW"LRK+*F"5$QMEEF -LBBG8O+K0"C* MSH-_)([ZD0X1FF+K$#$ _^@P)3-/DPG)LJH] BMY %/N=;6CNV#)@9\DD*)J M#[@T1?/XC4QH.[C 3:HTV+*^9-E0!HS!$DJ."NX1N$?@'JTL-X_;&*RVX &< MHYWIF&6S$%9,N.R7AM_LV@CFF\EO!D/;C3?PC, S.H!.AJ*:_,9;M1UXGL2@?7' &2X8/V!-P3>T+-F-!P';[<%%^ 5[2#L<-F1D_65 WOM]<(( MB&.#*R20@FH1M(SZQ]FW!5I==X2^LO9@8._=L;P%1P,/"#P@F'"]+[DXXN4M MVK0%3[5Y3J[LBN@FR?$A@;@#V DF/-[!A$>>M+0TQ>$7+84IC^#\PAA<(7@5 MA"3'\R1'<3D6S(*0W-.N/'84[OY=M[?WZNZSN4$DRWK^OXLPJX:.]A\W/AW2 MM7O<\PQG:(W'PW[/&AFN2UE)'XX<2Q][MF9K37?MUBC'O>BPO-DXVEP-CN!E M#S^9XUJUF;8K[)RB M["NST15\.7=ST7<^8.-ZRNE0JUU4WFP7?F2#[^?F/=%3PG;TICMW M%\;5(G&1)\LO*E.C_*;JRVRYE[IKVJIJN)YK&Q;'IM\FGZ;?SEG[7NLB][V6 MYK#3.TY K2X;X&Q:37=F?Q J'ZB@84.WSAE:K/FXXE2:M:DUWJFTL!2;7_D% M'%,)?4QU*J_T_,4TG?6T^#H"] T'X$^EBFXKKL4MB:*[2.F$NOX4WU/EG*1A MN\O73\:4KF@N9$^ 6MJ'6;ZER9RP6_7N8J4C MBBG'\5W(8BY5< K4TVYB>:KB:5#E!.II'V;Y+4F"AS!J0W73J:0P/,6 7N&@ MD?9BEC(E%I31FW32%,?DEP0#NJC-NF@5P9OC1PC?E9==.(K-3R>]W/CZC@(X M\\8/H*].Q=;SZ=Z@ME[!73F2R:M=<0$BVZ[4-JI][TE<@%)C2LT$E08JC1NR MPMA/9H0-/0.5]II*LQ3-JS\N"(@44Z5MYCOJYI-$U%/I5I9E/1]N+@>IJD^0U)9RQ[)(YE&:;>TSS3[O6\ MWEBSU:$QK+V4H-8R 48TY44.;IF1D#'J?<@I^:@9M:)?U:XURZEQM:P26%49 M\,[L9P#B_<)'L?T!90CNL_H![CNV492SF"I)]8C&.9U]!EY'"?MH8N(V_0\G7#YT4=UPG68/GIH1)K MMTD4+*,%/IG=DG1-6$-3$+,%>(>B@ &! 0]AP+V3(&6,.O#S[W;6DKUN@C88 M4G])N?U]1!G0#=(/F*L>XK7JA./)"@R5:Z25"<&3$GM[CICNU0PQ2=UML/8*N#K7ZTK6XJI@-#1MMLJM?)/D-R M3Z)D7F;>UJ?YZAZ$(!(@ZU" '1F6 *X.@&P_D'F*9?+KVM01>-7E"5J2!["J ME/?MV9-@B8+G!YZ?;*JP$W@S3$75ZB]K;@O49/3\>.LX_]#B@1HL4X'+OJ1+ M8H"Z)O : 9O<(JF.8CD 3G&+#H\M&MQ1@IC,YO1]Z*^_3CZ5;0=N\/?1]SF) M,](G,9F$^<&UAX.A.G0L<^@,]+ZE.7:OY_3T45_OF4[/'7AZTV.,ZAA2Y*_H MQ@H*UPT;$*EHAR9)6M89/E*>R1") Q*@%_QRS-,/J/LXYO8*GU5N+0,XYD:E M7<9K22^[M!RUI+.L O M0*[RTXMJPC]+.VE4VDE;39QZ0ES B<\XT9"^T)4[:T)-=3V)RL!JVUB-VP@9 M8#5@M==9;>^FI:U*G^?)E8,B38^. XX#CY*E1 M>THE5W9E6M:>C0DUQ/ AX[NX&\&BT(-;Q]RZ$[QXOK2F*IK&[?Q9E*UDUT%Z MQ_FT-8@!R<3 A:88+KM]"\*%MYJJU0 M6["N'0[&=8YS4F8518E_D*,AW80=#@A35 >J*R!FU&#,J#O@LCU^U;L +8 6 M0&M#;WFN">"JS6)LF6'X)8D_,..P%E"=-W.O!FSIBF/S U='^DY < 8@M1M2 M%M?AW I@%37(:4KN@&($B1T>.[F2!QJ/JO6$56ZWV:AYSG V!X_33<4S^(W MPOM8NHG"91 E:8&JY$KDDV8BU6NSFHKAG!^ZG6@@ ;@&7#>&:T=Q])H:P "N M^09>9;>JAV1"J$4=' /GMW++NYA"#A$1X!_@'^ ?>4I8.I5Z=GAM2P>/[FW% M,/8.\Y]@S%Y%?9V''L=3YEK:E: M!OE@IBF&P>U MV"#,CCM>$/1H6RK*F;TU"Y +R 7D2H="#J(X8B-*W!3I"UU1FZN /\HZE2)]&@*N M -7Z8T.ZP2^=#* *P=[3;-R7HV+K84Y>4ZQ%=[VX-3Y]>U3U6WPJ0\M4W5), MLZ:JS4-H)@K[U.U$0%!-"FDFA0Z60]3505O]JN#E1OVC!M*D'Z4^'_]^E]_^_GE;8;D-O\4 M9WE:S-B]5K^F9(X9+:_(Y)=WXR$;D/QW\\^;X3L4!O0+[.JXUU!W-T&Q3M\;:T'CWZ[.]V:3S33@C&?I"'M!5,L.[I?#&Y5$8DP_3 M:LBIIJOOGZ..A0\VMO]?19:'D\?JJS"FHC[_:-CT-SQ9XG/"I !)9RB@A&1$ MR\(LSU R01=AC/)I4F0X#K(?/K[*),>_Y6**[-XON?&D)YI#7=YV<1/V>7,I M<9+.PB"??O3,2\>P75/75$NW#)Z1C\L_?GHN)=9OL1G0 M6DD:=VN <_^06+5 QWC_MBC;*FVKZ[43+S_U>JDO;_;QAX5(SW;$L5M9GC"+ MFL,!AR/VZ7[]D[N'Q">S6Y*NR6AH2CWQ>6"^9\PGQB!Y7N=MC4R9YS:@JVG: MR18J "8]GDGM>N3G >>;LA]O7I'[)+JG:T-^2H(P1Q-JV$=A_GA.^,L=4N 7 MRVI_J,JR%+J@V@DF!=] O%[0>#V(,!!AKT3;51!A@E142&^-L<@]"K.LP+%/ MZ#JR/#O&DVA?];[#WQ_M=MD@Z/P6PZ4BAZMK.C<;2!0 -*]A!#*;:R+L[G1/ M=L//),L^KF8HS1-*H"1FAZ'1DW/2.H#7GK+;&A )2;KB %->W080ZS+$NNYO M5<4]1RNR,V1YRA %:"Z9LSU1),M4=+?!"A\9^*AN P+L!)!@(,$$C8.#!'MJ MGYV>7;XK+7Q7$GG5U><&?^]E&6 MU^M9/7OLFJ[CZ=;(U71[W#/,+F267],GA1/*[#%+*U_F^K-8RI,>2KBD=]4@ M?DUQ^C7[Y0O6.>Z<84LN(MJ:]77,[V\'5>5^XY_MI@:,,!20H_#QD1^UA MC()P,B%5?0V]-*E'HTF'+4U3/)M;MV=16 <1''TD'R0L!4-O"7PEO:E[&@V MCY)'0I9S&>MQE3HS/553U+HZ:W=P?BJX6DVX6IT!IZX8;DVS03H(3AAN_'*X M<96D 88H YNFF XS M8B;6*PXLQU,(>F$IKLTOBG\JW;K=F4X@$,NK/#N$74-Q5'['VX!=< K?= IC MDI_H&![ A)SZ;HA"0:%::PB3!*=9U#VH28IM(8THS #^]GF39:'#CQ!B2(X. M/[JA>$T.WY:!C2#&T41QY$87G*,J)-_L5-"D-R26ANA\1EX?9V&V2L#SRW2\ M2?B=23QQ_ M1UY]V1WDUC$% E(!X=3G>2K@1DCB'("5#I<7NJD8&C>7<5_Z=%MW@HH\+^+$ M34?D[(_6 DS[(UV_9&KJ7K3J]O# S3'=N&8PPL M5>W"5*B;*7DV#>J64;7,/P@JNJ+1M^M7)Q@IB'SWR;SL'X2R:?G3&05-#K.- MYFV8;:3I7(8;65Z7YOL(=KG$7O8?(3\&$G)S\!JP&KG<9J>S=,@=.U5X;OA+&?S BZ8*-WSII;T*$#LU:< MA^FJHGM&8S2!\RY!!))P:A(D4;5#TS6?706-=$#4@:LXPE-!1 M/!U$37V.5[O\JW^67BNK%J>OBN_*D]Q9$E=GL% M7B***F^;&Z)$V?BZ=32H MXG9#PK2Y59@") 2;8"$84)#^9/-*X%\NUK[0['$N/">(/IJQ,]9UER6LYS# M6YPQ:PSFPIZE5+KM[@Y$5AK07>V!F.7!X&6 %D"K!FBY#1Q,M@5:70_2+:I3 MT#4$Y2 H!Q$(B$!LAX2AJ!8W>PT@ 9!H R1TDUNM;UL@ 4&Y5WII^^NFI*M: MU'/*&N&->TB_>))SJEYRG,0'&:<048$T,)!#1W0YN>38XT3TK:_;1P!! X(& M!,TN0<.O=E?XK6_>\VJ7@[4,9(OE8HE"'6Z"12;YP=5A K\(0IH@(UHG([1+ MG=O<3E$VLFZ?!80 "(&6"0%^XS=$VI,>P%<=3%6S[+W[V'3>PX=0(F2!'D"G^H\* 5@ K X" M"XJ#SMRL_Z!.^SN:]9>E<>$]^50V@+O!WZ]P3JZ(G\1^&(6E(7=PQ_Z!8P^- M?D]SQXYJN;V!YPQ,S]('GF8/1X9N=*5C_Z*I'AM51;[/29RQKU!._P7[K)L_ MCA_I*NF=*WJVT>$Y_.HO W[ MT1^7UY=H0@*2XJB\;Y$GZ>/F0E)Z'7O,"X8]YB4-ZSV7^S"R<+G1UBZWQ]Q( MX;:>E]G"QZV'C7K@M::7OL91NY8G2\ZZ)9,D+1F,8CGE)>OS#A(GC'*KZNUO_29V,#(UB%EWMPK0)43D1 M&J_#. GH\7]&5H-Q$L!J,$Y"DG/A\8OPTT8 [)Q %CZX#%GO3Y)1%%>%L[O& M6*+#*K$Y22/%0&HAQ) D@\X]1>=GGGOM;9!T86C<>I9#\1U$\5H.%\V%#O^ !\##.@RFFU"9 M>;*E)9#W6&OP/4D)O?$B$P_G9;YGAB*292B?XKC*$"V_K -=[4ENOS 43:V_ MO1,8=!#: >P]QYZMN 8W*Q"P!]@#[.V-/4UQ^(T=[#CVNAX0')()25-"@33% MZ1VU0]G46QR1LM"IM$3#."=11/R\P!$K<9I3DCR"WT>O\UP8_@EQ$(B# !X M#X"'+8::I;@.'"S5;(\)Y!W52<'1OXLP?T2L*)W$65GU#V[2:P2S59C:"1$( M@?17>Z!U81D0?X#8'R"O<>3I*K?NGZU7:ET/[=W@[\A/21#F,"RWU%J:8GK@ MCG%53Z"%V@P83^.67@%P ;BT'BX&MP[1W8 +!/MV4/"/V*?OCL,R2Q#-DRR$ M>-^;KI&BFO5G)(G"(1#QDT"%M0=S0R&HMQ_]/K.N MP"PWK^K=!/6[B\B>I4.H D(5$*K8$S"F!Z$*@ O 94^X."ZW8]=NP 4B>SLH M.)CB^*XTX.YQ5%13&#&;P(%CG[#BB\FZ/'AQ>@ONTZON$[]YJ*UWGB R 9&) M@^D$T^, 8@ Q@)@P$.MZ")#-E$R*'.& C4ED4PG!22N#@!ZWI/1N.&D0T^@T M7!0-HAH & #,^4PU40#0O$4FD!M4)V&OR!SG:36CNXSHQ21GL;^703[H]?=Z MBTU;L6P(]$$40B -UAYT010"( 80 X@)!C$9 GT\Z?6%&H?!LA\?,PUQEM&O M4O)A1G!6I.3-6%]-"^,@*]OK%QJ*ZW*;SM,6Z$*DI,.(@$@)X )P ;B ""*? M)BZX@ #A6W1R=.CV!Z$+@;13>Z!E-3!\%* %T.H@M" JV,ZH8)WT^V>83Z=) MQ%97S9 #W^J.=7]Q8?H 1!L@V@#1!L %X )P 5$XCH2](GF1QBA/V "T^S"# M9GQOA>/X=8YMO4,#,0.(&4#, " &$ .(R0NQKH?E>K_?L/8MV/]W$=;7KEDZ M*-G\^O*)LM,0?1!'YTB'!X@^ "X %X +B,J=3MBO.?VW6CR9) U(NB2"-O^. MLB0* _3?:OF?%GDZGL$O;>Y8HHG"3A!DD$"Q=0>:KL5OY 9 $Z )T.37C<+T M )J"Q U=V:W8FR3'$2+?YR3.#AGG<0!;&92M@J2XCV*V!U=D\LN[\5!7->?OYI\WPWRU'%/-8;.P#3'SNC=K\_V='-_;L(9R= 7\H"NDAG>+7(W M+H_"F'R8DE+":[KZ_CDHF6.]P3:LUWPX>:R^"F,JU_./ADU_PY.52C)_N&5T MIA1;$QH]X RE*PHC^FF2L*E)&6(STJ>$T;=$!]UL!CKZ/ZQ9%NNU&I:,@"[* M'R9%AN,@^^'CJ\QY()7V(/83':(N*;L@(_N\^9PX26B(T-?:;U8U+E""? M1-'B-[^\4]^5GZD(\)>?#V>3AS#(IQ\][])5+=5V==W6&!^^7\HA*F,B-G_T MX_*/GY[+E?42-V,Y:]FD;XW;[1\.JE9H>>_?EGY;Y7!UO7;BY:=>+_7E MJI<_+#9Z-GM_MW'A'J<0W).L_?5BM1-/+&H^F/"I\"R6I&LZ&IIRA%T&W'6"7]SV+=Z2XMS;T&NG MAR@[?VJH%?+@:CI$ CG3?CFC\3NX%GWG02>1,G\S5&,G6^BIBD&1&8A8B*2EFH3N*S]#QT! M7 N -=-6:VA4[QB MF/QZQ;]!'5%X!D(7 NFMMB'*5DRKICX0@"A 5 <192J.WE@SMK8@JK9P8F<[ M/AT)P&UUY:WQU3S%-!NLQV^[,P>1DL;U8]WPW+^'1//85?F=PAU/U$XTV0!@ M [ ;]$"]NCQ0 /9N,YM#]QR^76^VM]89AW&8D\_A/0D^Q3F.[T*ZZEZ6$7KE MD\X\>S3-&8[=T<"S5%5W=G2IJNUP -BHPNDJ3+ M8]=C7/K6M5C05,7CEYLIRE;7K91!][88$M1^M;CU1 !$ "*D1X2N> 9TXCG9 MG!+(E:LU/)WB@* 8STA6!WK:4Q9C*Z8#[8HA4"*0:FH/N$Q%@^8[ "X 5STN MDF:!YH+ VW[T^\2R2F(<18_+QHQL_&\RR1]P6DMIM71XTJFRXG9D)LJV0\A! M'-4C(2)4FYN& 40 (J1'A*;8.HQ+@"#4>GAK2\NB MDX'7BCSA?:DD0[ZP[BBFQ\V'?I,THC #A)UJ-P- TH"D>6(#L1/2YEK>BL(, M(&E TH"D:=C;4IP&FVN+P@P<':O3.W+NW2QS1Z_-(B]2\CN]R:R871%ZA^@; M?F3#*[-QDGZ=$S:I*+[[3'!&CNB^:3O#8=_K&Y:N6J9GN9[JN8YG>L.1.79' M5A>Z;RYHBR)&0C1?$!<5]'$IHLSCX]@G4=DU,EF2N_IQV7$SF: 7?'7,,K:V M&$-;.ST=$]N(GH/4?/2,6S7U#75 MTFU#X]A#U.320M1UH)&D<,8HM.^3IM'52FOO*R8;75UE2M07A!;HQ*A.(Y2U M#V7=0YFUL-3MZ("NH0=AJ$&2"N\'=_Y8A-J,W HR(2:P00097'Y'4:$T/J$.XI;V*2%=,"^IG01'M2=D;^D\$3W*2@CIZO4&1:_%+EP1U M]*HZLJ0/AU>YVK.M9^W.SWS:GDKU6Y($#V$4'9(@90]J0+G'K4H>2* M7IEWN3-EDEO*\U$&H^B^#,P)>9(CKSJ*:<.DD*8"J]*+'O_?19B%K-HX^_%; MD5*KAYHZ/=]G=A&SD'H!L\H.=6S;&W^U>0X7%(4+A(V_R@XOZMI12SA&?I&F M)/8?49[B.(L.K>Z'UALOKKO0%)5C8]Y3Z;9F/8E2"G\ +BZ#'N-B$/.; MB5Y+#L2N/9+B5+NYY(A3 N)R9$UHCJYX7H-I$U)S'D=I>GH^Q8OTA^U9$I]B M/YF1/IE0_5_]?8._#^G_9'3_>G&PL L.;C73L[21-M9-=>"JEJ<[/;WGFGW5 M]0:]GCNT!UW(I*CHB6Y+XJ)YFMQ3UR:)$?V(PNK? M)>54U79UW::O[')LPZ+I7)(A+*]+?5@$NUSNU4OU\M"!YZ0./)IVAA8\0C7< M8;U8,M:,A03;7;!ZW%O@Q&><"+V@7K F3]^_>483J_,/L-I;K';67YX3K\(?\4$B\]/\+I=K@E>W$[A@[MGQFK$Y223%*8 0 M8DJ.XR6;W\F2U"S#KH.IC2"]!&!%D%X'M%Q2+)5?)H?4;'.J!(/TN_*8_9AX MQ*DE+])EXNF&HO/K-?D6>43AD+IM!# %.@PIRU1%<8 M1>/8$_1HDHG"/1#%$S2*!T4R MDDHZ.>* U'GR5./\!)6"\4!(@I"4A5=!2'(4DKIBUA6T!2&YVXL^O9#PJ K! M7<6&]R3.D_1Q4'89R ^N*K0'H]' =$;VN#>PK)'F6JYG.:ZM.?I(4_MF-ZH* M*R*&]&4HQ;(P*_LS2U,W^$2/P(#WDRH+72Z%A8[1I?(RP2Z'VKJ#E.MY*YH< ML4\QZL_TAW*Z\S$?%)Y .1W4.,E03@<8T^YDA< _D_0O-FMOGB8^R6#6#+O.4!R76PFA*!M=MTX&U=MB1&@\ M2]+:@@APQW=5G85QF$U)4 YWK6>>0F?F+9F&8O)31D?33136 L]2 O76'70: M+$<3T G.&!_ZW20YCM!&)HXHQN?^4<>F$>AIBN?P+C'M=G055%U7P62;BFWS M+KUJ-YC "=Q!V,\DRSZB+TG\H9K]E=>MU[IC=5[HJF)R',('0WC!9027L;$& MJY:B.C75]0%X.7N4+>CO<(S2/8#E>)7TR6 L-E>YUYJT*$=3++W! CT9V @< M^/-F08$ P&V_P&P-,NQ!J-!?S :>IIK>XYAVGVW=^;*X7+G:RT; M7E.250M'"8,\)28**#79_%'ZY0NN..8Y!\R\/N;V"*?DD'&I)Q0JORPOV7N# MI*M4GN'T+HRK1>(B3Y9?5%9&^0T4,^]UN=S5R%*]/-230C'S?M0J/T$QLT#, M)T:%*:\3WBY6.G-S@(2+20"3'L^D4"-].35:!@D(-9T#@!@#,09B[ Q!_TXF]U,#[)!S\/86D]: +%'VN&Y5 M#QH=<-%%7(!7OU.IZ(?4:^R?C]N:?-LF[3A1N (\3@GT$T"LRQ#KNC=T0_^) MX$E.4K#]Z'6:92JZRZTJ1)1=!G](''TC'R9,55%5;N7(;<$$^$*O=<_@9H# MW++S%0^T_W2!L[Z'P67@S[:GDDIJ7@4I*:P%"%)R7\/R]*JL_2JLME=G?TQDVK)U*+^R;MT54NU75VW MZ2N['.N?-)U+ 93E=:D&2+#+Y5Z]5"\/!3@G12$UK>OE7W]2\RM#(ZIF @2E M8.?C1#&J;(1B3?&JO:0.C0"K\:G9 E8#5CN-U?9N Z'9SO[!-)=(EF^B!&< M$[K"Y_X(444C3)#6U&':8&,,T6$5"'*FVW+&V%_+@YP!.0-R!N3,<24U_)I] MBK[QIXJ9KB>QKYRFQ8'J,0Y]Z])V+RQ%=37> K?=8PH@ M9EP)@&MQ0G@ O MI>UP,2P=X'((7"#HO6M0>9(2>F-43:CS']$=#F-T$259=H@LZF#)KZ:H&K_J MA;;[21".:4"1M0=<5,/QFYC4[?EO@#Q WB'(TQ2S@6.&;F"OZ]'!LN:B%KR= M-X6VAB&!CMA]7J[LT@"GGE:+\@3+++A:%8=H/3;;OM$4,TJJ:T/.A#(ZD@E*,/S85A MR2HCI>!5$* @0(5C2A"@7,]55-L4AZ =%J%Z^O;VD2%'[^3YRF M.,X?/X?X-HS"_/'@+E\]W1ZH0]7LCS3/\GJNZYG66!WTAI9CZ(;:[T*7KYLI M00')<1B5S;PH6<)[2DM4-O4BZ&%!9)22C*3W!.&4_C=#DR2BBBJ#YE\;LJ E MS;]TE4OS+Z-3+: $NUSNU4D$*NCAJRW^B/DX"7^PBH!=2^PF^]+"MFY'5N.]?:;J9I4MQ- MA5Q;S_]W$69A'B9Q!E %J#;!<[,+YL"X\, M34$\FW+#,3X8;;'//)P4AU>]!@Y8$, QG&C6:ZSFV^ P@P$& @P$" -2S %$?C-@ -1!B( M,!!A(,(:/GS0%=ML+HOEU#,&@;D/AMJU1,*)&[P55<")?3;0:":S#&S4_!F M0.>F31X.U'0F!2V^N<.V#2V^J3=J\1O5>#3)1.&>NAU1@60:V&_BLR,(LR/8 MSM4UO3F^$YZ'0*2!2!.('4&D'>J*.KH !6.BL ](,Y!F K$C2+/##@X,1?4: M3$"#@5(@ZZ27=7*<9,DA"24Y8&TZ45=NUN-X-''ZT)/]1I9L'W=R1;(\I1<7 M*67;7AQ.$33=)V3]G!,TC'*\^HT?*2QDB='$!>L%'IQSSK+71SO9> MQ]Q>>47+'74NL*U*Y9@;(1QSHN#6L[&CEA1FKPVVJ64HS1.+H&3VYR-G]L#9 MDYN(/K9&OU15QZ&2R%$]R](#A!@86/F&V#A.;=1GZETT0 *W8(" MJ(67(V22'+^N$B"E\VVV7#259TYF,D$[/7]N[9OJ"C>+FXW,+]K<^D8WANW6 M3BPI>.;4,#$XM*5W67J M!?L,:SPRIG6,##O +:]C2H2G33?_FS93K78"5AV/CP*V8Q/D:5ZW *@ MHFQQW:H+-%2+LQD=';)[ 0^0S;C6$*[&K9*D+8B ;$;(9CSQW-FHWZ'I1D@> M @TR1 &%L>\@FQ%B>4):AJ#<0+E!N ZR&4\!GJ9X7DW#<;N:\0'!CV:X2$IC M\L*"]&& F[ 69>OTFZY8-@ .,AH%RF@\Q-.!O(ZGUQDF/S!W.JL# C0RQ$#E MR(34+!U ":"4Q<;MAJ8T/6Y9*=T&9><#JI#_^ 17!G3J@@@,9#_6>#H.N.@, M+D!/= @/D ,).9 GGE:[]4<:NA'$AU"##/&_-EMYD ,)$ /E!LI-B!/JEMF3 MD -Y"/!L?JX:9(A X*,Y+I+2E+S@USX T 9H ^7V.MH?[SVIR0H(O)U#YE.]Y+"1JAL]SQEIGFI8:G_HV9ZN#7N&H=N6-QP8[WY]MH^;>W(3SDB&OI ' M=)7,\&YIO7%Y%,;DPY24RD'3U??/T).D,L^QI=/N([E841RFY8U^&&7.7)TE$ MU5:&+L(8Y=.DR.C-LA\^ON# _=?G':BW#B3R'GOU1'NIRXU9[ +[O/FB)\-?:;U8U+8"&?1-'B-[^\4]^5GZG4\)>?#^>RAS#(IQ\][])5+=5V==VF MK^Q:[Y>BBXJE",\S\G'YQT_/1=%ZB9O!H+4XT[>&__:/)U4KM+SW;PO,K3*] MNEX[\?)3KY?Z,#]PXC-.-,[ B&]0\MRLR?/L X(K MP&JOLQJW?HK :L!JK[/:WH7F<'2^@RL'25PR"HOUH$5$X:7[S\4 %*;[@5@H M[WS*\!]QR)CO.J<\>$C>,'?=(0I!N!U&R)0NH3NJXMK@AP .0!RX! Y8.J*:H$]T)0C*[T;,4Y20F],5U#$ M>1H>Y$IPJ])H3U&P;JB*IC4VH$'X[/>Z%;A \2;A-#O \\5UFJ$IFL=MV"7 M$^ )\.0)3T-Q]S^> 'AR-7O!)SZ"JSC5 8C"<OQ:DKU9120#'X$$ PD&$DP6">98BFO7Y/YU M58)!#M\;A8"WCZS\ /V.T[](+D$27[?R]&3GLB^D2)-:F IXI[NGMD-R'_HD M*XN8KQ^SG,S.F@(J?""5GS'6AAY;FJ,I!L9#0RUSHZZ+^3RJ*>=5NN0;RU,\ MBYM3(,H6UZV/0>VV&1*N8KLP%A0@ 9!87F>KU)T#+7&R)=652/4U26+, MT#1E-VAODAQ'J$SKB9*[QV7WMW,ZSZ*0IJ,=-PQ%L[C9YJ+L)02))#RNE"&? MN4DA(4?:NVZXBJ7S+MP1FPM O(!X ?'2D'AQ%$/E'9X0FPN:]W($"DK46\[P M0!D@1@.<'N+R0*E,_:ZU_&=%@E4UB$*63KK5CJ-8C@%>-9B]YS9[1>&=;HH! M7;%L;JZQ*%L)8@#$ (B!P\2 ;7L@!AKR4J7W).I,[&_/R;AI*([!+^[<]J-O MR$MI(B^E/>AR%-OA-I$%T 7H G1MH,M3/!=T5WVF8MLLPC/6(4@'+EU7#+VQ M-NRBL A$9<115/)!QE T ^;O 20 $JNR&$OQ-#C":RAHUY[,^G6&B0C)]3NI M+T4BE! -@N3(D]-,0[&-^CN52<$W$,UIT=&EW*P((NP@$69PG%,D-=^ " ,1 M)@@K@@@[8 2DJUAV_<=F4O!-\[YFNZH5OM(EDCP-_:/"_C"! 3*,9*E5$/X M4P@5*(R6<7 1-EB^O6R:!Z6PR)&I0*X )P ;AH+RX@="UB*41[ M"I#J\'.ZWEP:XBX-*#F *$ 4( H0!8BV%*(PHJ$L)%DG__ N(ZF]WK<5AQE[ M$DF&,PU-,Q7-Y9>4" 71$)HZDYR1(N]5)"$D1]KT.>PH&3@)1!B(,!!A(,(Z M+,)@EL5+PNZ. :S]QUJ=1H.R6Y 4MQ$Y312*'LNH20QN(5\KDN3-BR,HP_ MXC G ;K.<7Y0+09WP2<*03HYV5!3%4UW>;VY*%M9=YSK_';1V6TA$ -M$@.. MHNI0\@]20'"/J.TF9E=*@ I M>*8&X )PB6,A-4E$X0G7^>A<+[TC<1[&M1A)THEK3;$\;N):E"T&]U0.AC<5H@)'9*UK$)$"* E MD!T&$2'YNRNT[2&$>#(J.T(FG6BX//27SW.;PG02_+2)[U'W\CR5V* MYU.V%[V4X.R&+>&&XJT?)?Y?O_[7WWY^^93K*4Y)'VE_M>^]^?;:SF[MT$\Y( MAKZ0!W25S/#N7=ZX/ IC\F'9UT=7WS]G-Q;)WA!%_Z*$#2>/U5=A3%DI_VC8 M<[[M@&ZF!$V2B+(K70@J&01EQ6R&4_J[#*4KHM,;,ZH6C.P(+TC.@M,HI[=X MI-(-$;K& +U@S&.6-20^F=V2=,WOAJ8@MHE<;O_QE%5Z!X+Q> [PZ9:3='\& MV'C2$U&G+F^[N G[O+F4.$EG.'HB#37VF]6-*[[P210M?O/+._5=^9G*07_Y M^7"44#:["^-JD;C(D^47E; MOWD(@WSZT3,O'<-V35U3+=TV-.O]4OM3X1_A M>48^+O_XZ;DV7[]%NDUI.%OE^?Z!D6J!CO'^;26Z5:U7UVOZB==+?7FSCX=( MUYD'DC9CA[T4I&M*N,<1D%U6?GJH!.=M$@75?4J;Y:Q]N=K*;&\&\;O';/\L MOR"OUW><:W$]NDWX[O5!..=:VV\II@L2<65#G!,TQF$JY.K^@:/]1QM!O] = M_D9D5^ MARDG3 :10X(9YJ7A@0#C(< Z7^14QL??\!/$[!-;0X,^2]$<;J:5*#MW"03R3@.$DG)'SK M*(UC3:C<:EZW%%7E=SRQ)ZVZK>U!J8,'WBX/W+PTH;U*4QZX[!IZWT-S;AQU MOE889STW-Q7-Y#92##IC@ LOCK87GMO A7]B'SB7'*6YZ'O/T7#8K[Y+\(*D MU]_[E=HT+E5CAQ2DE3?\.F=_9D?7H)G:2/>L@:F:XYZE.5ZO;SDC6]5'ECXP MAD[OS#5H);O7M=_EQY>9]&6=6457M*3K"ZXX7ANYNJ8O'I)4#UE5LU$I0:IZ MMJK8#3-&R= \PG$F:ZD;"K-U05^ <+8H]\M$KH';@Y'E*'!;5*]YEZYJJ;:K MZS9]91>JU\0J/X/JM0ZX%5"]MKN^XTO!-!!*)OL*<:BM:P44H+8.:NMXK6WT MG:1^F)$U1WZCCA=4C7$,@"NOU(RA"U>S%=O34%:*2T2J_2@-6YPCC!X6G(UP MQ47+7Q T9QM%I3_Z'\V\M$PTI[J@O(N8*4O"1*H\PU!4K_YR/5%8$:+B$!6' MJ/AY9(UF7:HZ2)K:K(F6);:5G0Z@\NMYW)<7/439YKHU,BA>87 AKGX%62#$ M?C:O,[M2!+8,;4 5V.OIX9IA*EH#5BHDAH.W#-XR>,NO>,OF)<WTJ#;NMT<']!O<;W.\=QH%]:? ;9"GZWI_;_9;=-M@OP\U!%XZG M*I9CG);A9EUJM62XU3$H4QA .YZEJ"Z_QDIO$4L4UCP5VA 6: ^J!+89.$R8 M%4;4, 'M@J"INPS\\%+JM^N=7ZF>OGVC,+L7!UM+M8^MJ]8]U;'=7G]DCE3+ M,X;NT-9M73/Z0V^@NZX)LSW+8N8G@SQ?#/M0+[B9Y%KG)]HKG+O MGU!ZW.ICA MR4,._A'?4R^)A9BE&^ I3(3'4FW%<.N?%B(*S]0=1!8(>L*9(' 2W>V3:,.\ M=*%LNCZUW[(T-2B;7E^GVY9BFMS4M"A;7+,W!0=2M<%!%D57"^\D@8/\1+OKER:D M:H.#O"LQ657YDD#,P$!QP<\.XYX-:E"P,SFW+ 9=?0>YU0P[3, MTQ!I&XJKUE2E .,RP8$'!QX<^'UED7-I0JNS(\P&3G527"N;ME=0_1&GQ$_N M8DJ*X 9_[Y.83.@MKI(HHOXX*](YN#ZJ/S!T:S"P'$T?6EY?]2S;4L>60;_H M#VVM$_51/<3(&OMA%)8;Q^K#69'3+;D+XYB5/.$X8-5.Y9\SBHJ<_:38V V4 MX^_T]]5^H ORW8^*\NDVU[>@K(&CO*09#^P:8SK$8SH(HSI$Y,BH[_* M?OCX@HGW?RLH5I*F6,GD4JSD.E#N ][>3WTM M:0/8DNVW)17#X]?D0_2];SX$U2[9\RGV4T*MW\5L;&H)S9,L+/L#4,LJPBP( ME2>L]P[]9U8Y?DAMW=Z%BB<'DIH&F>YR.V\5A1,@F'M>B#&OQ2_2E!K2)=#J MP%E]D=PS:#D8I09:;D_Z?68^'O/[LQSG14ZA2/^.PEF8ETG1:[4D134/N MPK:YI1!#%@2HS),\8F[1VDOALG*:$W1N2[/\7Q'4%!.)D0JM?\ MO9MY=5.G76@ TT)%#%-X!/[@U<2CI<*8ICL8M 4,4A@ M MUZ*(4WMTVH6F&!Z_#A3@"'=9Z34=C&I;&I356"L843@&M&+],:FFNSQP&L,I MO(O4W'S.5J1*.4J3'"<\]W"4?*=7JA]:0;Z]#IV-D"EM[EX<_+V@=)L\4F;L M^3XKC9'25:D!Q6B:P-#]\:CP= Q5&O0-WOCD6M8YE#7G(%K](>U%Z*_ M-H3G)"XH/[X<,C;XO]'PC\\C].G3Q[7 _D?O\Q^]FT]?OZ#>ER'Z^Q^]SY_& M?W[Z\AOJ#09?__AR<_TJUPCT>F,6#%D,"LTX30K=_J3Z1H=N?YY2TWML34CF MR]T!MBWYYN,IGT4=S^C/=^*RC1!/,?_%ILYW#"?2IN9O#'F+RB4$G>*\& M357Y=6?0;"[M&4RK2^T9!+M<[M7#R\OR\C"$&.;"'D? W6,Z%W&=-5UQOLN3 M["_[5.WZ03)!W^B#D[/.LP+>[0SO]NCJ5D=RVQAR,,7I'0G6A,^373\=?6<- M]0XY5@#.!& X4Y5\SND'U7Z*XJ/XF"W@E__[#!-#^=J M.SC]3TKB1=R2R[G:_B!HD+XR2 ]AB-5>L0L$85W.BD%-)5G M!J,H6PEB ,0 B($#7OK"4G2=6XOV;A1&@9 (=$I(>$JGL.MBXKF+X-(5S0)P ;@ 7#6 JZ*3 MJVMZ_1P&$ .(=1!BEN+:,,"K/J^L>QE]AUA#>^<>=#'% *!P#_ /\ _P#_" MT@?X!T+81]!2X-PYX4UXF*GX--O.=B'\"+$1"4T!X;D-),V3C#Y%T^OO?2S* MWH.D 4D#DN9,28.:8NOU3P^!;$(01""(0! U5,HD_-Z?:O)TOB*RH<1$Z8Z8 M#<5SH"*P ?72,O7;7D34D-<$N !<2(^+"]WF%LP&]P[@TG*X<"WL$(7UFW=# M! J!G#MW[^4@"N@;!)VJ1"$<A H BD 4J#+4N!"4S2#FS$ YRL@)$!( MM$Y(<"TH$F4G3S45H)(1FO%Q.[/5+&X-<5N?4PJ1Y ;R'MH#+I=?KVF %D + MH%5KRBI #" &$*NI3J+UX-KPR7[,\6U$MOY^R]\__UAD'^XPGG^\]J"OO'DD7)&;W%Z.@PS/TJR(B4WE"#]*/'_^O6__O;S\]LDDW$8 MASGY'-Z3X%.#?.-RZ/PIA\F%9#ES5=??\<-\R'W6"4 M?Q593LE7?17&5)CD'PV;_H8G\S#:^3D)$(YCNET(;] 5D8JP*"419K_)D]6_ M4U*C<+4S")=;@\*,_H4F"?-@,W01QBB?)D6&XR#[X>,+?MQ_O=Z!$O! HC\1 M<"6)-VFNOD+RC0<]N8FZY1Z;*XF3=(:C)X)48[]9W;@$(O))%"U^\\L[]5WY MF4H9?_GY<+Y\"(-\^M$S+QW#=DU=4RW=-C3K_7+<.15C$9YGY./RCY^>BZ[U M$M-M6L;<*OGW#P%5"W2=]V_+UZU"O+I>._'R4Z\_['+(M-[5$U[5N,TS.88R MPNM^*#-_PBZ.HFKS!3Z>+5X4A)YR_IEN(:<%8%6GE?W.@J M!"!>I9"AV/P21$ 1M5X1'73Y"0%=42OLRPH^@%UM#]ZDAQ'Y:%)=:*RY2B%FR2NHO4+LACS M[V6E8D30?ZOE?_A&.Q=/*T\IZ*.R) J#U9-$H3Z_4.A;M#TE5EH'*6LP&QQ= ML3AV[#R:HE)P'D>!>NH!/(^3\R\WK] M@:8;0TLS===3AY8QL"W=U,>>>Y:#]DVLNOP.UN75]E&\'0" M:D"B03*C.'Q$R9RD.*=[%\:(8@*E)1.5Y]I9Q58*>IB&_I2E#[1#=3*E[NIN5]7A#XF#>E;\3E/EO(4BYR245*FR2]PS&]*J!D+/_M M%F?LZXHJ4X*C?.I30E B)D'AYUE)D(RD]Z%/&&F3^Y UJZJ(S7Y89/0CZV_ M;I#Y*2$Q)9>" I)3VX627$$Y=03R:I-F"14I2&CQFDR)>/)S,PXC, ML\=J:[.(D#D*PJQ4!MFES 9415'J9]FR*>/HRR;LMUDN31^5 1TMZ9)-@^I M'9DI5*%06>[3/R),*8G9%A#Z:3Y]S$(_Q#'].R[2C'V'BR L29GE646T.Y:( M&#-"LWVY([%/+[Y$OR=9ON2BK)45MQ^V+R(86_S693MZ)90OF 98>R-5@FQ M#@/#/8D+PKB>\6(ZHUL8E!1:,?^2;AN79>@VC**2/X. KD]N%KE:T(#M8I0P M&YXI\RK%BN[4A*4.E6+Q]A'=D>0NQ7,*;$JZ._:EI"E8>VAUJ1*LO$M7M53; MU76;OK++,<%*T[ED6%E>ES*L!+M<[M5+]?*'1:O.5HR^VS]UC],G[H'R>D=, M5]/>.BMYXMN_=-)K#OKZS&E(^9!KN^_&NKUF:+2[W6L]<5/@Q&><^&8;OQH8 M\0U*GILU6:R%5XP.*J6 U5YG->X#!8#5@-6VL]K>W=/A+'('5PZ2N&24LFYK M$5%XZ?YS,0!Y$G3_\Q[A4=[Y3KI_L(.H %WG[!#@G+I#%()TL@V6[JB*:T-. M)]A(T ZOTW+ 4A7;@V0ZD ,@!SHM!TQ=42VP!YIR9*5W(\8O\@6.\&+?K/AX M(\S2GHH0W5 5C5^-U=&$$X6]ZE;@ L6;A-/L ,^7F=>&IF@>MZ8G $^ )\"3 M)SP-Q3UHN"O DY_9"S[Q$5S%J3A,%(YKKLQ+)J_:4E7%OJQ(, M* 2\?63E!^AWG/Y%<@F2^+J5IR<[EY55];4P%?!.=T]MAZ1J/L"*F*\?LYS, MSIH"*GP@%1JY/^T_I"D&QS"[Z+M?MQ,HD,$DE@ '60.RQG857>47.A=]]T'6 M@*P!67,^6>,XW IIA=_]YD-#+7.CKHOY/*HIYU6ZY!O+4SR+FU,@RA;7K8]! M[;89$JYBN]Q&M0,D !+20\)6J3L'6N)D2ZHKD>KK19_<.L#3H<1H37%=?HY- MU_.B(,HEF. 5PUF[[G-7E%XIYMB0% MB(&&O%3I/8DZ$_O;P ) M@,2J+,92/ V.\!H*VK4GLWZ=82)"24YE']_SY$-.(&D(3$) MD/-ANP%D2>?H.<]YL2RW"SR49-L7GT+QEQ"*;PO:B&J60=.J>)7-F]NV((#X MAOB&^(;X9E?XAG;GT8L80Y+_UP::J[/(&3(Q,E$R43)1,E$]U3$Z57-+@'21:; M?XI^C&3CS_ONQRII%^YI>%ZMY+6*VY1(#T13:>J9>&8G]KUN$PGMQK;I MYXBC=@%)1&%$841A1&$OF,+H71;+BKV]!K#('S>:-%8!;H%*^J%X'!5N>RUC M0S2X0GU[L7FN7BZ7V@4^P/M@I6T+?JAS9KW4:FSH7-272&?KI:9;4W(;"=>-ASL!GYW6YE.O;F!SZ[+> M/A8@&]HD&FJ5RA1[Y)Q;8\HQHWT/,E_((<(]'/. /P=G+ M><-@O51N%!:8[7TIG^Y,%D#B+\>X:J5VS2/C(N/:G@CI*96X]8I[\=6YCAZ* MR,IH(T'2SM&U5ZJW"Z/K;5EB2D^W)[+9.8NHE+P*6019!!5LJ&#S!);Y08N0 M1P$EE7?NSRQY3:K84%*Y17'-_AA7I51_@I?CDG&1<5'%ABHV#U#9J8C&7'^G M[-35:[PZ;2JB[)3J-7.+:)(YD#E0L8:*-1NUS+L/EOELX2(V4%K N##!)+)Z M0V\]>CE'"+=KQ=5\7OK1P92V4DUHG5W+9:H(D6EM41Q&%:'=/UWAV=&V1HA0 MU$$QNW .Y=,=%O-,&MO /9-*J=PL;IOK3\^+V0484=F""(P(;$<(S&N6JM4J M$1@1V';&^R\\K#^V',QG5?LG W9.3:&,Q.'LE)M*^=5-Y6-=-V>8?R?&RL$T M_4I&H%A[4FW$Q1Z.:'M)]J9A9PGP:A73D#L4I:DK+AR@^3$618@86&'R(#W!28Z&9NEEAG\+_ ML=#>3_"\%:O8&'X&2/"H&'&\\JMB%*P&3*>'SA_=30;9W^^.$W,XY#P^N1!# M/*GHJX@5T&0T/)7&#Y5)M+@$Z^J&RO_^_M=?WLV;C[@676Y$T%/C6$2&6ZFB MSS'^VXF"#Y&/S[YUBN>V?U5N>\TVE5Z\U>K5/OUCN]3KEZZM7/>]VS@_,#&)ER6#,L@6EK M1\^I&1^F/T KS5$/#'7"QL*.5,#0#[NV&L_F,M+"5>F[K%D, JB@Q"8CZ8^8 M-&PH(J%Y&$X9+\;*!RK1A71TB(Z(70F#AII-O#ANM6(9;@^?I2-.L.V$A\P* M/69QHDW"H3N@T[ZW2C]C\1%I N)\=59!#U^&% T_O+MMZ MB+!'[ *0^4D!H+P:TK!UJ(]< N(P?"XC'@&>P_2\+B1;5NM*\:-!/O^NPR?G&THN$SMI!1G%@<;03K!J.9I/^W\-$K M(K:J0IAX*.WTB/4@TAA"KS)56*ZC=(Q<=\R'H 35 MJV7*78,!-'67+10_X%(OE.%^6[F0.XW/=?W.37_S%?0%*Y&>L(=*Z4RX#@Q[ M_:_L-5.5\MNO%YWY)^_M&T?"2]?A,7TW+_N6O^R(03\FO?CBFW',SC3'U&R: MNJR"/) = >X+)/?,]0QR3&!N"N-^_"'\!/&:R5:D3 5[U52DM\7,K5Y87)\9 M/L X0EEQ:59]>+FGWJ!=+9V)'4:L>#J@:TM))*K M$11A#S.(L===!>)B;Z? MKY5VKPI'EDJ*MY6"@*65RX860.I07LY8!VQR[G# MO.:T4^;,+L/M\L(N7,DG;A.#M#IV$;AS)=>=O#08_6&\?7L<^). ;6^\$NH" MT!Q!RNJ\DD$%75->$F?J P;5OC1.A=?S'S03%]MDZ0 TN&8^.ZTMB#$'0MHD MT\TM*2"*RE/G#%K,896G@0]\S 68V%J+*U F9'MR .KWA4'(8R2&L96!( ZD MR2S68)LL@1GDIA-(B*PT1))J#-=)BY'];&0,)7^6WH)1853B6#L2+D[,!6B+ M@4HP)6!..P)A5EVK(@@2D"(A (6?\N%-IA-WJ5,,7.YG%2R$R]HUHO6+/M=J M1A94#S/ZHE60^/9_7.-Z3.]?':K5VO7:6:=W=NK5JTVO6V_TSGJ56J,&7YR> M>T]6';K;(#9:(/HH>=\E!6[)XU23D/\X5?YL(_ C*U]/QHL@UI4,8+GX3+)K MXF:(SI=H%@5T<-JN3K_X!HPZ%-'0CH[8![!O!5S@ X;!L+08)B%/.63,I[/L M+(-I,>F406!<8)!4KG3^ MB'4.\PH$)F=90CD;$6?2%[/).&.%##&!L 96"(>$$;*II%2VF(NO#!85YJ)? M9+4M5%X @L,Z^O,RMT$-9K*!6Y_.)G"H)A%\,:N+H4UC8Z=S$ CZ&C/0^:Q! M*9M,RL4Z&+8-P2PNDZ8#H-^8A'Q G'[K2U2Q] M]9IO#: 58L>9\\(1H-\^WE>@$3O%DN2*>SGW<+<-<*^-;K55ZWGG];-RN5MMMVO-9K-5 M;9W6RE[M.=SM9F^^7'[N_>??GS^>GGV]R.&;G?WY[212]MR17E'YX.$ '><"K),*/?OK[7F1I)=P_H7#5&6X^H=@OO&T![/M?%3P ^V M&? 8RT/T SFPJR:YBKV+P<'#FWE5=)QNUDD]L;$NM_9Q']@ O6L(!5!)[%* M8];LULY2=1'C@)RF^MPDW[MP*ZXG0Z9IDJZ\2:S"( FVO'WS=,Z;*!V+?(EC#$,'R!R1Z M'Y4QGZ,/$19=7#1ZB='Q.L%8N]XZ;W4:C=9YHUOO>7/W&];NDJX 8;P5;O3Q#C7G/=-$_#Z+=VU/:WGF@[/%P\_Y82!W&?/P M6K+K89MYQVZ'*+!F&&9M?C\H'[C/)N;^[//ZL!MS/911.DG@+C7[(MU5Z[Z9 MR,".3MKMHU:Y7FZT*I4&**55?S7;YNT##'ALQ,GLC[R^W+;MA13YY]<6NX,K M*W?NWO\1N'2&%>_5S[=+K]S G5[_R,N;SSHZR4ZRD^PD.\E.LN^+[#ORX/OM M#ZFU'Q;%MM>L!=WVUN+Z(\\6VO Y)DNA=.MAZFK=6G2:9;_LUJ27GNTCF!4. ML^7GM';[9(]M);B?GB*S >"M_]3IDT*Q,QQJ,705UIXREG7QYOMR*9%HC\!7 M//C^T,H8MBBZ,JRZKG,J(H&/P%<8^+#$O8( M>Q3S$?CV&7P4\Q'XM@=\%/,1^G8CYMO86Q>> J;%%0"_'5T0=A[A[;^+;)=OA-V.C\Y_>ENA^V8_6P@*MP76Z&M#&059!5D M%6059!5D%6059!5D%605][2*=JG>*"PM)WL@>]AQ>R O059!5K%TRZ2R_++C M1Z+D)=\9(4O96TN!>*I6(<]Q7,? M+% )GI_[F*?1;EV.;#1W9N_2 MGSAIB\7#(PQB26))8DEB26))8DEB26))8DEB26))8DEB26))8DEB26+)?6') M:JU4;K>>7YU$D$201)!$D%M'D!1&$DL22Q)+$DO>N7:ZU/6X'8$JG M"A!S;ADDB3F+3,"]+2#/%Q%:YC93'EL.>EG9?L7?[XX3%O>5C, AV9-J ]H4"=[+D6"Q%C'7W$H5 MH5P#&?'(E[BQU8)X#D%,1@B.@=)C::=L(NV(<=\'D[4@ /0@X8HXA-4=BDAH M'H93_%W$UIT!PBP,\RV2^.G".JC!0)TQ3,OG[+4[./^/3N?+&Z;%/XG4\#O@ M@P_=X,PJ^/1=,#''*8\"QHU)QC%.VD#WW#(^& C?NJ% (*5Q,#[&*;K1H+VP MZ:6AY'T92BNSK@)I_%"91+MU12, H7#D6Z[)!.K!T,A(Z5L3YEJ[6&@-+UPQ M'QQ%BRL1)<(U$3]B$1GH.$@TJG-QB5,N:$D%1^PB\4EN!/ MRZ-A>IU30HD-E0HF,@Q+S(RX%H=];@3N^Q_CY%T?)1:(@=#:K3G\()CE/P1< M"@LJ]%4VPPG7FD> (M4'G+L+HK+MF ZW&T($R.9P'E?*Y>HQ_GR,#0^R]G8:0WLP9 %V'!Q@U\=+?;__ M]=TQ]B-/\-_W_P=02P,$% @ >W?T3*$E44(!%0 I_< !$ !B86)Y M+3(P,3,>V7#MI M]]L.1$(2;DA !4#;VK_^ N!3) @^I,3,4CO=5B9Q'C@_X.#@X,'?_O'B>^ ) M,8XI.1V,WXX& !&'NI@L3@=?'H>3Q_/KZ\$_?O_IM_\9#O]U]G #+J@3^(@( M<,X0%,@%SU@LP5\NXE_!G%$?_$795_P$A\.0".@?+]P]X!0)= M4>9?H#D,/'$Z",C? ?3P'"-7JN A)6*C0.:U@&R!Q!WT$5]!!YT.ED*L3@X. MGI^?WQ(H O[6H?[!X6C\87QX-!X 64?"3V9PMJY9U,/DZT;1EQGSWE*VD"5' M1P?J]0QR%!=2H#7[_"0"-(O97 ME E "M:?0S[3E $?+B!<::L.1^.ALFN(_0UUH- M+5ME(^$!\@2/GPQ35F^E M#@-PT$P=1CW$=Z2/YK6M0JI%[$HAS:N-0K965*).D43]-8SIANK1<'RXG19I M]VJF14RW"RT^'D#F**@E;(X8HI>5!Z6_H&Q])?^NIYG'V :7RY2)4O&C4G'\ M?@L5-6>"%LH-UUOQZL&%TA)K",I#(1N6:P9&A^.E 1 M_S".[?_M0.^MC'CC(@4!FQ&%'J$DB1-XNA(WJ9(Q!^6S3P=<&MM#4Z5< M-&]:*4F"">YPG3PX:UHG28*\CE9GQ5#3ZD@2+N>_K1J>8O!9%@!83NLFCL," MY-Y@.,,>5BH/@"KPY>&Z9"JLY1O(8B&QF+05_7XX'OTZ'HW $%Q@[GB4!PS) M/R(F(,/EMX,\;8YKP)$[);_KWWDC1,11$0MAKM?6IMOL&$:RZ&%LXT:6OT " M8J\M #&U#8?CT:_'H\,:.( W$;N?>XW(9SCS6O>(B-B&Q]'HUZ/1N!8>(;<^ MP7$6<$P0Y^?4GV&BE:D'A9'0[IX.#>XI9@.R?'IN_T\>G4'O#@6,7F"X()0+ M&>E.G+\#S+7<)CYL*P%V-R?_^5@+3_D\% FTS&%&*,A([:4_-.%S301:,+A# MQ,LY5D)<&,G*((YD[!$UV/^6$AG5+G>(:#G'2D1_K8MH)&./J,'^VI/]'2 N M=@BJE6DEKA_JXJK%_*'$[*$UH8"=)XR>=XEK*<R#^CPT\;QH:60ZOX*8_0F]0.(V MX1R)T $SY$Y(VYS?=U&DLBT=UVY+H6JZ*47* :T=2-53+Y6"0&NH_@IU!+&2 M ))]8M($?(/4I(74B<^( M^==Z*5IM4JP'4@-V]E3FD2&5J1C_HO\-,OQ_T9U+BQ@**0-DA.R!-%@^\_/< M@YSKW:9GZW-*!(.."*!W*T%E6*POH&@4NW]K'>Q>_?YMLTO&TTJ6Q^A4QNJ^:7C5X=S4#]&Z"4@:;G M*3W.T.\;H@W*!O%&8Z;V*.3($(6T:![[$,4"Q!?"$/3P?Y#["6)R0SF?DF_N M46H*K70>A>Q4*^>1:@.4.N"-4NAG(.<+I M"JF<+%GH8HUZ^#>1;.WFA\88P=82U!IAJ S08D"D#@B4/D J!%*-0*)25'C? MS3>,V6H]H@F_2O"+/KX"_'XO.5ALWR20J^1BC=P.C9&;%;<^!FF4<.IA5YVV M.H.>\DF/2X3JIHU*J2W0R%%5_J-&UD=I-7V25B.3L@(1+Q RV\,A^#UDLE9+ M)+#4?F_HFBV>Z#F40PFW^K!QI>U7"+"Y1!^320^:"O\*IG;83UL!&LJ3$\Y-\2! M4-X>[_FCH,[7)?5D.,[5-%VLMT+8P,Z.Z5$C3+/L_Q>$ GH$X@6:"=5S&'*Q MF,C06H9L]1>WRJFM\W_YO^+\7_$*NY7F!K+L]H"(=G.U^MRL,[7QV#!-MP'6 M^XE:J>'3Y98;2A8J)&6*(%4CDA M_J;H5XFI; F%1>,&+2$5'K>+,"F_;Q=YP!HD;*IX6-,UX[$A76-%M(?9FOAR M,VGE2R)D#'A-YFJ/I&)?#R(; PL^HR1GD]ROEOFI$ K9@0R_'N%R"1G!9,'O M$7M<0E9OLE@@LD>C[PS1:,P"2!Y ,^FQT=5$EY)P.G8&.79D([_ 7B!G4Y>K M:#VW%3"U&-N'JW>&R+0(7IB@CF2I@4E+T]TKD@K#?RF.CLR^\CD\.+N("(#5!\^FW] M)F&YA=R^!CHZ-O0'$Q:]#)Z30PZW""KCU$]-F2GM_<(4"&1.,60Y]1V#)GW# MRL#>.]X9TA(EB.S[1VR)5IG">IPJT2K$8F5H]3U!:+1W@^#+1F_?O6&*P$K[ M5/_"L$^4NL_8JS>A20I;!Y;1!\/ $I/VT+1-_%*>QNJ!1A\,'BCFT$LW$U>^ M@6?)D5B=R>B#P9FD!N^?]PAW 7R&+S6-G2UOSU)]-/B0D!IH\GX:.!-)/EG(%]D'4//&T.K&:V- MOA+&PLTJ.1C[/7G-F/8!.90XTFE%UY+DQ\PK1OWP+$! Y[LH&P)Y);2*F$O MW)F4@WU3?F;T%IG16W\,*]4BW3;:][;28!)2I+(O*WTTS$,VL.OW7$0=@G7H M@JACL/)!-,RT#9\JN%7VLL*MD;E>EN6OA[]80D\[D(!D@67K#>]0JHE6CLB> MH'IOG%S&+*++FWIL\^R$X1.3L9N<)=PAD2L6G=EIV*UV(%7MOG)'FT"W, M4;1T/2V1\@OEXP-*^SZIC*>&?D>HN]=( +V)3YG _]$ZMDI&M&1>V0H,46VQ M%<3B0"@/9 7V/$.QB4O+64D%DTH0#3/,(HA]GY]L&CG=&[WCKEF+<26BAMQ1 M$='L)NM]ERP!NM$,PTAJ7^YX;YQFY,'JY5SC22I/6=V[8[+E[:'IL3$T3:C[ M:>-F/JM 9O=(Q\8Q)F'24T>3U+_EL%].7XF&(7A/T=B/]8DM&GG_/)7=\1\; M'7^F3_3/Y<='RZ9BB5C3#PV6$ML' ],BN#YCIL\>:F8]_>Q@F4&;.*DJ'G9' M95K\LF#32V=59N$&GJN"A=V-F=+D5HSZY]:F; %)-+=2%USB!<%S[$ B)H[^ M3CDFBWOJX=K7)#9B:'=_IGL3LNS#FS!3 2"5 &(1>RB-EF\5U6TEP.Y-33& MZ6O85G3Z%W;>,[I"3*S5_1%_!WBESM_40L5(: \C3><<8S;AE1,QHYX#T,1Y MV>CMH9[IV)P9CEZZ+9-A6T7KM1A50E5(QI9 U??8VV3M!H.-A=R>XC =;RSK M3?T;9AZD\NP)75$F;>(&COA+-5)2.V]KH[?'S8>&02?BIG>[1_Q RG /2],$ M;@TV]C#ZT# 4V4'JI6^SV+F!BZOF8H^J39]QK *KEQY/,&F&@&&RB,Q3%YXB MH=W'FFY_1OZM%)ZNS,S'08WHM%7'U:P:S/G549N]UJF$^,EJ/3/ M6<6;_*ZQNHPC3B__$4 /S]?2-E'.MQY$M9E9G=IA=#8@V7^8^7E]?0(2WOJS M+RGW.#_=IS"NKL6;^+^F/*T^\?!]>-U8:S![Z2H?T4+-%\\#+JB/F#3-)T07 M#*Z6V&EZ3VQ=7O8^:5H(CCC_ F+>>K:;^1IIO7FT"Y M[Y'E"+1*$[;E70ES(1AM!'/?\XDU86D0PC;C:(UJ#TUWK#?KQ3T,=M5-OV=0 M4JN#AXCP!J.HF=0^.S<=Z]HM+B> M3V-'?TF+.E\GSY"Y$T<:"8OU]GC6X5X)<>$HJ@7B5&#XN2Z@18)8YAYX S1? MI*1O ;F);R78A6M5ZH&M9.U1+J)A?AIMH9EX'G6:3VEV(:BR'10CX/)V$+Z: M%5_%YUU3^?NFD2*F_.-TI;-$.^O]%J:5D!?.-ML@U\X]%+3O]T4=2T/HX;6GW?=-FWS&5TQ73P>>>?ZVT:,-&SJV4VN[%C@V?Z# !\=_N MJ7X[>.'N"5RM,)E3]2AZ0 @-M=?/U"/DA5_>59C-X&S][XGCL$#.%Y G^2ZB M$?P\8$SO#BC+8\Y2K.1T(66H >##C HM R?W$:+ Z';S,F(=/L$#^ M BI=?S$IT3BPM;7\HVJS0"$SV?A#4:G T=_ R]^O$(,4_>S9H )%U")/ZBL MVV<&GY!GKE/^77?KDKE8A,[S5V1$&TKD.TC<.TI6R=])?=O3?T.;N&AF-HD; ML"CG9+')6< Q05S=S#7#1) M.'J13@I==:*F=E[9+"F>QF?N*[V^]!+!S.> M[;/30I^UF/C;2/N1_$ K"\@Z(_D?L6O+9OAVS890RF=2]UBAQ*;GB,F(B=PA M>G;SY?)^2055QX+@:AV-%?P6^3/$8ELU*-_&!H02$O@G+O6ED+P)MJ^LQ&P& MR=<[&&(GFSQUPIN$<[6L4;"#U3,/7[FJ511ZM6IEJL&%NAI>!6ON%6472(9N M5!\8T/X*,8G(%ZZ_71K(OQ[I7#SK+]/&-6Q-W[&1IASI\#O4"X9TP1S")2\[ M@&S@Z^G2$XH_.'HA9T*.ON@?X442Q-8HU]D _B+]FD4FM%%?N^47>"[?(2GD MFESA%W6?J%LVVF_/IFL6*FW,%T@*5.]T>E-&A!02E)XYVFS<=0MWSSM';DB& MP^1)!@FJ\"<&771&BL.5L7R-?E)1)34 MJU[9]AU2K<>1Q=;N]U+Z#35A1E"M;X0,S8]>]_- <$CE>C>H8#1 M"PP71,XJL9.K3D69UY]Q7?LKB)EZ5EP,4',J&3O?R#[EHA?'DZZ$+-*/[X8U MW(;!#S,#25Q*,IQLPFQYWP&($W^XX0O/EQ(K-)VG9Y8\CSXKZTU)U N5NXSL MF*OG5JRZYF6K+'4#5US6[E% J2220;P>5!^1$"&#*?DBA>NTIVH"-(Q;*VS6 MFFG7K&?I- (M&,SWE,V'7>@>X1W1ZVCQ=Z(7/IW-5>*J0AW+"R:5NX4O:DYU MZ6'MEC=W\8=5LQ?Y85K;+260.B2#+8W-^>;3;!6R>Z%&[ON547'0W\$B.=R=X;G'57>HXN2]:_RUUVLRO.,,G(.]9=U MC94I+]#!ZF#G3XR>R>VMDK9-62&_6P&V>O[S,[SZ;S:%L)]%34H+GR M='6YZI+;&QF*ZT11;)E7D/M:&<[7MKW>@ON=[1[+K&=S5YPLI1F9$\PT6M_' M^NK,I3I*DG,[AN<=[+:)DF;?:7G?OS*J5O7S]Z?U!% MZ#S>67-.GQ"#BZ2OE;]N[XI6LO/9]*X3EV]6>O7[;2C\=>*5V8R.]C!YMS48ZJ67\0MUG]"+./.I\ MC2NV SY;&$/$;';N--)Z9;X\70@S*DMU+B@P:KPQA%M+='C 3?4VGSZ:J&L( M%YK)V3HM<@_7>OE:G>D-#U)DV;Z\7(STM(PE-A/#X55F*P[R>XRS@@ MIG1W;?_8+7R"FM_A:>OW_ZC!>-)LF \U0O& MVNNO/"3'\F3>%2Z"7)-HX3FS/T^/ZJ\] MCM;TKRB3;\(]H7I'KUIQBG>&[M;PNY+;=0SR6R1,MK#4\ P1&=^*G(%WQO2_ MP7H;+6E>LR7%6WW7+2R[M< ?9KG^RV/U%MJ*,J\_]/PIE9-@3.>YRWS4E2O) MY*JJ4'>/'%HUU]%=O4HF1;>81FH6M0$+SU1S.:/QX>\__3]02P,$% @ M>W?T3-THIVQ+WVZ>P[6.K['=GILU]3,$P\M,3-Y2TEF4Y+M[%]_ 4FY M:Z%$$E)ZJIF:;(9\7XU?=R M=OGJ]W$Q_>/5>5-?O?J];OXHO^6O7R\+O5K\85)6?_PU_N-K/BU>_9B6?YV. M+HNK_%T]RF>+MB]GL^N_OGGS_?OWO_SXVDS^4C<7;Q ^,U=J8U?Q+^]OOWL M=?S1:XA>8_B7']/Q+Z]"#ZOIHNT6C=Q^_N/9]]_QXFLHI7RS^.W=I]-RW8>A M6OCFO]^_^[SHY^NRFL[R:E3\\H]_>_5J"4=33XI/Q?FK^._?/KU]5$F5S^;3 MOXSJJS?QMV_4:-3,B_&[,O]:3LI964Q#ZXM*+IOB_.^_?,V_WH2.0P[1LMO_ MOKG$[.:Z^/LOT_+J>A*Z^Z8G>6PQR\O) 6(]*3B,=%_RKY-#,'MSLK15(W^.2^G9?RB MY8#W4?=0?7Q;S8J+)N^G4SLK&ZH7[^LJ;T:7_?1B9V5#]6+!AG_.B^FLGXZT MJ6^POI2C;V7QO:>.[*ILJ%ZJK8M8\GID?\J8)O_Y6=.C17A4/U;M/Q6R4 M7_4S1+OJ&JH/T;08SR?%V?G'IO9U7-31!@ M'G11L,H^!K(4:C)9&8MGYSXOF__*)_,@I)I.B]F224TQ5M4!1DE*&8;"K)V% ML[MD'_*9?'H9_^\"'M_R27 6I@&3SY=U,_M2-%=OJV]!+4\^]>45OX' M?S23?#HMS\MBK&],7JFG-W8X"NUI&.BYM,B=:]5VI?I':\> MA$B+6KM9?6A]:?OR6]44^:3\5S'^-2^K=_5T>E8-.=C[M=<+%O755;FL/<@4 M9V%9711AY6PQA+N+#BSA^[(JK^97[XJXUN4W\9O?JG'1?*@K$S_> J@;N04L5TK:"?J2MIO6D',?M0YU/XD!_OBR* M%N; KH*#2OA7\N1G.YU/E)_7TO=+=6,*2T MJ\D>?KO@X=5U4UP6U31,F[=5*%PO3'93T)"FX:UZ_9S:&] MV5Q3'_+;XNLLHA1\F7*F@M8*JJ"5N;ZSX*#2[:NK]ZYH4.GO;=-W=741;9GX M:=>NM*HU4;]6ODA84H;J8\L6!NUON_6V9?%>)%T=V(7F7%C69S=OJ_.XJQ.5 MX4XQ6Y3M0T:7-U4P.*8?B^;S95@@=\FUZ?LA9(F+15TM]:[.I^4H@&'+R3RH M9'>]?.H?H4SN2;B_5BURA<'U3%+JHBO-R]C'823N%VEQD((E:ZJ?= M)?N0[V[7\7UPAN9-NW5Y:Z'!I&J)6YNR@\FXK\VP5R6#2=UN^K8HVH>$O];U M^'LYV:D#GW[79]LM1V_#YWU*TFYHUG_=AQQ+;^9+_F.W$&L^[5F"NV7N[/SN MI^['=?"[VLZW@RH;JA=AL;;%>=$$HRW\8G'H<]!Y4Q]U]]S'Y1_C)JDN@H57 M?&SJ;V4,"ENM9KYN[K[>OY<=:N^YG_OJ^Q9%>Y;P4S&JJU$8]-4QXU.N^Z:^ M6N[/S>OY]&Y;8__^]--0S[UOISXW%NA9FGB$,*HOJGB($'ZP8NL!T[Q=1?U( M/PN^9!E 61Y*[Q9R_?=#R/)0V?W:!&T0--R'8O;DL]5N:7N4>VQDB%['Z32: MQ;" :IY/U%7=S,I_+:;2ODMAMWJ'Z-O^ZK1=^2%DO=\FZF\,]JESB#ZU59?; M2O4CU[P1Y[ZKW)"RM1S/EL6'E+3= +<9\U%7JVT90S?*(-I=%Z.\FJF1J-Z MOCA]_EA/RC:A$X?4E;H/^ZJ /NI.W<\O(Y;GKM$VU9F*)E:#FR+HD-) MN*_&VJ>.H61N1\7=)?N0[U,Q+9IOA:^;T-YX/IK]'L&HVI@T+8H.+&'+,6]? MP\#RMAOXUA7T).VL"6W,F["#&,D/)U'ZH=Q4=2L+6@[NC9!_RW?K[ M;\MXL'9KPOSG/)^4YS>AX94%LU/:?>M)*7M+1AQ872\]*2ZBTC;S:;Q)UH1F M?RWJBR:_OBQ'>P2W[%E-0LG;#L%!M27LQ[Y&1,=J$_:LG5(ZJ+)>>A'#=70^ M+1:AKL'<;C_:&^Y\U8C8((\<)5EZ[L M47&*WOU6E;.>^[6ERN%ZM/ZG*W_T_FIGIRX>UL: ?8X$.KM>+,]]#.'N^H;K M2TNEVZ)L+S+N'7[^)@+XI M)K/I[4\6$+\&<)6&Z-]7/\Z>2V3F3?-@RVF2?RTF?_\EM)[M+)-IC T"Q"'! M%/4.*V6=9%)KS!'T!CWNYD+YU,T*UV'[>1L-^ZF8Q,LK>_5W9]G,.F6I1 0Z MK2DQ3@O F-?84*&Y]+I-OQ\P2C6C5W43^/_W7^ OK[X7Y<7E;/''92UY,WI& MM,?IHU9?O)G&K &QQM?EK+BZ+1_38O4^HO6PF(4>)>')(CSF8WX3U?-N9JSY M.J/,8>*]IHH@JC54W%(A-<*"^# VK>; >BZ@%\J%[BBE&OW'&W$W"RCRR7TN M@]V,:%E#%OJN/ '(!M93CZD@F@04(#9,\O#SPUF"7RA+AD$N%7-N?>I@',WO MXV1O=A-F>\%,&P,X0QPK1JEF0(0^V_!OQ8##$/K#>4)>*$]Z!2P5/58P!(Z? M%],8:9Q/?+&'K;6A8(:Q@%@)Z16PE"FNN(! "Q) Y9[)#FJ$OE!Z] K8;GH\ M=U_B3VZE^%Q,PK<7*W=[\VCO+),1S1&UQ&$I%-722,@Y-$$%(FX@M>+P@68O M;*#[QBJ5"EB3Z^HNK\4L7JPOQZN0]CN=MD4O'%!;QH7&A&,K*(.4R.=UA+>$OC$/I4.RJ0;XT^;=BTDYS//HV$V'10Y0#Q @-5C87$L1)X(D7 MVFNK#A]M\<)&NR^,4FF*VXM7GR()%S?R=]L)&\MD@(:.2&VL%)Y: *2P2GO M=;"/E!(=>"!?& _ZQBH5'Q;!:H=LU&TOF)GH/A$3S*&P7@)%9?"^#::&("D0 M,[C#KA5XH=3H%;%[?OSMS;I-X_YWD]>=*O2X?;T[\?? C1V6J7M@H5IFVAY8 MBI:9L@>6HGV:ZZ$%:9>F>F I#D@M/;!$[7)##RS$OBF=AQ9GT-S*"0_SUG3N MT]T]W[?CL(*5YV5^=^_NMA.WV1\>=R9\,[\JQ@_N%;1S0_MH,0/(4NP8L1@0 MRAE1&$EDI//<.D0L.-Y!XH$]7MO3F,EP%?:]RAW;/]0M&\Z@"_ BR8*QZZFD M1EH%%*/1(U+:.'GJ1YA'9^+NK87C#=<1][@.[_32YEY^&6HI0M\?6K=#3Y$- MS6?8>7&,6S"GT[]?/>GGBC]#-I+G"ZWMZ'WW#3NWEY& M)$'.6>04\-1R*X#5.CC<0D"(N.H0_)+F*/MGGA"'CM)+G &W%^EBIL/9NMN3 M \^(C>UG0%'KH2'7)D7%,*#4(0*42-T1($9>8(MQI[9 P]]3B'GWD&]3UZ MJ692"Y+?]< ;H)&5"A.$*4)* PCA[Y)(L6ZMNW,:*<(U$8+;:C77B/#!0#$.4X)9!W,D31Q(*=&YE,;L9^\-?K"YLKP+'TV[[;)8CHYH2)9GS$"-*"5/2*(R##TSN,*1%-=@6V M9:?4^:QH0I^^7#;U_.+2E]\6W9NN7C2(:72F6V_,]ME.1BUGSB#FA!04(BC# MP!D'!#):5S8"2W JC M!0&0*@\$QY1(PRT0%'#H3G'I.]XB?YI+UMYCV5HW[ E:LKP=R]#:I_-W9O*F MB6EC=QD_K1;H29@C\3F>1.!F_,#[X MED_BHOMK7E;QY<.SZD4L3-VMOL?FAC>(R,!,0@-/.61*""2<-8X3Y00Z8H:Z M+3T8C>97\T4>M<4+'CL_+4+/I$Z?B.QJ.#[?J!;+/ZZJI<&C71K+Q- MYO/\T:X^S;#-;;XOJ_)J?O6NB+>*\YOXS6^AU1CA9>*#KPM,5V\95Q>+SXYM MBSV69NKGLWE3K/JQZL+4;O6)6M:0>2H4] B \M>%66048=8<)@" )1XHPT+^E8";T&,G#[YC87>1_YI>I8AX4R6SJ== M)]Y67[[7BPW3[ORZKRM3U@II@L;W/"P"5@4?FE-A'&0>.L!/WF(Z$8H=C.CI ML2RT6O3'L[O:,FZIM3;"#R$-=H8"EB F+=$(059=I 0ZQUW%A /20*$,88X-01B##K$&6:YG[ER3#M4$A/CVBWAXV] M$.VVLBQXO91Y$!!'ACIC%%0,.<0=M-081T[]&N+I$.U 2$^,:%\NBZ;(XSEW M=Y[=UY4%.&RP)@S7&E'DG330.X )1L @),RIWS8\$9H=C.@1-RF2)8?;(L/0 MIU9U-:TGY3AN/>I\$K=!/E\6Q<;@Q02[B;ON9*ZNX4EH&/0>FT!4>Z6TAE0"226SRG1)990HCF'/ M87FZJ=D!C#_C$TZ/"'N/9-)8A&%YLBT8? TMUGV>(26UE$8['TPQK:@"0EL* M'8).0*([[#XF.DSKA04]0)/L%&QUM_4^T]F'HD6N^&W%,A#\/4P0##:YIIA! MR30R.*:_D=1[VR'31:*3L%Y(T"-$J\;6AY]EAG"G.($^X$(QL(HZ MB.*+2=C"8!YWR "?Z'6I7@:[ R2I!O=C4USGY?CVW=YJF2>BK=77HG2&,#66 M!+_+2D6AI-IJ+!Q#2@FG1)=S@40O2?5"A?Z12L>0#7G,MJN#;<4RXCSD@?S8 M$T\!0!H1$N:'0U/T83>;C8+ZVR'?5IGB& MI?+*8,FUY10BIPBW'GNFO?(4Z0ZW:5-:" >S8@",_G=E/$MI&AP\RB>>H.SV MSO3;:E1?Q3B].RYN&=O-A3(A$31 206-#38L%8[$?Q@J4.@W[O"\8,K5_^#1 M[@V99.<3]V9)JW0+:[_/@##,0QQ8S%4PEX*6HA#KX,D$U468/?ESAHZCW@MIM$JV/A6YJVA&PL(4;!]PS*KK&G[O'3[L$!&O%'*P(B:H-!AC:1$V!&@.";4G/PK M)#U2H!>$DGHR^V:/VUPH0P!1PX$ A!MJK)<:.A^ "]WFCK9[.>Y$5,'!5D!O M\"0S_>KJ(AZYQ@0RVXR^!Y]EWH9YX3EG5 0_SS@M,)>.:A5F!B6G?U#9B[EW M."!'VZEZR,O]MJL>E\P,@MAS:^.[1E0)K)75PFD.JP9Y5FA[(/ O2+ M4;)@E7VV+];XP AQ*>+N>H0+@X 24$IJ;FRT;L#)IU,9S,GOC%6RL+;ZZJJN M%N+NC&![\FF&-+,:,0H#C6-Z.Q5)'=2>U5)A(4[^DF2707H:L=8-FX31"TLU MU6K UWR=*>PXT( 9)R75U&J')60< &4EY[[#3G6:&=_CF'>')]6P?XHA[%4Q M=GE3E=7%PY038=TJ1^6VU7]WX;!H"D(A,5PQ1X$QBGG*<;!F)0UJ$G58!M)8 M@#V2HG>T$NX#W0JZ\%J"1KMNBLNBFI;?BJ55$_.1!%OF['Q',IG]:LH(X1HJ M"QB0D#I@)+?0*N MD5@+>_+F8X_L&1:ZE#;%CM0?&\R+#:4RY:T+_C*$VGJ* MG94@Z%3M"8>&."I;):@X$1>S7SNS/]"&OVJUX;+1QSSNAUP6LS)4_%BF@>XZ M?9Z%?RXP6^:,]9/Z^_'N/*V_[/"Q:,HZ>I/-,A7-\M_;IL\>U60.26LXX@AJ M0@.A%;7&>"D"0RCRX(CWIV)T=^C"QZ;^5HYCNOK?IM&IOKMHJ$:S\MNN<^CV ME614064DI2+,$@JYT(SU0K4NC _>JYG3CW MWV6ZPZJ3AQA##]IP9!P.6:O"C9[8<@$E0 M]''AB6OEIV):--^*_17M(=5ES&)'O8^):6)*&JP@58X+ IT B'@ M4@)<4S'._0C"3X.!KHLJ.'TS'_#\?!GL'!UD'D>C/ECTB[[NMZYUJCX2U4>4XZ>G3^ZCW-W&6<+A]I5D&GFC2$$<(L9Y08J;3!1V$@DK*1=DK_2 MGT9##0)ELEM15]=YV40!S\Z?7M]Y&_SM\[(* $_*;\5XK]M2':K-/ '&!)R4 MQ(1*Y+236B!IXI5B#;IY^ #Q"4 H)DX($:]1Z:[W6P:<^G#W\9V%/+\BE2]^QSMC;%A6QMD"& M)12<24Z]Q%1($[QB$6:"ALY@#V$'@TC\++SH!;ET]WD?>YYOJ^>9*;:M4"V* M9TIPI)P5VE-"A?,J^!.>:^_#NFUE%P$0'H\NBR/A>UAVY3F,.'3.BJ#N>R?:/5]GMO]1J%%!J"CV?EE41W(!E=.X"Q>5O MQMMVE?>H)B->8( ]-%Z[8"$:C20*,XU[!A2FL(NE?51-U6G4GVXV#P?HT:BU M,?WA/L3:6$D&I(:20@\=(F'Z*JEIT-;Q:CHFUG4)KD8_+ZWZ@O-HI'IZCK$>J$TD])3PA1V86YUB90\;FC1H!3JB.+1F+-GAOM6Y3-F MJ=72*.(5H";XL0@32)SR1!$M73]9+G\V!O6 9,+S]E%1C*>+@+I%X,J^-&I5 M0884(9PJ&6!%U#DJ*):.,!I^"L./.KQUF"9_9@H:#8'DD;TY7U9Y->KHS:VI M).AD"1277 +KJ,5,<\"8(S18AQ1R M@P@(!1S1[N0S!R8@:TJ 4WL7OFX^%=?S9G09^G)V_B"?2@O78G/A#'G(A89A M\7**>BMDZ"_6W!CE//"@GVR$1_ K>E6"?<.8FCR?BD7*A"]UF!N_E[/+>+<^ M0!/ZLW MNE [,B=N+),)P)5PPLK05^JU4U($-Q['U^2#V2 [6&M']5R'LM:Z@'=8=+&S^TZU0W?%+Q9/;\\VP M7GX-0$08[]( S6+6FP!5LQJP)@\_7?3/7,8_OJW458Q"C+;>VB*WX64W< OG M$DF0(0FHUE(;QC15#&O(#='6<,&A ;[#]8BC7JGID[ZG.12IID)P7AY-WRV< M??II%JJ4!#ECE><4*:X10(X!PPRQ87YW6$J/>_>F3W9U!"W9_M;Y>3$*-'8_ M1@MB?PJ^QEFU?B-\VW;6'M5DG@;7Q/NXQ^(H")8H@H2K>%+"O0\+1B_>WTL_ M)A@0T7MN#9^][F'ZN%609?CM(OW>LVR-CZ5,F57NN2PM4G=N*95IAX4F#" . M#/5 B)C3Q&-I ":*HE8[:8.="?XOS.[5RUB]P'1>]P)&GVYIJ\S# G<_%75Q M7C?%@\CD]V55-\%P>5O-BJ:8QGBMQ[4LLW"^+V:74=VU"4=(*$7F;;"P& VK M-6;4.R5,,+:\, X&]U2C+C=D4AF^A[#J>0SZB2*>BOEW$?VMM-V:KS,MM(58 M,N\=H@1Z 8+-)V@,%P$ X@Z)NM,PZ20Y\/3-G\ZX)TOKU 39@L-POC7_^X.O M,NX\PHHH"^(;13[FI@+AOP@*8,,/3W[-[#0V3Q,Q'8Q+.G]X<;UKFY*X_21S M AKK@ (\](![H@03S@5G4 8M+42'<](T(WO0:#SS;P\"(]5PQEW(L_/=MR8? M?9N"Z9^1)%]_[;>9 MPT@S$-,'$$(Y,4HC906ARE"%#>[GV<4A![W/-;HK/*F&_',QF<0]VFK\/F_^ M*!Y(O&7L-Q?*F*#.(F"M8Y0"S83B1E,.!$9"&T5/?37O,&Y/DXSU!5(ZHVU: MA+;BEJ@-Z]6D7MPJV\V&K>4RC+RG0=6QH$)I]%\ PC$:T'H/J)(G_VQ7?X3H M$Z=DCEI1A>Y/8K+@\559E=-9!.-;L9L5.TIF!#M( 08!24,)PII0*I#7U'!% M#>P0=)3F>D-_O.@7J53,>&C./,_-NH48VPMFV$B%'8#!$?(46R>8TU)#+0V' M5I_^DZ[]\:)7H!(N(K-F/IK-FP"!NE<@LATQ*&D.)7+SW M'F.'D$?28Z0@=/V\B3-PR$UOYUI=X4FV.='M;=!6KUIRBIVST'DG).74*!:6 M5(:-0,0C3_O9LGQA)_,# '>LF)G-C\[W_NICC%*+@3E-,2YG#T,>T[?X(::_ MCPZ%C2\$3XX@P>?193&>3YZ$OV\79WB%\E"6L!:.YDVS/;/1^@(91.&_W @K M@[H,EIYTC"@3V!_67Z-XJ\WN87JXB"2OH@D9A\$$'MS$':E%L.V6?FXKE@7/ MTT*N@RLJ-:48"".MY-)(:1'FZN2?K>PZB,_>5NH-JU0+Z6T"Q66 [O**05#D M6PFQMD0F##4,6641"8X,1%I:&)89SV7\.^DGX>"0=E3O9.@#IZ%7QQ9J^GT> M7=<3JXS]+18"1#%GWFXZGGAV+>(_XPUOUC M\/M'Y74^>5M]"#!_^5Y,OA7O@S=YN6U3I5.]&=8* HR@0$A2LE!?%E/ D/&0 M(G3RD3:'#7Y]/ A3Z?V]^O0_1=Y\^5[WQ;)5=1GT*&:X1-!A19V RKNXET6( MHT)BV6%K+XV#E9YMYTR>Q8GT90L81*Z$0+MAPB M&@2?6$*,(-;I# M3$N:TZCC\.H Z(YF]'Z)CZ ,N"=2CQ:>84S46\T6V_OG=7/U*+BN]T9=WE3! M"XVWZ!9I39(U%+<)ZVK)"9U/RU&,=2@G\UDQ=M?3I?=P-.?A]\5T*\;J6]'D M%\6'^=77HCD[7\FWS+QV-I]-9WD5<\)LT25[UI2YH%4Q(WRQ00\PD\ I;ZRS MCF B0*MK-$DQ>=:%Q6#NC\CZ>C( @;7$:PX@HLP:Y3 3D'L13)S@:I]\R/=@ MXU^G0S75.KZV#YN04N/_-U\>:^[+M=TU9E)#A@W#C#$:WY>)P3,,&AA<-6*P MZN?4[V=E7>_X#KW@/UV:!E[GW=7UI+XI;L]08VK.E&T-?;3C\[+YKWPR+]X7 M^73>#'R4M;:UHW0QV=G9VM8'YNS3]^T':V!H\&[;&1BO-8]_#=G&G3$=@_\> M1VH<>Q_^M$)Q!KH5M3P,VK^KVPMF$(9542+'G;54"""IU@!CSRB$6-I^WE(: M/+2MPT@^O2;5)US)KLPMA?9%3%$U.8 =FTIFV%)(H(.::TH-1I(B$VPH"SS6 MR)&3/U_O:SC7LZ0GV!+39!&#I*KQNS!:AY!E>_G,:>P<( 9ZXBB#2C-$E-84 M,^TPT?+4'9MA*=,K>*GU2]T$^*M#],N&DAG#VCB"@O\'%95:"*P]-AYJ@C1S M^N1/2@;6+_W ECJ49W\C94?)C A@!9+,&DNHXU9:")6G4C#++;8G_RA"WU9* MOW@E#_5:+IN'TV1[!1D5AB+K/58JS Z@)82<$^_"7XQ%K(-226.T]#:ZFP+" M^H0O-7D>+:"'4ZA--1F",FA3%&:I150R(8Q0U,9,C,@J*#HD0TVC=H8FT@ @ M)M=%RR6V@R[:6D'&D6&QIT&A((##L%,* M/16 <.@4HTIL8H'M$]^0[WK\.YB2V_0'8U"X0_+P+V#Z;.^ABS@:^.FCH.:4469 M=D1K!P63AAG>1&HDXOL!V3-K<_6QFY,053\ZV(*?/5:-3,\\F^+-I= M84:DLTI:%N-?:'P3#!,2T.&0Q$ \=$:P$,9@1@0,FI\*(1Q'!FLL-$+>=WB6/M&=WV%-\\Z( M'>WHZ(&SNL^YT8-BF:/66BUDS#I#%99:,\LQ-5@8)Y3I<'7T6-SHV8/O ;7= M_/B:?[U9C#I$JS&//WG8MP>MQ]#QJ2W/P^^*0-;X;->/8KS(/;4SHU\?U6;( MQR>=L7>4Q9?JH8!(!X4:IJ, T+J3OPO0S]#61T/T""O3@U[]5HUCOLOR:PPN M7^U,WT9NMUNH6E:6$1-TO(J(A'E+G%86.H."TF?&4ZY./K53KSQ+AN-QV;4W M@S(O,-46*1/<6^HPEV'R%>R@?J78>CZ%:=0S/KTN[(,? MI=TG<%MFH5P\W3D-U:V\FS#G[[X^]F':GX^N'?+HVLF,A0U_F,ZVWAWM4&NF M$=?2"*7"(A03ZVJ&('(T_(QQX]"?SXKUD"AAGQ<]]8NY/X\1AMZ(BZO4P38PKG0<:;^_+Y;-LV<:_M M9%0K)P0,[@/F5%@ID9/""?!"(1VWK"[\A\>AKJ&F?$[1;JK,PG^_-J M5XV98 X[2QT3&%.@I:!A^DD-$(':0-+!(4ES^)^(7SWC>&2>V7)Z74_+I4&T M\P&D]I7$I(\(4^@M,!UL!=KD8R-*< MIR2BTL&0G0!-%L[^11%^>(BE_K2&+$X0@9PAQ(HP0YP&!A NN9%*&.X[6.C\ M9U(^'7$[.(QD@SCO\NMI$5_8B5YH]!S4/+#Y &2FPH1EP&JX!H)1TQTAC>P8H2+XI11X>V;]*9RYC& M]^S\>=#=676?R6&I6/>DVCY59U@"3Z&S5DI.B72*,<&4HA80BZWO$/$Y>-%OYH4]VN./S9W<_JB[>!B2G,1JFGL^VIBOMN86,@#"A ME*882TJY4"I&&@N'*'. ,-I!BT'P\EAV-&"/;'#%K.NSYO;PI7W$W"'59918 MXP GGDE!PS I[0%T1A$DE6:XRU,P/]7>?)\H#JK,HH:=SZ9Y-?Z_]=>I&LWJ M\UC1QA?A^JDX,Y)XIR5G0B(JG=;>$O6 MTQHR8*$W*D9L(D0]]U(*)0DASAO&".Z2-O.GVBKO"-R@NN13,9LWU9?Z+ARU MBU)Y5EEF);0(($&YA90$SY4S H*+X864UNHNVN5E;6LGPW!0MJC)K&BJ1?C3 M^[(JK^97X;.S2HW^.2^7NQ,;[RSU5'WFA%%0!/$EX!0B*R@18PE#WU,0] 2Y9/,/4V',"" " 2N]$E]"HGVHO MO _T$H9MIGNFX+>J":A<5.6_%C=>;B^O#Q\NNO[NZ. -F0!=TX;-+G-NSIVTOF$$,8W($PCTU80XHJ0+E 14$ M"62T.N*#]%L$WY4H;%?13%#D($2,P=!;HJ@"6,K@!FD'M7)=@A;2[%7U-:CU MH+@=?H1S=9V73?0YZO.G@MB@E:IBO!"R^#&:S./+4D]?IWEV<'-HA9D%WEG% M(:$!402]4-P:R1!3B.M@6,4>QQ!APPP0%'BH'O;92$,Z-HUV\3?PB298,RN$-N<=21]-V M%$6NJGD^>2CXB3S6]*>9\9!CS\?G0QB++]^+27!)ZVIV>: 1TJ+B#"N$$+50 M+?;ML=54&&=VKQ&OOWNC?JK>K+.) 6 40 M,)I:3I2!5,;HG*!2M>(GG_7D)!AW&)@G3+30_+;[?0?6F''.1%B:F7764XJM MPDS$;/(0">>@[? .59K3N],AVP%PGB[=?#UO>F5;K###C*NXL8=C(#W#1'") MB-5$2$6HDAWV1M.<]YT,V0Y \X2Y%K[MEVOAVPQ::[QD$C$JJ81 &V4(\49P M!*2+!\2''I<&U_-$^3:^I\5C2]$^Y1K1DS!@"N8B@BIXQZ0;3PX5_< M(@<-[^ MI#ECQO^/+HLQO-)<7:^]_9%_\(,?CKV+>YQ M-F6:-@[?_-EX%6)9]\WJQ'WNOGC;?6Q MJ4?%='\*;2Z=L=!%J!P!G#O*-9$>2V\H":N9E(1V\$F&W6U)09S>8$M.EVAP M3,,"&0^\]J?+YM(9E$XI"!2TP0:B'$N%-&=,,R$D Y*>ZGY)"KKT!MOP1MS= M6I_0?KMK;;:7+L+90@@:CB(#P@8 M:JR7&CHO '?,!"5H6RT5P_3T5MX;7S?K[ORVZ_H>M63*Q)?9G0OZ0E)OD?#" MZ."B!9N!4R6[Q.XG<73[&.8Z%7RIEL_;S-B?BJ"KYD4KTFPLDPFF)9)02V_# MZL&IU))HK[4F4,>SOU.UK :D2%]@I2+$ H+/\VKJ-,@%!JBRPU$.B3/WD:@!X]8S:T&;5IW1_8OCEK+O)JM=\5W=GRHBK/RU$> M[-G1*-ZU+*N+C_6D' UI\^PC1#(;QF^-?]T#5.GV8);B M[:;ZDR\S#:5#P2A6-I@\T%.)D(J)%Q3!D%G>(?PV48SW$&/?!:)DY[#+[!G+ M7:71S9B.YC]?%/ 5: M.:<[Y"A,8SSVSY3AT$OJ;!RR9&XOF&$LF&-.,*$8]=S*,(6 8 QK0H&U';B2 M)NJH?Z[T"MC07L9:RVY@%^-C$Z&9W00C.KYIM'/[$O=UUP7%[P0PP:"F! M'L/@KEO/M&.8Z/ ?C*P$I[])VL]PU@-BEFIM>G#-R1;733%:)3$OKB?%RMM^ M&(:SL8];N-17$UE," .=E%!!2*&4D@O(F/" 42U@ERC;1&;T(+0[$KQ#KX[K M%H]D^TWK&A]X95Z=* =K-S0>\[C_'CM;#7J^N:7-H1'>TO3P0,^:T."\"?;A M2HRDC26 ]EF; V-Z&[/YMKS/J%N-_W.>3\KSFR#%:I?V^ (,C?WGXB+J"C.? MSH)9WP09?BWJBR:_OBQ';ZO@IEX]NMU]K/9/!(9D^KRE/$//DK7/<21N+AWF M:YM?**3-6,5%7.;LYMD2_5>7LN+*L_^GM[8')PJ1-,7W7 M"Q<'[.QZH5N/BM+0TS3V\[*>!,]@NGSX-6%3NQ%=F=OQ'U\#,O_XM_\/4$L# M!!0 ( 'MW]$PZL&=3*V8 $CK! 5 8F%B>2TR,#$W,3(S,5]D968N M>&UL[+UK=QLWUB;Z?7Y%3N9S.KAM7-XU/;-PS?$9)_;83O=\J\50)8MO4RPU M+X[U_OJS05TLRQ)95:PJ%N4DW9%$%E# LQ\ ^P)L_(__]?ER_L.G+E;;=]=XR=WC M^=NS]7V!AP_#SS=?WC_Z3=5_\NVSU!CS\_;;^T=7LZ<>Q$KIS__WU]?OMY#\ M-%NLUI/%M/SQ?_ZW'WZX06Y9S?O[UY]5S.8MFO6H8#^M^S#Y8]X&LZ_+==$VMUG-%N5JY:O+ M/V:+[3#9VZY=9?IJTR_SZH_)_+=RLZS";/)Q4:W6L^G*3O^]F:UF^8F: N^B M[K[Z^&JQ+C\N)]UT:F]E??7BUVHQ64XONNG%WLKZZL66#?_>E*MU-QVI4U]O M?9E-/\W*/SOJR+[*^NK%FW5U6:Z77X_,WR;+)7[]J3R@1XTJ[JMW[\KU='+9 MC8CVU=57'[)J<;:9EV_.WRZK5"TO)PF_6DQGD_D!O:E?:V_]VEQ>3I;7V( - MSD6HP+U%LI1V/K_5*]^@+LWH: MSOZ27;3/3U87^?\1\?@TF:-=L4),WE]4R_6'L>CE;7PJ@$<.B5F]4MZUOV+[\OEB6D_GLO\JS7R:SQ>MJM7JSZ%/8S=[7"1;5Y>7L MIG9L4QZ%L\7'$E?.&B+<7[3G%OXZ6\PN-Y>OR[S63:[S,[\OSLKE;]7"9\?% M/%/GS569M;3%Q^UC=476YTM[1J6IOMNBJIY[4',*J5M!-ZU=K*KY["Q[&MUD MG@7]_J(L:Z@#^PKVVKJWDR7BK2O/JS M$;H[*^BSM;>#';_=\O#R:EE>E(L5#IM7"RQO]77;WCQ?4Q?M#^4?ZXP2VC*SM<59"Z>"6NKZWH*]MJ[I7-VXHEY;_T4W M?5TM/F9=)C]Z:%=JU3I0OVYM$5Q2^NICS3?TVM]ZZVW-XIVT]#:VAZ^+N*RO MKU\MSK-7)T^&>YM9HVP7;8R3Y0(5CM7;UZ[OD^VI(7BVIQ,^^Z MR6HV13#";+[!*3E>W9H13=O;I,X^^E2/I+M+==(N+%Q=EZ4K%^7Y;/T6]:2] MC7J^2$\MJCD_[2_91?ONO8Z_HC&T6=9;EW<6ZJU5-7&K4[:W-C;5&1I5TENK MZPW?&D6[:.$O577VYVR^=PY\_%R7[ZXIO6<>[[(E]43S]--=M./&FODP^;R_ M$4\\VG$+[I>Y-^?WG\;/5VAWU1UOK2KKJQ>X6(?RO%RBTH9?;(,^K>)-7=3= M<1]O?LU.4E>BAE>^75:?9GG_V.UJEJKE_=/->WE [1WWL^E\7Z-HQRU\5TZK MQ12%?AMF?,SUM*PN;_QSFVJSNG=K-.]/-R_JN/?UIL]G"W3M7Z,M.4-0;H+2^QOY]/-]M.7A9/?+$F<#G.%^*]>/'KOU MEM9'N<.7]-'K/)RFZ[PM8+&9S.UEM5S/_FL[E)HNA8?5VT??FD^G]ZW%6JFW9]PA%7+6M$.I]XM.,6U);EZBW:^67Z<+&YG MR[Q]8X:JT?EL.EFL[71:;;;1Y[?5?%9GZT2;NH;N0],IH(NZA^YC'_+J16Z9 MW3>Z^>U"C>KAWD;O*M1;J^JRI4;9WMI8;VJI4;2+%KY=5FBGKJ]SO.K?F]E5 M=GGN:]JN,GVUJ:9@:Q3MJX5-9ZPF=?35YGI4W%^RB_:]*U?E\E.9JB6^[VPS M7?\S@[&HH]+4*-IS"VO*O'X-/;>WGN!K5]!1:]=+?,=FB=+VFU4^2;;$U_Y25A^7DZN+V;3!YI:&U0S8\KHB:%7;@/UH MJD0<6.V /:LW*;6JK)->Y.TZ;K(JMUM=4=VN-R!VENJO78UITJB6_MJ]77-F MT^W>W&KZ+_OG9'EFI]B$?.#JD*XTJ'B(WOV^F*T[[M>.*OOKT=.?WMJC7XYV M'M3%=N_HL<^90&^NMLMS%R+<7U]_?:DYZ=8HVTD;&^_F[W?7_K>UUQ7TOH+/ MMFZRG-XU\/;7AVV\SZ\S6ZQ_/IM=_GS[S,^3QYO%GLG@4)V?_@6U3)S6V MC[5L%/Z>SX-4BY_.RO/)9KYNV<1GZ^FQP=7E9+8XO+U?5=-Y<[>U_W197OY1 M+MNV]:DZNF[H!=:WG&[^*'^ZAZ9E+L_*LCS<].5?T^<*G9O+NWK<_UU*_[VJ7&^F^3;E%=VU"7>,IWFXY M>SY9_;$E[F;UT\?)Y.KGO"+\7,[7J[M/MFO$3X3>IES[[[-?M D['+Y M:EU>WC=J/OFCG/_]1VQ 4:=8X8A+WE"3*+<@P5KADLI+%&C/12)?=W:K0U7+ M6_S[[>V7#1Y/=&#EKA_\M>7E#@2:5E5$&9FCG#&$ H2U6DDCN3=6)"5T-'50 M^<)+NYS^4"UQC?_[C_2NY.V4UVC%SND ^Q!M-2A:V#'\8#M?_\=T7J&R^/9&2DP&\9,8'9SD3CFC\F*GCD.>K?HV!.\U@VD^-;\W] M_$GQM)KYZU>&U0,Q[RU3!&M8GG2M\@&8(4X($,J%@+RGUOLAQ?N4E5A/MBUE M4?6#TE #_S;SSNI#=0O '33E:KN#?L>XWU>TH(1XI;5.D250!IQ,P4>/RW44 MS*?3X,7AZFS'.+4>]T^8G._N3Z:\.L,FSLYGD_N=XGG+3X*^XX)W*/K>-3]E ML96O9Y\>-OJFA_\L9Q\O\L&N3^5R\K'\?56>;^:O9^>[G$N'5%M(,&BC@+;1 M 407; ))G4@V6$FHI*V)*$Z*B -B.!3;'N=<>((Y=X\4 J=U;84V)&L@SEI# M!7?&0,31H@Y83>&D6- 2CR,N?SE)W.SL]GCVA^5DL;K)(_!@>GRUF&[R1\U6 MN085%\E*@PHL,RPQB%HZZ@DD+HFS,BCC6K-'GA1[!D6Q2RO@/N7G^JOVYA10 M;S9K7)#+V:>\"-_F@L_[.[>[/V9/JDX]O*6(0CI#*!KAH$&!MR+12)F,8&+P MM+TEJ4Z"8<>'] O=_L?/3P0]>PB&UKQ3Y<2CGTD!I2%IPKQ&W<%82RED3Q'= M^HEK+;PO+_KI:1241QV$X: 4,5YJG 49CA)% TDG$?VL+=I#HY_-T/I.HI^, M 8T!89>(NA;&,@H,5/#>\YC,D!3J-_I96_HUHY_-@'L9\:F4A&%,>B)C]"I( M7)!IB(YL%2^JR N+?M86<>,(5L= O@QV10&:*^Z" @R/.\U@:FW_W.J5N\.=7SU4"(*\MH(ER3V T99%%:+$_DM/TZ#J2&?Q MS=IH5QW!\A("FM&CO<2BB32R#)HS0%6RSGK'.$1Q$D0X7$/M&*>_ IHYXF:< MHHFF9%62()6WP5L)S'&KE'(';*(X3D"S*;?&!>]? &HHXD<8+@@E9> MNR"9"3P&'6P0O#5]CQ/0;#LUC@/>[SF@"1:X%HXP-#% >^<8<.M9"DXJXEU[ M4^TX _)P[ ];S\/?BDX-%1+YA(R4@TK(RE0#1B[*6+-KKV ?3CA$#'L/RUA_>( M;J/5W;W9[\I/Y6*S:Y6K4;I0R@,S7#M'-> T;(P5BD8)1# >>?MM8L>)>QY* MJ^Z@&CZ>^6NUP)=>O/!XII$$J!96$]0V0RM[R6>B9T/3CNFJ00KG;9> MJKQ=@[H(2K7?ISFV>&9MZ=>-9S8"[F5$G P AZ@LCDWI!6I+-._CITPQ3J6Q M+RZ>65?$C6-2'0/Y,MBE.3A!I4V:)0"<_HF6WE"AP8 #-N1JUD$\LS?N-(.I M=1#D5J_\M3S+EXH_.';X^K7?'>3<7[*P(J!"S;R7TH U05N7))-<&:\-X^W= M*$>,?-:62]4G5B\A')J$LM0)9AQ"AW:X=I! $!HT=4&K4SO?V5;![1BG[VQG MM[4\&:DLQP54)D1?!$$\ZGX1@8?VFV..$_9LRJ'C0WJ*OMZ[-/[YGN7U4WWN\YIN^(T9X(GR"@XA2= M,R0"4S08;KBR[=T5QXGFMB7B@!B.,:9/!4[KTGBC& #3!BWVI'6P!"?[&$E[ M%^AQ8JQM6= 2C^$C7ML\2/_>E*OU"P]Z.4Y @#"<4P/4>!Q;-'HA;5+6)JZ_ MSZ 7#YIPRR%*&B'99"AHS17E$:@4M%9BUZ,'O6J+]M"@5S.TOI.@%\YN(1"6 MST9S1)]:FH\<.(<2L$3%(?,&]AOTJBW]FD&O9L"]C+"$!R6H4!J7U.28TC(X MZ5*R1'+/2* O+.A56\2- Q<= _DRV&4=$TP+$;TT.=/G5NWRBD=B@5H#QR%/ MRZ!7?]QI!E-K5_=6M?P_6;7<'>)Z_%QAB0U<:RJ\B,"9T58EK5SRTK.H_6F< MX&J+>=4=,B\A?,6%1],W2"DDAQ31!E:2Y?2NJ-U%T*=QK/-P5;5CG(Z;#.NI MH,F=%^ZZQ@+0H+;"@G(.N C&.E Z1_*\I\1%_%@7ON =$K1/")J)21 &YI(V*C##)8W0V4=%>>SM2!M,1+'_MX3U" M+'0V_30K_WSA@5"=HJ)*: A*@E%**R&4DI1$'W(.H.\S$!JE=D%I:624P!37 ME/)(DW?>1K2!ASRZU3X06ENTA]_EV 2M[R00*DA 12LX0KP!A=.LHTX$:87+ M:W4<1JB*)"5[S&RF==&N.H+E)<0_ M >"ZLYB)QE#M5]%HQ /=];VWYSV'%" ME!U.-OVA^/UL%PK&.P#K4'D0H+C4^+?E23G!0J"Q?03@.''';MG5)73#>_?? MK*O+G),V_5C2$]_;=$>ZNEOAM:H/?WOUY/U]K7O MI^5BLIQ5>_S\3SY?1,XITTZ9X 48(9VSVB54X:*)-J@A-Z?WZ^6O+?G'%.L MMJ$4CKLF_KY87953-,_*L[W>UV?+%%(88D%8 EY2U-^%5BH0F;2"8 S3)^K3 M/U"@W\Q \%WFAR**LA\QRLH*Q&+8%V^)Q!5YOD^EG__M,/YLPX!C1A3J(J[@W^XP1P!RX$B'2,QYPZD,QCO^XAD!PS5M=N MBX!F)$KE3((DP GA0I0$0#%A#!C6?G0W]Y2.4WGH!KB7$<1E,2CF'$1M@!.I M-%KO=^NA%"F#3*$(-KY_B4B XQ MK[I#YB7L%=#).69Q'F-$@H[:976*$R&$M\P[L!YW=;'U3%.0S'CS?JB M7.YH^PYF["M:8/=8I#2*Y"1XSHT@0C(1@_&X!%%Z-LRHV.U) MNQAP]TA!O*1":Q.Y=^ 9-0B0#L%$(7%EY.VS,1TGN-Y6TBWQ&&RL7VW#9XN/ MKQ937+9>[Y[XGWBZT!*-[60-26H$MNME8/$-VCF2(OFC"&>FWP9K9.G=KEF6X+T MAEB7^2[>EU<3I'$YO_ZR86R[@6,RW3I8[-G9MKGY4HM5CJMMEN7*7E;+]>R_ MMA6\.7]\+/@Y V*8MQ?Y^H1@DT03.@) TB3Q/!@#2\SYU'X?Q7%.[C9EWWBA M/CIML?TE_GAJUVHO[RF8TYIG!T_DB(]/!I@P(EGM#95>M,\@=9Q#O4>E8DM0 MA]_L\ZY<3R>7+_PD+Y6!>^J8\=&#B%0K*[A6@0$@&V0M_^_+V]\CF:(TB,BX M0&9:;1/)M\)9I2*C9%#'9OO]/;5%>_ ]GHW0&O7^GN["=$Q&+8PW@= ,.+?4 MQA"T)RPA/J[]CGE=*X/^XT@ZFU M$81JI9]<[@[1/7PF)^P5$92PWG"P*F@: I<0F591,GX:QS?;8EUU@\I+",T% M$RW2W%,OT5Y*PEE(N,AZ*Y.F(@ZI471AA+953SO&Z?LYET0X#UYS ,,8.!\L M22)ZH837+ K9/CW1<0)X;?G3/W1'I-3;9?5IMMJZ7%XMSO.NR/SIJRRRR=Q. MI]5F<1_IN)J7Z]*>_>=FM;Y\W/4'1_^:L;"'!A2>@PPN$)Y(HY)JRP)W M,D@XX#ZPX\0C.R3N\='NTA=\NBF[%;5<:^5D9 Z"4#ES!(^4$Q<4<-)^;\1Q M(JE-&3HN>$\Q,<=Q4W9SD6Q0/*A$ J!-K GCBFH'P/%SVOXXXW'BO!U.L$> M=RCZWC5_3"F[8S;B C,LY:W6,5B7K$Z*>S3PN*/M/17'"?FV)>* &(XQN4L M9AD/PB1*0=BD1:*04"\1RBM#V^]+.DZTM2T+6N)QBLO?<5-VB[S103+N(R- M2#"6^$BL1U&92%7[C2;ZI/@V#GB'C_-_B7C=G23$>7>RF*()]1(C_B!2-%I M%#;F*Z@- 2UI\C0EPR*OY49\>1'_R"P14ND0#05 Q,>.8H&U(I MZ2SR7QOSG0=SFR%SQ$&]NK,I;D^3-1O6CTL72B>"MIT#XQ00[[365"F;"*0$ M< MY#Q.R+\/NAP"V%"DB9/E8K;XN'I;+M]?3);E7=OM'ZOU1M5[DA MP#L2L;9-_J8C=V.F/J%VUU-X@1,W&JUY/S%HT);A"$N);6]3":G]2>#>%KV> M9;Z;89VB.=@F_MOF/>K+-]W8OP8VK*DP3BAE'%6>.$B(CE)""Z>=U-%QTGZ: MZFT!')9=_>)YA-#SYO)RLKQ^<_YVLYQ>3%:H/\RFI9UO)3O+J1K29+;\QV2^ M*=^<[PJ[O\1 M0PX"60G/3 -1CC++3@MI03M;-"U?%TO+U MA0\&) -B)2@< M,7F/MF8R'XKCR;7?'#7HU1-U17OPT?1&:'TG@>H4I;'2N6A\1..3Y_RF.IH4 MP'@T(88\4-CST?2ZTJ\9J&X&W,L()1*&"AJSU%*MM'<6:.2>$$:IUDKY],(" MU;5%W/QH>K= O@QV>1<4H40;$P-:LTIKPEUVAEG%+2X2)Q6H[H\[S6 Z0J : M]6EB@Z I*O")&<*]X9Y9;61P?H16<8>8[PY4-T+F%/=N^\GJXO9VV4^3>3Z9 M/= 6[F]?7 ")+!#&O9,.- ,G+]D\ 8G%P.[C'PNQNL3Y'EKQ:? M\/EJV3#1Q.'O*SS3GM'$I9$$A+7&&%P: ]&2:Z#TU#8=C('';<$]1>(^>[/] M0$1^]OV%X(RC:A>2E18"4R;%Z#Q$K;SG5+3?L7FDE.HC('978)\BT1^?^MU> M/O'A8K*H<9QVT'84.@ /8#U8:T%J;YDW*(AL^8K(1/O-0$=*%3\"XG<-^AB/ M>OL@E;&.ZT03@/ F<&RZ8FA62$$/O= MT]B3[RZH!99LH'GC#"CJ-..)95>/)<"D;;])^DC)W44Q4:>N=2O& ,/3W&__K&/21T__.$'\2BM_* M'IB^[XT%L80+FVR"D/*5@B8&8:UDUEEB:3S@=N[O(NC7,;[#[Q'_\%7D^='. M[MNFM']C#N_G_S^([R-2[R^JY?I#N;S,4:6;?-$C:,_U\LEJAO,LS=YVS MM^=3!9O)_%>L>CE;7X?)NMR])7[ 9G_9MEJ_S+'W\]_N^GC4V/M!O&,:W%.R ML-JJZ&40^9(>9;QQ4<1\UEYH;5F]1&M][^I_N@_UM_+O*%\(<$Y)[Q7#7D.> M9"2C7!L@X!(/H[E:KC,Y/KN%OSN41KUO_^EN[MFZ_WRA@L8X M2'GBA K$.2^&W./6@)L* 7U'4[UR]ET?;_#[E'3G_[TV7VY751; MR(C8.Z:93^ 3U2I$C4.<$:F2Y4:(0T9PX0W!J3(2)6"$]YH-3X/N<1QJU7EFLES[R7)Y/5M\W!Z.KY$W MIE$]10@\1\LW5F&QV%2N ,X7Z'?%* MX&H;C26.NV@X3]H;+?7XUJO>?$'=P304(>RGR6R>/16I6KY''-Z7T^QQWKW1 MY?E"A54I.4*"TLKBD@Z&\N3 :R:X,L&W)T-ODT8W0GM\XU57"!V?!WYO3'QO MV<)'DI3G'H&T^9)S%YWF(2DA$J>'^/AZ.Q_5UQ31-5;]QN_J!WC&$M7[?;$L M)_,<0OT%Q9QS(+]9C"@.]<5I_#P1ZD2E&M53X R6HC&!*<.@H7%*IZ,A\E2<"RE\ YHL!J92S7?C2QJIZD^VSDJEO< M1AV]^G7RG]7R [9S]>8\E'_<'J"11#LD8+9B5 M I$S,BIU EFI.J-%-02"0VE*-5J_-Y%0[3J*G&K92J]BD,&:E+3,=F1@B+-V M3IWJO4J=4Z YQ?H!^&6R,' !QC!)#&(@$[61.2J=3(J(8/2@KJ#:8:GQ<*P9 M?.,)2%&+ABG.\B8Y#P+'AO D<*Z8H%%Z-V@TLI[9UH-,:D>?FJ$UUNB3-LQK M)4GBC $+6@L%S!+PWH>\&WI\WKR>9=X]:,?WZ=A+M)RSD>RK53O/SE_T&,;'ZP6\$_)E.-Y>;^61=GOVRK%:/ MO"ZN/*^6Y8?)YW;,JE=W(8,V/J (=+3YO(8+D;*D@5M.G6#M$T?W-E$=G7.] M(#MF-F;_7U]L_*KN F6C:1!*1 X0+!A<8P QLY$J[6)[5:DW#_=XV7@(LL=G M8[NX&2@JA8< 5A"0+**=::71UC-+B:/M9[/>$FT=FS\-(>LY4%)=7LYN8X>+ MLWR"9[;X6"ZFLQYC(L^_\E>L[7)S^;K,-W!,KO,SO^-+3'&&\*->SZ60^Q-O?K_&_6\AO3DFD>?7G(-U^^.);HN.W6[E?7BW+B^Q" M^E3>7)0Z='O>KZOIORZJ.0[(U8VA>KQPY%VS7M>).7[S<)%#X,XEGX2FH%30 M1/%\6SVUU'%>+\;1<\_V1@^_>K"(1DI* JY6RH.,V"\E@(,$D0_SAB$3^.\. M$1X@C,=QP$,0&'6P[[YG-\,LC_UJ4>.TVLYR!;=6,:\IJAH"@D9P'5 NF3%6 M)<_;W^K9=V"OI9R?HTL'X REK3]JZM[(R)//%T;1K&M2SQ7ES D1@@M$)JT, M"<*K$XW%=230QQ=0#P'A:?$GT1 9VSJ<+5#-3:1$.6-!:.D8##EQU(^B##8=JL=7:]A[^^^;90CJ;M&=>^B"!2&6B2Y)+D^_%1@OX@'0G?1GV M!\KF\6[Y Q$9[C0H6I^+\NSN-NH:YSR?*E!X$(1PHX&9!$%I)V3T#A*0I!&Z M]EGZ^KOSNU-Y=P++8%Z\+S[(;8K7)ZS#O3RH74?AD?!DH)8 +H394"",H M9=)39T:X"[I;:O2%U%!LP28N;WQE-S]?+;XUY=]5\WFJEG].EKON46Y84V$) M"9P$$HR18+S5/'+& S5"Y,WA8SQ5T9U]VB]8@YV\>M;K\Z0!^OCA AA:9D(' M%1,'18B&%'7,>1II]-$/>K-@/0KT)K=O#-(#P1KN\%V^UOO5:K79>I(RMD<+-& ,#%@#$<0#:)]7NO>U(G!Q-X>IL'4B[/_W-R=CZGLV=E6 M!I/YV\GL[-7"3ZYFZ\G\P^1S/#\OI^N$2&[[Y!"TK9\:%\:MWWJ7\M'-&PJ> MO+?1>^YM$IPT=Z"[2TTW3M'W'?S)"M MA'Y3M+#!)LL2DM1Q" Z][L%Z?BB;P7=H%KHS9H9-DOL MP]MR.:O.MBD+'G7&9GQ^*]=OSA&K\W*VWCQ-IJZJ+IAPV&K&DE0.(@?#@E'4 M*#3[0E AMB9;;W6S6?[%+.6]57L,2T MR2F\%8M@DC/Y4FH3P/L8D^?M>=?;349CF :[PG,4<]^SG6D]XSU?(VJJ@L:D MM O$ .JG6@D1P2>E($GCVNMXO5TK-(IYKC-$QS"[-?8[-*^L$"[?BV"E3DD# M"*LCY'TFPH"SD:L#HM^]7>8SAHFM$S1',:MU1;)=M14&=.+$)QFYA.P1I(X0 M4%QHSB..R_8L>QE^\E[A')1F[\JKVUGWVT&SCU2[RA;.&D$$*!O04LJW&XI\ M]16:[ P559(.2-QQ^C[WCL$; V&>]9+5+UP0:K44AGI#(_:=:"&I4"$YPJ31 MYH"#\B?O/^\%B'#1;G,!.V_'#>M:FND(1JFD@ :W-^ M;N44R9>C.D[1E+&V??"9GJS_?T \1V$8YN_>7&U/3\7/Y7(Z6^W>N]"TKD(S MHE&?9$D;#@PUA$@85])R\,"X:'_PE;YHMW\78([#*NR&83LJ*SPA3'!K8PH: M*"%&JH2Z*0S=9VN9PL/I:]W@7[[ MK M)CWHG_VYA:\6J_5R4_<8^#,EBB"5R2< >I\(-E4W6-Q:C/A_]CLMS> ML/UNLB[W' E__&BA)'#)=>14&D!8M2<6E6X?M5 )%[8!*='H%/A!(JTZ!66H M%?YA,_<>W?WVX2+OXR,6[2H?0?%$E2 R&.ZU,-*@>76BY[[;2V\'#?J![%28 M@GUS#H)7G D0-AGLF?&*!,L M9UQYDGNDP?- !E*S*^KQ5FU>(4+S_*/R>)? M;\[/2]30;1XJ,I M FW1&%2B^T_T?WFJB,'FQ8A9X$:R2),4_G8!4RQ1CYZ]KK>K>R;@;!4*+\=?(Y9[K<*\ROGBN2 MUT%R[R'JG*[=:R(X8D.Y30+@D+AF7RMS*TE\PP&D^=-YM+]\GSX7*%5 MS.%[G8,2(),TBH )!G58$S4N80,NP4/*\P ,AI+GUTK&'IWJVX<+3PUQ3.)D MY3D 948+0@7.7PZ54/#M)=M\7]71E*N#83F.L'^;7.ZWH9\K4F"?1+(.,J&E M(HY2!7>JA4WD5.^].D26.VG1'W2GR![K<#K46D1)!!@7+6AJA&1$1J"6'A"= MZU%?&X(;S8!I?2S]-N#U<5ENO?J[;R5Z\N%"2J^C]A$8E2!MTA'U$QTY#]0E M2=OG4>M-1SL<]*IC5 ;SI\T6Y9OSFQ:GR70VGZVO]ZSUSQ4I$MHD)"FK(DY; MRCF;G+<)M1C#-=C0/A-)\SVN1UOQ.P+GF.)_G0/8R[TS^+ZB""&Q'G2>!0EP M:5D2YFXQ"X&%$]4##I=P#1+X):&Q&*PU+F()J\)3G'J95*>HB4ES#BU MA.&9TPRF]CH#HIA#!;]-;C(LV=6JFLZV?^S1'_85+/)E5J!3$)($(!:U*$H$ M44'3?$%C''2.J*=+=">4JD>DAIH$&FD63PP-(02EU"O%<.$U5CJ)0P+G.\H2 M!'G !N#FQQB.IE,<#,MQA+UWEG_J\<)Q&GF2D/>6)NMU,H3=+78B.7>B6L,A M,MQ)AWY@.R7&A*"4 V%98!3'D;0N$:4-#=I1L&2<.S?ZYD,S4 8+WY6?JOFG MV>+CUVVND;!]1[G":Q \,1YB2@@8-5&[I$E6EA.NJR-,L7R8R+Y)V]X=. -N MX_FX+I>7>9G,]S_OJVE O"$6.H9/R!?1//39\=S M-QP.S+%$OM\(?+) (9"\3C"B47]ZKR^TV 7C0#YAC^H_W[.K]YN!"*&685 M8\XCF0-SE&D9<0D,!#_D!YSYZ\UU<*!X=KB'6F%R3$_A[9875RV7U9]9N9E< MX3<[KUYH4DT1-7':,THUSH8)%U_/-.612%2_K5TI1 M &_.7RW.$)_R;%&N5A\J;.[M#0%T!VGV%2V8$ FDM&"5 A>II81;2,9KCY88 M#+D)ZD@DZ1BBUC&*;3NJ\^VQAG*U]M6G5QZDJ@'<)RC.6AYM1?<.$XS@;SMQD-5N]O\+UYNS-XN%!J%U3=]TJ"AJ,DH%PA3^1 MRL%Z050D^7J[J+QOOYNIMR1'_1XE[PRJXY#E;NK*+;ZY^6?VJ40598K?/;T> MM*JG\$)%$2F3,N_A3,90HL%Q@39[WLS1WMG06^*B?FG3+5Y?N#-HLI'WTXOR M;#/'Z3&;ZA]N3?7=B4#ZRT3RI36_8HDEUENNQM&RK5.[O]=6TYM]MHNSN%AO MC8[S:GGY51[%KM]Y=R9YYI]CI,)MO4)6.5ZL;^0[5 MEGZE>I>5WY4+++Y^>$'' *_J>:2DR6RY3?[W*QK%FV6_J8N>?-FQLQ7=-^HU M*@S958"3U6W[4(]X5TXWRYS$;JM=_+ZH_EB5RT^9;Z\65YLU?ETMLH-A<@O% MWE1'?;RN,,[;D*\EU4R"231[X:7T'#SAGM3;:3!Z=/KZ507WGO-$5 +A M@.>[A**R.E ;O;"6#'D][LX,3<>E5#4J*4S&G!OJ'AMW?8?.M9]/5JL]NPQV MEBM4$)J8&+4U!((4*"PO!:7.*>$##+G-J-%V@^,QY3G*=@#O4+9CA^ ][O7> M*';O[RX@FL12BB:ZQ( 8K4,,1"8ME12@)"&P0%7RO2X:>141T SL-N?5T'E!!N*^@C^MIJA..J< M5=E5J "CG7+6<&P_,,4,"91+EO?O)6?9H#2IY^X;D32KGF ^P1G03^;3S7S[ MZX.$SL/,@$^_NTB03RB+J!48"!ZG"VFCT%((J@CYKVGH]:OHLNWU<0)9( S2A!O3!QI05+CI@48PJ) MN?:[77K;X_;RV-^EA$Z4_>_+]7K^=/[;L9!>S&=Z&#X!<6?KV=YM9C.-V?EV:O%79QVN+'Q?!L* MBNMQXE9'Z@U M,X[9:(BFA""/]L?QNQM@^1W,U0ZDUJ_NV^>#%^/YM:=^];9 MU:I$\1/=,Z2F^)(>"ITE:KX(PA3GD;0ZVS M4./%LW;(^M!W%%I1JKD(Q($"EF_0<]*2& Q1SHE! R+U8M7#LN>Y^6M@W$<= MG<[[\U[C1'9V \K_6\[S/;3O)_/276\_JGD>OE8=A8W*"\F9I]Z#(]0*QX& M%1X-!@9#YD9H%[4>CCI/G)7M ^,A3TT_W?Y:"5KK%"^X"IX%'1@)-E$A+!#A MDG'4Y-,?(IYH +D'T=2H-((*&0$\UR[O07$FVN2$I'2\1_E' M0*MFV+4.LOZZ08U\7LX6>[/\['J\H(:@#:\UMR/ /Y0M'UU>840YP;>G*5Y,)0_5*Z\Z3GV[WP'-VO741C.)*$&%_"@(6FB M/2 *.((3+NX@V]]%VG^$Y:@$[ OAH5CVS=IPWXE[?/-H0N-UL]SEVFA43Z$D MLX%%H0@'4"PZH<%(A-D1S:QI'\_K/XYQ5+;UB?(1G*G]'N3ZI:K._IS->SN6 M=E=_ST>V[E[3+UBX=E:7Y8?)YT%><7^:,"?DN/TT?KY"^V6/7[V71JS>G(?R MO%SB",8OMF/LZ_$]7)MN?LW!$5>>5\L2E99/LVS4W1X1Q&%___1PK>H@Z/&, M80'AIB?<^6BJUTH;((3V:M1SJG0FZZ@>AH13N)]M;RR&Y MIV21/-<6G/0NW] :HG,N!4>U9/BQ4J=ZBJH# =>A3'] GCZS A?61&)EQ('H MJ;21Y[SP+!\'PW_'F=E^>-XT@VFPM(+EJL1W7=1(;O_PP4(8K5V,EBBF@"6O MDX4$441"F&5FR./P-6WTSN3S36+[ X 9S%UXMZ#:S?JB6NZ_Y.;I D6BVC'0 MGGF-ZW!@5@7-&-&6&TF,;)^MN+DC\*AZ12?P'$_X>^?\YXH4TDA01@"H$&0@ M47O0=ZL?X>14+[XY5)Y[Z=$/?*?(("T3)\GD-(TFGTHSQLA(O:3X:L$/N$N] M3W5A*'XT V>PO>'5LIQ]7/AJLU@O]]^#\]3C"!7)M\<19@(NKU+F5=)!\%PZ M*I,=82;SPX7T>*/AX;@,)?'WZ\EZZP3YI:P^+B=7%[/I9+Y'97BV3$&,QJ'! M:;)" [%@(!K)B8F4!TO#D/FECZHU=(708"RX\7\];.W>>?_9,D7.G1T]C3P& MX9D1BK%XM_9Y+_V)J@X="/4Q38:"\#1Y!/D$+7&>,@T G%EJC8E@N, )E,.@ MIF=M!6)(EC0#J!D)5N7T;Q^K3S]/;Q:Q&P[<_O%8_+K=#;.E=8;C*\XKQPF%/;;X# MDC@-0E#N/*>JM=AZVQ34O=@:P]"_V+S=(39OBP3.: V2!NF BV04MI=9DA10 MBGT9W^Z:[L76&(8!)LG_O6N2_-^%T9Y@7PVE2H$TSEJ*>F?@1-I W '7PO5V M8K6'2;(I#(-YT7-.\3WFT?TS!:?1*I90DV,6DK4N*&">!8*68,#^#2C*HYI# M;1$95*K[ R-?GBHT-?DNB9BTH(!=44*1._V<.T%.U,1I(:BG1-T/2.-E0Z*. M$8+=],&!ECCAD<02JO1!L^!U>P6I3T.E6UDW@V H4?Z*D%YN+O<*\ZOG"B^X M]U%S%0'7*F.=<SE22J[C 83)XW]T'NE^?#YPIIB-"4)!^- MA4B8Y=2*R*6V3E*M1WBHH1-Y'H#!L.&F>Y?)ZPQ]AKA.R/K)4@4327J**KXD M$H*5EO-HA,//K$V.M->>F]^7-H*X=1<8'9D+->./SY0K>+1$Y^.,%HJ**6B?BK4>9?H \;589$IAF7#(?+.@$5AG+G*8Z<<&#&M21V3"T M/21GFL'4^FCW_:1Y?TQB]]GNYYXODA#$4+1-;$I@HC<*E2 '/!]Y-\*/<*]; M1_A7W:,SU "_O[SOOMWY2K^O$Y#9=2ISYNYY!FJ#,KO^ZN$=TT 'M1=!H! , M0W4+%-#('0298A(:53%->7OULW-6]7&RXWA(MIY/\@;2S7HU69S]?]4?*SM= M5^?YH6U;KN;ENK33K:-RMOAX/T8F\\]_H-\\VVE]DH_#5XG8P/#ZJN*-/>RC8 M[\L+IX6E@A#'#,%AFXQT-' ;I8LL.M9^)W'G8:B^J3DJH(>@[(?E!%73FZNZ M/J=JB=]L+G-"TO+L=HO<_9V>O;*WDW;D8%;40G )FH-AJ%(%*3ACB+!1%-K' M4SL/S(V!R,? O#6G_4W34#NY:Q0.O-ET>] Z-_4Y#NXK5T0CE=1*)D(EB&@M M(89$:B!9A4.S?;JHYNZH8W&F8XR&LBMN$P8M/N93^ ]/$NWR3#Y?J "9)-)6 M2!\=@ /+):*(?U&M6:+M#\_)4V!"YP =]32EO["A5$.D]+M/2AHC0 M>6DH4]JB4@F),VW;FX/JE(C0'4)#,>&Q*K;*>6QNS-;YO/ISLICN+<6IV85X[R]JY+N@7*1-P'%8!R5C!(&!W@[R2DP<=1H#S41_IXSWE4?%[/_V@Z\ M6Y_:ZFVYG%5GB,*RG.0,7S<_=\R"C>HI0%,AJ="&*,2"YHL1';.:.!S>5D%L MS[R3AULT+"LI M&4V,+3Q'%O^'B\GZG]5F?I8S_T[7]]'-_2'E=A465CHG M4_2* ,\WAYB\T48R3IBTC*<#5K>3<#\/BMZ1N?4.@9O>WC3[8.)\/;E:(9SV MZFH^F^;-@3=1QRMIZT7/,.>5L!WEB'DHL.W]A@[8(;OG M3L+!/1YHCZ^9W6X:*M$^R^-5QN[A*I-JO[RT2&R[T] M6-KW9X3;>T_7D\7'&?;QQN<_U'L>)G__95FM,F5_*]>/'G.3>?8E[P%A@%LZ MIO_>S);E6U]//):N_UK ?56S KF23,,,45$$4,*"X]KJC40"!B MR O"=E[)V@\)'J>N&1#*R9B3ON] ^6&_]QQ\:U!+ @WIC9%XS((?;D_6IG%=7:*F4TXM%-:\^7K^;?;S /NS+$+"G9*'S M8;G(:!#40Q+1!>-MA*V^0Z1J?S5=?S=Q]B71;_9G=8G<4$SQF]4:3=SENW)^ MXU^]F%WM9\F.4H7R+E][K9*.%K0&P\%:*;FT2D9CV^^XZN^JS($8TAUJ@^WR M74[.MM<$*S]_K?>TO<- M18>N,!N*%V\GZ^P8W,N%KYXK$J4@:#XF*FA.=&A9I%;QZ//.O.3:3P>=!T2' MEO\A.(W 4MFZA]N9)MNBA=2*&"$DIYY"(,1%ZHE//"3P5J1!L\358\8@/L*. M<6N?1>3^"N_J_'%#\HFU17FV;63Y^?9Z^<<7"W^39J1MA04.!(-6?(K,HA5O ME7:*DB04#I*0W $)Z'I3+7MERJ!HCF"F>; 'W%Y6R_7LO[9J=+NYYYG*"L^( MB9%SH@D#SH.)P7HMN<4O@C?M]93>U-9CST;=(#D"?OU6[CIZM+M@X6A01&3? MNL^I(1,.+H/=IIK38!1OG_JJ-_WVV+QICEK?VQZ^;E_>XC#-I%XL-I/Y0VH/ M=1?[([P.OV;\=,/MW 9N$F--[+J7;&+!-7I_J MU0.]4.+ H&?'4+]\;D*0%OL?!/<6%6;N&,X&^7:S2*369LC-;_V$VX=B7C,@ MQ^T1YR:(F*PW"!-$3W5.&,VM!-""V$,.:(S%(UY;6CL]XLUP.OTM%DF ,#9? MA@L$N$.E%W]70@G'=/)\R"OF1\:+;I$[W2T6F@2E$#D(3())%%=7XHR7ACC0 MR;0_,#V:T'I;AG2'VBELL;<%X!$F^R>).N4+8WF.(4MI!*Z<%,E.;890.X$+Z0&&SVA" M[ZVGBQ[P.[XU\_NJ/-_,7\_.=[D7ZQ0OI!8FX:1)G6;@0G0071*!1J6D!C9" M%740?V(/V+4.S_MJM3UBFK/'Y-18#W81Y>.:2.[%9([->DSUYZ+S;>LK5-ZJ MA,,/""=@?+Z]69A\IT:B7,5TZL'YIEP9$LS!EJO)U6P]F>.(V+>= MI(8$==C [ /??-.@[%&=C'6"HK4HD8@@*:5H42L!H$3G38>)2@B16)%8'<;W M'0S=T9'ZD<]]E13< (^*TK2]GTL1$W&%)8DHM]7T:R$Q1)BS6[$^&][L&*^_ M8IE?.;DCXY;H0+4W#(2W:#\2X92+1FJ?Y D<'>Z.'P<$+IO!>'QSJN_@D(T: MC(B.HJE !:>")7\;3:.,R/ =!"YK4^+ \%''4+]\;G+K>8B>2RXCKD76:;1% M$@5/2?[J2-3K,' Y%/.: 7GZ02Q#4L0QI)C5 -EU%HFRBH(.EB'<@]X$VX_/ ML;9$&P:QFB%WND$L+X6):%I29RU(PXS2!ERT2D.R3+77ID83YFS+D.Y0.X4@ M%G(]R.BE5, !<7(VQW#!!V&D9*I]\L#1!#/;\N! J$[SG'!(>993WKG@(;C@ M?+[,UFFNHC/!MP\YC":FV98.76$V[EU1$E5P!03RB6=PC&(G/!%!BDB24PY_?D" .Z]7O.Y/KIWQ$=CD;Y!6]GPR[ M?U/-0V%=OK)?0;VN%A\_E,O+-^N+ML*CB84O/+MKTMME MN4*RWZ:\QFE\LIC.)O-\&\$VSK$*LU4.AVR6Y;X.O-X1\CM*.]"&4,8DEWP" M#T8PDYCT(>^DIM*%4"M:/BZ,GPLG#MZ&PGIBHB8A.2+0'!>&D!@D-<(QP:@\ M( ]^-]'(D3.N.@VYC3HJ:O-]P1^PG7OBGE\]5X"4BEE*4.%$]5-XX[CW0*(& MES2%(4\+UXILCI@B57'/@" 5U2YH#A$:JV@R0NNC5*<>7O A8D]1F5'3.5F> [%U'AY M-:^NR_+]NIK^Z\U5[N=>7^JS90K$FMJ<@P#'+$2C#'#MN;/X+UOZS MXXJZZ@?8H?+YPAA/M1$Z4ARE!J+3SCF=@F76,A#M MMU?V%J,=%6FZ '6P$.YL?7,AVMGLT^PL)[S:;4 \^7QA)8\,]0!EN864\P!$ MKZ0!8#%:KMM'[YH3YH49$EW@?30N_7.VOGBXF^%#%1&:]?5>]:EA385EQAH< M64%PAUI$BHZX.Z4TIG"J=ZX<*/Q]5!H6U)?/0N4]MHD1KAG'I8-8+0(@; H2 M& F#;GZKK9\?EV/-(&L=SKY3XY[?E?#48X4%FM!0H=LH+=71X;KMO4(-CTC MZ7Q\RG-O^%>=P328'?6YG&YR$.G-.2[-Y7*_$?5D@0(U?"=0QQ=*,M3:E E) M2B9X8/F.AMA^!T)ORG#?).@4L,'V/,^6Y10ELW^+\UP/![3-'*.. M.TV3)AP\:[^*-Q?X"[-EVJ,\,%OV:H9?/5<(5(>3)510*B-P$Y#Y=XHR +#XOY8B&$.4X@E93$ 2ZJ37J"1S87T(5+:_8*(W6Z*E M'.M%;CK :#Q<^?!GU0%7[FLI1+1:@=*)1M2_HC,D.JI<9#'?XJQ&:'(,Q96V M& UV^&%9H_2/SKK<[KUJ2XW219 ^.)DS9FKJM+%<*KC5W+2S M,9ZHBMNIR.O2J3]87P[?E#.X>&"'&7/@#!B=1.3Y)V,18GNO2Y_*\['9U RT MP;)8;)8HA9O9.\T^Y]_V'PY\OE 1*'>!"R:I3CG+LQ;"I4=H\34G0%U& 9!6YS'MZ#4#O;[:,2101"J??6AL# !FL2MR!(\C:Q!&Z$ M6G*?1.@&I=81ME!>HEZW7MYI=:^KR:(\VR_D^H4+&97F&J3"Z1.(Q]42[0FP M@/_CC(D17M'8A[Q[ VRH"G>^LHC/4.M64"D@N<])*EUEJF$%O* M0:CV\T-O*03Z)$A?N VVDS7OW-SC+[E_IM#!:HI+G"%" \6V>Q,T3GVH 4EO M#CC)U%SV+\PKTA;C07FR?Y_SEZ<*IQBSUG!@'I4CC_\+Y,[H#I*<:N+%%H)Z M2M3]@#1>-@CPC!H3F* $@J-61 N*),F$RZ-CE)Z&;F7=#(*A1/DK0GJYN=PK MS*^>*R!R&D&D@)! Q)5->M[_ JG.']FFQM'OL MA^+<-BM@'EK+\B)[ CZ5KQ;3ZK)\7:WRI5TEXN;SG7*+Z77>#[>:3&_QW_YU M<\##GOWG9K7.W?VM7+\Y_S#YO(.F_;RP(!)L9"1XI@&,X2@P)H%S!8981=J? MF^O<$W]:S!Z%N ;;-_)LAWY!B>8NN_("%0&T-6C0:G!1)<^8T59; MU/AKG:3LRU-EIUA-QIR1M?^3(-8[AGSRQ)"ING#4O^2!';9&WV'K? M,:POAV].,6D)2T%8P'^$$YI$H;1*7%B=!HW'=WJ0HT\V-0-M*+*\GBS.]D;O MOSQ4**J49.D.!UAZM%.95-U!,S8]V5+81 &A;!X@1HA M-Y(0P<'X",80&.&%CGV*^2!P!AO)Y6157E3SLU4^.W#WQZO+JV7UZ<8]M'^< MUZRB0&)3!U:;2!B@YJ:YDAZ\LT0!.-O>J7;44QNM9X%^8#O5LWS1H1;$ ZZ? M7 #"YJQCQGAE4?$GSIWHF8ZVY.@,J-,[RR=E"-(Z84FPD#1JSDD*YKGR23'% MVE^A<]2S&VV)T U*8S[+%]$TLL%SXA$:0X,S-O#D8R34:W/ P.\\U-*GO'L# M[.CVXR_+:M7*O[4M6.BD+%I2RALF(1+II.&:2PL\.!KX"*^1[]%[VBE60S'# M3J>;R\U\LB[/0GFU+*>S+;_Q]WEY2_2'UYD^V\<='.KJ%84A42KM@HH4('FM MHP=#:% !AQBA([SNH$>V'0G5H\]8#\*I3>8K+(;*&8XZQ:PB28-*Q'(2F$;M MC(B07&KO,AW>Q.EQMFJ.5+_1_:T]T?_, M75WT><7NCE>.(/+]H$'7=Q?Q7K^N%_C>7;;(6IFG6EM/ Q@1')KPUJB$"F'P M2/;CQ;V?:_N^8/?.<@41- 7#0#,E05J*JJHA1AD2^W;2 MZPR?L4>U.HHYH2 M34XW$GV /)\F1__HG2:%<'Q1X);ZF#P$XYUAD7I%B9+4WUY4ZRIOY)Q<7=\U;;>[L&[Y@C!E-3+7"9L@,:J-(+=ZO)XNS?"@,C9];E?_1TOIJ,5WF MV%@H;WZ^J^9S-"/R(;(=\T1';RALDM(J8V54 J+Q)D5) 044(5EKA[P5O1G3 M>E!LCX/IP*O170?L=+K<3.;[EZ)'!8KH7>(A)<\-Q;66&B48+K2$$DYHB"-T M5P\NU]T&4SL@CTL3>W:V%=G]!H[01P6+A,IM((YH M2&B :F&92#*AC6,I]3*V-]][V]LS3AJU!+3?X,D.WW[O<8SU$M^W6>94$C>M M&/)=QXYUX"-.MBQ!]-#A8GWCZS( M,F\(M2/!()/$:Y^XB5[(X%4VR<<: NF%$1Y6)NT4NZ&TJ'(+\ $JA_O+/S6F M\M9'42K2!,Y,="7CD6V]^ZAX@N@F&AOIC+0/N\X/!>0TN4DX(A$BNA@26(J> M.5<[U:+Q>+^F:W9>Z/CSS^=,6%"HQK M[J-7H(QSDLX#)8V,[O:^N-#UG":9-@]^GRE M,B) QD9%)FMOF=4)M-P^S9-NX3HG>QS)$_D0Y(02*28A0#OI MM-"<7# $+J1!:\NT8813:-6 !XZ$YRR$#^]FJ^NZN2UY]WAE?3[=2F$)B+'< M+G.TS0]4FF1*WK6O'=I?6?PA"-\.GM:JW&/?IK^N;F[?;-?X,>LHLYO':'O$ MZ'Q4LM*[CUR)%V3;Q>8E* ",(2;+;/N:];V%8[HF=7]HG7.OOP]&?J['N:\+ M0K,75)BQ- Z" VO?+;[?B-IG MG^ZS^9^SF]O/6[>U3H]^_?/'7D[,+O[>KJ_-@C#'?VN4FZ* M@$,*2 DX"SZQ1"H*KE627C8JHW)>7 Y%Y8YZ3Z6=BE:DTB@F0")R)%R041J- MC"EH?])U')?KD=++X? ;=9CNR\)O;I;_GBVNZO47[\*Z0;'-9B_(YPY77$JC M'#+@O+1'==$Y;\B+?'8,V7C^J*!=3XSQ)/MU".)0"M?^R1\,O3097A'C23!" MBUG"DP$KA-J&HAR/H 6?:$RO:[H?Q5;]0'M)7">\XQA3B-(*",)[EH(4UB:G M&$4:M.-=X]C?&'CJ.. &*ZOR><;9B(G+V]>;M[&SK?;C.W93V"HA(( MX(P$*1PZ3"Y8S)J%28&/,#0QG*K>/Y[C.,+\[*;\U/H,VXW/XAN4$1Z3= :B M4V@(I4FI5%L#R4>=7]4#A8\ZSMIA. [^N7/SOWFUW$6,=XUA6O/3$^^KP%M* MBGD3# /*IP)JXX%AL( NJ?;7,0=(K#HW?W6#Z3CX+=8EE:%DAK57N^]?43DE M30&;.>'S*6'0<*_U,OK MU>S#N_G5L\7;Y>K][.O4S\Y=Y # MF'=<&R0&Q9$%HS"-)F>E6T(_F;/2%W"C=HK?=WK\LD/,;@[XP9\<4WDAO.8\ M9+PE>)%\$(H@8P5!)3ZH,=K+0JT::+>[0Z(^I!-AH)PHGR41+($2"0#:$E6!!^E2YIC M##P,ZC9J[*\>E$N. N@X)EC75_]YO?SX7UN/U^K3'0_L_O*0_+N?JS]>/D+G M+_]8D00*PFD374$A%?O "!<=EC7P0>6^F174 ?;+$V$82G9_6R[^.!PW^.JI MBJMLCP6B;'PE,%YXZ8S6TL?,YFA@A+72NR/GZ7CT+XX!]XACP(IG53J?');I MZ$$Q85''X&PR%H'C"8TW>G-*="^.1\/0/]GPQ1ZRX8O*&I\43UC^!(S>F^3! M.31&LW)K<7P7>[LGV]$P]$^V9[2';,^HBF5OD)8KE??YX((72H%!JTOS2"[: MMT#L[?)M]V0[&H;^R1;_MH=L\6^5C$9)BGDK,!8,YVB#$#9SF Y:.N%;DZVW M[D3=D^UH&%IGT:3EJIY?+\+VP_,]#>7V/%V12 R2R3O"(,@A)^=!C8ZP/WQ+M9>=@G$"Z M?[]>KA9AMJJ;$N^) 9536D6&R@#/,Y+5N1K^GGL_S320310LRKUJ0$^4R+*.@,3C2[:6O;[?2*>3K"(W! MLHH[Z-V4L8A;3[9& 4EQ+PRCS*F91RU/)YA9Q]-YM"IV!\ -S!(=M>.1G&6; MU2MO[-9KH(R_5QL)XU1CP*?1LW'#GH[1FR8+L5@\NE)EA07RYDF.8K )GG[AGD.&Q:ZP2QWGZT?/_3NES!.M3O_=''*Y4TF>2D24!@D!P7 MS%KT)$2,E@^:>'9ROZ:FR"\[!Z8U&5_>?OAP<]";^NU3E57(4DJ<1:[ J(#Y MW&-&9/,?!6D<85FICHEV$A[M:;6;^0%:??-4Q8!IJ?AH907/!B9C(L4$I=2EB&08!\N2 MR&9C>]GMV]O1#Z5/Q&<4.1]#M8YO.)V>:T:]FZUJ/UN7@O_O2[Y7OVDOCWZM M(> #A!T>G1Z6?CC7=S[Z3U\>V14APY([]6N39)B37UZ4& -:9RT3!'!MK I9 MDJ(26B>G8B.KN^]4&7K_X6;YJ:YW9_H3J[[93B[_7RDJ?;6\7LS_+R^Z7LV7 MQS9^Z?![E3/Y',IFN_.H0%CI9"A=P"/H:)QV[3?SKM-M!F2E)Y-QS@?\J--U M7LTW!9UGBS?SC_,WMP=3=1Y]OMHNFQBHZ T$&[P"\MFR= PX:3.!MC)G88^' M'2(ZP'8H)?2[N?YCOGFW;8E0JQXSW1T K/U):V0-%%G[XG$/\1*PX)Z^5Q(03MM5+1D"9PT:+@IR14A26.M M'_+L;>XO/B^/'0?94"P4YZOZ*M/F8#+*MP]60"&&4G: V;RQ>W3".H4JBTXB M\C3&1CA]T6O9(5!#D7VK7S8HT?G-!9&7FEO1,$S),!L2M(]" M#W;1B1JF0C9B5C\-S*$Z]/[XVRZM_/?]0UGE0<7MR3!4#%:\2R"R"@%FKD5;' MF)?*(V81'F/Z^KORO*(&>@D<,]R;!UW8.W6Y;VT)8\BRHP619VM9R%9 MLAX3.-CBS^%VF^W957/WV[_=8VWFW?+53';^XCQ/O6M M2J."H*(V8/(^;I(71%$%!;'D)?A&W8)&IE'U&)P\,_R#LO3KP^M\_7"=]->' M^6K[\)WOZ1 K=_&-BH&53/#DO/* F+S17A,/Z'U2T0V9S#T1%CX#[*/?C;=_ M_)E5E?GB^FZ%^[IL=OF92@;R2D/PPA.@]8Y[;O,QB)C7DQ]MZ[UJ^5F=O/UOQ>W_V_+S3_KS9> P%=V_[X0RB#? MK[3/BJ#2R2JK@0&AXPYC=,)IR&8 3E!![H_KQTB2T6_INV717_7J:KZNU\]V M1]<6F&>E^,UB/;\JY>7W7@4+JW'6%MMNC+1$U4N1R[^4<^OWY5G/M:KV77]>0_Y M?37?V[;JO!.K,DV(Z^*8)PVJ7 SB+#-8K:I!U/)6L^I*DF]S**0)#Q(M(XXI0A"6A6CM>V-%OM3GLY&IM&[5=ON M+R_JPB+Y][#,^,RN-K>SFU?UZOU!S]8H)EE9S%NAC<9;&2!SG0WH6=8XP' F M@VQ?&,)=JK!-D6Y3.1,Q\Q9Y5>O7KV;+# G"I#R3KFA&&10]:Z'49F54I2<9DBML_FY#_O M#)R/3I.7I;L@+E@E$3IWW=T$,'[>NGKGW^[^U\\^G98KU9W6YS +;"OODB[%\Y"--LOGK* M#CK#+"H6F1>244#R$%/T7(,!4,B\2>F4PL*7=(-@_)09O:WS. A?G8A/V'Q? M8=/+3?G3IU6IS$6<2"BC4^:G4G()@&J4;OC/O[[*_Y M^]OW]^?Q[>OUU6J^1>-%QJ$/7]N!3U8QHB;KF8C.@!32\F"UE-Q:3!I/:&G- M?X;_>R-#:YWI\S1NYM?SUS?U8_5K'RHX>X94%H+@!ITJ_;\5H.?&:N[R+UZ5 M>CSMF>>2PMD=PSAZU>'WV]75N]DNGO+\;1[]?KG87LK/]L)5O=CTH1@<_&B% MQ@BII$Y(#K+Q[JSGC$4'6F8SGI^04W>QX>8Q$&(H=O]JHF'V89ZMW^WZUB_J M=3:;ZV+EIMO-[:I^ME[?SA9[(\A'OROO_SP@*$K (CAA$;TCE[3$H,F?T@'P M$F/!?>,[>D4RSM?;5N4I4^7OL]6_ZLU6W#[+7NQ)F6SPV4HX3\';&*VQD!3S M-JEL!4>E$()T)W31^1F;[944YRF?]>]%O2IU/TN-#7KY_/>O82@1L,5Z'R1_V0.W(_E3KC/-,I/)D3*#D&2H//D4G5(205602+"DU9#?OOGMJ-&:HY80H M,AMSLXUV1:>-CXISR;.^G,!)98D' T8'(TGY$RH;]-1<8^Q\LK<:]7%@C\98 MF4"!7E]<;:6J(T/NDE.3\QQ-B@CV(JI1-V:?(4KX=HSX3V9O#KU$2#*B MB.@! K=>><)2W$I"5LA/N;=Y"B\?58UZ5*Q\')[3*BA,Q#A0!E6E!" 91F_0 M.L:CLHZ?G&[&$_UKZ:!&TN2%+Z2[L]=@X5%$98SANWRSL\K0MU.HHC7!$)#( MX(,(P9O &3@G>!(RVO9WW,<7H;L4&3J)@M.7H4R8M_7\W&+TW2RJ9)BW"@@8 M3T#.9'4 O4,%4J%QMOVMHO'E%EZ*))U*Q.D+TSVA'N0Y;\_I6!= "4OM0VOA4Q$GX(7HDWH\DC".7P"JK(YQ" ME!YMN?VF'"(^=8F6P[ M\*2E#QI :,"LL7DOF#&"P%IU02?G#R/"_?+ ].7X6\MZG')\Y!RK("@A1.V- MEJ"CLM&@SA:7X$ZJR-O?;YRR@V?BVJ7H]3B(^98(7$C)4" M2:* O/LZ12KOQRX:2\EB^Y-XRHZEB4MPCPQPWC2/TIWY9X)',S^-\ZGD[Z#6 M6H%U6=>RS$:BS*Z4S:1&SJF?"1Z'KHD;<%QQ !N(@*5HR:*1SF0#E7OAAO1% M])W@T9BASIO@<1Q%+C#!0S/!\V[N4Z1\'AEC!5-,*F9TXH*?4@?FHA(\&O/) MW@2/X\ >C?([@3OOP@FIG544O&3MDGFC;!(]1L?)Q>)XIP:-8,^L7+_\X M-M'CVW%5J;_/HV4\K'&F3."#/.>\I$VP7!8KR3?G_!Q$KBCV?(N-/'# M<>8UWJ_T>C2':41_Q^8H% MA]Y)9CA3@$RX?/0&Z5C>_HP0YH1*TJ.3BIY9LRL)ZH]ZHY>;"69ZD-*20):V M>0B(SD6E!4/*5H\0(?V8EQ'.*C_]4G#Z,C2^3 ]CO,J(>\6#@V"CU=D"M"$$ M21(Y:W\5=LH7 <8M0R=1*66E4 MUDD ?-+6@0&F40 #K4S[0NY3=A#VP_LCE.$CR3]]P;W$A"F*/C$O- _"@DF MR9,DC.2899#:5X 88# ,:4?TC\[<0GN MD0'.D3#U^*^[OCYXL^7)_,.Y,Z@:-;/_,MWG;Q^VJR^-[->_-DBGZOA+5>;? M()*+P5@-Z*W56J$MV[=PTME6N54=[>+W>13=K/FI=*M>OU@Z>H/0_MHTL]95F-A%66?2$\E)K\Q(P/IHWL M'5I=X$):21$TUVZH2\S5BF'R"GS55!(0^$:*P5)7B* MS$/*.JIC04A&9I191'TP0^N[92G*N&5?$F)- MTF.,TF4C2W)"QOT(,R4ZHM%W_:5/0V8P[TM]D]]YC8LW=RV \__O[+6#Q#\T MM/):VFRI.J\5AVRKHHY.*I\P0?(:VY\=O<4.^N&%CH$:,&NPSM]ZE^<=ZX_U MS?)#P:0I=S087>7MDYG 3;$[(!'8B.666D+'I0ARA%6\^F&0[K$:BD=^J1?U M:G:3)XYOWFK#,C'NBF7-!I?!70VN,"(&0498HN>1Q.%+!@HW][FZ"SN*&WK>:W'O9F1;MV$^QZ'EL717_?+*M\M[S)S+F^"S0,]Z7# M<.ZH7?YXG7'Y[__X?U!+ P04 " ![=_1,(RV-+KY 0")-@X %0 &)A M8GDM,C Q-S$R,S%?;&%B+GAM;.R]:W,;298E^'U^16QUVTZ5&57I[T>_QOQ9 M*UME2B,IJVJ0_F]>L_ M_(]_^V__\G^]>O6_]/LWA:TN;J[+Q;HPRW*Z+B^+WV?KS\6_7Y:KOQ57R^JZ M^/=J^;?9U^FK5YM?*NHOYK/%W_XI_M_Y=%46WU:S?UI=?"ZOIV^JB^FZ;OOS M>OWEGW[ZZ????__SM_/E_,_5\M-/" #\T^ZWGOV)^+=7S8^]BM]Z!=$K#/_\ M;77YAR)8N%C5;;=HI/GQ;X]^_G=<_S244OY4_^ON1U>SIWXP?"S\Z7_]_.9# M;>>KV6*UGBXNRC_\VW\KB@T=RVI>OB^OBOCGK^]?/XM._A1_XJ=%^2GR_:Y< MSJK+#^OIE[. XSZTSXORZNG/V*^7-[[A,B0C Q!%AGZAQ<^>'W[I?S7 M/ZQFUU_F@9Z?>N#O 'C]&&PN=#4)OW0!>8C5AQ\X,-Z/8>B6PR)^_)$#8]YT M-+>XS-%_'W[LP-B'A9RU9U3KZ7S@GO'H(Y_%/(\_]29\M?W!^.D'Y+=N?"NJ M>Q]Q]=S"[_]0_AJ\G-ZM6GZ?3+Y.WZ<[E\,YN>S^:S]:Q< MV=GJ8EZM;I:E.E^ME].+]80 )ZBB GF)L>6"*>&TEQIJ3(R$=%)_\J1;()5@!AC M]0;UO]7@BCUTQ1V\XK<&X/_W+S_=67>/V^KBJ?VC/V$.ZJXL<=&_8F\>4HUINN^N]7J66%T6UO"R7(15J M?FFZO'C!3=N?^.FB"O']R_K5/8_%E"B?056VKKGA*ICV%$^/1E_3YJVOEK\& M%I;KZ6SQ,0QJS6%;E[\QI8FG+JS)\_N7[\FNYN"GWVD,P_*>L M)=(S0A SROMFO%K);8HT/M^*QUQ# QA24H5\R"L/L424<@:))=9D%L* Y-46 M2G&Y!5DL-RC3I+ 'D>V$[S@*'F\7E\G8O8]QKUCE&-9(J""!0@DHMU&ZZQ!Q$*6+T8F-,2H^E!HXA M3*4$,BBL%Q;BD+!0:%1F3:KQI8E/?_X2IIO'HJ[+9'.#;7_.>3I)>HFLE^:9 M0_ \#H$:SIRGYIC#\90D5T\W*(!@!@%-G5-84Z(T(LU DX"&K&FW;I6\N+/7 M#*!1=#&U5$**?3!3:2X9#I99#RE*DJAG5M(.#+9Z\:V#1'7DK-M:6":Z>JZ! MG5B/.BE1/U)'I$$]#7EAA:LS-ZTG:[LEM+=7IKK^4BY6]:K-^W(>E\1-M5JO M/GR>+LNX>WCY;GH;]T97N^4V:VV(_YIKJ[ A4EE@-N-,<8\TEFTG(OU0<,&= M]T0I"%'((*&R(04!3!*A TV$9YRMW*T^5U?%/O1BB[VHP9\5-?Q7-?ZB,>!D M*];]^#XT_SF.(\;IX^Z5>ME(7Z]G7 M\",?I^?S3L1=.TX-\YKH(BFVEN)B*4& M .L0\(3 I#PK?2K8&%R\O=IH4E$;=%^[]JPN].V]G]M:7M2F%QO;BSWCBTUZ M$LTOMO87#0'%;S4%SXO==]&U#H>T'Z!7I87 _].A^G:HR^V1L[K]'[ECW3/T MQ^A@#]*SZ*0ZZ8)HFW*=QFU/I&@C[S^G3>G&3D[U76A VM2S1O(Q_(KZ-EM- M0B8J$-*>>:>AY80AQ1J5M,2QE.7X^Y\<)J<$0@RQ,IY*3(2#AE/.#,>.:)5[ M[7TC.Q%-F.X%/"V#54>6VLVW\Q&4ECNTYR;+-/@>#0=FM=WH&L6X6LTI0:*#313L& $%/C+D!Z3^K <2CX:2FH1C2@TN+)^S*DM[.+=7GY85U=_.WG\OJ\ M7$Z8AZ\)+MV@.X:\E-0#)#DE M $KFK&,X3 ZF\'L3Z3N3$\ M?'D3\\]X0FS3HXK?(AG%EHWO);YU*, M$Z]MD&G'N87*8VLLIKOCLM@H,OGRH$C-&(1[BYU"8AB!V%$CJ518*>^,DQ!Q M)"#@25<"'YK96KY_W6GJ>?EIMEC,%I^BK&X^;WO(=GP!NZWW1Q.K,[C\NPG3 M/UPTWIAUVD"O%IFK6Q&'O*&52"P"456$>6,4892[90USB(.;$B#M -)\Z1] M"UOK<(VG'%UD3?7NJ0-K1K>.-:YN3(ZU:39&_RAA];XK3Q)5._:F'SVH=J7E M:#&UE]].'U+_6N<#._A((,N)U=(J(ZVE3!#7B"ZW2$\>U=L\H0 _P&X%-]Q1 MAP+K%!FCN8& 2HF@1]@*UTJ 7ZI4^J(8_W4[[QA7;$UU\ZEC:P[7CCRV;DS^ M\6+K?5>>)+9V[$T_>FSM2LO18FLOOYT^MOIJ>57.]BW "$-G@9& 6 $8$['> MPU9W#19FLE]C^83R^QBYYT +0AT%T%,GN?).::D(Q2168,4=@FM:7-U!&EMH M[>#E4T?73.X=>8#=6?WCQ=A'#CU)F.W>K7[T2-N#F:,%V[[>.WV\?;B\3;1E M.LR^-<=&*ZPE(ZC18:1ELS';O+XPHCTZ"0 2$#)M'*94. FM-8PIY9 CS"0= M\OQRX(F)5INRY>(R83OV.U/.,6ZHM?7^CZZ:G7DYV89:FN=&I)C_7LX^?0Y_ MJJ_EE[SEBG4'OG:MKUU),50QQ9[SAM7I&E'__=9!]YV#M^CI*Q%WQ/ MF7=!XU4QW8:-3W78N(QAXRJ&C:_?9X+S]D^ KD64E.@B"'08BB<;D((I&HD M=WI3K>+8"N@9UH91BAA5!$"M$> <.2H$R;RBLCOL_+WE'H/WGE,G(*?L.&/- M0AX>J/Y[2T82^\0(3F8/UV]_]+0D&V\G.ML]M.=/GZ# MA3=<0<99$V*XX\GVX?KMCYZ?9./M1.?CA_;\Z?.3 M[9'$FR"%;>:_3J,05CA1@&$3'U&037P1"O-Q)"=))BD'N,!(.:SB*T- $D=" M9BDM%\X+E7OI9._(_?>6G S;\!3!L9_W1 M&9Q$SFR\/O82RF03&;9^OO8)[L8'9K @\( MV/!.&(?*9+#KJ3=4,C#7.DO;/7/Z#)+ZH?N/Y;>U#L3\;:( 7Q?WQ'?Y6+K^FKKP,[8>62R0G=,%0&EI#W#XA742H18WUV/=; MTI@\E UF\LDX)#6;=0]SK*PLMI77OU35Y>^S^3PT^WJQ#OUY%CJI6JW*]D&YSU:+Y#6FR@%G=83Y8;)3%Y8$CG\<@X!G0FVZIC].FN MN9*Z"!.Q97GI9XO9NGPS^UH^1*5O?Y[^1[4T\^EJM7G>G3IHC"?2AICM#8>0 M.]8,[K@8U2USZH)$2D^%8\X#["A16&DB,+<.*>FP=39S'M6 WV12&_C%!O^K MVH!'6A#W*&HCBMJ*;:Q/?70NK_=2\ZU3.RYQ)RF[SS(G91WH;I6BY73C./3] M2+8^F[[E9[BM_C^/8+4/07V;K2;>2,0T@B&+XXXJ1@W=Z05").ED9DJ[]9D^ M*8/=@@;-PB)8+Q%'8;9HD70\]PF%0Y*P>J0)$7*BC _JA':B?2K^TR1Z4.JS MJ'$"CP>T-XIW3S2 M6U:S.V-(:>WBAV/KZU.$=M/87JX9O<[VLZZ]U@[ 8EN]?3==QYWBG\M-"4Z. M..=80J.!],RJD!TU8UFB@@!%> M6S#%;QLXB1*82%([@=%-:\^W;Z/)T6:5D.6)Q5'D&#!&6(X;GTT75\@FI1MO=26)Y1( M9>.T#%"LL;+A:TXXT4AX@W.O0]ZAZB@:O;EL)R/'I#%-6';(BCTN-]A.)#8O M<'5 ?H9B>1R"-)@U59Z^F"9:YF:UKJ[+9;US&X^Y?9Y]:5J4=8D-"16E"E*" MG%!F%ZLQ3EIH.]2. );SD)91BQB5'DJ"@):&2:"I\#+WU9\&6K'[-%7ZN)Q>EG'ZUC2C M29@T:("L$%!("2 5S7*S=AZ)M.=O'WV\UUB'8:E"3@%B)J$%),(!;R!5).0: M*8.GTS.U-:)B$2%UE)]TRMII3E:NTH1F0](O[4C*HBX/R3@@*9UY&X>.=(=? M#=1_$O.8ZOK+30C^'ZJK]>_39?E@56C;-B=8"FRY)]82(QUWO(G#6CL.DS*: M5BU*A1U4G#%)PAPSC$$/55QV$IJ$*6?:$; .N4T 52X7T_G\MKC/3ZN<:),J USAW*B09D?AZH-;-/#/"D#8VWU M[^6C'*LWLT7Y>EU>KR8,,PR4X" ,3&P]A#(D;=NQ:8&E*3*8U'"8M&+I$<)" M6DH1%$ JQ:6),8%[DUL-VQVO"LE%1%S4D!.U<5@WM)/(DWD@32D')3^+8J80 M>4 XL_AC'/J9Q[3J"/UYJ(,4OZ[*JYOYF]E5O.5)4)!NX1@0%A'JL5/-\.7: M#'1Z8J]!)HCT8;8-M4!46Z>ITR&]@HYS)BC*O0VXNW_>W#Z?!U#QU.KL;@Q/ M:_<,=48BA>R^!R,R\3S@:8BS8H.QB"#'-5/) .%AHCMA7".OF/$AG4' M4"%9LZNOJ6>MI+ ? HX5Y491"C"@T@"E,9$""N\AYL[GSBPW%R5G6^#%5;5L MYMMUQ:>-2-;@BYM565PTL\9F*MY.,3,[Z;"$CL<_J3/TZ)K7^ZZQ]UW3X([Z M6CR:T(_"-9?515V5HEY__PY<= _OT4;1G]M&Q4A4'>L@VD:Z7M0]$?J.XXK3 MQL(CV5@=LW,GKCI/O\S6T_GLO\K+IJ4]1#78 ++YIP_5_/)CU>RFK2:4,")# M$&>>2, 1Q#9,6K:C'D@@DE:C>R$A2AOKI0I_8HJ(U]Q 804 %$IJ8>[R#R^/ M^]V2];HJSLOPU_EEXJ)U7D^U7,P>C9,20^@=[EU8O!=$-PZ,?MO]6,"4L0]X!@83'U@+F!0<*$#7 G8Z7,0@7 # D>*S0"+14DBBAM37$ M!WI QOK]+UWP^"4N;.Q#+[;8SPH_6UV$5.]_E]-E\?,T%AE9WYZL7D4?^CLM MC0SHU7'(R7%,;7]19&A^!Q"3)\#\4GY;?_R]G'\M?ZX6Z\^KB=+*(\IH0 &( MTT9R@QHY(4J:@2[MM8'BD<(,0TH@EU1K(1P4T#*"/&?2H]QW^,)(%8-=QQN$ M^MY*?FS6A]7RIV4\&E!L+"@V)HQ&N5O0W4V[A_3CZ-5[4&/;Z_?P'.=1\)B_ M?/R]FCCA7= /Y)%5SL;ZK,(TZF&]2CI\UA&!LX$'*[4+(B:TD)0CB2%Q*.X= MT-P;B&%\RIQZW9KH'#*=@^-CJ'.=70?@8];D+;>#27&JK[Y'!4ZVL9?P=F,T MH]Z&SEI.#$%88R@8(%Q#8@CVNWQ-FK2Z<%TQ>&AHC#Q6(4TM$<(S ^/U'\#B MZB'.KKD(9-?<=F1G4]W!>3Z>[D;HHU?>"')8[4WRV'>KOFE6]M??#JSF4V ? MALM$2J$Q5@@KCJ7#F'L/&TU0&"25-.\(P0@M%==2X,"']%1"+SGPE@)JE15' MT%^86W_;49U+?@=G^6CJ&Y&/77PCQD&U-\E=WZOTIAG96WD[<)I1>,//3BR" M,?G20'O&E!*8>-^H@;809Q;>" %#&A)^2,(4P% EPF2 <<^D941J&Q+%_,*+ ML@MO*ZJS">_0+!]/>&<'WO 8B_"&GQU6>%/<]=T*;Y*1_84WG=,\PJNN@D3M M$%&C!##,<&V55@9;AV@C"=@XGT]][^,0PGGCK0%$"QK:U8!;0BCG#'!FD,\L MP1\_E\MR&A'E%.)$ZG.H<3[6CR')M8>^#V&^1_1@ZMS-?=^C1'>TM)=.]V%W M +'^I5Q/%#'2*B."#EC/$>#&XMW2) 1PLJ[6TWEO/8Y-^6"/-J$1$:R2UBJ( MC*;,,4LP<-0D2>X.57O)C;]2E('YB_JFWOZ +S?^&$R+6S';6VZ')G7PTVNC MTM5+,J:]L*5SU+J(\++Z4B[7M^]"QUNK1?T0;7W4=7<,S1-, M@CIR*IF$BF@F%3/,(A"^I:QI6R?@Y89B-7H,'2* M6RLE0-*),,5TTGO0C$'&<-*"6E+#5H*@+AXKQ#UE0FLF.+.>00*(02IW)=\& MZ_T1F5@!?%"B>XI=;HZ'U+W]9QI/]OIJ"I-=]+"/0T8NC;U,:ZN2_?EK*YCZ M9C5;E*N5J:[/9XM-*="=1EO)E)"2QE>2&04^"#;5WBN H7($M]U_/-@&UD$9 M)(;40$<1US(* C:8<2?B79I\X[2!5>SC.EE>2&,:7*T/>Z MOGO:-%Y7/UK-ZL;U[=[?-L_O":B0LYBI@$%ICCPFLAYF#'/C%.GVU&G+QK$5 M "M,'0L<>.4EI$)@#K&CD!$(,NT8/:"=V9PS#CW-9]ZSCX]FX3$UE=EKKGZ7+][3#2-60P14 M2)TTP])MA[(A-DU>GVM#,VDM0)X#B"F44$'@/=':&:( S_Z.Z%/CM=-SH9TY M3,L$<]+7,0E,8"YK_O> FA:I7UJ3.4$TBX M$$1YC;A@5K-FY"!@DVZ(O=R:THC$I6QGF*3" !G?PS(<.Z#"+$[2$^C06?," M>M?W-@?@N+LZY:.WOTZE,'LTS;I'6*)Z=2-[O#K6T9X6BM:'J59E(W\I;Y;5 M_[PI5TV)*-1JL?SI3U9 62Q$O%[D*$92A Q# MA,\VS" G3.ZGHN[P)+Z=T)&GPUJ4GZ(TW3DV.PE%$;.RU*W880I;[?D+@^=0\P_VS!Y MK(QNQU):,I=.[FCSN ZFO)S"=>6G_3OFMS%^K3Y6VV2QP5"N_K*L5JN)P 1Q MHBP%QM"X%J?!=H6;,Z'2+M*_V!@F!DML&2,,4^^X"HT@(((6*^^HR'UJ_5WX M_N?IJBR^+&<7X?^GL\MBMB@NIJO/L9[E= .Z"";,UK>I3Z'WY;GEX8=C4IQX MX&$++5*Y!5?A.:4!@9X):BRUG,"P&8(2JZP3Y*Z+NTKRK6F MF%BI=)C\6,&-,1!H%[Y-C$\[0-ZE%'.#K[C8!]@M21N4^+3<[52<=TSI]N"> M%7M.N(?XK-AA/OF!DY=(33N',IB+QB&D62U\^=3*P&RV6@1\ L;[\J+ZM(B% MG%]?QG3I:C:]NRBT?>1KNKAL8,W*5?BWF^OR\N.]H_<3"H335@9M8)0B30'% M6V4P2?CDQ(T;B!.)42:M-R-"-%D 2 TQ0+@J\ABJS;#=HM@]P-5EJRR+Y M)W=@BW7.[\1W0\C_G5W%OF'- XF[AQ3C8>$]XXJM=6?%Q_O7E+Z33I"PG/N= M=(9N"\,G[A3MUIKS>>"Y5>L1^'P$Z]]C8*$:UTCL/2=L U@]!?CNDN!JPH!$ M$'GF0A+E+3',4+V1-R>%(4D7A')AM X8#12G$F-JD5(,.$TU)P&T@D9G3E+V M[L]V2E-.[L+.,]#1>6\4:*5M M&&OQ2';S7K/:/->\]W2L$HX)Z:5F! O-%3&(;$Y60$"I35KC[ 6$>8ZQ%0H! MABC34 IEE274.VHT,;FWIN_)UJ-7K'?1Z6SWXO7-Y@'F^:$'F$_@KG9Q:32> M2@L^NSBR#1?SYVIQ[-XGWZ(_W7/9?9@^$#>.XL!Q!(?CF%J=8("DR?Q?JNKR M]]E\/L%,,JL)H%9K)X#!EFR.+7/,A"9)1\-W'VJ@4EPS&B96(31!I@UT\5D4 M(D'HV"*W_#8XTJ2T/27M9#$+&VD2]R(1652J:?6 XB1S,P[U2(==]>P3IUN# MV/O.1 '/ -#4*B7"H+ *\NV(H!H(DU1W,AM&38CR@'L')=5>2.X00 P[IY6' M)/=&R?Y$=+I!%T_W3.\.6YUN+2+)E<=?B\CEQ5&L1>Q]\_M=?MC[SI&6'[KT MB7'$B).SD''YH;M76M>M6$_79=S:>GL5LN7IXF(VG;^KMA>.=G7KG/#4:V9B MA3P3R]#JU==2-L',+1%?S#]:4^'*2)@;E9+O%A"UACI1Q&U)LPIB@07,9:+8H31[EC MN6_F;N%LE^[_J8M&)'.6(A4YZ>JB&&=%P]AII>,!+R\J2%<>QR0DG6UX4D_Z M,=)65LQT]3G,->(?L?+DU^D\WN=0:S-=+F]GBT]_GT#Z^] M],2;87%AH;XB5MXA31.A@1AN)TK'IS9-I':O%UW*UKB^Q3:@7$'!-I'&&ARR. MXB4.Y]N1K3J_"+U\7L M#E5B$("T!U=KUO0E6>QYPE*#BWN]&%P')K3SX2'BS?]^6A_ M<.NBN@D?_[Z\*(.6G<_+7\KU-H>;$*F EE(S*!TT$H*0OC4#A'/"T@YF'6@( M2"8-1MA81*AQ,C0*E62>:TY@_CI*#;9BN0-W5BS*>@EU.I]7OT]#'RBNJF5Q M6=V1L?2J)"!M'DG%L* MM8]OMU"W'4-*,2-39.S>!_/P8=H"A'!(ZK@D.HBS1PXJH"AQ".4^+[K% !VVBE,-F+2%&4'XP2/H>U3<$ N.C$U#GGH!KT:H*>DOJ54QD(YS9./B\NW MZ\_E\MX"U42%>1FRVGE.0V1E'#C=K*T+IY?8D 2*>E\:(*RJP$\@[ MAZ'UUAI&L]>WW4)LGEUE*%6$6%_<6JU,?4QJ Z78*1!J:K4Z[;!/$N 7 B5BX1G/+'%/- MG$$!(G3*^[+W/QE[!C0/4Q%C')7""TL(B84[4*SX9H[SG&P?N4HDJL.6VJ < M]=I*.^'^6=M]L]9DC4,\.F(_M$^6R$#OQR1CSD6$,)X;12&BS MDD81-M^=& MTT$>CXP-,4N\-0A91A6U6$HAI6,$*A\?8\O^0-.]QR++!EB]LC/0BY&MV&R; MW1R)R-2TYL"+D">88QVBZ6 B,P"[XQ"A84QI^YQC.C_MEV@>/6GMOEW,;RYG MBT]W%UZHY, 32N,K 2$V4\[);G!9K]*6;EHT2!WPTA!)B4&4>J@D)I 2+YQ% M7N'\2SH/;OUV4*MAB&V[ZG-D3E-7@QY=RPT(BS_N,!8-R#\=>ZGH9=X.+B$- M2/LX9&U8DQXM.0W.5UN9L^55&3*]R]>+B^JZ_#C]MD,PX9@Q)Q%F@AD/PV10 M4]^,009(4AYVH)EX 9@+K:%SA(99C2*2&$DQA@(8PG(_V=T@*V8UM&(]_9:F M9WT8;*=B1R(O3;MVO&U0%0'6OH@=5Z^>9^B 2@U ZSBT:0A#JL&[7)H.[:U% M_1*LWLX^M1<$,:NA5PB%R2<5:I<&R#"A29&@IUOP81A2@SG6((BJH5J&OWMM MJ5(X3'1S)U2;)=@N2T4="6NG./FY2A.;^RO5=Y".JS)/LG) 8/JQ. YMZ6E# M-62_ZK+H/.%24A52)$X$0TY 0U1SA4D):EGZ:O,DQ'1IF;8::TFI9!HS(YQ6 M7!A" 4K+6+HN,W=?7GZ9DI1UY4'9Z+*@?(IUY!<7D%NS,HY1G@KZR27C1)O; MCN/]"]N+RP_KZN)OGZMY(&055X'6MW MNE'*/32>8TN]I9Q:;3F#%CL?KZ4IDOOP\9O72K]^\_KC:_>A4+_8XL/'M^;_ M_7_>OK'N_8?_^Q\$@OR?"_<_?WW]\7^G*<5PI+?3DI/PG:8V]VJA;)>9U[,0L^'-JC)WULZ"^/ VFS-,,"N]5\9A:1WB?A?9'4-=)?!A M,QY0[[R!6&I( 61*/=]#:>FM[="0#>JM"<"$HGJ7;>:;V; M7C"7M"GV3!-,<"BAD!YJ1!64(=>$W B P9)TJZ:MGG0L:7#:QN%RI2:6LY M*\O/6.(LK2%KB^C$ER?N\W)H(M>/R''(3%\CGKDJT8N3!'E9WMPKS]6T!SU' MRA#I-%8ZT&*\Q,U0H2[M@=7G6_'2>(0])09CZCF,+VIXH"S22$O(4+"94&;8K]Z H$C!EH^J)CY=N_4'/JU9FD59G6W(U#2OH8\.(J3"(7 M'23D;B_];E_&2H]X794!8&*\X[09%5I:GE3<_G!+'E +XCU9[RT5%"K),0T& M(J@,E<[EW@&K%I\VY60&60[N0F6RP&1FL8?6W"$;P[KP8Y[:B5 /?D>G1WUL M>5Z:>C.4=*[OR88G @@=YFGQA>,0J0E!BC;WKC7@U"4?[GNZ&!:/S;',8Z&,.2I(VQ#<-,Z MSH< %XMMV?)\/3&&&"N\E"'-%4)S%+YNQHPW-NEAJWL?S"$-H]U[3SRF#DD) MG!'$ L"@0(SF'B5W4?PRH$F,WDD$M0S6N;A)C,T[6NPA6O+$X3T*#H7=+DR- M0QVZ07\85+O;W_F.SK[\Q&LF0H5F.([;+IY0I 30NP25<=WKHLZ#M@BFX1,) M9QSZ$*ZA=A[6UUR8Q$RIW#NOP]_62>4R;:7RV7++P^U(YA54'I#N0 T1'0%A)4(8RX11<;!S&G*'K3-6P?[X(H_ M_E*MRP*!YR_U#\]K._TX%J5I>O*0S7NXCOR>P?,$'5"<(6@=AP(-8LG#%PL& M8Z?]>XS/'MDGQ$F'H3,^+O1CH@!KKNQKP=+*;AYJAB)FH*+&($ 1"$U896&( M^08'4V'N:=0^LN::4%DC3-PYZ<-D.TDZ$HEIBK0/ZK\W-X'4>KVK!R(FY1$JEK4S6Y>;;$L3!$\)-A:%28% MU(09VVY($91TLO[QARO,@25",J:HY4(KXX5!ECD2)B0J]VN5&SS%*@(Z*_X1 M_!D 6'R9+HNO$=T_%Q"!,P#J_Q6KSV%HA5S@9OVY6L87?_^Y^=9LM;K9/EQ= MW:Q7Z_!%+*.$\1G$Y R&CYPMBCA@ZA_!Z$R&CT6$;;_-TC.R- >U3\.R^28] M]PIN^;!Q2XWFK'A=LWS\S&N?DQ?2K4[TC4.ZNL-_(K'JP4-"-?/- M->2PP( M+!$4$F"@0N(FF&H.?&J*2-*;!D]]OO-,&ZTM:?X01!8UR7*C<9_-W MD [HU4&Y6E0O*-:^3'72IDY>:2=/N1V2IE!WOCB]2#W!S &=ZL/C.*2JEP6/ MRY/W9*.M8+TOU]/9HKQTT^4BC+65NKBXN;Z93]?EI2VO9A>S]41S'ERL&/*, M86\E0,+NUE/"/#1%OUHT1[EAS#F%#.$4FV"J4411*>NZR]GO,S8(BW(+,4UJ MAN"SG?(WYMJ%7?ZWEY]G'Z;.,0T!%H2Q8GR@L5Z?LU0 MU-XG25MJV\ +C G 3CM)L06"$VY"(HJY@=IBG5GG]H?C]FV9?<#%/&!-OF,Y M+/GM=/"4O*>)XC[EFZ.0][ VIQ#^&.'^:5/^N+J*AQ*.?EDSA= #FIG+->,0 MT&S6/;[NF9'%[OL$$\,DH\1B[)$U"I)X]?UNA_AA*C_E2WDZ:CLIPF5$]7,!Q7V<)VY[;Z M,3L.O1K.G,3RA(D\M=ZMG*X^Q_,;X8_8SM?IO#[1L:NKAS!V#& L//>6>:<9 M,,PBP*E G+6=^;S0"B<0,TNB.$,J+)<64.\S[A1%A!M3B?%+_:P MG>P P&&J#NV?#Z6^3F?SF%OZ:ODA MM/VAO+A9UD/^8_SN1"F.K14! 4%&(PF)W8TV11Q).L;4NE5MN<>4.42(I\AI MC72\R:D$EPH+DWMYIP$:5Q!V4%]=5# M& EFRX""Y];*&F91XXQ#-R+=KVJ^/VXCW$2I'(SX=D)Y"L[39'(PNK.H9$O^ M#FCDT!X8AT(.;E65M]\.KHZVNI[.%A.DN57,<&>95=)[P9QOAJG6?&A]W+8: MJWE)B1B0-H0&#Y5#&C+-/ ?$2I'[C%?"D-T 'EXCV](_F$IF8#Z;3KY$^JF4 M+K^6JOJCTE^7TLM35XG+U M:( M0,>,SGU,[-<_?_AS,=O!*SY%?,5Y!-A.^@;@\;#4'9?"-&G[]4-QAZNH@14U MLN*W#;:6\6, $B^KBYOXF]/UK%J,A,Q[F(Y!ZH/X$*VM51^BK>:_:/\3&C\< M9Z?5] 'MJ(;N30F:;Z M,2&1$9P!CQ&BR I!.$4*4&-BU2J6^^6D'<3^,CX(M2W4_-BLIHGZ':'#:?L@ MS"9(_+$9[J;T_9EN)_@MV'A.]XF4EKF2GHXV.JB&M,O<+:Q(('FEH J6 @]QL0 M"9LZ$7-1@\ZPFY;@BN%VU/)X(=NN6AL'G&QK;<=ES^VU=)^,8TDDDVT=MMFZ M,MCZ%LJS+:OK:KF.MUY-M5I/J ; (N8!Q=)"KH%3N!G(!O"D5R[:M@F)(=8# M80CTL:ZUE!QR!30RX;M2Y#Y4K3Y]6I:?ZAL0$4ZAIZM9ZC63H=AM)Y.G(#9- M( ^*XEFQ@]F&\3P72MI1>$ 7AW;".!1Q<*L>7AS)PMH *GAWH>4ORVJU^G6Q M+*?S".]-E9 M<5Y;<8*+?7U9[Z;0 WMT]-H]M+WM53T+TSGU/MY;O,,E':<8("<=4)@QK,.? MC;AXK/5DL4D=/^:5_?N@PH1 0$LX<9A2JZ@$TM) EG*0"^W:[>O(C= \PM]= M_2/(Y$=P\WLHG_QG\,K1Y3_:\'W)_SW6!Y;_;A[]?N6_H[T#R'\?IOO+_T0X M&.872"F&"*8*$N=)HQJ$,S!,'C^A'#)BJ*6* ,I0?/-2L9"G&J0@T#!W@KZW MM.&GL^6F]-90 OTRAWV5=U#Z!I34L6AD)_%K3>K85:V](:WE*I&;]&TM?;.: M+;HJBW?+V459J'G= M*P/:KGM:0_JAGV7PUSBD-:^)SVZ"9>.SK1P_ >#=L@K!X'KZ>G$5_[B/@A-HH+.>0L(TI,BI M,/Z]5DXB2;5.RA53VQ;><&T4I=112@202B$4Z\):XB7':34_NA32K8H:7.%G MB^GB8C:=%WLXT^1W<-[;*>\I*4\3W:>$]JRX\\$>W)/+;2*K!Y0VEW_&(;+9 MK*N.T\O3I#7.,NM)IIVM+N;5ZB;T]KL7K!'F2',H$5W.%I_J0Q2_+JKS5;G\&F/#Z\67 MFW7XY\!6^*W-\*\O\S-E47PM-<#D7AAI*67-.(3*)!4?&1P<-@9C#[BG1%,L ML5".*V&ANQV2!(-3)=O/H(748*L!A98)ZBG5@5LL M MV4L'@+X6C9=]Q=>#3<.]5Q&8&+CYY6'\&[G1='NCAV[/GRTWP?)X'NZ>N1 M1933\Y$OQ1[$4ZWJ*NP>Z5Z'KU:SX+P:P/;NKK3QF(Y3E&-#N!><.=GH%<68 MMZZH<+@9*H7F6DD;.[74R\ MLH@(;:PG6"##L12[/3@JDDZ590$HM5'6QV?9$:-ADJ>5@XP93 W !H#<:S2Y M%H3?=*W#<)I>F\XMXXR1\^;Z:SWVU_'VZO)PH@T"L92Z5,C"^.V@\;R0/2)GTK&I^M)Y: MJ#UQ@E-)K2'2,^6(8(1 #@!$WV44/"OVK"U^B_866X-/%Q2[=I>C1\@C])0Q MA,M.G63LT?-IWQTGE/;L-S]<7.W+1[X@.XBGDB/N%FQ946RA0F/88$B9#4$J(DR89#TWJL@ITL;^J$*]C?YHMXC/UQ?DT_,I% MXIW-$_DV,22.UJ'=P^">2<7OP:8GPMWJ0;P+,?%1D+S;'SM\83=OV!O2/VU" MW4GZP\C"VVDX>"ZDG= CN8@$9I"59NNS?G%I>GW)FS@3WG@!9,,NJ=DC06@G6(F=!7 M$4DZG'W?H 'VY._+ M+_%5E\6GNR)01FM,E>#:"$&U<1ANKZ@+SZED;EJTVP^:7FWBA MY.W5IKTXH+< 5A,LD,58J3!*$362*,Q],W" T#IE3_) ,\!!I AA#F)'@1'2 M8@8 =R),T4SX:^:-Q0VR6'5VN1M&JRVVM"EL'RK;:="16$Q3H3L"[V 5'UYB M,(L,/<_/ 2$:@-1Q2-$0AE2#=[BNAG-[&MYJ5:K01?3"/Z8K97#O;\MOBT,R5HYZ?DZKRG]'7+G._[<'-BUKA7 M:+WQ=A23HK&KV!E6]X)HVJO:MF)C7%V(?=^^HC;PY 6"\WGK4!I[^BXRCN@S M!B*>K0!_8M^TC7ZO%^LP4F>AI0V.NY*O>V64@94NS)SCSH4 #"@.=?T&#O-< M:4!3PEB;]L+]FM%!N4^EV2U(.R"^0U(^#A4=U*(J7P?MFM6[ZR_SZK8,TXCEU]E% M^>'S=%GJZ2J^P7S]I5RLZMSR[K6=J-P7U:=%?+_M7;VV'M]J7NV-71J2.^,X M54H3ZD08MFSS(A@TV(FD2[;Y4 ++%- M(OY7M0'%O@4AXXM?)][U.:$S4[/V,?NQ>]+>6%5LS2HV_CU_Y-^SO7>K-ME^ M8UVQ,:^H[1M1XCZPPUKE[:?J).,(."/@X=FL_;2>20]N3P/\L YMO_U2[XNI MB_7LZVQ]^V V82C04'@&C=6.(>N]-HWP<9Y6*F( .-A!1 S5A),I3<2,6]A M?+1%@WB;*G>XB@B++<2BP=@U2.5S2FHT&H4_$L/.LY'EGI/.=EX:42SI2G>K MH)'=EV.+#OD-?C8,'(GKCGI__A#8^W*U7LXNUN5E#5$M+A]\Y]?%;/T<9.64 M(AI)A21!C"N+$6A$1VF9M+J3%:@&@!B* 21.4"ZUL,:%[S # 34A<\^^3=$@ MW2J1BI4K!HH61W9IIS@R7F]VG]@\'VT>N3MN3#SZ9FWA:$/1H!YK'Z1.TU%& M&;Y.1,7AP'9*_PPUQ7D28!3D9U 2(KP$U'LI'+6Z=" Q1RSXAQ/"@/ M%M9IH)CE5KM6![B>^%@"O">*(,^PH50*A8*V.0:I"%'3 Y]_@SN"Z?*\02(] MA\4Y,S/)N]5'(B7AC8=\Y'1[TZ$U2>V><+AGWA/JW8.#$3S1T!%XU=O_:9GV M$X^JKYI7U;>'F";4:H =\-AIAZFV7BH0^[3VV""/DAYX:],>YX8BB8764%"M MD92*<.@8!01AAW/O7F]AI&6^@_#8+IL]-H5I2MJ@*_;@G14!7U$#+%YB-TNJ MV8*R ^GCD(2/(R4KB8GDSG=\]7$^,-T0CH["Q MRB&))!?;F6004HM;CKU#35BJ,%$A#;564@^Y5MB'.2K6<>[J2<9=LP95O4K9 MX#K9W;P#'!T89$,P.X[!-8@EU?#]+FTPA6:JF\5ZM6VY:;B\W*L"_N3A5HN4 MCQ5/PVC6"ADFG&X&6HAY24<+.F,0W"&LH.*84 6TL%(+2:B@\:P7SUXZ= -R M_\F M&0B&_?M1&X,M*<)8(.XV$*^$\+[;AC'&>2._!X0S]P>&X>P9K>R.NXX M2%B8>E^NS?1Z.Q,$6C(4'PHG(9^QFJ$PI=#>,VY".D4@;KTN=>]3%5#$44Z4 MD3B@M ):BQEU*%C#$,[]F.D&2Y<%F#1N6BQ*9:,E3=2.Q4C"BE0V9KHM2+5E MJ-UZU+YQSRU'=2)@!*M1W7!7?5W?;2W*5-?GLT7=%<+$\6N81%:+Z?SUW5W@ MUXN@O=/Y5I]GBT^O%Q?5]9=YN2[OZ@'>>\;TXW*Z6%V5RV5Y.>'0$.JH$!)9 M89"7.EX["0-"ZV -2[J7?23()N"RV@+LM0OS9: A@T(ABS6S8=(,T=T46 MBW5UOV14L;[#V6W)[-3N3EMU^XX\W7'A;L_">N&NL;'8,_*LV)I9W-E9W!EZ M5MR9>O;@ >B/+?I+UD7 O!YLL8XXDBXTCJ1^;*0\LYHY%GA) =7]Y\UL?7NW M!HI("-2:!^FC%#IIN.=UD0H-$)6VK1(^^%3O,%+6:8R1#I^"!/ &6V6PXE Y MF[%:[ ;(R=8Y[_-P8-QW)&PU*^/F*S4S?ISM8SW MLR:(,2H I?%M00P5D6'^TW1^KYA(R?H.M2.$L!H2J&RLEXJ9E@HIQ;RP1CNE M6H?7BLYV8'(O*-&6YS^(&6*%>9C&+SAR@Z(#H M#$'L.!1H$$NJX;M=9VUZ-UV^77Y8QXKW=8'2=^6R!C'ACL974CP&TL$XH8;( M;\<4]A"KCAKU;'M&(*$H$AA@2HDQTCB)7+P%[VB+XK*:SZ?+5?&E7&Y4[$^=I:L[WZ$I+;"SBGB*A:=.2(V=A)P SI%1)/NF\ [=1N\ZYV1]"6UYSN5X M7"8>==G1.([D[#!1A\Z[#,/P.+1K*&,>GGH9DJ-NBO6L7"*CA:8$2FQL+%1% MF 7-0 MYHYQ\+9?G53?M>K91J%EH$B%M<6C""^F-M8I;;#Q&4H"4<;>/KZN* M#9VU#<5]%Y$["ND]Q6Y$Z5L[\EH+8&_VQRB$_8TZ*(@#<=8GE:L?E[V<&.6Y M)-)@@#1DL5X-8LV Y, G;:D>: 8@JB@@!'&D*)=8.4\E YH3Y1D5N4M5/TSA M9C6J_NE;6Q*[IVX9^!LF;7M]F,*CI6P;'(GI6B*K8U2H;H:T2-,Z<=-'B=[> MK%?K:?UZU41B$?0NC"(G$ 5A3 75VRWL>,_ZRM&]M@0)C1 2E#5,N)B24%F* M-'+$(TQHTOO! VA2=0>MOS E<=I=G7+1.8Q$O6W!Z-%T:@],HEAU(7F\BM7) MFA:RU9VE]B77+ZKK\N/TV]W)X=VN*.084@VYX![;T*+VWFQ>D9#$ LM;%P9_ MOHF0% )D)>?1-N&0$L1+!@EBB$A',IXOVJ J JQ[I_!/M'E_@*,# VL(9LKM!/O[ZJ7I$6 T720+!$E MM^,.A*71])EQQ+;QT%&-=&RG1=EG8$ZDU )"'_0MQ'.F()%*-HH'".?;Y[8_ MK*?+=;L0^5Q+2#/L)=4A6>!4&A+D%1@F%&%>8$Y(BF8]!-7^@'SY:;:(7GCU MK&REA:3.O+:+),<@,RT I/.61:F?(>: P/:E/ ^OKGV+HSQY>9-AO"S[ZIM'9*)5U0[*;%!S&(BH %F-[0,ADFE MC 8!%$@26G#K*?;46R61T2QN:5OH-&+Y7SO;@BVNJF6Q#D/R2P.M6);S>ILQ M)%M?(OKBMIPNAY&X@9W62P]/YZ^!Q#/>Q=J84.Q,V#RP61O1/+T3?V5GQR@$ M-XGY='7.X]A12WDFD]OI?DZ^LP0)<[-7[[$!8K<0 MRUFK"@L#0P+, MAGAQ',=ECQA;,[ZWF/$L^T-%C?[N_0[CQ@!&]XD<0W'>,W:\+R]O+NIV[Z%[ M,_VR*M]>J2]?YK.+6!XH'L2Z68=OO9E=SS:%3%831:"T%$#*A1<6&@.(VRT* M&VXFB_)3U,Y>H:070FD#% 44A@Q2*@(P)@2)^S/26 3;;0C*C3SM&]-:I6J8 M<3%XM8&WBE_/[Q .$D+R.K%7/#F]]X8.+CN+'D:7G:OOK"JV9L7OOFGA]&/& MFCZ>20\\1^D'HXY"QV&@74@ZHC=ZQB=;/A4\?;4L9Y\6FQAZ<5O7FIAO*GP! M!B B-H TD#"K$9!@*V?*>NF:F/2Q]QPG&1IBPC/KO#"<4"^ID-HSC+ (R!QE M[9:F[P>CC^ESG2W HOQV\3E\ORPN9U=7902;6!3\:![K%8!.XZ6A@TYCQ<.8 MTSBS,:38LV0442:5_O3(DLW!HXXF^:QN%T$RLYYE1>P .LRAMTAKKSQ#,2,. MN R03ILP_R(VZ:'0H3 YK312'E@*#:4AOEK(K(!&A@%(B,A=OR!WG!C>1QD6 MOH[DGNPK7Z./$ZGT#[7T-8"#1QTG\EG=9_%K,-;['O)1CD!AB-.:286Q AXT M9](##*FWAWS$ZQ]/$'!@K/9D< MQU#I:T0U:.]*'RBO%Z&)NNZ[F2Z7M[L3KQ/GK0P)*\06$P\0%Q+ID,AR"ZB5 M#+NTXAH'FT("*^DDX&&^14,#,@Y3RK!E5 *&DH[#=RJI\;[\6LV_QCPTY &7 MLW5Q-8U'A%.?7N['9WOY.0J1:2+TI@I1.\S?KHL(\*SXR[):'3E8'V+F!17J M3>AXM*B_*4\HTD#\M->ES:50/UM,@^&F6JU7OY1A"(7I--3 .6LE)%AC)- V M@E-%)>VP:OY<4SADVJ$MR5Q(1T0L"0$\(0A1)!E4I-U(ZKT*7H?V>(T_8BMJ M<&=%@)J?=D<&OU3+YFK@?!?4+P/:--'IQ&,[P9^248NFT,Q>LY]3U] MKAPP\5TGWXP0((R:K*OU=)ZN-'M-$"8T@"%ELTQ1XIB.RR$\) % 46MTTAOV M=VA:#Y>/\5<&4Y84ZM+%)1-K_?3E[E+VF)3FCJJ68M.!V_'I312SMC5H, MPKBAP"G&+6'*>,/VQI"4*1.%IS[?(*^(19@8+.(:L,:8 R)QF*TSIF'NAVT" MDE?--*&!E_RP=B?>$K4G$V4=->>LN,-S(J5I%9[[T#EBP7.*TIF-A.7. M6$[$5(OU8/ \18(@:PFV$#*E0DCW$IAL),.&B0SILQ; M"XI]$XH(\X1[HX-P>GCM\*A>&\> /[K5C]Z:[R)W+(0.)^5NS<= _]_9_< MX#^]^K?G.E'T,SAQO%J?P]@6$I^-X[;*_I>JNOQ]-I_?A9*/Y;>U#G3];6*8 M]!P ;1FQ(8R$N,*D818!QBR#/*E>ZJ%V!*!(N)!TRO@0C&?222@<%-I2)X3* M??*_@98FOKV(:Z>LQ^(L338;5/<6P"*PHD9VY'SX $<'Y&X(9L>A98-84@W? M[])4J"[:_KF:![)6F\>E?ZG6Y5/M>QGFHUP""9#F2$'KI=H,+:Z I4DO/[=O M%8=9L#%".2P%E1)*HC46&L*05BNB66:%V@?ZWXL-U#2U&I#@=MIU&F[3E.PI M6HL($FEBLH MX\&EMU?ORU6Y_%JN)EH)A*4-$W_'+:((,ZTVZ]X&$B*39MAI+5,"@/":<80@ MM=*KT+"RB&M M4@.0/C*M&\*BYQ1N,+:2=YR/MC@G-SB)E]5%?;-U4]AE M)&3> ]6!U(L]4A<[B']N&P"BM;6L0[05]9?M?T++!R3MM!(^I"'5X!VJ_[EE MZQ1D)N2Y1E+%!?2$T&:08,=!6HGLIUKP$DD(+;<.0$J$DYPCI\.$,S[8*'27 MJJ)I,KVYY)AZ@GFDIW+;LCFRQ*>+!2U.Y::QT7:;T5PB!7EGFB$*$1AZB(L" T" M#30A*.G66*=7=\(O+:;S^6VQQ1;FUPW:EP?+T)2VW,<_"IN)^_8-9WN@3B0V MS])S:$^^-Z7CD)\!['BXYSX0,VT%*:YQK,LWLZ_E91BE6JW*]:HN M.S6!'(5DP#$@G3#<,>4A; 81L&GU.EYLC D.8@5!# T,"0?0+CZ.Z+'UU"CB M>>YCD!%$T91E>NEX-KH]:EX#*ILR#\VQSDEC M05LT%T4V@_J/.S.*QHX_I2PRYG-;FU7E/7A4;BIX]IQ/G>U M7%SN2MZS"\_9O3&&1>G\1E9'[>񋃓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